{
  "filename": "2025_ESC_EACTS_Valvular_Heart_Disease_ehaf194.pdf",
  "title": null,
  "type": "valvular_heart_disease",
  "year": 2025,
  "chapters": [
    {
      "number": "1",
      "title": "2025 ESC/EACTS Guidelines for the management of valvular heart disease",
      "start_page": 0,
      "end_page": 9,
      "content": "2025 ESC/EACTS Guidelines for the \nmanagement of valvular heart disease \nDeveloped by the task force for the management of valvular heart \ndisease of the European Society of Cardiology (ESC) and the \nEuropean Association for Cardio-Thoracic Surgery (EACTS) \nAuthors/Task Force Members: Fabien Praz  *†, (ESC Chairperson) (Switzerland), \nMichael A. Borger  *†, (EACTS Chairperson) (Germany), Jonas Lanz  \n‡, (ESC Task \nForce Co-ordinator) (Switzerland), Mateo Marin-Cuartas  \n‡, (EACTS Task Force \nCo-ordinator) (Germany), Ana Abreu  \n(Portugal), Marianna Adamo (Italy), \nNina Ajmone Marsan (Netherlands), Fabio Barili  \n(Italy), Nikolaos Bonaros  \n(Austria), Bernard Cosyns  \n(Belgium), Ruggero De Paulis  \n(Italy), Habib Gamra  \n(Tunisia), Marjan Jahangiri (United Kingdom), Anders Jeppsson  \n(Sweden),  \nRobert J.M. Klautz  \n(Netherlands), Benoit Mores  \n(Belgium),  \nEsther Pérez-David  \n(Spain), Janine Pöss (Germany), Bernard D. Prendergast \n(United Kingdom), Bianca Rocca  \n(Italy), Xavier Rossello  \n(Spain), Mikio Suzuki \n(Serbia), Holger Thiele  \n(Germany), Christophe Michel Tribouilloy  \n(France), \nWojtek Wojakowski  \n(Poland), and ESC/EACTS Scientific Document Group \n* Corresponding authors: Fabien Praz, Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, Tel: +41 31 632 83 50, Email: fabien.praz@insel.ch and \nMichael A. Borger, University Clinic of Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany, Tel: +49 341 865 1422, Email: michael.borger@helios-gesundheit.de \n† The two Chairpersons contributed equally to the document and are joint corresponding authors. \n‡ The two Task Force Co-ordinators contributed equally to the document. \nAuthor/Task Force Member affiliations are listed in author information. \nESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix. \nESC subspecialty communities having participated in the development of this document: \nAssociations: Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging (EACVI), European Association of Preventive Cardiology (EAPC), \nEuropean Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), and Heart Failure Association (HFA) \nWorking Groups: Cardiovascular Pharmacotherapy \nPatient Forum \nDisclaimer. The European Society of Cardiology (ESC)/European Association for Cardio-Thoracic Surgery (EACTS) Guidelines represent the views of the ESC and the EACTS and were produced \nafter careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC and the EACTS are not responsible in the event of any contra-\ndiction, discrepancy and/or ambiguity between the ESC/EACTS Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation \nto good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC/EACTS Guidelines fully into account when exercising their clinical judgement, as well as in the \ndetermination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC/EACTS Guidelines do not override, in any way whatsoever, the individual re-\nsponsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or \nnecessary, the patient’s caregiver. Nor do the ESC/EACTS Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or \nguidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional \nobligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices prior to making any clinical decision and to check whether \na more recent version of this document exists. The ESC and the EACTS warn readers that the technical language may be misinterpreted and decline any responsibility in this respect. \nPermissions. The content of these ESC/EACTS Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC/EACTS \nGuidelines may be translated or reproduced in any form without written permission from the ESC and the EACTS. Permissions can be obtained upon submission of a written request \nto Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com). \nThis article has been co-published with permission in the European Heart Journal and European Journal of Cardio-Thoracic Surgery. All rights reserved. © The European Society of Cardiology and \nthe European Association for Cardio-Thoracic Surgery 2025.  \nThe articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. Either citation can be used when citing this article.  \nEuropean Heart Journal (2025) 46, 4635–4736 \nhttps://doi.org/10.1093/eurheartj/ehaf194 \nESC GUIDELINES \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nDocument Reviewers: Alec Vahanian, (ESC Review Co-ordinator) (France), Carlos-A. Mestres, (EACTS Review \nCo-ordinator) (South Africa), Leila Abid (Tunisia), Suleman Aktaa (United Kingdom), Enoch F. Akowuah (United \nKingdom), Elena Arbelo (Spain), Folkert W. Asselbergs (Netherlands), Emanuele Barbato (Italy), Giuseppe Boriani \n(Italy), Margarita Brida (Croatia), Sergio Buccheri (Sweden), Robert A. Byrne (Republic of Ireland), Ovidiu Chioncel \n(Romania), Lenard Conradi (Germany), Michele De Bonis (Italy), Victoria Delgado (Spain), Anna Franzone (Italy), \nKristina Hermann Haugaa (Norway), Bettina Heidecker (Germany), Borja Ibanez (Spain), Bernard Iung (France), \nStefan James (Sweden), Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), Ulf Landmesser (Germany), \nGregory Y.H. Lip (United Kingdom), John William McEvoy (Ireland), Gil Meltzer (Israel), David Messika-Zeitoun \n(Canada), Borislava Mihaylova (United Kingdom), Richard Mindham (United Kingdom), Inge Moelgaard (Denmark), \nJens Cosedis Nielsen (Denmark), Gareth Owens (United Kingdom), Agnes A. Pasquet (Belgium), Thomas Pilgrim \n(Switzerland), Eva Prescott (Denmark), Eduard Quintana (Spain), Volker Rudolph (Germany), Rafael Sadaba (Spain), \nAnna Sannino (Germany), Felix C. Tanner (Switzerland), Marina Urena (France), Ilonca Vaartjes (Netherlands), \nChristiaan Vrints (Belgium), Alexander Wahba (Norway), Thomas Walther (Germany), Adam Witkowski (Poland), \nand Katja Zeppenfeld (Netherlands) \nAll experts involved in the development of these guidelines have submitted declarations of interest, \nwhich are reported in a supplementary document to the guidelines. See the European Heart Journal online or  \nhttps://www.escardio.org/Guidelines for supplementary documents as well as evidence tables.  \n- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - \nKeywords \nGuidelines • European Society of Cardiology (ESC) • European Association for Cardio-Thoracic Surgery (EACTS) • \nValvular heart disease • Aortic stenosis • Aortic regurgitation • Mitral stenosis • Mitral regurgitation • Tricuspid \nregurgitation • Tricuspid stenosis • Multivalvular disease • TAVI • SAVR • Heart surgery • Transcatheter edge-to- \nedge repair • Transcatheter valve replacement  \nTable of contents \n1. Preamble .............................................................................................................. 4640 \n2. Introduction ....................................................................................................... 4642 \n2.1. What is new .............................................................................................\n4643 \n3. The Heart Team and Heart Valve Centre ............................................ 4649 \n3.1. The Heart Valve Network .................................................................\n4649 \n3.1.1. Composition of the Heart Team ............................................. 4650 \n3.1.2. Procedural volume and clinical outcomes ........................... 4651 \n4. Imaging of patients with valvular heart disease ................................... 4652 \n4.1. Initial valve assessment .........................................................................\n4652 \n4.2. Associated diseases and conditions ................................................\n4653 \n4.3. Evaluation of valvular heart disease dynamics and variability\n4653 \n4.4. Assessment of extravalvular cardiac consequences from \nvalvular heart disease .....................................................................................\n4653 \n4.5. Evaluation of eligibility, planning, and guiding of interventions\n4653 \n5. Clinical evaluation of patients with valvular heart disease ............. 4653 \n5.1. Clinical examination ..............................................................................\n4653 \n5.2. Assessment of comorbidities and risk stratification ................\n4653 \n5.3. Biomarkers ................................................................................................\n4654 \n5.4. Exercise testing .......................................................................................\n4655 \n5.5. Invasive investigations ...........................................................................\n4655 \n5.5.1. Coronary angiography .................................................................. 4655 \n5.5.2. Cardiac catheterization ................................................................ 4655 \n5.6. Patient-centred care and shared decision-making ...................\n4655 \n6. Management of conditions associated with valvular heart disease\n4655 \n6.1. Diagnosis and management of coronary artery disease ........\n4655 \n6.2. Atrial fibrillation ......................................................................................\n4657 \n6.3. Cancer and radiation therapy ...........................................................\n4657 \n6.4. Prophylaxis of rheumatic fever ........................................................\n4658 \n6.5. Cardiogenic shock and acute heart failure ..................................\n4658 \n6.6. Palliative care ............................................................................................\n4658 \n7. Aortic regurgitation ........................................................................................ 4658 \n7.1. Prevalence and aetiology .....................................................................\n4658 \n7.2. Evaluation ...................................................................................................\n4658 \n7.3. Medical therapy .......................................................................................\n4660 \n7.4. Indications for intervention ................................................................\n4660 \n7.5. Follow-up ...................................................................................................\n4660 \n7.6. Special patient populations ................................................................\n4662 \n8. Aortic stenosis .................................................................................................. 4662 \n8.1. Prevalence and aetiology .....................................................................\n4662 \n8.2. Evaluation ...................................................................................................\n4662 \n8.2.1. Echocardiography and cardiac computed tomography . 4662 \n8.2.2. Additional diagnostic and prognostic parameters ............ 4663 \n8.2.3. Procedural planning ....................................................................... 4663 \n8.3. Medical therapy .......................................................................................\n4663 \n8.4. Indication for intervention ..................................................................\n4665 \n8.4.1. Symptomatic severe aortic stenosis ....................................... 4665 \n8.4.2. Asymptomatic severe aortic stenosis .................................... 4665 \n8.4.3. Moderate aortic stenosis ............................................................. 4665 \n8.5. Treatment options .................................................................................\n4667 \n8.5.1. The mode of intervention in candidates for a \nbioprosthesis ................................................................................................. 4667 \n8.5.1.1. Age and life expectancy .......................................................\n4668 \n8.5.1.2. Anatomical features ..............................................................\n4668 \n8.5.1.3. Lifetime management ...........................................................\n4668  \n4636                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n8.6. Follow-up ...................................................................................................\n4671 \n9. Mitral regurgitation ......................................................................................... 4671 \n9.1. Primary mitral regurgitation ..............................................................\n4671 \n9.1.1. Prevalence and aetiology ............................................................. 4671 \n9.1.2. Evaluation ........................................................................................... 4671 \n9.1.2.1. Echocardiography and right heart catheterization ..\n4671 \n9.1.2.2. Biomarkers ................................................................................\n4671 \n9.1.2.3. Cardiac magnetic resonance and computed \ntomography ..............................................................................................\n4672 \n9.1.2.4. Genetic evaluation .................................................................\n4674 \n9.1.3. Medical therapy ............................................................................... 4674 \n9.1.4. Indications for intervention ........................................................ 4674 \n9.1.5. Follow-up ........................................................................................... 4675 \n9.2. Secondary mitral regurgitation .........................................................\n4675 \n9.2.1. Prevalence and aetiology ............................................................. 4675 \n9.2.2. Evaluation ........................................................................................... 4675 \n9.2.3. Definition of atrial secondary mitral regurgitation ........... 4675 \n9.2.4. Management of ventricular secondary mitral  \nregurgitation .................................................................................................. 4676 \n9.2.4.1. Medical and device therapy ...............................................\n4676 \n9.2.4.2. Indications for intervention ...............................................\n4677 \n9.2.4.3. Follow-up ...................................................................................\n4678 \n9.2.5. Management of atrial secondary mitral regurgitation ..... 4679 \n9.2.5.1. Medical therapy and rhythm management .................\n4679 \n9.2.5.2. Indications for intervention ...............................................\n4679 \n9.2.5.3. Follow-up ...................................................................................\n4679 \n10. Mitral stenosis ................................................................................................. 4679 \n10.1. Prevalence and aetiology ..................................................................\n4679 \n10.2. Rheumatic mitral stenosis ................................................................\n4679 \n10.2.1. Evaluation ........................................................................................ 4679 \n10.2.2. Medical therapy ............................................................................. 4680 \n10.2.3. Indications for intervention ..................................................... 4680 \n10.2.4. Follow-up ......................................................................................... 4680 \n10.3. Degenerative mitral stenosis with mitral annular \ncalcification .........................................................................................................\n4680 \n10.3.1. Evaluation ........................................................................................ 4681 \n10.3.2. Indications for intervention ..................................................... 4681 \n11. Tricuspid regurgitation ................................................................................ 4682 \n11.1. Prevalence and aetiology ..................................................................\n4682 \n11.2. Evaluation ................................................................................................\n4683 \n11.3. Medical therapy ....................................................................................\n4683 \n11.4. Indications for intervention .............................................................\n4683 \n11.4.1. Surgery .............................................................................................. 4683 \n11.4.1.1. Patients without indication for left-sided valve  \nsurgery ........................................................................................................\n4685 \n11.4.1.2. Patients with indication for left-sided valve surgery\n4685 \n11.4.2. Transcatheter techniques ......................................................... 4686 \n12. Tricuspid stenosis .......................................................................................... 4687 \n12.1. Prevalence and aetiology ..................................................................\n4687 \n12.2. Evaluation ................................................................................................\n4687 \n12.3. Medical therapy ....................................................................................\n4688 \n12.4. Indications for intervention .............................................................\n4688 \n13. Multiple and mixed valvular heart disease .......................................... 4688 \n13.1. Prevalence and undertreatment ....................................................\n4688 \n13.2. Evaluation and diagnostic pitfalls ...................................................\n4688 \n13.3. Indications for intervention .............................................................\n4688 \n13.3.1. Multiple valvular heart disease ................................................ 4688 \n13.3.2. Mixed aortic valve disease ........................................................ 4690 \n13.3.3. Mixed mitral valve disease ........................................................ 4690 \n13.4. Follow-up ................................................................................................\n4690 \n14. Management of patients with prosthetic valves or valve repair\n4690 \n14.1. Choice of prosthetic valve ...............................................................\n4690 \n14.2. Follow-up of patients with prosthetic valves ...........................\n4691 \n14.3. Antithrombotic therapy in patients with treated valvular \nheart disease .....................................................................................................\n4691 \n14.3.1. Mechanical heart valves ............................................................. 4691 \n14.3.1.1. Post-operative anticoagulation and therapeutic \ntargets .........................................................................................................\n4691 \n14.3.1.2. Prevention and management of bleeding ..................\n4693 \n14.3.1.3. Management of anticoagulation therapy before and \nafter non-cardiac invasive procedures ..........................................\n4693 \n14.3.2. Biological heart valves ................................................................ 4695 \n14.3.2.1. Patients with a surgical biological heart valve and no \nindication for oral anticoagulation ..................................................\n4695 \n14.3.2.2. Patients with a transcatheter heart valve and no \nindication for oral anticoagulation ..................................................\n4695 \n14.3.2.3. Patients with a surgical biological heart valve and an \nindication for oral anticoagulation ..................................................\n4696 \n14.3.2.4. Patients with a transcatheter biological heart valve \nand an indication for oral anticoagulation ...................................\n4696 \n14.4. Management of prosthetic valve dysfunction and \ncomplications ....................................................................................................\n4697 \n14.4.1. Structural valve deterioration ................................................. 4697 \n14.4.2. Non-structural valve dysfunction .......................................... 4698 \n14.4.2.1. Prosthesis–patient mismatch ..........................................\n4698 \n14.4.2.2. Paravalvular leak and haemolysis ..................................\n4698 \n14.4.3. Endocarditis .................................................................................... 4698 \n14.4.4. Valve thrombosis .......................................................................... 4698 \n14.4.4.1. Hypo-attenuated leaflet thickening ..............................\n4698 \n14.4.4.2. Clinically significant valve thrombosis .........................\n4698 \n15. Management during non-cardiac surgery ............................................ 4700 \n15.1. Pre-operative evaluation ...................................................................\n4700 \n15.2. Specific valve lesions ...........................................................................\n4700 \n15.2.1. Aortic stenosis ............................................................................... 4700 \n15.2.2. Mitral stenosis ................................................................................ 4701 \n15.2.3. Aortic and mitral regurgitation .............................................. 4701 \n15.3. Peri-operative monitoring ................................................................\n4702 \n16. Management of valvular heart disease during pregnancy ............. 4702 \n16.1. Management before pregnancy .....................................................\n4702 \n16.2. Management during pregnancy ......................................................\n4703 \n16.2.1. Patients with native valve disease ......................................... 4703 \n16.2.2. Patients with prosthetic valves ............................................... 4703 \n17. Sex-specific considerations in patients with valvular heart \ndisease ........................................................................................................................ 4703 \n17.1. Aortic valve disease ............................................................................\n4703 \n17.2. Mitral valve disease ..............................................................................\n4704 \n17.3. Tricuspid valve disease ......................................................................\n4704 \n18. Key messages .................................................................................................. 4704 \n19. Gaps in evidence ............................................................................................ 4705 \n20. ‘What to do’ and ‘What not to do’ messages from the \nGuidelines ................................................................................................................. 4707 \n21. Evidence tables ............................................................................................... 4710 \n22. Data availability statement ......................................................................... 4710 \n23. Author information ...................................................................................... 4710 \n24. Appendix ........................................................................................................... 4710 \n25. References ........................................................................................................ 4711  \nESC Guidelines                                                                                                                                                                                          4637 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nTables of Recommendations \nRecommendation Table 1 — Recommendations for the \nmanagement of chronic coronary syndrome in patients with valvular \nheart disease (see also Supplementary data online, Evidence \nTable 1) ...................................................................................................................... 4656 \nRecommendation Table 2 — Recommendations for the \nmanagement of atrial fibrillation in patients with native valvular \nheart disease (see also Supplementary data online, Evidence \nTables 2 and 3) ....................................................................................................... 4657 \nRecommendation Table 3 — Recommendations on indications for \nintervention in severe aortic regurgitation (see also Supplementary \ndata online, Evidence Tables 4–8) ................................................................... 4662 \nRecommendation Table 4 — Recommendations on indications for \nintervention in symptomatic and asymptomatic severe aortic stenosis, \nand recommended mode of intervention (see also Supplementary data \nonline, Evidence Tables 9–13) ...................................................................................\n4670 \nRecommendation Table 5 — Recommendations on indications for \nconcomitant aortic valve replacement at the time of coronary artery \nbypass grafting or ascending aorta surgery ................................................ 4671 \nRecommendation Table 6 — Recommendations on indications for \nintervention in severe primary mitral regurgitation (see also \nSupplementary data online, Evidence Tables 14–16) .............................. 4674 \nRecommendation Table 7 — Recommendations on indications for \nintervention in secondary mitral regurgitation (see also \nSupplementary data online, Evidence Tables 17–20) .............................. 4679 \nRecommendation Table 8 — Recommendations on indications for \npercutaneous mitral commissurotomy, mitral valve surgery, and \ntranscatheter intervention in clinically severe rheumatic and \ndegenerative mitral stenosis (see also Supplementary data online, \nEvidence Table 21) ........................................................................................ 4682 \nRecommendation Table 9 — Recommendations on indications for \nintervention in tricuspid regurgitation (see also Supplementary data \nonline, Evidence Tables 22 and 23) ....................................................................... 4687 \nRecommendation Table 10 — Recommendations on indications for \nintervention in tricuspid stenosis ................................................................... 4688 \nRecommendation Table 11 — Recommendations on indications for \nsurgery of concomitant left-sided valvular heart disease ..................... 4690 \nRecommendation Table 12 — Recommendations on indications for \nintervention in patients with mixed moderate aortic stenosis and \nmoderate aortic regurgitation (see also Supplementary data online, \nEvidence Table 24) ................................................................................................. 4690 \nRecommendation Table 13 — Recommendations for prosthetic \nvalve selection ......................................................................................................... 4691 \nRecommendation Table 14 — Recommendations for the \nmanagement of antithrombotic therapy in patients with a \nmechanical heart valve ........................................................................................ 4693 \nRecommendation Table 15 — Recommendations for the \nmanagement of antithrombotic therapy in patients with a \nmechanical heart valve undergoing elective non-cardiac surgery or \ninvasive procedures .............................................................................................. 4694 \nRecommendation Table 16 — Recommendations for the \nmanagement of antithrombotic therapy in patients with a biological \nheart valve or valve repair ................................................................................. 4696 \nRecommendation Table 17 — Recommendations for the \nmanagement of prosthetic valve dysfunction (see also \nSupplementary data online, Evidence Table 25) ....................................... 4700  \nList of tables \nTable 1 Classes of recommendations .......................................................... 4641 \nTable 2 Levels of evidence ................................................................................ 4641 \nTable 3 New recommendations .................................................................... 4643 \nTable 4 Revised recommendations ............................................................... 4645 \nTable 5 Requirements for a Heart Valve Centre ................................... 4651 \nTable 6 Complex procedures ideally performed in the most \nexperienced Heart Valve Centres ................................................................. 4651 \nTable 7 Clinical and echocardiographic criteria predicting outcome \nimprovement in patients with severe ventricular secondary mitral \nregurgitation undergoing mitral transcatheter edge-to-edge repair\n4678 \nTable 8 Contraindications for percutaneous mitral \ncommissurotomy in rheumatic mitral stenosis ........................................ 4682 \nTable 9 Echocardiographic pitfalls, robust measures, and \ncomplementary multimodality imaging parameters in multiple or \nmixed valvular heart disease ............................................................................ 4689 \nTable 10 International normalized ratio targets and therapeutic \nranges for patients with a mechanical heart valve .................................. 4693 \nTable 11 Peri-operative management of antithrombotic treatment \nin patients with a mechanical heart valve undergoing non-cardiac \nsurgery based on type of procedure and underlying risk .................... 4694 \nTable 12 Criteria for the diagnosis of moderate or severe aortic \nand mitral haemodynamic valve deterioration ..................................... 4697 \nTable 13 ‘What to do’ and ‘what not to do’ ............................................ 4707   \nList of figures \nFigure 1 The Heart Valve Network .............................................................. 4650 \nFigure 2 Integrative imaging assessment of patients with valvular \nheart disease ........................................................................................................... 4652 \nFigure 3 Central illustration. Patient-centred evaluation for \ntreatment of valvular heart disease ............................................................... 4654 \nFigure 4 Imaging assessment of patients with aortic regurgitation . 4659 \nFigure 5 Management of patients with aortic regurgitation ............... 4661 \nFigure 6 Integrative imaging assessment of patients with aortic \nstenosis ...................................................................................................................... 4664 \nFigure 7 Management of patients with severe aortic stenosis .......... 4666 \nFigure 8 Aortic valve treatment options .................................................... 4667 \nFigure 9 Factors to be considered when selecting the mode of \nintervention for aortic stenosis ....................................................................... 4669 \nFigure 10 Echocardiographic assessment of patients with mitral \nregurgitation ............................................................................................................ 4672 \nFigure 11 Management of patients with severe primary mitral \nregurgitation ............................................................................................................ 4673 \nFigure 12 Most frequently used criteria for the diagnosis of atrial \nsecondary mitral regurgitation ........................................................................ 4676 \nFigure 13 Treatment of severe secondary mitral regurgitation \nwithout concomitant coronary artery disease ......................................... 4677 \nFigure 14 Management of clinically severe rheumatic mitral stenosis \n(mitral valve area ≤1.5 cm2) ............................................................................. 4681 \nFigure 15 Echocardiographic and invasive assessment of tricuspid \nregurgitation ............................................................................................................ 4684 \nFigure 16 Stepwise evaluation of patients with tricuspid \nregurgitation ............................................................................................................ 4685 \nFigure 17 Management of patients with tricuspid regurgitation ....... 4686 \nFigure 18 Antithrombotic therapy following mechanical heart valve \nimplantation .........................................................................................................................\n4692 \nFigure 19 Antithrombotic therapy following biological heart valve \nimplantation or surgical valve repair ............................................................. 4695 \nFigure 20 Management of left-sided obstructive and non-obstructive \nmechanical heart valve thrombosis ............................................................... 4699 \nFigure 21 Management of non-cardiac surgery in patients with \nsevere aortic stenosis .......................................................................................... 4701 \nFigure 22 The Pregnancy Heart Team model of care .......................... 4702  \n4638                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nAbbreviations and acronyms \n2D \nTwo-dimensional \n3D \nThree-dimensional \n4D \nFour-dimensional \nACE-I \nAngiotensin-converting enzyme-inhibitor \nACTIVATION \nPercutAneous Coronary inTervention prIor to \ntranscatheter aortic VAlve implantaTION trial \nAF \nAtrial fibrillation \nAO \nAorta \nAP \nAnteroposterior \nAR \nAortic regurgitation \nARB \nAngiotensin receptor blocker \nAS \nAortic stenosis \nASA \nAcetylsalicylic acid \nATLANTIS \nAnti-Thrombotic Strategy to Lower All \nCardiovascular and Neurologic Ischemic and \nHemorrhagic Events after Trans-Aortic Valve \nImplantation for Aortic Stenosis \nAU \nAgatston units \nAV \nAortic valve \nAVA \nAortic valve area \nAVAi \nAortic valve area indexed for body surface area \nAVATAR \nAortic Valve Replacement Versus \nConservative Treatment in Asymptomatic \nSevere Aortic Stenosis \nAVCS \nAortic valve calcium score \nAVr \nAortic valve repair \nBASILICA \nBioprosthetic or native Aortic Scallop \nIntentional Laceration to prevent Iatrogenic \nCoronary Artery obstruction \nBAV \nBicuspid aortic valve \nBHV \nBiological heart valve \nBNP \nBrain natriuretic peptide \nBP \nBlood pressure \nBSA \nBody surface area \nCABG \nCoronary artery bypass grafting \nCAD \nCoronary artery disease \nCCT \nCardiac computed tomography \nCCTA \nCoronary computed tomography \nangiography \nCHA2DS2-VASc \nCongestive heart failure or left ventricular \ndysfunction, hypertension, age ≥75 (doubled), \ndiabetes, stroke (doubled), vascular disease, \nage 65–74, sex category (female) \nCI \nConfidence interval \nCIED \nCardiac implantable electronic device \nCKD \nChronic kidney disease \nCMR \nCardiac magnetic resonance \nCOAPT \nCardiovascular Outcomes Assessment of the \nMitraClip Percutaneous Therapy for Heart Failure \nPatients with Functional Mitral Regurgitation \nCRT \nCardiac resynchronization therapy \nCT \nComputed tomography \nCW \nContinuous wave \nCYP \nCytochrome P \nDAPT \nDual antiplatelet therapy \nDEDICATE \nRandomized, Multicenter, Event-Driven Trial \nof TAVI versus SAVR in Patients with \nSymptomatic Severe Aortic-Valve Stenosis \nDOAC \nDirect oral anticoagulant  \nDSE \nDobutamine stress echocardiography \nDVI \nDoppler velocity index \nEACTS \nEuropean Association for Cardio-Thoracic \nSurgery \nEARLY TAVR \nEvaluation of TAVR Compared to Surveillance \nfor Patients with Asymptomatic Severe Aortic \nStenosis trial \nECG \nElectrocardiogram \nEDV \nEnd-diastolic velocity \nENVISAGE-TAVI AF \nEdoxaban vs. Standard of Care and Their \nEffects on Clinical Outcomes in Patients \nHaving Undergone Transcatheter Aortic Valve \nImplantation–Atrial Fibrillation \nEOA \nEffective orifice area \nEROA \nEffective regurgitant orifice area \nESC \nEuropean Society of Cardiology \nEuroSCORE \nEuropean System for Cardiac Operative Risk \nEvaluation \nEVoLVeD \nEarly Valve Replacement guided by Biomarkers \nof LV Decompensation in Asymptomatic \nPatients with Severe Aortic Stenosis \nFAC \nFractional area change \nFFR \nFractional flow reserve \nFWS \nFree wall strain \nGALILEO \nGlobal multicenter, open-label, randomized, \nevent-driven, active-controlled study \ncomparing a rivAroxaban-based \nantithrombotic strategy to an \nantipLatelet-based strategy after transcatheter \naortIc vaLve rEplacement (TAVR) to Optimize \nclinical outcomes trial \nGDMT \nGuideline-directed medical therapy \nGLS \nGlobal longitudinal strain \nh \nHour \nHALT \nHypo-attenuated leaflet thickening \nHF \nHeart failure \nHFpEF \nHeart failure with preserved ejection fraction \nHFrEF \nHeart failure with reduced ejection fraction \nHR \nHazard ratio \nHTx \nHeart transplantation \nINR \nInternational normalized ratio \nIU \nInternational unit \nKCCQ \nKansas City Cardiomyopathy Questionnaire \nLA \nLeft atrium/left atrial \nLAAO \nLeft atrial appendage occlusion \nLAAOS \nLeft Atrial Appendage Occlusion Study \nLAMPOON \nLaceration of the Anterior Mitral leaflet to \nPrevent Outflow ObstructioN \nLAVI \nLeft atrial volume index \nLMWH \nLow-molecular-weight heparin \nLV \nLeft ventricle/left ventricular \nLVAD \nLeft ventricular assist device \nLVEF \nLeft ventricular ejection fraction \nLVESD \nLeft ventricular end-systolic diameter \nLVESDi \nLeft ventricular end-systolic diameter indexed \nto BSA \nLVESVi \nLeft ventricular end-systolic volume indexed to \nBSA \nLVOT \nLeft ventricular outflow tract \nMA \nMitral annulus \nMAC \nMitral annular calcification  \nESC Guidelines                                                                                                                                                                                          4639 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nMATTERHORN \nMulticenter, Randomized, Controlled Study to \nAssess Mitral Valve Reconstruction for \nAdvanced Insufficiency of Functional or \nIschemic Origin trial \nMHV \nMechanical heart valve \nMITRA-FR \nPercutaneous Repair with the MitraClip \nDevice for Severe Functional/Secondary Mitral \nRegurgitation trial \nmPAP \nMean pulmonary artery pressure \nMR \nMitral regurgitation \nMRI \nMagnetic resonance imaging \nMS \nMitral stenosis \nM-TEER \nMitral transcatheter edge-to-edge repair \nMV \nMitral valve \nMVA \nMitral valve area \nMVHD \nMultiple valvular heart disease \nN \nNo \nNCS \nNon-cardiac surgery \nNOTION \nNordic Aortic Valve Intervention trial \nNT-proBNP \nN-terminal pro-B-type natriuretic protein \nNYHA \nNew York Heart Association \nOAC \nOral anticoagulation \nPAWP \nPulmonary artery wedge pressure \nPCI \nPercutaneous coronary intervention \nPET \nPositron emission tomography \nPH \nPulmonary hypertension \nPHT \nPressure half-time \nPISA \nProximal isovelocity surface area \nP mean \nMean pressure gradient \nPMC \nPercutaneous mitral commissurotomy \nPMR \nPrimary mitral regurgitation \nPOPular TAVI \nAntiplatelet Therapy for Patients Undergoing \nTranscatheter Aortic Valve Implantation \nPPM \nProsthesis–patient mismatch \nPROM \nPatient-reported outcome measure \nPVL \nParavalvular leak \nPVR \nPulmonary vascular resistance \nRA \nRight atrium/right atrial \nRCT \nRandomized controlled trial \nRECOVERY \nRandomized Comparison of Early Surgery \nversus Conventional Treatment in Very Severe \nAortic Stenosis \nRESHAPE-HF2 \nRandomized Investigation of the MitraClip \nDevice in Heart Failure: 2nd Trial in Patients \nwith Clinically Significant Functional Mitral \nRegurgitation \nRF \nRegurgitant fraction \nRHC \nRight heart catheterization \nRHD \nRheumatic heart disease \nRV \nRight ventricle/right ventricular \nRVEF \nRight ventricular ejection fraction \nRVol \nRegurgitant volume \nSAM \nSystolic anterior movement \nSAPT \nSingle antiplatelet therapy \nSAV \nSurgical aortic valve \nSAVR \nSurgical aortic valve replacement \nSGLT2i \nSodium–glucose co-transporter 2 inhibitor \nSMR \nSecondary mitral regurgitation \nSPAP \nSystolic pulmonary artery pressure  \nSTS \nSociety of Thoracic Surgeons \nSTS-PROM \nSociety of Thoracic Surgeons predicted risk of \nmortality \nSVD \nStructural valve deterioration \nSVi \nStroke volume index \nTAPSE \nTricuspid annular plane systolic excursion \nTAV \nTranscatheter aortic valve \nTAVI \nTranscatheter aortic valve implantation \nTDI \nTissue Doppler imaging \nTEER \nTranscatheter edge-to-edge repair \nTHV \nTranscatheter heart valve \nTMVI \nTranscatheter mitral valve implantation \nTOE \nTransoesophageal echocardiography \nTR \nTricuspid regurgitation \nTRILUMINATE \nClinical Trial to Evaluate Cardiovascular \nOutcomes in Patients Treated With the \nTricuspid Valve Repair System trial \nTRISCEND \nEdwards EVOQUE Transcatheter Tricuspid \nValve Replacement: Pivotal Clinical \nInvestigation of Safety and Clinical Efficacy \nusing a Novel Device \nTS \nTricuspid stenosis \nTTE \nTransthoracic echocardiography \nTTR \nTime in therapeutic range \nTV \nTricuspid valve \nUFH \nUnfractionated heparin \nVCA \nVena contracta area \nVHD \nValvular heart disease \nVKA \nVitamin K antagonist \nVmax \nPeak transvalvular velocity \nVSARR \nValve-sparing aortic root replacement \nVTE \nVenous thromboembolism \nVTI \nVelocity time integral \nWHO \nWorld Health Organisation \nWU \nWood unit \nY \nYes \n1. Preamble \nGuidelines evaluate and summarize available evidence with the aim of \nassisting health professionals in proposing the best diagnostic or thera-\npeutic approach for an individual patient with a given condition. ESC/ \nEACTS Guidelines are intended for use by health professionals but \ndo not override their individual responsibility to make appropriate \nand accurate decisions in consideration of each patient’s health condi-\ntion and in consultation with the patient or the patient’s caregiver \nwhere appropriate and/or necessary. It is also the health professional’s \nresponsibility to verify the rules and regulations applicable in each coun-\ntry to drugs and devices at the time of prescription and to respect the \nethical rules of their profession. \nESC Guidelines represent the official position of the ESC on a given \ntopic. Guideline topics are selected for updating after annual expert re-\nview of new evidence conducted by the ESC Clinical Practice \nGuidelines (CPG) Committee. ESC Policies and Procedures for formu-\nlating and issuing ESC Guidelines can be found on the ESC website \n(https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/ \nGuidelines-development/Writing-ESC-Guidelines). \nThis guideline updates and replaces the previous version from 2021. This \nTask Force was selected by the ESC and the EACTS to include professionals  \n4640                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\ninvolved with the medical care of patients with this pathology and to include \npatient representatives and methodologists. The selection procedure in-\ncluded an open call for authors and aimed to include members from across \nthe whole of the ESC region and from relevant ESC Subspecialty \nCommunities. Consideration was given to diversity and inclusion. \nGuidelines Task Forces perform a critical review and evaluation of the \npublished literature on diagnostic and therapeutic approaches including \nassessment of the risk–benefit ratio. Recommendations are based on \nmajor randomized trials and relevant systematic reviews and \nmeta-analyses, when available. Systematic literature searches are con-\nducted in cases of controversy or uncertainty to ensure that all key \nstudies were considered. For recommendations related to diagnosis \nand prognosis, additional types of evidence are included, such as diagnos-\ntic accuracy studies and studies focused on the development and valid-\nation of prognostic models. The strength of each recommendation and \nthe level of evidence supporting it are weighed and scored according \nto pre-defined criteria as outlined in Tables 1 and 2. Patient-Reported \nOutcome Measures (PROMs) and Patient-Reported Experience \nMeasures (PREMs) are also evaluated when available as the basis for re-\ncommendations and/or discussion in these guidelines. \nEvidence tables summarizing key information from relevant studies \nare generated to facilitate the formulation of recommendations, to \nTable 1 Classes of recommendations  \n©\u001f\u001e\u001d\u001c\u001f\u001b\u001d\u001a\u001e\u0019\u0018\u0017\u0018\u0016\n\u001d\u0015\u0014\u0013\u0013\u0012\u0013\u0019\u0011\u0010\u0019\u000f\u0012\u000e\u0011\r\r\u0012\f\u000b\u0014\n\t\u0011\f\u0013\n\u001d\u0015\u0014\u0013\u0013\u0019\b\u0019\n\u001f\u0007\t\u000b\u0012\f\u000e\u0012\u0019\u0014\f\u000b\u001c\u0011\u000f\u0019\u0006\u0012\f\u0012\u000f\u0014\u0015\u0019\u0014\u0006\u000f\u0012\u0012\r\u0012\f\n\n\u0005\u0014\n\u0019\u0014\u0019\u0006\t\u0007\u0012\f\u0019\n\u000f\u0012\u0014\n\r\u0012\f\n\u0019\u0011\u000f\u0019\u0004\u000f\u0011\u000e\u0012\u000b\u0003\u000f\u0012\u0019\t\u0013\n\u0002\u0012\f\u0012\u0001\u000e\t\u0014\u0015\u0019\u0003\u0013\u0012\u0010\u0003\u0015\u0019\u0012\u0012\u000e\n\t\u0007\u0012\u0019\n\u001d\u0011\f\t\u000e\n\t\f\u0006\u0019\u0012\u0007\t\u000b\u0012\f\u000e\u0012\u0019\u0014\f\u000b\u001c\u0011\u000f\u0019\u0014\u0019\u000b\t\u0007\u0012\u000f\u0006\u0012\f\u000e\u0012\u0019\u0011\u0010\u0019\u0011\u0004\t\f\t\u0011\f\u0019\u0014\u0002\u0011\u0003\n\u0019\n\u0005\u0012\u0019\u0003\u0013\u0012\u0010\u0003\u0015\f\u0012\u0013\u0013\u001c\u0019\n\u0012\u000e\u0014\u000e\u0019\u0011\u0010\u0019\n\u0005\u0012\u0019\u0006\t\u0007\u0012\f\u0019\n\u000f\u0012\u0014\n\r\u0012\f\n\u0019\u0011\u000f\u0019\u0004\u000f\u0011\u000e\u0012\u000b\u0003\u000f\u0012\u0019\n\b\u0013\u0019\u000f\u0012\u000e\u0011\r\r\u0012\f\u000b\u0012\u000b\u0019\u0011\u000f\u0019\t\u0013\u0019\t\f\u000b\t\u000e\u0014\n\u0012\u000b\n \u0011\u000f\u000b\t\f\u0006\u0019\n\u0011\u0019\u0003\u0013\u0012\n­\u0012\u0001\f\t\n\t\u0011\f\n\u001d\u0015\u0014\u0013\u0013\u0019\b\b\b\u0019\n\u001f\u0007\t\u000b\u0012\f\u000e\u0012\u0019\u0011\u000f\u0019\u0006\u0012\f\u0012\u000f\u0014\u0015\u0019\u0014\u0006\u000f\u0012\u0012\r\u0012\f\n\u0019\n\u0005\u0014\n\u0019\n\u0005\u0012\n\u0006\t\u0007\u0012\f\u0019\n\u000f\u0012\u0014\n\r\u0012\f\n\u0019\u0011\u000f\u0019\u0004\u000f\u0011\u000e\u0012\u000b\u0003\u000f\u0012\u0019\t\u0013\u0019\f\u0011\n\u0003\u0013\u0012\u0010\u0003\u0015\u001c\u0012\u0012\u000e\n\t\u0007\u0012\u0019\u0014\f\u000b\u0019\t\f\u0019\u0013\u0011\r\u0012\u0019\u000e\u0014\u0013\u0012\u0013\n\r\u0014\u0019\u0002\u0012\u0019\u0005\u0014\u000f\r\u0010\u0003\u0015\u0019\n\b\u0013\u0019\f\u0011\n\u0019\u000f\u0012\u000e\u0011\r\r\u0012\f\u000b\u0012\u000b\n\u0019\u0019 \u0019\u0019\u0019\u001d\u0015\u0014\u0013\u0013\u0019\b\b\u0002\n\u0013\u0012\u0010\u0003\u0015\f\u0012\u0013\u0013\u001c\u0012\u000e\u0014\u000e\u0019\t\u0013\u0019\u0015\u0012\u0013\u0013\u0019\u0012\u0015\u0015\n\u0012\u0013\n\u0014\u0002\u0015\t\u0013\u0005\u0012\u000b\u0019\u0002\u0019\u0012\u0007\t\u000b\u0012\f\u000e\u0012\u001c\u0011\u0004\t\f\t\u0011\f\n\u0014\u0019\u0002\u0012\u0019\u000e\u0011\f\u0013\t\u000b\u0012\u000f\u0012\u000b\n\u0019\n\u0019\u0019\u0019\u001d\u0015\u0014\u0013\u0013\u0019\b\b\u0014\n \u0012\t\u0006\u0005\n\u0019\u0011\u0010\u0019\u0012\u0007\t\u000b\u0012\f\u000e\u0012\u001c\u0011\u0004\t\f\t\u0011\f\u0019\t\u0013\u0019\t\f\n\u0010\u0014\u0007\u0011\u0003\u000f\u0019\u0011\u0010\u0019\u0003\u0013\u0012\u0010\u0003\u0015\f\u0012\u0013\u0013\u001c\u0012\u000e\u0014\u000e\u0019\n\u001e\u0005\u0011\u0003\u0015\u000b\u0019\u0002\u0012\u0019\u000e\u0011\f\u0013\t\u000b\u0012\u000f\u0012\u000b\n\u001d\u0015\u0014\u0013\u0013\u0019\b\b\u0019\nTable 2 Levels of evidence  \n\u001f\u001e\u001d\u001e\u001c\u001b\u001a\u0019\n\u001e\u001d\u0018\u0017\u001e\u0016\u0015\u001e\u001b\u0014\n\u001f\u001e\u001d\u001e\u001c\u001b\u001a\u0019\n\u001e\u001d\u0018\u0017\u001e\u0016\u0015\u001e\u001b\u0013\n\u001f\u001e\u001d\u001e\u001c\u001b\u001a\u0019\n\u001e\u001d\u0018\u0017\u001e\u0016\u0015\u001e\u001b\u0012\n\u0011\u0010\u000f\u0010\u001b\u0017\u001e\u000e\u0018\u001d\u001e\u0017\u001b\u0019\u000e\u001a\r\u001b\r\f\u001c\u000f\u0018\u000b\u001c\u001e\u001b\u000e\u0010\u0016\u0017\u001a\r\u0018\n\u001e\u0017\u001b\u0015\u001c\u0018\u0016\u0018\u0015\u0010\u001c\u001b\u000f\u000e\u0018\u0010\u001c\t\n\u001a\u000e\u001b\r\u001e\u000f\u0010\b\u0010\u0016\u0010\u001c\u0007\t\u001e\t\u0006\n\u0011\u0010\u000f\u0010\u001b\u0017\u001e\u000e\u0018\u001d\u001e\u0017\u001b\u0019\u000e\u001a\r\u001b\u0010\u001b\t\u0018\u0016\u0005\u001c\u001e\u001b\u000e\u0010\u0016\u0017\u001a\r\u0018\n\u001e\u0017\u001b\u0015\u001c\u0018\u0016\u0018\u0015\u0010\u001c\u001b\u000f\u000e\u0018\u0010\u001c\n\u001a\u000e\u001b\u001c\u0010\u000e\u0005\u001e\u001b\u0016\u001a\u0016\b\u000e\u0010\u0016\u0017\u001a\r\u0018\n\u001e\u0017\u001b\t\u000f\f\u0017\u0018\u001e\t\u0006\n\u0012\u001a\u0016\t\u001e\u0016\t\f\t\u001b\u001a\u0019\u001b\u001a\u000b\u0018\u0016\u0018\u001a\u0016\u001b\u001a\u0019\u001b\u000f\u0004\u001e\u001b\u001e\u0003\u000b\u001e\u000e\u000f\t\u001b\u0010\u0016\u0017\u0002\u001a\u000e\u001b\t\r\u0010\u001c\u001c\u001b\t\u000f\f\u0017\u0018\u001e\t\u0001\n\u000e\u001e\u000f\u000e\u001a\t\u000b\u001e\u0015\u000f\u0018\u001d\u001e\u001b\t\u000f\f\u0017\u0018\u001e\t\u0001\u001b\u000e\u001e\u0005\u0018\t\u000f\u000e\u0018\u001e\t\u0006\n©\u0012\u0002\u0014\u0012\u001b\nESC Guidelines                                                                                                                                                                                          4641 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nenhance comprehension of recommendations after publication, and to \nreinforce transparency in the guidelines development process. The ta-\nbles are published in their own section of the guidelines and reference \nspecific recommendation tables. \nAfter an iterative process of deliberations, a first Task Force vote on \nall recommendations is conducted prior to the initiation of rounds of \nreview. A second Task Force vote on all recommendations is con-\nducted after the final round of review and revision. For each vote, \nthe Task Force follows ESC voting procedures and all recommenda-\ntions require at least 75% agreement among voting members to be ap-\nproved. Voting restrictions may be applied based on declarations of \ninterests. \nThe writing and reviewing panels provide declaration-of-interest \nforms for all relationships that might be perceived as real or potential \nsources of conflicts of interest. Their declarations of interest are re-\nviewed according to the ESC declaration-of-interest rules, which can \nbe found on the ESC website (http://www.escardio.org/doi) and are \ncompiled in a report published in a supplementary document with \nthe guidelines. Funding for the development of these ESC/EACTS \nGuidelines was derived entirely from the ESC and the EACTS with \nno involvement of the healthcare industry. \nThe ESC CPG Committee supervises and co-ordinates the prepar-\nation of new guidelines and approves their publication. In addition to \nreview by the ESC CPG Committee, these ESC/EACTS Guidelines \nunderwent multiple rounds of double-blind peer review on a dedicated \nonline review platform. The review was conducted by topic experts, in-\ncluding members from ESC National Cardiac Societies, EACTS \nNetwork of National Cardiac Surgery Societies and from relevant \nESC Subspecialty Communities. The Guideline Task Force considered \nall review comments and was required to respond to all those classified \nas major. After appropriate revisions, the Task Force, the ESC CPG \nCommittee members and the EACTS Council members approved \nthe final document for publication in the European Heart Journal and \nin the European Journal of Cardio-Thoracic Surgery. \nUnless otherwise stated, the guideline content refers to sex, under-\nstood as the biological condition of being male or female, defined by \ngenes, hormones, and sexual organs. Off-label use of medication may \nbe presented in this guideline if a sufficient level of evidence shows \nthat it can be considered medically appropriate for a given condition. \nHowever, decisions on off-label use must be made by the responsible \nhealth professional giving special consideration to ethical rules concern-\ning healthcare, the specific situation of the patient, patient consent, and \ncountry-specific health regulations. \n2. Introduction \nNew evidence has accumulated since the publication of the 2021 \nEuropean Society of Cardiology (ESC)/European Association for \nCardio-Thoracic Surgery (EACTS) Guidelines for the management of valvular \nheart disease, leading to the need for new recommendations (Table 3 \nNew recommendations) and revision of existing recommendations \n(Table 4 Revised recommendations) concerning the following topics: \n• The importance of shared and patient-centred decision-making by \nmultidisciplinary expert Heart Teams working within a regional net-\nwork has been reinforced. Patients with complex conditions or re-\nquiring complex procedures should be referred to high-volume \ncentres, where corresponding expertise is concentrated to ensure \nhigh-quality treatment. \n• Advanced imaging modalities—such as three-dimensional (3D) echo-\ncardiography, cardiac computed tomography (CCT), and cardiac \nmagnetic resonance (CMR) imaging—have gained importance and \nbecome a central aspect in the screening and evaluation of patients \nwith valvular heart disease (VHD). \n• Emphasis is put on the importance of correctly assessing the cause(s) \nand mechanism(s) of all valve diseases. In particular, the distinction \nbetween atrial and ventricular secondary mitral regurgitation (SMR) \nhas clear implications in terms of prognosis and management. \n• New evidence has been published regarding the benefits of \nintervention for the treatment of severe aortic stenosis (AS) irre-\nspective of symptoms, left ventricular ejection fraction (LVEF), and \nflow reserve. \n• The criteria used for decision-making concerning the optimal modal-\nity of AS treatment [transcatheter aortic valve (AV) implantation \n(TAVI) or surgical AV replacement (SAVR)] based on a Heart Team \napproach have been refined, including the combination of key aspects \nsuch as age, procedural risk, and anatomical suitability, incorporating \nestimated life expectancy and lifetime management considerations. \n• Further randomized evidence confirming the mid-term safety and ef-\nficacy of TAVI in low-risk patients has been published. \n• The indications for TAVI in patients with bicuspid AV (BAV) stenosis \nor severe aortic regurgitation (AR) at high surgical risk, based on ana-\ntomical suitability and a comprehensive Heart Team evaluation, are \ndiscussed. \n• Several advancements have been made regarding the treatment of \npatients with primary mitral regurgitation (PMR): refinement of the \ncriteria for intervention in asymptomatic patients; demonstration \nof the value of minimally invasive mitral valve (MV) surgery to reduce \nthe length of hospital stay and accelerate recovery; and large-scale \ndata confirming the role of transcatheter edge-to-edge repair \n(TEER) in high-risk patients. \n• Longer-term follow-up data and two new randomized controlled \ntrials (RCTs) concerning the management of patients with ventricular \nSMR have been published. \n• The evidence for the treatment of tricuspid valve (TV) disease is \ngrowing—including new randomized data supporting concomitant \nTV repair during left-sided valve surgery, and transcatheter options \n(repair and replacement) that reduce tricuspid regurgitation (TR), \npromote reverse right ventricular (RV) remodelling, and improve \nquality of life compared with medical treatment. \n• Efforts have been made to provide improved guidance regarding the \ndiagnostic steps and management of patients with multiple and mixed \nVHD. \n• Definitions of structural valve deterioration (SVD) have been up-\ndated and unified. \n• The recommendations concerning the use of direct oral anticoagu-\nlants (DOACs) in patients with VHD have been updated, and the im-\nportance of education and (self-)monitoring is emphasized. \n• Sex-specific considerations in patients with VHD have been ex-\ntended and regrouped into a new dedicated section (see Section 17).   \nBecause of demographic changes, patients with VHD frequently \npresent with concomitant cardiovascular diseases, increasing the com-\nplexity of treatment strategies. These Guidelines focus on acquired  \n4642                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nVHD and do not deal in detail with overlapping cardiovascular diseases \nsuch as infective endocarditis,5 chronic coronary syndrome,6 and atrial \nfibrillation (AF),7 as well as all scenarios of aortic or congenital dis-\nease,8,9 because these topics are covered in separate Guidelines. \nThe 2025 ESC/EACTS Guidelines for the management of valvular heart \ndisease aim to be concise, focused on relevant issues for clinicians and \npatients, and to provide clear and simple practical recommendations, \nassisting healthcare providers in their daily clinical decision-making. A \ncompilation of the evidence considered for new recommendations, or \nthose with an updated class of recommendation or level of evidence, \ncan be consulted online (see Supplementary data online, Evidence \nTables). The Task Force for these Guidelines acknowledges that \nmultiple factors influence and ultimately determine the most appro-\npriate treatment of individual patients within a given community. \nThese factors include the availability of equipment and technology, \nand the expertise and volumes, in complex procedures, such as valve \nrepair or transcatheter interventions. Moreover, given the lack of evi-\ndence on some topics related to VHD, several recommendations are \nthe result of expert consensus opinion. Therefore, deviations from \nthese Guidelines may be appropriate in certain clinical circumstances, \nand decision-making should always be based on a collaborative, multi-\ndisciplinary Heart Team approach centred on individual characteris-\ntics, needs, and prognosis, as well as the preferences of the informed \npatient. \n2.1. What is new  \nTable 3 New recommendations \nRecommendations \nClassa \nLevelb  \nDiagnosis of coronary artery disease—Section 6.1 \nOmission of invasive coronary angiography should be considered in TAVI candidates, if procedural planning CT angiography is of sufficient \nquality to rule out significant CAD. \nIIa \nB \nPCI should be considered in patients with a primary indication to undergo TAVI and ≥90% coronary artery stenosis in segments with a \nreference diameter ≥2.5 mm. \nIIa \nB \nIndications for intervention in severe aortic regurgitation—Section 7.4 \nTAVI may be considered for the treatment of severe AR in symptomatic patients ineligible for surgery according to the Heart Team, if the \nanatomy is suitable. \nIIb \nB \nIndications for intervention in symptomatic and asymptomatic severe aortic stenosis, and recommended mode of intervention—Section 8.5 \nIntervention should be considered in asymptomatic patients (confirmed by a normal exercise test, if feasible) with severe, high-gradient AS \nand LVEF ≥50%, as an alternative to close active surveillance, if the procedural risk is low. \nIIa \nA \nTAVI may be considered for the treatment of severe BAV stenosis in patients at increased surgical risk, if the anatomy is suitable. \nIIb \nB \nIndications for intervention in severe primary mitral regurgitation—Section 9.1 \nSurgical MV repair is recommended in low-risk asymptomatic patients with severe PMR without LV dysfunction (LVESD <40 mm, LVESDi  \n<20 mm/m2, and LVEF >60%) when a durable result is likely, if at least three of the following criteria are fulfilled: \n• AF \n• SPAP at rest >50 mmHg \n• LA dilatation (LAVI ≥60 mL/m2 or LA diameter ≥55 mm) \n• Concomitant secondary TR ≥ moderate. \nI \nB \nMinimally invasive MV surgery may be considered at experienced centres to reduce the length of stay and accelerate recovery. \nIIb \nB \nIndications for intervention in secondary mitral regurgitation—Section 9.2 \nMV surgery, surgical AF ablation, if indicated, and LAAO should be considered in symptomatic patients with severe atrial SMR under optimal \nmedical therapy. \nIIa \nB \nTEER may be considered in symptomatic patients with severe atrial SMR not eligible for surgery after optimization of medical therapy \nincluding rhythm control, when appropriate. \nIIb \nB \nMV surgery may be considered in patients with moderate SMR undergoing CABG. \nIIb \nB \nIndications for mitral valve surgery and transcatheter intervention in clinically severe rheumatic and degenerative mitral stenosis— \nSection 10.3 \nTMVI may be considered in symptomatic patients with extensive MAC and severe MV dysfunction at experienced Heart Valve Centres with \nexpertise in complex MV surgery and transcatheter interventions. \nIIb \nC                       \nContinued  \nESC Guidelines                                                                                                                                                                                          4643 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "keywords": [
        "aortic stenosis",
        "anticoagulant",
        "angiography",
        "mri",
        "blood pressure",
        "heart failure",
        "echo",
        "recommended",
        "pulmonary hypertension",
        "indication",
        "ecg",
        "hfref",
        "hfpef",
        "female",
        "disease",
        "glucose",
        "valve repair",
        "eacts",
        "anticoagulation",
        "hypertension",
        "lvef",
        "bnp",
        "crt",
        "echocardiography",
        "guidelines",
        "should be considered",
        "management",
        "prosthetic valve",
        "heart",
        "mitral stenosis"
      ],
      "tables": [
        {
          "title": "\u0011\u000f\u000b\t\f\u0006\u0019\n\u0011\u0019\u0003\u0013\u0012 ­\u0012\u0001\f\t\n\t\u0011",
          "page_number": 6,
          "content": "\u0015\u0014\u0013\u0013\u0019\b\u0019 | \u0007 \u0012 \u000e\u0012\u0019\u0014 \u0011\u000f\u0019\u0006\u0012 \u0012\u000f\u0014\u0015\u0019\u0014\u0006\u000f\u0012\u0012 \u0012\n\u0005\u0014 \u0019\u0014\u0019\u0006 \u0007\u0012 \u0019 \u000f\u0012\u0014 \u0012 \u0019\u0011\u000f\u0019\u0004\u000f\u0011\u000e\u0012 \u0003\u000f\u0012\u0019 \u0013\n\u0002\u0012 \u0012\u0001\u000e \u0014\u0015\u0019\u0003\u0013\u0012\u0010\u0003\u0015\u0019\u0012\u0012\u000e \u0007\u0012\u0019 | \b\u0013\u0019\u000f\u0012\u000e\u0011 \u0012 \u0012 \u0019\u0011\u000f\u0019 \u0013\u0019 \u000e\u0014 \u0012",
          "bbox": [
            89.5363998413086,
            106.41897583007812,
            531.5152638753256,
            154.26597595214844
          ],
          "function_potential": "raw"
        },
        {
          "title": "\u0011\u000f\u000b\t\f\u0006\u0019\n\u0011\u0019\u0003\u0013\u0012 ­\u0012\u0001\f\t\n\t\u0011",
          "page_number": 6,
          "content": "\u0015\u0014\u0013\u0013\u0019\b\b\u0019 | \u0011  \u000e \u0006\u0019\u0012\u0007 \u0012 \u000e\u0012\u0019\u0014 \u0011\u000f\u0019\u0014\u0019 \u0007\u0012\u000f\u0006\u0012 \u000e\u0012\u0019\u0011\u0010\u0019\u0011\u0004 \u0011 \u0019\u0014\u0002\u0011\u0003 \u0019 \u0005\u0012\u0019\u0003\u0013\u0012\u0010\u0003\u0015 \u0012\u0013\u0013 \u0019\n\u0012\u000e\u0014\u000e\u0019\u0011\u0010\u0019 \u0005\u0012\u0019\u0006 \u0007\u0012 \u0019 \u000f\u0012\u0014 \u0012 \u0019\u0011\u000f\u0019\u0004\u000f\u0011\u000e\u0012 \u0003\u000f\u0012\u0019 |  |  | \n |  |  |  | \n\u0019\u0019\u0019 \u0015\u0014\u0013\u0013\u0019\b\b\u0014 |  | \u0012 \u0006\u0005 \u0019\u0011\u0010\u0019\u0012\u0007 \u0012 \u000e\u0012 \u0011\u0004 \u0011 \u0019 \u0013\u0019\n\u0010\u0014\u0007\u0011\u0003\u000f\u0019\u0011\u0010\u0019\u0003\u0013\u0012\u0010\u0003\u0015 \u0012\u0013\u0013 \u0012\u000e\u0014\u000e\u0019 | \u0005\u0011\u0003\u0015 \u0019\u0002\u0012\u0019\u000e\u0011 \u0013 \u0012\u000f\u0012 | \n |  |  |  | \n\u0019\u0019 \u0019\u0019\u0019 \u0015\u0014\u0013\u0013\u0019\b\b\u0002 |  | \u0013\u0012\u0010\u0003\u0015 \u0012\u0013\u0013 \u0012\u000e\u0014\u000e\u0019 \u0013\u0019\u0015\u0012\u0013\u0013\u0019\u0012\u0015\u0015\n\u0012\u0013 \u0014\u0002\u0015 \u0013\u0005\u0012 \u0019\u0002\u0019\u0012\u0007 \u0012 \u000e\u0012 \u0011\u0004 \u0011  | \u0014\u0019\u0002\u0012\u0019\u000e\u0011 \u0013 \u0012\u000f\u0012 | ",
          "bbox": [
            89.5363998413086,
            160.55972290039062,
            531.5152638753256,
            277.8817952473958
          ],
          "function_potential": "raw"
        },
        {
          "title": "\u0015\u0014\u0013\u0013\u0019\b\b\u0019",
          "page_number": 6,
          "content": "\u0015\u0014\u0013\u0013\u0019\b\b\b\u0019 | \u0007 \u0012 \u000e\u0012\u0019\u0011\u000f\u0019\u0006\u0012 \u0012\u000f\u0014\u0015\u0019\u0014\u0006\u000f\u0012\u0012 \u0012 \u0019 \u0005\u0014 \u0019 \u0005\u0012\n\u0006 \u0007\u0012 \u0019 \u000f\u0012\u0014 \u0012 \u0019\u0011\u000f\u0019\u0004\u000f\u0011\u000e\u0012 \u0003\u000f\u0012\u0019 \u0013\u0019 \u0011\n\u0003\u0013\u0012\u0010\u0003\u0015 \u0012\u0012\u000e \u0007\u0012\u0019\u0014 \u0019 \u0019\u0013\u0011 \u0012\u0019\u000e\u0014\u0013\u0012\u0013\n\u0014\u0019\u0002\u0012\u0019\u0005\u0014\u000f \u0010\u0003\u0015\u0019 | \b\u0013\u0019 \u0011 \u0019\u000f\u0012\u000e\u0011 \u0012 \u0012",
          "bbox": [
            89.5363998413086,
            285.99395751953125,
            531.5152638753256,
            348.0315795898438
          ],
          "function_potential": "raw"
        },
        {
          "title": "Table 3  New recommendations",
          "page_number": 8,
          "content": "Recommendations |  | Classa | Levelb | \n | Diagnosis of coronary artery disease—Section 6.1 |  |  | \nOmission of invasive coronary angiography should be considered in TAVI candidates, if procedural planning CT angiography is of suffci ient\nquality to rule out significant CAD. |  | IIa | B | \nPCI should be considered in patients with a primary indication to undergo TAVI and ≥90% coronary artery stenosis in segments with a\nreference diameter ≥2.5 mm. |  | IIa | B | \n | Indications for intervention in severe aortic regurgitation—Section 7.4 |  |  | \nTAVI may be considered for the treatment of severe AR in symptomatic patients ineligible for surgery according to the Heart Team, if the\nanatomy is suitable. |  | IIb | B | \n | Indications for intervention in symptomatic and asymptomatic severe aortic stenosis, and recommended mode of intervention—Section 8.5 |  |  | \nIntervention should be considered in asymptomatic patients (confirmed by a normal exercise test, if feasible) with severe, high-gradient AS\nand LVEF ≥50%, as an alternative to close active surveillance, if the procedural risk is low. |  | IIa | A | \nTAVI may be considered for the treatment of severe BAV stenosis in patients at increased surgical risk, if the anatomy is suitable. |  | IIb | B | \n | Indications for intervention in severe primary mitral regurgitation—Section 9.1 |  |  | \nSurgical MV repair is recommended in low-risk asymptomatic patients with severe PMR without LV dysfunction (LVESD <40 mm, LVESDi\n<20 mm/m2, and LVEF >60%) when a durable result is likely, if at least three of the following criteria are fulfliled:\n• AF\n• SPAP at rest >50 mmHg\n• LA dilatation (LAVI ≥60 mL/m2 or LA diameter ≥55 mm)\n• Concomitant secondary TR ≥ moderate. |  | I | B | \nMinimally invasive MV surgery may be considered at experienced centres to reduce the length of stay and accelerate recovery. |  | IIb | B | \n | Indications for intervention in secondary mitral regurgitation—Section 9.2 |  |  | \nMV surgery, surgical AF ablation, if indicated, and LAAO should be considered in symptomatic patients with severe atrial SMR under optimal\nmedical therapy. |  | IIa | B | \nTEER may be considered in symptomatic patients with severe atrial SMR not eligible for surgery after optimization of medical therapy\nincluding rhythm control, when appropriate. |  | IIb | B | \nMV surgery may be considered in patients with moderate SMR undergoing CABG. |  | IIb | B | \n | Indications for mitral valve surgery and transcatheter intervention in clinically severe rheumatic and degenerative mitral stenosis—\nSection 10.3 |  |  | \nTMVI may be considered in symptomatic patients with extensive MAC and severe MV dysfunction at experienced Heart Valve Centres with\nexpertise in complex MV surgery and transcatheter interventions. |  | IIb | C | ",
          "bbox": [
            42.51969909667969,
            278.833984375,
            558.4249877929688,
            696.4320678710938
          ],
          "function_potential": "raw"
        },
        {
          "title": "Table on page 10",
          "page_number": 9,
          "content": " | Indications for intervention in tricuspid regurgitation—Section 11.4 |  |  | \nCareful evaluation of TR aetiology, stage of the disease (i.e. degree of TR severity, RV and LV dysfunction, and PH), patient operative risk,\nand likelihood of recovery by a multidisciplinary Heart Team is recommended in patients with severe TR prior to intervention. |  | I | C | \n | Surgery of concomitant severe mitral regurgitation—Section 13.3 |  |  | \nMV surgery is recommended in patients with severe MR undergoing surgery for another valve. |  | I | C | \n | Indications for intervention in patients with mixed moderate aortic stenosis and moderate aortic regurgitation—Section 13.3 |  |  | \nIntervention is recommended in symptomatic patients with mixed moderate AV stenosis and moderate regurgitation, and a mean\ngradient ≥40 mmHg or V ≥4.0 m/s.\nmax |  | I | B | \nIntervention is recommended in asymptomatic patients with mixed moderate AV stenosis and moderate regurgitation, with V ≥4.0 m/s\nmax\nand LVEF <50% not attributable to other cardiac disease. |  | I | C | \n | Prosthetic valve selection—Section 14.1 |  |  | \nAn MHV should be considered in patients with an estimated long life expectancy, if there are no contraindications for long-term OAC. |  | IIa | B | \n | Management of antithrombotic therapy in patients with a mechanical heart valve—Section 14.3 |  |  | \nIt is recommended that INR targets are based on the type and position of MHV, patient’s risk factors, and comorbidities. |  | I | A | \nPatient education is recommended to improve the quality of OAC. |  | I | A | \n | Management of antithrombotic therapy in patients with mechanical heart valves undergoing elective non-cardiac surgery or invasive\nprocedures—Section 14.3 |  |  | \nContinuing VKA treatment is recommended in patients with an MHV for minor or minimally invasive interventions associated with no or\nminimal bleeding. |  | I | A | \nInterruption (3–4 days before surgery), and resumption of VKA without bridging, may be considered to reduce bleeding in patients with\nnew-generation aortic MHV and no other thromboembolic risk factors undergoing major non-cardiac surgery or invasive procedures. |  | IIb | B | \nManagement of antithrombotic therapy in patients with a biological heart valve or valve repair—Section 14.3 |  |  |  | \nSurgical biological heart valve without indication for oral anticoagulation |  |  |  | \nLifelong low-dose ASA (75–100 mg/day) may be considered 3 months after surgical implantation of an aortic or mitral BHV in patients\nwithout clear indication for OAC. |  | IIb | C | \n | Transcatheter aortic valve implantation without indication for oral anticoagulation |  |  | \nDAPT is not recommended to prevent thrombosis after TAVI, unless there is a clear indication. |  | III | B | \n | Surgical repair without indication for oral anticoagulation |  |  | \nLow-dose ASA (75–100 mg/day) may be considered after surgical MV or TV repair in preference to OAC in patients without clear\nindication for OAC and at high bleeding risk. |  | IIb | B | \n | Surgical biological heart valve with indication for oral anticoagulation |  |  | \nOAC continuation is recommended in patients with a clear indication for OAC undergoing surgical BHV implantation. |  | I | B | \nDOAC continuation may be considered after surgical BHV implantation in patients with an indication for DOAC. |  | IIb | B | \n | Surgical repair with indication for oral anticoagulation and/or antiplatelet therapy |  |  | \nContinuation of OAC or antiplatelet therapy should be considered after surgical valve repair in patients with a clear indication for an\nantithrombotic therapy. |  | IIa | B | \n | Management of mechanical heart valve failure—Section 14.4 |  |  | \nReoperation is recommended in symptomatic patients with significant valve dysfunction not attributable to valve thrombosis. |  | I | C | \n | Management of valve thrombosis—Section 14.4 |  |  | \nTOE and/or 4D-CT are recommended in patients with suspected valve thrombosis to confirm the diagnosis. |  | I | C | ",
          "bbox": [
            36.850399017333984,
            60.2,
            552.7559814453125,
            610.9970092773438
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "2",
      "title": "3. The Heart Team and Heart Valve Centre",
      "start_page": 14,
      "end_page": 15,
      "content": "3. The Heart Team and Heart Valve \nCentre \n3.1. The Heart Valve Network \nDespite increasing attention within the medical community, VHD con-\ntinues to be underdiagnosed and undertreated in the general popula-\ntion, and public awareness remains low.10–13 Beside screening using \nauscultation and imaging when appropriate, the co-ordinated imple-\nmentation of Heart Teams, Heart Valve Centres, and Heart Valve \nNetworks at a local level represents an essential step to timely diagnose \nand treat patients with VHD. \nAn integrated regional Heart Valve Network, incorporating out-\npatient Heart Valve Clinics (for initial diagnosis and ongoing surveil-\nlance) and specialist Heart Valve Centres (for advanced imaging and \nsurgical or transcatheter intervention), allows optimal patient care \nthrough timely access to specialist assessment, accurate diagnosis, im-\nproved decision-making, and matching of patients to healthcare provi-\nders with appropriate expertise, experience, and resources (Figure 1).12 \nIn addition, dedicated Heart Valve Clinics ensure consistent application \nof clinical guidelines, efficient use of resources, and overall high-quality \npatient care, which in turn may improve outcomes.14,15 Medical goals \ninclude careful clinical and echocardiographic evaluation, monitoring \nat appropriate time intervals (so-called ‘watchful waiting’), application \nTranscatheter closure should be considered for suitable \nPVLs with clinically significant regurgitation and/or \nhaemolysis in patients at high or prohibitive surgical risk. \nIIa \nB \nTranscatheter closure should be considered for suitable \nPVLs with clinically significant regurgitation and/or \nhaemolysis. \nIIa \nB \nManagement of biological heart valve failure—Section 14.4 \nReoperation is recommended in symptomatic patients \nwith a significant increase in transprosthetic gradient \n(after exclusion of valve thrombosis) or severe \nregurgitation. \nI \nC \nReintervention is recommended in symptomatic \npatients with significant valve dysfunction not \nattributable to valve thrombosis. \nI \nC \nTranscatheter, transfemoral valve-in-valve implantation \nin the aortic position should be considered by the Heart \nTeam depending on anatomical considerations, features \nof the prosthesis, and in patients who are at high \noperative risk or inoperable. \nIIa \nB \nTranscatheter transfemoral valve-in-valve implantation \nin the aortic position should be considered in patients \nwith significant valve dysfunction who are at \nintermediate or high surgical risk, and have suitable \nanatomical and prosthesis features, as assessed by the \nHeart Team. \nIIa \nB \nTranscatheter valve-in-valve implantation in the mitral \nand tricuspid position may be considered in selected \npatients at high risk for surgical reintervention. \nIIb \nB \nTranscatheter transvenous mitral or tricuspid \nvalve-in-valve implantation should be considered in \npatients with significant valve dysfunction at intermediate \nor high surgical risk, if the anatomy is suitable. \nIIa \nB \nManagement of mechanical heart valve thrombosis—Section 14.4 \nUrgent or emergency valve replacement is \nrecommended for obstructive thrombosis in critically ill \npatients without serious comorbidity. \nI \nB \nHeart Team evaluation is recommended in patients \nwith acute HF (NYHA class III or IV) due to obstructive \nMHV thrombosis to determine appropriate \nmanagement (repeat valve replacement or low-dose \nslow infusion fibrinolysis). \nI \nB \nFibrinolysis (using recombinant tissue plasminogen \nactivator 10 mg bolus + 90 mg in 90 min with UFH or \nstreptokinase 1 500 000 U in 60 min without UFH) \nshould be considered when surgery is not available or is \nvery high risk, or for thrombosis of right-sided \nprostheses. \nIIa \nB \nManagement of biological heart valve thrombosis—Section 14.4 \nAnticoagulation using a VKA and/or UFH is \nrecommended in BHV thrombosis before considering \nreintervention. \nI \nC \nOAC using VKA is recommended in BHV thrombosis \nbefore considering reintervention. \nI \nB \n© ESC/EACTS 2025\n2D, two-dimensional; AF, atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; ASA, acetylsalicylic acid; AV, aortic valve; BHV, biological heart valve; BNP, brain natriuretic peptide; \nBSA, body surface area; CAD, coronary artery disease; CCT, cardiac computed tomography; CCTA, coronary computed tomography angiography; CHA2DS2-VASc, congestive heart failure \nor left ventricular dysfunction, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vascular disease, age 65–74, sex category (female); CRT, cardiac resynchronization therapy; \nDAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulant; EuroSCORE, European System for Cardiac Operative Risk Evaluation; GDMT, guideline-directed medical therapy; h, \nhour; HF, heart failure; HTx, heart transplantation; INR, international normalized ratio; LA, left atrium/left atrial; LAAO, left atrial appendage occlusion; LAVI, left atrial volume index; \nLMWH, low-molecular-weight heparin; LV, left ventricle/left ventricular; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic \ndiameter; LVESDi, left ventricular end-systolic diameter indexed to BSA; LVESVi, left ventricular end-systolic volume indexed to BSA; MHV, mechanical heart valve; min, minute; MR, \nmitral regurgitation; MS, mitral stenosis; MV, mitral valve; MVA, mitral valve area; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; OAC, \noral anticoagulation; PCI, percutaneous coronary intervention; PH, pulmonary hypertension; PMR, primary mitral regurgitation; PVL, paravalvular leak; RV, right ventricle/right \nventricular; SAPT, single antiplatelet therapy; SAVR, surgical aortic valve replacement; SMR, secondary mitral regurgitation; SPAP, systolic pulmonary artery pressure; STS-PROM, Society \nof Thoracic Surgeons predicted risk of mortality; SVi, stroke volume index; TAVI, transcatheter aortic valve implantation; TEER, transcatheter edge-to-edge repair; TR, tricuspid \nregurgitation; TV, tricuspid valve; UFH, unfractionated heparin; VHD, valvular heart disease; VKA, vitamin K antagonist; Vmax, peak transvalvular velocity. \naClass of recommendation. \nbLevel of evidence.   \nESC Guidelines                                                                                                                                                                                          4649 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "keywords": [
        "aortic stenosis",
        "anticoagulant",
        "angiography",
        "heart failure",
        "recommended",
        "pulmonary hypertension",
        "centre",
        "class iii",
        "female",
        "anticoagulation",
        "hypertension",
        "lvef",
        "bnp",
        "crt",
        "heart",
        "should be considered",
        "mitral stenosis",
        "coronary artery",
        "mitral regurgitation",
        "nt-probnp",
        "nyha",
        "aortic",
        "weight",
        "tricuspid",
        "may be considered",
        "valve",
        "aortic regurgitation",
        "savr",
        "sex",
        "guideline"
      ],
      "tables": [
        {
          "title": "Table on page 15",
          "page_number": 14,
          "content": "Transcatheter closure should be considered for suitable\nPVLs with clinically significant regurgitation and/or\nhaemolysis in patients at high or prohibitive surgical risk. | IIa | B | Transcatheter closure should be considered for suitable\nPVLs with clinically significant regurgitation and/or\nhaemolysis. | IIa | B\nManagement of biological heart valve failure—Section 14.4 |  |  |  |  | \nReoperation is recommended in symptomatic patients\nwith a signifci ant increase in transprosthetic gradient\n(after exclusion of valve thrombosis) or severe\nregurgitation. | I | C | Reintervention is recommended in symptomatic\npatients with signifci ant valve dysfunction not\nattributable to valve thrombosis. | I | C\nTranscatheter, transfemoral valve-in-valve implantation\nin the aortic position should be considered by the Heart\nTeam depending on anatomical considerations, features\nof the prosthesis, and in patients who are at high\noperative risk or inoperable. | IIa | B | Transcatheter transfemoral valve-in-valve implantation\nin the aortic position should be considered in patients\nwith signifci ant valve dysfunction who are at\nintermediate or high surgical risk, and have suitable\nanatomical and prosthesis features, as assessed by the\nHeart Team. | IIa | B\nTranscatheter valve-in-valve implantation in the mitral\nand tricuspid position may be considered in selected\npatients at high risk for surgical reintervention. | IIb | B | Transcatheter transvenous mitral or tricuspid\nvalve-in-valve implantation should be considered in\npatients with signifci ant valve dysfunction at intermediate\nor high surgical risk, if the anatomy is suitable. | IIa | B\nManagement of mechanical heart valve thrombosis—Section 14.4 |  |  |  |  | \nUrgent or emergency valve replacement is\nrecommended for obstructive thrombosis in critically ill\npatients without serious comorbidity. | I | B | Heart Team evaluation is recommended in patients\nwith acute HF (NYHA class III or IV) due to obstructive\nMHV thrombosis to determine appropriate\nmanagement (repeat valve replacement or low-dose\nslow infusion fbi rinolysis). | I | B\nFibrinolysis (using recombinant tissue plasminogen\nactivator 10 mg bolus + 90 mg in 90 min with UFH or\nstreptokinase 1 500 000 U in 60 min without UFH)\nshould be considered when surgery is not available or is\nvery high risk, or for thrombosis of right-sided\nprostheses. | IIa | B |  |  | \nManagement of biological heart valve thrombosis—Section 14.4 |  |  |  |  | \nAnticoagulation using a VKA and/or UFH is\nrecommended in BHV thrombosis before considering\nreintervention. | I | C | OAC using VKA is recommended in BHV thrombosis\nbefore considering reintervention. | I | B",
          "bbox": [
            42.51969909667969,
            59.0,
            558.4249877929688,
            460.99798583984375
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "2",
      "title": "4. Imaging of patients with valvular heart disease",
      "start_page": 17,
      "end_page": 18,
      "content": "Internal quality assessment (see dedicated document concerning TAVI \nfrom the ESC41), systematic recording, and public availability of the volume \nand outcome data of the performed procedures are essential. Participation \nin national or international registries should be encouraged. These consid-\nerations are of particular importance regarding asymptomatic low-risk pa-\ntients (where low mortality and procedural safety are paramount), those \nwith multiple comorbidities (where the need for multidisciplinary collabor-\nation is essential), and new techniques with a steep learning curve (where \nbetter results may be obtained at experienced centres). \nThere is a pressing need to ensure higher dispersion and adoption of \ninterventions for VHD, especially (but not exclusively) in middle- and \nlower-income countries where rheumatic heart disease (RHD) remains \nthe principal cause of VHD.42,43 Key strategies include awareness pro-\ngrammes, increased public and medical education, simplified and im-\nproved diagnostic tools, and measures to reduce costs and facilitate \naccess to evidence-based treatment options.44 \n4. Imaging of patients with valvular \nheart disease \nMultimodality imaging is now the standard approach in VHD \nmanagement to determine the pathophysiology, assess severity, \nplan interventions, and identify complications (Figure 2). The use \nof imaging for the assessment of each specific valve lesion is de-\nscribed in the corresponding sections. The role of imaging is trans-\nversal from diagnosis to follow-up and should encompass an \nintegrative assessment. \n4.1. Initial valve assessment \nComprehensive transthoracic echocardiography (TTE) is the first-line \nexamination to confirm valve dysfunction, and determine the aetiology, \nmechanism, and severity of VHD, as well as cardiac chamber anatomy \nand damage.45,46 It should be performed by properly trained ima-\ngers.47–49 Quantitative imaging analysis (as opposed to visual) should \nbe the goal in all patients with relevant VHD, complemented by quali-\ntative and semi-quantitative evaluation. The severity of VHD should be \nassessed using an integrative approach of all criteria checked for con-\nsistency. When TTE is of poor quality or inconclusive, transoesophageal \nechocardiography (TOE) and/or additional diagnostic imaging modal-\nities should be applied (e.g. calcium scoring and anatomy of the \nvalve using CCT). In specific clinical scenarios [e.g. thrombosis, pros-\nthetic valve dysfunction, endocarditis, mitral stenosis (MS), assessment \nof MV or TV anatomy], TOE has a central diagnostic role.50,51 \n\u001f\u001e\u001d\n\u001c\u001c\u001f\n\u001c\u001b\u001a\u0019\n\u001f\u001e\u001d\u001c\u001b\u001e\u001a\u0019\u001e\u0018\u001e\u0017\u0016\u0015\u0014\u0019\u001e\u0018\u001c\u0019\u001e\u001a\u001a\u0013\u0012\u0012\n\u0011\u0012\u0012\u0013\u0012\u0012\u0015\u0013\u0018\u0017\u0019\u0016\u0010\u0019\u001a\u001e\u000f\u001a\u001b\u000e\u001a\u001e\u0017\u001b\u0016\u0018\u0012\n\r\f\u001a\u000f\u000b\u0012\u001b\u0016\u0018\u0019\u0016\u0010\u0019\u001f\u0011\n\u001f\t\u001e\u0015\b\u0013\u001d\u0019\u0007\u0016\u000f\u000b\u0015\u0013\u0012\u0019\u001e\u0018\u001c\u0019\u0010\u000b\u0018\u001a\u0017\u001b\u0016\u0018\n\u0006\u0013\u0005\u000b\u001d\u0005\u001b\u0017\u001e\u0018\u0017\u0019\u0010\u001d\u001e\u001a\u0017\u001b\u0016\u0018\n\u0004\u0014\u0016\u001a\u001e\u001d\u001c\u001b\u001e\u000f\u0019\u000e\b\u001d\u0016\u0012\u001b\u0012\n\n\u001b\u001e\u0005\u0018\u0016\u0012\u001b\u0012\u0019\u001e\u0018\u001c\u0019\u0003\u000b\u001e\u0018\u0017\u001b\u000e\u001a\u001e\u0017\u001b\u0016\u0018\u0019\u0016\u0010\u0019\u0007\u001e\u000f\u0007\u0013\n\u001c\u0014\u0012\u0010\u000b\u0018\u001a\u0017\u001b\u0016\u0018\n\u001f\u001e\u001d\u001c\u001b\u001e\u001a\u0019\u001a\t\u001e\u0015\b\u0013\u001d\u0019\u001e\u0018\u001e\u0017\u0016\u0015\u0014\u0019\u001e\u0018\u001c\u0019\u0010\u000b\u0018\u001a\u0017\u001b\u0016\u0018\n\u001f\u001e\u001d\u001c\u001b\u001e\u001a\u0019\u001c\u001e\u0015\u001e\u0005\u0013\u0019\u001e\u0018\u001c\u0019\u001d\u0013\u0015\u0016\u001c\u0013\u000f\u000f\u001b\u0018\u0005\n\u0002\u0016\u000f\u000f\u0016\u0001\u000b\n\u001f\u001f\u001d\n\u0011\u0012\u0012\u0016\u001a\u001b\u001e\u0017\u0013\u001c\u0019\u001c\u001b\u0012\u0013\u001e\u0012\u0013\u0012\n\u001e\u0018\u001c\u0019\u001a\u0016\u0018\u001c\u001b\u0017\u001b\u0016\u0018\u0012\n\r\u0007\u001e\u000f\u000b\u001e\u0017\u001b\u0016\u0018\u0019\u0016\u0010\u0019\n\u001c\u0014\u0018\u001e\u0015\u001b\u001a\u0012\u0019\u001e\u0018\u001c\u0019\u0007\u001e\u001d\u001b\u001e\b\u001b\u000f\u001b\u0017\u0014\n\u0011\u0012\u0012\u0013\u0012\u0012\u0015\u0013\u0018\u0017\u0019\u0016\u0010\u0019\u0013\f\u0017\u001d\u001e\u0007\u001e\u000f\u0007\u000b\u000f\u001e\u001d\u0019\n\u001a\u001e\u001d\u001c\u001b\u001e\u001a\u0019\u001a\u0016\u0018\u0012\u0013\u0003\u000b\u0013\u0018\u001a\u0013\u0012\u0019\u0010\u001d\u0016\u0015\u0019\n\r\u0007\u001e\u000f\u000b\u001e\u0017\u001b\u0016\u0018\u0019\u0016\u0010\u0019\u0013\u000f\u001b\u0005\u001b\b\u001b\u000f\u001b\u0017\u0014\u0019\u0010\u0016\u001d\u0019\n\u001b\u0018\u0017\u0013\u001d\u0007\u0013\u0018\u0017\u001b\u0016\u0018\u0019\u001e\u0018\u001c\u0019\u001d\u001b\u0012\u0019\u0012\u0017\u001d\u001e\u0017\u001b\u000e\u001a\u001e\u0017\u001b\u0016\u0018\n\u000f\u001e\u0018\u0018\u001b\u0018\u0005\u0019\u001e\u0018\u001c\u0019\u0005\u000b\u001b\u001c\u001b\u0018\u0005\u0019\u0016\u0010\u0019\u001b\u0018\u0017\u0013\u001d\u0007\u0013\u0018\u0017\u001b\u0016\u0018\u0012 \n\u001e\u0012\u0012\u0013\u0012\u0012\u0015\u0013\u0018\u0017\u0019\u0016\u0010\u0019\u001a\u0016\u0015\u000f\u001b\u001a\u001e\u0017\u001b\u0016\u0018\u0012\n\u001b\u0005\t\u0013\u001d\u0019\u001d\u0013\u0012\u0016\u000f\u000b\u0017\u001b\u0016\u0018\u0019\u0017\u0016\u0019\u001e\u0012\u0012\u0013\u0012\u0012\u0019\u0007\u001e\u000f\u0007\u0013\u0019\n\u001e\u0018\u001e\u0017\u0016\u0015\u0014\n\u0004\u0013\u001a\t\u001e\u0018\u001b\u0012\u0015­\u0012\u0019\u0016\u0010\u0019\n\n\u0019\u0007\u001b\u0012\u000b\u001e\u000f\u001b\u001e\u0017\u001b\u0016\u0018\u0019\u0016\u0010\u0019\u0007\u001e\u000f\u0007\u0013\u0012\n\u000b\u001b\u001c\u001b\u0018\u0005\u0019\u0016\u0010\u0019\u001b\u0018\u0017\u0013\u001d\u0007\u0013\u0018\u0017\u001b\u0016\u0018\u0012\nFigure 2 Integrative imaging assessment of patients with valvular heart disease. 3D, three-dimensional; CAD, coronary artery disease; CCT, cardiac \ncomputed tomography; CMR: cardiac magnetic resonance; TOE; transoesophageal echocardiography; TTE, transthoracic echocardiography; VHD, \nvalvular heart disease.   \n4652                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "keywords": [
        "disease",
        "echocardiography",
        "patients",
        "heart",
        "tavi",
        "coronary artery",
        "mitral stenosis",
        "valvular",
        "stenosis",
        "imaging"
      ],
      "tables": []
    },
    {
      "number": "2",
      "title": "5. Clinical evaluation of patients with valvular heart disease",
      "start_page": 18,
      "end_page": 19,
      "content": "Moreover, in patients with regurgitant lesions, particularly AR, CMR has \ngained key value in clinical practice. \n4.2. Associated diseases and conditions \nImaging plays a crucial role in identifying associated diseases and condi-\ntions. The presence of concomitant left ventricular (LV) systolic or dia-\nstolic dysfunction, RV systolic dysfunction, red flags indicating \ncardiomyopathies (e.g. amyloidosis, hypertrophic cardiomyopathy), \nand aortopathy should prompt further examinations to ensure optimal \nrisk stratification and VHD management. In addition to TTE, advanced \nimaging modalities, like CCT, may be required to assess the aorta, \nsingle-photon emission computed tomography (CT) for detection of \nischaemia/necrosis, positron emission tomography (PET) for inflamma-\ntion, nuclear scintigraphy for cardiac amyloidosis, or CMR for tissue \ncharacterization. \n4.3. Evaluation of valvular heart disease \ndynamics and variability \nSerial imaging studies to detect changes over time, or variability due to \nhaemodynamic conditions or initiation/up-titration of medical ther-\napy, are of utmost importance to guide decisions. The dynamic pat-\ntern of VHD may convey additional prognostic information. \nExercise echocardiography helps to identify the cause of dyspnoea, \nunveil symptoms in apparently asymptomatic patients, identifies dy-\nnamic changes of VHD severity, and can contribute to refinement \nof the indication for an intervention, especially for AS and mitral re-\ngurgitation (MR).52 \n4.4. Assessment of extravalvular cardiac \nconsequences from valvular heart disease \nSeveral studies investigating different valve lesions have established \nthe relevance of extravalvular cardiac damage in terms of progno-\nsis,53–55 recovery after intervention,56 and quality of life.57 The pres-\nence of LV hypertrophy, left atrium (LA) dilatation, LV or RV \ndysfunction and/or remodelling, myocardial fibrosis, and pulmonary \nhypertension (PH) provide important prognostic information, and \nmay influence the timing and type of treatment. Although not neces-\nsarily chronological in their order of appearance, the understanding \nof cardiac damage, particularly damage involving the LV, is essential \nto guide appropriate medical therapy before and after any interven-\ntion. Transthoracic echocardiography (TTE) including global longitu-\ndinal strain (GLS) and CMR can be particularly useful in that \nregard.58–60 \n4.5. Evaluation of eligibility, planning, and \nguiding of interventions \nTransoesophageal echocardiography (TOE) (preferentially 3D) is the \npreferred tool for the assessment of suitability for aortic, mitral, and \nTV repair.45,49,61–63 Risk stratification for an intervention should inte-\ngrate all the points mentioned above. \nTransoesophageal echocardiography (TOE), including standard 3D \nviews, is also the modality of choice to guide atrioventricular trans-\ncatheter interventions and should be performed by specially trained \ninterventional echocardiographers.61,64 Cardiac computed tomog-\nraphy (CCT) is frequently used to evaluate the relationship of the \nvalve with adjacent structures [e.g. coronary arteries and left ventricu-\nlar outflow tract (LVOT)], the extension of calcification [e.g. in mi-\ntral annular calcification (MAC)], and for sizing of the prosthesis. \nCT angiography is frequently employed to evaluate the anatomy \nof surgical, arterial, or venous access routes and detect cardiac or \nextracardiac complications (e.g. bleeding or embolic events). \nCoronary CT angiography (CCTA) is increasingly utilized to assess \nthe presence of CAD. \n5. Clinical evaluation of patients \nwith valvular heart disease \n5.1. Clinical examination \nPatients with VHD can be either asymptomatic or present with a wide \nspectrum of symptoms, including acute or chronic HF. An initial meticu-\nlous history and a comprehensive physical examination of the patient \nwith auscultation, documentation of clinical signs of HF such as dys-\npnoea, impaired physical capacity and fatigue, peripheral oedema, and \npleural effusion, as well as a systematic frailty assessment, are crucial.65 \nIn addition, comorbidities and coexisting cardiac conditions should be \ndocumented (Figure 3). Particular attention should be given to recent \nchanges in symptoms or physical findings indicating a potential worsen-\ning of the valve lesion or ventricular function. \n5.2. Assessment of comorbidities and risk \nstratification \nRisk stratification of patients with VHD has been mainly developed \nbased on surgical populations. The European System for Cardiac \nOperative Risk Evaluation II (EuroSCORE II)66,67 (https://www. \neuroscore.org) and the Society of Thoracic Surgeons predicted risk \nof \nmortality \n(STS-PROM) \nscore68 \n(http://riskcalc.sts.org/ \nstswebriskcalc/calculate) are the most commonly used scoring systems \nto estimate surgical risk. Both risk scores have been calibrated to pre-\ndict post-operative outcomes.69–71 The STS-PROM score is dynamic to \naccount for changes in patient risk profiles, the type of procedure (aor-\ntic, mitral, and tricuspid), and outcomes over time. The outdated (logis-\ntic) EuroSCORE I model systematically overestimated surgical \nmortality.70,72 \nIn patients considered for TAVI, surgical risk scores have lower ac-\ncuracy and tend to overestimate the risk of events.73–75 Discrepancies \nbetween observed and predicted peri-procedural mortality after \nTAVI using surgical risk scores point towards a need for \nTAVI-specific scores. Models predicting short- and medium-term sur-\nvival specifically designed for TAVI are rarely used in daily clinical prac-\ntice due to limitations of their predictive performance.76–79 Specific \nscores have also been developed for patients undergoing mitral \nTEER (M-TEER),80–82 but the high heterogeneity of the population \nwith MR limits their external validity and therefore routine clinical \nuse so far.83 Recently, a dedicated clinical score has been calibrated \nand validated to stratify the risk associated with first-time and repeat \nisolated TV surgery (TRI-SCORE; https://www.tri-score.com/), and its \nuse should be encouraged for patients with TV disease,84,85 as an al-\nternative to the more complex Society of Thoracic Surgeons (STS) \nscore for isolated TV surgery (https://isolatedtvsurgcalc.research.sts. \norg/).  \nESC Guidelines                                                                                                                                                                                          4653 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "keywords": [
        "disease",
        "angiography",
        "systolic",
        "evaluation",
        "echocardiography",
        "hypertension",
        "clinical",
        "risk stratification",
        "patients",
        "heart",
        "tavi",
        "valvular",
        "aortic",
        "systolic dysfunction",
        "indication",
        "cardiomyopathy",
        "tricuspid",
        "exercise"
      ],
      "tables": []
    },
    {
      "number": "2",
      "title": "6. Management of conditions associated with valvular heart disease",
      "start_page": 20,
      "end_page": 21,
      "content": "(NT-proBNP) to upper limit of normal for age, sex, and assay] \nhas been shown to be a powerful, independent, and incremental \npredictor of mortality.96–98 In patients undergoing AV replacement, \nthe accumulation of several elevated biomarkers of cardiovascular \nstress was associated with higher all-cause and cardiovascular mortal-\nity, and a higher rate of repeat hospitalization.99,100 \n5.4. Exercise testing \nBecause of the slow progression of valve lesions, patients may gradually \nlimit their activity levels over several years and deny having actual symp-\ntoms that can be unmasked by exercise testing.12 This is particularly im-\nportant in cases of AS, because once symptoms occur there is a sharp \nincrease in the risk of sudden cardiac death, unless a valve intervention \nis performed.101–104 Exercise testing may provide additional informa-\ntion about the haemodynamic severity of VHD and help determine \nthe risk and optimal timing of intervention by objectively evaluating \nfunctional capacity.101,103 Cardiopulmonary exercise testing has a \nprognostic role and can assist decision-making in patients with VHD \nof intermediate severity, particularly those with asymptomatic \nAR.101,105,106 \nExercise echocardiography is used for the assessment of LV global \nand segmental function, pulmonary artery pressure, and aortic and mi-\ntral pressure gradients.101,107 It also documents exercise-induced in-\ncrease of MR and TR severity, especially in patients with secondary \ndisease.108,109 Prognostic impact has been shown mainly for AS and \nMR.110,111 Misconceptions regarding its risk and tolerability contribute \nto the overall underuse of exercise testing in patients with VHD,12 des-\npite data confirming its safety in most asymptomatic patients.112,113 \n5.5. Invasive investigations \n5.5.1. Coronary angiography \nCoronary artery assessment is recommended to evaluate the need for \nrevascularization when valve surgery or an intervention is planned. The \ninformation regarding the existence of concomitant CAD should be \navailable at the time of Heart Team discussion. CCTA is recommended \nas an alternative to coronary angiography to rule out CAD in patients \nwho are at low or moderate risk of obstructive CAD. \nCoronary blood flow and fractional flow reserve (FFR) are altered in \nthe setting of concomitant VHD, and functional haemodynamic assess-\nment of CAD in these patients is not well established.114–118 \n5.5.2. Cardiac catheterization \nRight heart catheterization (RHC) should be performed in patients with \nequivocal echocardiographic findings, particularly those with MV dis-\nease, as well as in all candidates for the treatment of severe TR. In ex-\nceptional cases with unclear AS severity, it can be combined with \nmeasurements of the transaortic gradients allowing estimation of the \naortic valve area (AVA). Right heart catheterization contributes to as-\nsess the repercussions of any left-sided VHD or LV impairment on \nthe pulmonary circulation and right side of the heart. It provides infor-\nmation regarding volume state, cardiac output, and vascular resistance, \ndifferentiating between pre- and post-capillary PH, and should be ideally \nperformed in euvolaemia. \nMeasurements of the pulmonary capillary wedge pressure v-wave \ncan inform about MR severity, but are neither sensitive nor specific, \nand may also be increased if the compliance of the LA is reduced or \nin case of diastolic LV dysfunction, as in patients with MS or chronic \nHF.119 \nSimilarly, the height of the right atrium (RA) v-wave, and the pres-\nsure curve mimicking the RV pattern (‘ventricularization’ of the RA \npressure), are signs of relevant TR, which are frequently accompan-\nied by increased RV end-diastolic pressure in case of associated RV \ndysfunction. In patients with severe TR, pulmonary vascular resist-\nance (PVR) should be calculated to unmask pulmonary vascular dis-\nease, which may not be captured by echocardiography due to RV \nsystolic dysfunction or underestimation of pulmonary pressures be-\ncause of TR. \n5.6. Patient-centred care and shared \ndecision-making \nGiven that treatment of VHD typically involves several modalities and \nspecialities, and may result in a complex and sometimes time- \nconsuming decision-making process, patient education and informa-\ntion, using online material and face-to-face conversations, are essen-\ntial at each step. A clearly defined point of contact for all questions \nrelating to the disease or type of treatments should be communicated \nto the patient and their relatives.120 The symptomatic and prognostic \nbenefits, as well as the advantages and disadvantages of any treatment \noption, should be presented in an open and evidence-based manner. \nThis includes mortality and risks of reintervention and complications \n(also over the long term), as well as recovery time and the need for \ncardiac, and if necessary psychological, rehabilitation until return to \nphysical activity and work. Other issues to be discussed before the \nprocedure include the need for oral anticoagulation (OAC) and its \nmonitoring, as well as the noise generated by mechanical heart valves \n(MHVs). Information regarding centre experience and volume for a \nspecific procedure should be provided. Misconceptions (e.g. subject-\nive overestimation of the risk of surgery) should be addressed and po-\ntential interactions with individual lifestyle factors—including social \nactivities, family and professional life, and hobbies—should be dis-\ncussed in detail. \nThe Heart Team recommendation regarding the treatment and its \nmodality must be based on evidence and anatomical considerations, \nbalancing the risks and benefits of available treatment options.16 The \npatient and patient’s relatives need to be well informed about the ra-\ntionale leading to the Heart Team recommendation, and given ample \ntime to share personal preferences.121 At the end of the process, a \nshared decision is made between the treating team and the informed \npatient and relatives (Figure 3). \n6. Management of conditions \nassociated with valvular heart \ndisease \n6.1. Diagnosis and management of \ncoronary artery disease \nThe presence of CAD plays an important role in decision-making \nregarding the timing and modality of treatment, and should be \nassessed before Heart Team discussion. In patients with a low \nor moderate pre-test likelihood of obstructive CAD (≤50%), \nCCTA is recommended to rule out relevant CAD with high sensi-\ntivity.122–124 \nSeveral studies have investigated the value of CCT angiography for \nCAD screening in elderly TAVI candidates. While sensitivity for the de-\ntection of obstructive CAD is high (95%–97%), specificity (68%–73%) is  \nESC Guidelines                                                                                                                                                                                          4655 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "keywords": [
        "elderly",
        "angiography",
        "conditions",
        "recommended",
        "systolic dysfunction",
        "physical activity",
        "disease",
        "anticoagulation",
        "echocardiography",
        "heart",
        "management",
        "coronary artery",
        "associated",
        "diastolic",
        "nt-probnp",
        "aortic",
        "valvular",
        "catheterization",
        "sex",
        "systolic",
        "tavi",
        "age",
        "sudden cardiac death",
        "exercise"
      ],
      "tables": [
        {
          "title": "Table on page 22",
          "page_number": 21,
          "content": "Recommendations | Classa | Levelb\nDiagnosis of coronary artery disease |  | \nCCTA is recommended before valve intervention in\npatients with moderate or lower (≤50%) pre-test\nlikelihood of obstructive CAD.122–124 | I | B\nInvasive coronary angiography is recommended\nbefore valve intervention in patients with high and\nvery high (>50%) pre-test likelihood of obstructive\nCAD. | I | C\nInvasive coronary angiography is recommended in\nthe evaluation of CAD in patients with severe\nventricular SMR. | I | C\nOmission of invasive coronary angiography should be\nconsidered in TAVI candidates, if procedural planning\nCT angiography is of sufficient quality to rule out\nsignificant CAD.125–129 | IIa | B",
          "bbox": [
            303.8030090332031,
            517.051025390625,
            552.7559814453125,
            734.6501595633371
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "7. Aortic regurgitation",
      "start_page": 23,
      "end_page": 24,
      "content": "Radiotherapy may lead to aortic and/or valvular calcification, CAD of \nproximal segments, restrictive cardiomyopathy, pericardial adhesions \nand calcifications with constriction, restrictive lung disease, chest wall \nscarring, and impaired wound healing, especially in patients who under-\nwent radiation by means of older techniques (>20 years ago). The above \nfactors complicate any surgical approach and increase the operative risk, \nwhich is underestimated by traditional risk scores.179–181 TAVI is pro-\nposed as an alternative for patients presenting with radiation-induced \nAS in the 2022 ESC Guidelines on cardio-oncology182 based on favourable, \nbut limited, observational data,183,184 because this category of patients \nhas been excluded from RCTs.183,184 Furthermore, M-TEER in patients \npresenting with radiation-induced MV disease with MR is often limited \nby thickened leaflets with restricted movement and subsequent risk of \niatrogenic stenosis. \nIn patients with active or stable cancer and severe AS, both TAVI and \nSAVR can be considered based on life expectancy, age, prognosis, and \ndisability following cancer treatment, with a trend towards more TAVI \nutilization.185 TAVI procedural complication rates appear similar com-\npared with those of control subjects without cancer.186 To avoid futil-\nity, treatment decisions discussed by the Heart Team should involve the \ntreating oncologists.5,182 \n6.4. Prophylaxis of rheumatic fever \nRheumatic heart disease remains the most common cause of death \nfrom VHD worldwide.187 Prevention should preferentially target the \nfirst occurrence of acute rheumatic fever. Correct diagnosis and early \nantibiotic treatment of group A Streptococcus throat or skin infection \nis key for primary prevention. Large-scale screening combined with \nprophylaxis in children or adolescents with latent RHD appears to be \nan effective strategy to reduce the risk of disease progression and \nRHD prevalence.188–190 In patients with established RHD, secondary \nlong-term prophylaxis with benzathine benzyl penicillin 1.2 million \ninternational units (IU) every 3–4 weeks over 10 years is recom-\nmended to prevent recurrent episodes, especially in children and ado-\nlescents. Long-term prophylaxis into adulthood should be considered \nin high-risk patients according to the severity of VHD and exposure \nto group A Streptococcus.191,192 \n6.5. Cardiogenic shock and acute heart \nfailure \nAcute presentation or decompensation of VHD can result in cardio-\ngenic shock due to rapid haemodynamic deterioration and altered car-\ndiac function. Alternatively, pre-existing VHD can be a bystander of an \nacute cardiovascular condition further exacerbating circulatory impair-\nment until the occurrence of cardiogenic shock. In this setting, assess-\nment of the severity of VHD, as well as its contribution to acute HF, \nmay be difficult. Evidence concerning acute VHD management in this \ncontext is scarce and only exists for the MV and AV.193,194 \nHospital admission for acute decompensated AS is a frequent prob-\nlem seen in up to 25% of AS hospitalizations.195,196 However, only a mi-\nnority of these patients (1.6%–3.2%) present with cardiogenic \nshock.197,198 While intensive care treatment remains the cornerstone \nof haemodynamic stabilization and support, an intervention should be \nconsidered early, because it represents the only way to reverse pro-\ngressive organ dysfunction due to low cardiac output. Balloon aortic \nvalvuloplasty has been used in this context in the past, but has been \nlargely replaced by TAVI in recent years, due to the high risk of severe \nAR and mortality in the acute setting.199–201 Several large observational \nstudies have established the feasibility of TAVI in patients with \ncardiogenic shock with similar device success, even if LVEF is low, al-\nthough 30-day mortality remains higher (13%–19%) compared with \nroutine TAVI.194,197,198 Surgery represents the preferred treatment \nin patients with acute AR, while TAVI has only been described in indi-\nvidual cases or patients with a failed surgical valve (valve-in-valve). Fast \npacing over a temporary pacemaker lead shortens the diastole and may \ntemporarily improve haemodynamics until the intervention.5,8 \nExcept for papillary muscle rupture, acute PMR rarely leads to car-\ndiogenic shock and may be best treated by surgical valve repair or re-\nplacement. In contrast, increasing evidence supports the use of \nM-TEER in patients with acute ventricular SMR, particularly following \nacute myocardial infarction, due to lower mortality compared with sur-\ngery or medical treatment in propensity-matched analyses.194,202,203 \nThis strategy might also be helpful to facilitate weaning from mechanical \ncirculatory support. \n6.6. Palliative care \nIn some patients with advanced VHD not qualifying for surgical or \ntranscatheter therapies, medical HF treatment remains the only, and \nsometimes best, available option. These patients usually present late, \nhave extensive cardiac damage, develop terminal HF during the natural \nevolution of VHD, and are ineligible for mechanical circulatory support \nor heart transplantation (HTx). Early implementation of expert multi-\ndisciplinary palliative and end-of-life care, with the support of HF spe-\ncialists,204–206 reduces the number of hospitalizations and improves \nquality of life and symptom burden, in particular dyspnoea, pain, and \nanxiety.207 Continuous co-ordination between all involved subspecial-\nties, and transparent communication with the patient and their rela-\ntives, are key to ensure high quality of care. \n7. Aortic regurgitation \n7.1. Prevalence and aetiology \nChronic AR is mainly due to intrinsic abnormalities of the AV cusps and/ \nor secondary to progressive dilatation of the aortic root and/or ascend-\ning aorta. In high-income countries, degenerative changes are the lead-\ning cause of AR, while RHD is more frequent in middle- and \nlow-income countries.12 Acute presentations are usually related to in-\nfective endocarditis or extension of aortic dissection into the aortic \nroot. Chronic pure severe AR is more frequent in men and is associated \nwith BAV and concomitant dilatation of the aorta in more than one-half \nof cases.208 \n7.2. Evaluation \nDuring stepwise AR evaluation, the following aspects should be ad-\ndressed: the severity of AR, its mechanism, and aetiology; the haemo-\ndynamic impact on LV function and pulmonary pressure; and \nevaluation of the ascending aorta. While echocardiography is the first- \nline modality, CMR and CCT are more accurate for the measurement \nof specific parameters (Figure 4). The results of the evaluation need to \ntake into consideration the haemodynamic condition of the patient, \nparticularly the blood pressure (BP), since high pressures can lead to \noverestimation of the regurgitant volume (RVol). \nAssessment of AR severity with TTE follows an integrative approach \nconsidering qualitative, semi-quantitative, and quantitative parameters, \nbut remains challenging.45 Consequences of AR on LV size and function \nmust be carefully assessed. Cut-offs for intervention are mostly \nbased on two-dimensional (2D) echocardiographic measurements. \nHowever, 3D echocardiography and CMR allow more accurate  \n4658                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "keywords": [
        "primary prevention",
        "valve repair",
        "regurgitation",
        "blood pressure",
        "echocardiography",
        "lvef",
        "pacemaker",
        "tavi",
        "age",
        "should be considered",
        "aortic",
        "older",
        "cardiomyopathy",
        "stenosis",
        "aortic regurgitation",
        "savr"
      ],
      "tables": []
    },
    {
      "number": "2",
      "title": "8. Aortic stenosis",
      "start_page": 27,
      "end_page": 28,
      "content": "to confirm maximal diameter, rule out isolated single sinus dilatation, \nand provide a baseline reference. When the baseline aortic diameter \nis >45 mm, a second TTE examination is recommended at 6 months \nto confirm the stability of the finding, followed by serial examinations \non a yearly basis thereafter.275 Any increase of >3 mm should be vali-\ndated by CT angiography/CMR and compared with baseline data.275 \nAfter repair of the ascending aorta, patients with Marfan syndrome \nand other connective tissue diseases remain at risk for dissection of un-\ntreated portions of the aorta, and require lifelong regular multidisciplin-\nary follow-up at an expert centre.8 \n7.6. Special patient populations \nPatients with concomitant VHD and those with AS combined with AR \nare discussed in Section 13.3.3. In patients with moderate AR and indica-\ntion for CABG or MV surgery, the decision to treat the AV should be \ndiscussed by the Heart Team based on the aetiology of AR and other \nclinical factors, like the estimated life expectancy and the operative risk, \nas data show that progression of moderate AR may be very slow.276 \nThe presence of aortic dilation and AR in asymptomatic patients \nposes the problem of limiting the level of physical activity, but consist-\nent data are lacking. Current recommendations for participation in \ncompetitive sport are restrictive, especially regarding isometric exer-\ncise in patients with connective tissue disease,277 while a more liberal \napproach is likely to be appropriate in other patients. \nGiven the familial risk of thoracic aortic aneurysms, screening with \nappropriate imaging studies and testing for genetic abnormalities in \nfirst-degree relatives is indicated in patients with connective tissue dis-\nease.278 Since aortic dilation is present in ∼10% of first-degree relatives \nof patients with a BAV, it is also considered appropriate to encourage \nechocardiographic screening in this specific population.275,279 \n8. Aortic stenosis \n8.1. Prevalence and aetiology \nEven if AS is the most common primary valve lesion referred for inter-\nvention in Europe and North America,12 underdiagnosis and under-\ntreatment remain relevant concerns.10 Degenerative pathogenesis \nwith cusps calcification is most common in developed countries and \nprevalence is rising rapidly because of the ageing population.11,12,187 \nBAVs, or more rarely unicuspid AVs, are prone to earlier degeneration, \nconstitute the dominant valve morphology in younger patients requir-\ning AV replacement, and are frequently associated with dilatation of the \naortic root or ascending aorta.280,281 In low- and middle-income coun-\ntries, rheumatic aetiology remains frequent and AS usually presents \ncombined with rheumatic MV disease.282 \n8.2. Evaluation \n8.2.1. Echocardiography and cardiac computed \ntomography \nAortic stenosis is a disease slowly evolving from mild to severe valve \nobstruction as a consequence of increasing valve fibrosis and calcifi-\ncation, although progression accelerates as haemodynamic severity \nincreases.283 \nEchocardiography is key to confirm the diagnosis and allows compre-\nhensive assessment of the anatomy and severity of stenosis. Evaluation \nof the haemodynamic consequences on cardiac function and geometry, \nand the detection of aortic pathology or concomitant valve disease, \nprovide important prognostic information that may influence manage-\nment.284 Staging of extravalvular damage has been proposed,53 but \nit may be difficult to attribute other cardiac abnormalities to AS itself, \nbecause comorbidities are frequent in patients with AS and the \nobserved damage may not occur in the expected chronological se-\nquence. However, the detection of concomitant cardiac conditions \n[e.g. HF with preserved EF (HFpEF), amyloidosis, or hypertrophic \nRecommendation Table 3 — Recommendations on in-\ndications for intervention in severe aortic regurgitation \n(see also Supplementary data online, Evidence Tables 4–8) \nRecommendations \nClassa \nLevelb \nSevere aortic regurgitation  \nAV surgery is recommended in symptomatic patients \nwith severe AR regardless of LV function.224–228 \nI \nB \nAV surgery is recommended in asymptomatic \npatients with severe AR and LVESD >50 mm or \nLVESDi >25 mm/m2 [especially in patients with small \nbody size (BSA <1.68 m2)] or resting \nLVEF ≤50%.226,228,231,233,234 \nI \nB \nAV surgery is recommended in symptomatic and \nasymptomatic patients with severe AR undergoing \nCABG or surgery of the ascending aorta. \nI \nC \nAV repair should be considered in selected patients \nwith severe AR at experienced centres, when \ndurable results are expected.220,245,246,259 \nIIa \nB \nAV surgery may be considered in asymptomatic patients \nwith severe AR and LVESDi  \n>22 mm/m2,226,228,231–234 or LVESVic >45 mL/m2 \n[especially in patients with small body size (BSA  \n<1.68 m2)],235–241 or resting LVEF ≤55%, if the surgical \nrisk is low. \nIIb \nB                                                                                                   \nContinued \nTAVI may be considered for the treatment of severe \nAR in symptomatic patients ineligible for surgery \naccording to the Heart Team, if the anatomy is \nsuitable.264,265,268,269 \nIIb \nB \nConcomitant surgery of the ascending aorta \nValve-sparing aortic root replacement is \nrecommended in young patients with aortic root \ndilatation at experienced centres, when durable \nresults are expected.247,250–253,255 \nI \nB \nWhen AV surgery is indicated and the predicted \nsurgical risk is low, replacement of the aortic root or \nascending aorta should be considered if the maximal \ndiameter is ≥45 mm.d \nIIa \nC \n© ESC/EACTS 2025\nAR, aortic regurgitation; AV, aortic valve; BSA, body surface area; CABG, coronary artery \nbypass grafting; CMR, cardiac magnetic resonance; LV, left ventricle/left ventricular; LVEF, \nleft ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; LVESDi, left \nventricular end-systolic diameter indexed to BSA; LVESVi, left ventricular end-systolic \nvolume indexed to BSA; TAVI, transcatheter aortic valve implantation. \naClass of recommendation. \nbLevel of evidence. \ncUsing echocardiography or CMR. \ndConsidering age, BSA, the aetiology of the valvular disease, the presence of a bicuspid AV, \nand the intraoperative shape and thickness of the ascending aorta.   \n4662                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "keywords": [
        "genetic",
        "hfpef",
        "aortic stenosis",
        "ejection fraction",
        "angiography",
        "systolic",
        "echocardiography",
        "lvef",
        "tavi",
        "age",
        "recommended",
        "should be considered",
        "aortic",
        "coronary artery",
        "may be considered",
        "stenosis",
        "aortic regurgitation",
        "physical activity"
      ],
      "tables": [
        {
          "title": "Table on page 28",
          "page_number": 27,
          "content": "TAVI may be considered for the treatment of severe\nAR in symptomatic patients ineligible for surgery\naccording to the Heart Team, if the anatomy is\nsuitable.264,265,268,269 |  | IIb | B | \n | Concomitant surgery of the ascending aorta |  |  | \nValve-sparing aortic root replacement is\nrecommended in young patients with aortic root\ndilatation at experienced centres, when durable\nresults are expected.247,250–253,255 |  | I | B | \nWhen AV surgery is indicated and the predicted\nsurgical risk is low, replacement of the aortic root or\nascending aorta should be considered if the maximal\ndiameter is ≥45 mm.d |  | IIa | C | ",
          "bbox": [
            303.8030090332031,
            59.0,
            552.7559814453125,
            220.99896240234375
          ],
          "function_potential": "raw"
        },
        {
          "title": "©  ESC / EACTS 2025",
          "page_number": 27,
          "content": "Recommendations | Classa | Levelb\nSevere aortic regurgitation |  | \nAV surgery is recommended in symptomatic patients\nwith severe AR regardless of LV function.224–228 | I | B\nAV surgery is recommended in asymptomatic\npatients with severe AR and LVESD >50 mm or\nLVESDi >25 mm/m2 [especially in patients with small\nbody size (BSA <1.68 m2)] or resting\nLVEF ≤50%.226,228,231,233,234 | I | B\nAV surgery is recommended in symptomatic and\nasymptomatic patients with severe AR undergoing\nCABG or surgery of the ascending aorta. | I | C\nAV repair should be considered in selected patients\nwith severe AR at experienced centres, when\ndurable results are expected.220,245,246,259 | IIa | B\nAV surgery may be considered in asymptomatic patients\nwith severe AR and LVESDi\n>22 mm/m2,226,228,231–234 or LVESVic >45 mL/m2\n[especially in patients with small body size (BSA\n<1.68 m2)],235–241 or resting LVEF ≤55%, if the surgical\nrisk is low. | IIb | B",
          "bbox": [
            36.850399017333984,
            455.0459899902344,
            285.8030090332031,
            733.6446969168527
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "9. Mitral regurgitation",
      "start_page": 36,
      "end_page": 37,
      "content": "8.6. Follow-up \nThe rate of progression of AS varies widely and asymptomatic patients, \ntheir family, and medical caregivers need careful education, with particu-\nlar emphasis on the importance of regular follow-up (ideally at a Heart \nValve Centre)14 and prompt reporting of symptoms. Asymptomatic pa-\ntients with severe AS should be followed up at least every 6 months to \nallow detection of early symptoms (using exercise testing if complaints \nare inconclusive) and any change in echocardiographic parameters (par-\nticularly LVEF). Serial measurements of natriuretic peptides can provide \nadditional useful information regarding the timing of treatment. \nYounger patients with mild AS and no significant leaflet calcification \nmay be followed up every 2–3 years. With increasing stenosis severity, \nprogression accelerates and follow-up intervals should be gradually re-\nduced.283,503 Several studies suggest that the prognosis of moderate de-\ngenerative AS is worse than previously considered,504,505 particularly if \nthere is significant valve calcification, and these patients should be re- \nevaluated at least annually. \nCardiac rehabilitation is frequently performed after AV intervention, \nespecially after surgery and in elderly patients, and is associated with im-\nproved activities of daily living and 6-minute walking distance.506 After \nvalve intervention, an early echocardiographic examination within the \nfirst weeks after valve replacement is recommended to document base-\nline prosthetic valve function. Cardiological evaluations and echocardio-\ngraphic examinations are recommended annually in patients with a \nbioprosthesis, and whenever changes in clinical symptoms or signs sug-\ngestive of valve dysfunction are noted. \n9. Mitral regurgitation \nChronic MR is one of the most common acquired valve patholo-\ngies,12,187 while acute MR is observed in the context of infective endo-\ncarditis, chordal rupture, or as a complication of myocardial infarction \n(papillary muscle rupture). MR either relates to anatomical changes of \nthe MV apparatus (primary), or to LV or LA dilatation and dysfunction \n(secondary).193 Since natural history, prognosis, and management differ \naccording to aetiologies, populations should be clearly distinguished in \nclinical practice and research.12,507 \n9.1. Primary mitral regurgitation \n9.1.1. Prevalence and aetiology \nPrimary mitral regurgitation relates to an anatomical lesion of one or \nmore of the three main components (not including the annulus) of the \nMV apparatus (valve leaflets, chordae tendineae, and papillary muscles). \nPMR is observed in 55% of patients with MR who require treatment.507 \nWhile degenerative disease related to fibroelastic deficiency or myxoma-\ntous alterations (in its most severe form, Barlow’s disease) are the most \ncommon aetiologies in higher-income countries, RHD is most frequently \nfound in the rest of the world. MV endocarditis is a separate entity of PMR \ncaused by acute or chronic infectious conditions and is discussed in the \ncorresponding Guidelines.5 In a small subgroup of patients, PMR is asso-\nciated with a higher incidence of ventricular arrhythmias, and sudden car-\ndiac death has been reported in individual cases, especially in patients with \nBarlow’s disease.508 The arrhythmogenic burden is independent from MR \nseverity and has been associated with mitral annular disjunction. Atrial dis-\nplacement of the posterior MV leaflet hinge point is assumed to cause ex-\ncessive mobility of the valvular apparatus and increases tension on the \npapillary muscles and the posterobasal myocardium, causing local fibrosis, \nwhich may lead to ventricular arrhythmias and sudden cardiac death.509 \n9.1.2. Evaluation \n9.1.2.1. Echocardiography and right heart catheterization \nEchocardiography is the diagnostic method of choice for the quantifica-\ntion of MR, determination of its aetiology, and identification of cardiac \nconsequences (Figure 10). TTE is used for initial evaluation that includes: \n(i) assessment of valve morphology (presence and location of prolapse \nor flail, calcifications, and/or mitral annular disjunction); (ii) integrative \nseverity grading; and (iii) quantification of LV and LA dimensions and \nfunction, as well as assessment of concomitant RV dysfunction.46 \nQuantitative parameters such as the effective regurgitant orifice area \n(EROA) have prognostic implications.510,511 Volumetric methods pro-\nvide additional information on MR severity [RVol and regurgitant frac-\ntion (RF)].512 Accurate colour flow settings must be used to avoid \noverestimation of MR severity. \nTransoesophageal echocardiography (TOE) represents the method of \nchoice to assess valve anatomy, leaflet quality, motion, and coaptation, as \nwell as to confirm MR severity.513 Three-dimensional TOE provides an \nexcellent morphological and functional view of the different valve seg-\nments, and should be used systematically when planning and performing \nsurgical or transcatheter repair.514 \nExercise echocardiography evaluates dynamic changes in regurgitant jet \nand pulmonary pressures during peak exercise, and might be helpful in pa-\ntients with discordant symptoms and regurgitation severity at rest.515,516 \nIn asymptomatic patients with severe PMR, increased LV or LA di-\nmensions, as well as elevated pulmonary pressures (>50 mmHg at \nrest), moderate or more secondary TR, and AF are important markers \nof worse prognosis, and should be considered for intervention timing \n(Figure 11; Section 9.1.4).517,518 \nRight heart catheterization remains important in patients with PMR \nfor confirmation of pulmonary artery pressures in case of discrepancy \nbetween echocardiographic MR severity and clinical symptoms, as well \nas in the presence of concomitant lung disease.519 \n9.1.2.2. Biomarkers \nCardiac biomarkers are recognized indicators of disease \nseverity with prognostic implications, but may also be non- \nspecific. NT-proBNP levels are directly related to the \nNew York Heart Association (NYHA) functional class in PMR.520 \nRecommendation Table 5 — Recommendations on in-\ndications for concomitant aortic valve replacement at \nthe time of coronary artery bypass grafting or ascending \naorta surgery \nRecommendations \nClassa \nLevelb  \nSAVR is recommended in symptomatic and \nasymptomatic patients with severe AS undergoing \nCABG or surgical intervention on the ascending \naorta. \nI \nC \nSAVR should be considered in symptomatic and \nasymptomatic patients with moderate ASc \nundergoing CABG or surgical intervention on the \nascending aorta. \nIIa \nC \n© ESC/EACTS 2025\nAS, aortic stenosis; AVA, aortic valve area; CABG, coronary artery bypass grafting; SAVR, \nsurgical aortic valve replacement. \naClass of recommendation. \nbLevel of evidence. \ncDefined as an AVA of 1.0–1.5 cm2 (or mean aortic gradient of 25–40 mmHg) in \nnormal-flow conditions. Clinical assessment is essential to determine whether SAVR is \nappropriate for an individual patient.   \nESC Guidelines                                                                                                                                                                                          4671 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "keywords": [
        "aortic stenosis",
        "elderly",
        "recommended",
        "echocardiography",
        "lvef",
        "should be considered",
        "prosthetic valve",
        "coronary artery",
        "regurgitation",
        "mitral",
        "mitral regurgitation",
        "nt-probnp",
        "nyha",
        "aortic",
        "catheterization",
        "savr",
        "valve replacement",
        "stenosis",
        "sudden cardiac death",
        "exercise"
      ],
      "tables": [
        {
          "title": "Table on page 37",
          "page_number": 36,
          "content": "Recommendations | Classa | Levelb\nSAVR is recommended in symptomatic and\nasymptomatic patients with severe AS undergoing\nCABG or surgical intervention on the ascending\naorta. | I | C\nSAVR should be considered in symptomatic and\nasymptomatic patients with moderate ASc\nundergoing CABG or surgical intervention on the\nascending aorta. | IIa | C",
          "bbox": [
            42.51969909667969,
            104.0009765625,
            291.47198486328125,
            224.0
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "10. Mitral stenosis",
      "start_page": 44,
      "end_page": 45,
      "content": "9.2.5. Management of atrial secondary mitral \nregurgitation \n9.2.5.1. Medical therapy and rhythm management \nIn patients with atrial SMR, underlying causes need to be recognized and \ntreated. Associated HFpEF and AF should be managed according to the \nrelevant Guidelines.7,340 The use of SGLT2is should be encouraged in \npatients with HFpEF due to their proven efficacy in reducing cardiovas-\ncular death and HF hospitalization.625 Limited data show that rhythm \ncontrol may contribute to reduce atrial SMR severity and reverse LA \ndilatation.626 \n9.2.5.2. Indications for intervention \nRegistry data demonstrate that patients with atrial SMR are typically \nelderly with associated AF. Mitral valve surgery has been recently asso-\nciated with lower rates of HF hospitalizations and mortality compared \nwith GDMT in a matched population, despite a higher risk profile in the \nsurgical arm at baseline.627 Data from several observational studies also \nsuggest that surgical annuloplasty is effective and durable in patients with \natrial SMR, because it counteracts the main mechanism of MR progres-\nsion.628–630 Its combination with surgical AF ablation (Maze procedure) \nand concomitant LAAO may have further advantages,630,631 while the fre-\nquently associated relevant TR can also be addressed during the same pro-\ncedure.627 Transcatheter edge-to-edge repair may also be considered \nbecause observational studies have demonstrated high safety and proced-\nural success,588–590,632,633 as well as compared with surgery in a small sub-\ngroup (n = 34) of the MATTERHORN RCT.634 However, the risk of \nincreased gradient due to planar leaflet coaptation, large regurgitant jet, \nand limited MV area (MVA) needs to be taken into consideration.592,635 \nFurther studies are warranted to investigate the treatment modalities of \npatients with atrial SMR. \n9.2.5.3. Follow-up \nPatients with atrial SMR undergoing surgical or transcatheter interven-\ntion should be followed up on a yearly basis, including clinical and echo-\ncardiographic evaluation. In cases of HFpEF, as an underlying cause of \natrial SMR, consultation with an HF specialist is necessary. \nAsymptomatic patients with severe atrial SMR not fulfilling the cri-\nteria for an intervention should undergo clinical and echocardiographic \nfollow-up at least once per year. \n10. Mitral stenosis \n10.1. Prevalence and aetiology \nThe aetiology of MS is most frequently rheumatic or degenerative, \nwhile rare forms can be drug-induced, inflammatory, or \ncarcinoid-related. Rheumatic fever is the most common cause of \nMS and death due to VHD worldwide. Its prevalence has decreased \nin high- and middle-income countries, but remains a major health-\ncare problem in low-income countries, where it predominantly \naffects young patients.12,187,644 Degenerative MS related to MAC \nis \na \ndistinct \nage-dependent \npathology \nrequiring \ndifferent \ntreatment strategies.645–647 Both aetiologies are more frequent in \nfemales.648 \n10.2. Rheumatic mitral stenosis \n10.2.1. Evaluation \nEchocardiography is the preferred method for screening in endemic re-\ngions and the assessment of the severity, extent of anatomical lesions, \nand haemodynamic consequences of MS. Involvement of other valves, \nparticularly secondary TR, should be identified. Mitral valve area using \nRecommendation Table 7 — Recommendations on in-\ndications \nfor \nintervention \nin \nsecondary \nmitral \nregurgitation (see also Supplementary data online, \nEvidence Tables 17–20) \nRecommendations \nClassa \nLevelb \nSevere atrial secondary mitral regurgitation  \nMV surgery, surgical AF ablation, if indicated, and \nLAAO should be considered in symptomatic patients \nwith severe atrial SMR under optimal medical \ntherapy.627–630,636,637 \nIIa \nB \nTEER may be considered in symptomatic patients \nwith severe atrial SMR not eligible for surgery after \noptimization of medical therapy including rhythm \ncontrol, when appropriate.588,590,638,639 \nIIb \nB                                                                                                   \nContinued \nVentricular secondary mitral regurgitation and concomitant \ncoronary artery disease \nMV surgery is recommended in patients with severe \nventricular SMR undergoing CABG.640 \nI \nB \nMV surgery may be considered in patients with \nmoderate SMR undergoing CABG.622–624,641,642 \nIIb \nB \nPCI followed by TEER after re-evaluation of MR may \nbe considered in symptomatic patients with chronic \nsevere ventricular SMR and non-complex CAD.150 \nIIb \nC \nSevere ventricular secondary mitral regurgitation without \nconcomitant coronary artery disease \nTEER is recommended to reduce HF hospitalizations \nand improve quality of life in haemodynamically \nstable, symptomatic patients with impaired LVEF \n(<50%) and persistent severe ventricular SMR, \ndespite optimized GDMT and CRT (if indicated), \nfulfilling specific clinical and echocardiographic \ncriteria.c 583,584,606,608,643 \nI \nA \nTEER may be considered for symptom improvement \nin selected symptomatic patients with severe \nventricular SMR not fulfilling the specific clinical and \nechocardiographic criteria,c after careful evaluation \nof LVAD or HTx.203,608–610 \nIIb \nB \nMV surgery may be considered in symptomatic \npatients with severe ventricular SMR without \nadvanced HF who are not suitable for TEER.617 \nIIb \nC \n© ESC/EACTS 2025\nAF, atrial fibrillation; CABG, coronary artery bypass grafting; CAD, coronary artery disease; \nCRT, cardiac resynchronization therapy; GDMT, guideline-directed medical therapy; HF, \nheart failure; HTx, heart transplantation; LAAO, left atrial appendage occlusion; LVAD, \nleft ventricular assist device; LVEF, left ventricular ejection faction; MR, mitral \nregurgitation; MV, mitral valve; PCI, percutaneous coronary intervention; SMR, \nsecondary mitral regurgitation; TEER, transcatheter edge-to-edge repair. \naClass of recommendation. \nbLevel of evidence. \ncSee Table 7.   \nESC Guidelines                                                                                                                                                                                          4679 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "keywords": [
        "elderly",
        "heart failure",
        "echo",
        "recommended",
        "hfpef",
        "echocardiography",
        "lvef",
        "crt",
        "should be considered",
        "coronary artery",
        "mitral stenosis",
        "mitral",
        "mitral regurgitation",
        "may be considered",
        "guideline",
        "atrial fibrillation",
        "ablation",
        "age",
        "stenosis"
      ],
      "tables": [
        {
          "title": "Table on page 45",
          "page_number": 44,
          "content": " | Ventricular secondary mitral regurgitation and concomitant\ncoronary artery disease |  |  | \nMV surgery is recommended in patients with severe\nventricular SMR undergoing CABG.640 |  | I | B | \nMV surgery may be considered in patients with\nmoderate SMR undergoing CABG.622–624,641,642 |  | IIb | B | \nPCI followed by TEER after re-evaluation of MR may\nbe considered in symptomatic patients with chronic\nsevere ventricular SMR and non-complex CAD.150 |  | IIb | C | \n | Severe ventricular secondary mitral regurgitation without\nconcomitant coronary artery disease |  |  | \nTEER is recommended to reduce HF hospitalizations\nand improve quality of life in haemodynamically\nstable, symptomatic patients with impaired LVEF\n(<50%) and persistent severe ventricular SMR,\ndespite optimized GDMT and CRT (if indicated),\nfulfilling specific clinical and echocardiographic\ncriteria.c 583,584,606,608,643 |  | I | A | \nTEER may be considered for symptom improvement\nin selected symptomatic patients with severe\nventricular SMR not fulfliling the specifci clinical and\nechocardiographic criteria,c after careful evaluation\nof LVAD or HTx.203,608–610 |  | IIb | B | \nMV surgery may be considered in symptomatic\npatients with severe ventricular SMR without\nadvanced HF who are not suitable for TEER.617 |  | IIb | C | ",
          "bbox": [
            309.47198486328125,
            60.2,
            558.4249877929688,
            383.99798583984375
          ],
          "function_potential": "raw"
        },
        {
          "title": "©  ESC / EACTS 2025",
          "page_number": 44,
          "content": "Recommendations | Classa | Levelb\nSevere atrial secondary mitral regurgitation |  | \nMV surgery, surgical AF ablation, if indicated, and\nLAAO should be considered in symptomatic patients\nwith severe atrial SMR under optimal medical\ntherapy.627–630,636,637 | IIa | B\nTEER may be considered in symptomatic patients\nwith severe atrial SMR not eligible for surgery after\noptimization of medical therapy including rhythm\ncontrol, when appropriate.588,590,638,639 | IIb | B",
          "bbox": [
            42.51969909667969,
            591.949951171875,
            291.47198486328125,
            735.5498918805804
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "11. Tricuspid regurgitation",
      "start_page": 47,
      "end_page": 48,
      "content": "surgical MV repair or replacement with extensive decalcification and \npatch reconstruction of the annulus can be performed in selected patients \nat experienced centres (e.g. young patients post-chest radiation), where \nmortality rates of <5% have been reported.677–679 \nDegenerative MS is not amenable to PMC because commissural fu-\nsion is absent. In symptomatic high-risk patients with suitable anat-\nomy, transcatheter implantation of a TAVI prosthesis in the mitral \nposition is feasible but associated with frequent complications, includ-\ning LVOT obstruction, valve embolization, stroke, and haemolysis due \nto PVL. Open surgical valve replacement via the LA with a TAVI device \nis an alternative that allows complete anterior leaflet removal;680 \nhowever, mortality remains high. The use of dedicated TMVI devices \nis therefore encouraged because it appears to be safer.542,681 Heart \nTeam evaluation should guide the choice of treatment avoiding futility, \nbecause mortality remains high, even after successful treatment \n(10%–30% within 1 year). \n11. Tricuspid regurgitation \n11.1. Prevalence and aetiology \nTR is a common echocardiographic finding in the general population, \nwith higher prevalence in women and older patients. Trivial or mild \nTR is mostly a benign condition. Significant TR (≥ moderate) has a re-\nported age- and sex-adjusted prevalence of 0.55% (4% in people aged \n≥75 years).682 Severe TR is associated with increased risk of death \nand HF, independent of comorbidities, ventricular function, and pul-\nmonary pressures.683–686 \nOnly 8%–10% of patients with TR present with clear anatomical ab-\nnormalities of the TV apparatus (primary TR), which can be due to infect-\nive endocarditis, RHD, carcinoid syndrome, congenital abnormalities (e.g. \nEbstein’s anomaly), chest radiation, or myxomatous disease, as well as \ntrauma or iatrogenic valve damage (e.g. after endomyocardial biopsy).682 \nCardiac implantable electronic device (CIED)-related TR represents a \nseparate entity requiring a specific diagnostic approach and manage-\nment.687 In patients with a CIED, diagnostic efforts should be made to \nclarify if the lead is the cause of TR (CIED-related TR) or incidental \n(CIED-associated TR).688 \nIn patients with secondary TR, TV leaflets are structurally normal and \nregurgitation is caused by annular dilatation and/or leaflet tethering due \nto RA dilatation, and/or RV dilation and dysfunction. Based on the main \nmorphological and haemodynamic characteristics, two phenotypes of \nsecondary TR have been proposed:689 (i) atrial secondary TR, mainly \ndue to AF and characterized by the absence of significant leaflet tether-\ning, but with marked RA and annular dilatation along with preserved RV \nsize/function, pulmonary pressure, and LV function; and (ii) ventricular \nsecondary TR, due to annular dilatation and leaflet tethering as a con-\nsequence of left-sided ventricular or valvular disease (post-capillary \nPH), pre-capillary PH, or primary RV cardiomyopathy/ischaemia (also \nafter left-sided valve surgery).690 At an advanced disease stage, these \ntwo phenotypes may no longer be distinguishable, and therefore early \ncharacterization is key to determine outcome.691,692 Evidence of an im-\npact on patient management is currently lacking; therefore, current \nrecommendations for intervention consider mainly primary vs second-\nary TR. \nRecommendation Table 8 — Recommendations on \nindications for percutaneous mitral commissurotomy, \nmitral valve surgery, and transcatheter intervention \nin clinically severe rheumatic and degenerative mitral \nstenosis \n(see \nalso \nSupplementary \ndata \nonline, \nEvidence Table 21) \nRecommendations \nClassa \nLevelb  \nPMC is recommended in symptomatic patients in the \nabsence of unfavourable characteristics for PMC.c \n651–653,662,665 \nI \nB \nPMC is recommended in any symptomatic patients \nwith a contraindication or at high risk for surgery. \nI \nC \nMV surgery is recommended in symptomatic \npatients who are not suitable for PMC. \nI \nC \nPMC should be considered as initial treatment in \nsymptomatic patients with suboptimal anatomy but \nno unfavourable clinical characteristics for PMC.c \nIIa \nC \nPMC should be considered in asymptomatic patients \nwithout unfavourable clinical and anatomical \ncharacteristics for PMC, and: \n• High thromboembolic risk (history of systemic \nembolism, dense spontaneous contrast in the LA, \nnew-onset or paroxysmal AF), and/or \n• High risk of haemodynamic decompensation \n(SPAP >50 mmHg at rest, need for major NCS, \npregnant or desire for pregnancy). \nIIa \nC \nTMVI may be considered in symptomatic patients \nwith extensive MAC and severe MV dysfunction at \nexperienced Heart Valve Centres with expertise in \ncomplex MV surgery and transcatheter \ninterventions.542,680,681 \nIIb \nC \n© ESC/EACTS 2025\nAF, atrial fibrillation; LA, left atrium/left atrial; MAC, mitral annular calcification; MV, mitral \nvalve; NCS, non-cardiac surgery; NYHA, New York Heart Association; PH, pulmonary \nhypertension; PMC, percutaneous mitral commissurotomy; SPAP, systolic pulmonary \nartery pressure; TMVI, transcatheter mitral valve implantation; TR, tricuspid regurgitation. \naClass of recommendation. \nbLevel of evidence. \ncUnfavourable characteristics for PMC can be defined by the presence of several of the \nfollowing characteristics: clinical characteristics (old age, history of commissurotomy, NYHA \nclass IV, permanent AF, severe PH); anatomical characteristics [echocardiographic score >8, \nCormier score group 3 (calcification of MV of any extent as assessed by fluoroscopy), \nsevere TR] (for the definition of scores see Supplementary data online, Table S3).  \nTable 8 Contraindications for percutaneous mitral \ncommissurotomy in rheumatic mitral stenosis \nContraindications  \nMVA >1.5 cm2 a \nLA thrombusb \nMore than mild MR \nSevere or bi-commissural calcification \nAbsence of commissural fusion \nSevere concomitant AV disease, or severe combined tricuspid stenosis and \nregurgitation requiring surgery \nConcomitant CAD requiring bypass surgery \n© ESC/EACTS 2025\nAV, aortic valve; CAD, coronary artery disease; LA, left atrium/left atrial; MR, mitral \nregurgitation; MVA, mitral valve area; OAC, oral anticoagulation; PMC, percutaneous \nmitral commissurotomy; TOE, transoesophageal echocardiography. \naPMC may be considered in patients with MVA of >1.5 cm2 with symptoms that cannot be \nexplained by another cause and if the anatomy is favourable. \nbWhen the thrombus is located in the LA appendage, PMC may be considered in patients \nwith contraindications to surgery or those without urgent need for intervention, in whom \nOAC can be safely given for 1–3 months, provided repeat TOE confirms resolution of \nthrombus.   \n4682                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "keywords": [
        "recommended",
        "contraindication",
        "anticoagulation",
        "hypertension",
        "echocardiography",
        "should be considered",
        "coronary artery",
        "mitral stenosis",
        "regurgitation",
        "nyha",
        "aortic",
        "older",
        "may be considered",
        "tricuspid",
        "sex",
        "atrial fibrillation",
        "valve replacement",
        "systolic",
        "tavi",
        "age",
        "cardiomyopathy",
        "stenosis"
      ],
      "tables": [
        {
          "title": "©  ESC / EACTS 2025",
          "page_number": 47,
          "content": "Recommendations | Classa | Levelb\nPMC is recommended in symptomatic patients in the\nabsence of unfavourable characteristics for PMC.c\n651–653,662,665 | I | B\nPMC is recommended in any symptomatic patients\nwith a contraindication or at high risk for surgery. | I | C\nMV surgery is recommended in symptomatic\npatients who are not suitable for PMC. | I | C\nPMC should be considered as initial treatment in\nsymptomatic patients with suboptimal anatomy but\nno unfavourable clinical characteristics for PMC.c | IIa | C\nPMC should be considered in asymptomatic patients\nwithout unfavourable clinical and anatomical\ncharacteristics for PMC, and:\n• High thromboembolic risk (history of systemic\nembolism, dense spontaneous contrast in the LA,\nnew-onset or paroxysmal AF), and/or\n• High risk of haemodynamic decompensation\n(SPAP >50 mmHg at rest, need for major NCS,\npregnant or desire for pregnancy). | IIa | C\nTMVI may be considered in symptomatic patients\nwith extensive MAC and severe MV dysfunction at\nexperienced Heart Valve Centres with expertise in\ncomplex MV surgery and transcatheter\ninterventions.542,680,681 | IIb | C",
          "bbox": [
            36.850399017333984,
            326.052001953125,
            285.8030090332031,
            642.0499877929688
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "12. Tricuspid stenosis",
      "start_page": 52,
      "end_page": 53,
      "content": "more than 80% of cases when anatomical suitability was con-\nfirmed.713,733–735 The Clinical Trial to Evaluate Cardiovascular \nOutcomes in Patients Treated With the Tricuspid Valve Repair \nSystem (TRILUMINATE) Pivotal Trial showed also a lower incidence \nof the composite endpoint of death from any cause or TV surgery, \nHF hospitalization, and improvement in quality of life as measured \nwith the KCCQ score after tricuspid TEER compared with medical \ntreatment that was exclusively driven by improved quality of life \n[11.7 points (95% CI, 6.8–16.6); P <0.001].713 At 2 years, a lower inci-\ndence of HF hospitalizations has been observed in the intervention \ngroup, despite a high rate of crossovers (59%).736 \nAnother investigator-initiated RCT (the Tri.Fr trial) demonstrated \nthe benefit of tricuspid TEER in combination with GDMT over medical \ntherapy alone, for a composite score driven by improved PROMs.737 \nAnother recent RCT (the Edwards EVOQUE Transcatheter \nTricuspid Valve Replacement: Pivotal Clinical Investigation of Safety \nand Clinical Efficacy using a Novel Device (TRISCEND) II trial), compar-\ning transcatheter TV replacement with optimized medical therapy in \npatients with symptomatic severe TR, showed similar results with a \nwin ratio favouring TV replacement mainly explained by symptom \nand quality-of-life improvement. In these studies, reverse RV remodel-\nling was also observed. However, the safety profile of transcatheter TV \nreplacement was less favourable, including higher risk for major bleed-\ning (15%) and post-procedural pacemaker implantation in about one- \nquarter of the pacemaker-naïve patients after 12 months of follow- \nup.738 Based on these data, transcatheter treatment should be consid-\nered to improve quality of life and RV remodelling in high-risk patients \nwith symptomatic severe TR, despite optimal medical therapy, but \nwithout severe RV dysfunction or pre-capillary PH. \nTransvenous CIED lead repositioning or extraction can be consid-\nered in selected patients to improve TR or avoid lead jailing before \nany tricuspid interventions, although the efficacy of this procedure is \nuncertain and the risk of damaging the TV not negligible.688,717,739 \nRecurrent TR after previous tricuspid annuloplasty usually requires car-\ndiac reoperation for surgical TV replacement. Transcatheter valve-in-ring \nimplantation is an off-label procedure to treat residual TR in high-risk pa-\ntients. Challenges are the non-circular shape and the open form of the sur-\ngical annuloplasty ring.740 However, transcatheter tricuspid valve-in-valve \nprocedures have been performed with satisfactory results.741 \nTranscatheter TV procedures should be performed at an ex-\nperienced Heart Valve Centre with expertise in the treatment of \nTV disease (Table 6). Careful evaluation of clinical and anatomical \nsuitability is key for appropriate patient and device selection to \nachieve optimal TR reduction and symptomatic response to the \ntherapy. \n12. Tricuspid stenosis \n12.1. Prevalence and aetiology \nTricuspid stenosis (TS) is a relatively rare disease that is most commonly \nassociated with congenital conditions or enzymatic disorders, such as \nWhipple’s or Fabry’s disease. It can also be acquired as an isolated mani-\nfestation of RHD or occur in combination with aortic and/or MV involve-\nment. Moreover, TS can be the consequence of carcinoid disease due to \nserotonin-mediated proliferation, causing apposition of fibroblasts and \nextracellular matrix on the valve leaflets and the subvalvular apparatus. \nRare causes include medications (e.g. fenfluramine or methysergide) or in-\nflow obstruction due to CIED-associated thrombus formation or endo-\ncarditis with large vegetations. \n12.2. Evaluation \nValve evaluation and diagnosis of TS is based on echocardiography, and \nconsists of the anatomical assessment of the leaflet tissue and the sub-\nvalvular apparatus. Leaflet thickening with or without calcifications and \nRecommendation Table 9 — Recommendations on in-\ndications for intervention in tricuspid regurgitation (see \nalso Supplementary data online, Evidence Tables 22 and 23) \nRecommendations \nClassa \nLevelb  \nCareful evaluation of TR aetiology, stage of the \ndisease (i.e. degree of TR severity, RV and LV \ndysfunction, and PH), patient operative risk, and \nlikelihood of recovery by a multidisciplinary Heart \nTeam is recommended in patients with severe TR \nprior to intervention.691,742 \nI \nC                                                                                                   \nContinued \nPatients with tricuspid regurgitation and left-sided valvular \nheart disease requiring surgery \nConcomitant TV surgeryc is recommended in \npatients with severe primary or secondary \nTR.725,731,743,744 \nI \nB \nConcomitant TV repair should be considered in \npatients with moderate primary or secondary TR, to \navoid progression of TR and RV \nremodelling.723,724,726,731 \nIIa \nB \nConcomitant TV repair may be considered \nin selected patients with mild secondary TR \nand tricuspid annulus dilatation (≥40 mm or \n>21 mm/m2), to avoid progression of TR and RV \nremodelling.723–726,731,743 \nIIb \nB \nPatients with severe tricuspid regurgitation without left-sided \nvalvular heart disease requiring surgery \nTV surgeryc is recommended in symptomatic \npatients with severe primary TR without severe RV \ndysfunction or severe PH. \nI \nC \nTV surgeryc should be considered in asymptomatic \npatients with severe primary TR who have RV \ndilatation/RV function deterioration, but without \nsevere LV/RV dysfunction or severe PH. \nIIa \nC \nTV surgeryc should be considered in patients with \nsevere secondary TR who are symptomatic or have \nRV dilatation/RV function deterioration, but without \nsevere LV/RV dysfunction or PH.685,720,745–747 \nIIa \nB \nTranscatheter TV treatment should be considered to \nimprove quality of life and RV remodelling in high-risk \npatients with symptomatic severe TR despite optimal \nmedical therapy in the absence of severe RV \ndysfunction or pre-capillary PH.713,733,735,738,748–751 \nIIa \nA \n© ESC/EACTS 2025\nLV, left ventricle/left ventricular; PH, pulmonary hypertension; RV, right ventricle/right \nventricular; TR, tricuspid regurgitation; TV, tricuspid valve. \naClass of recommendation. \nbLevel of evidence. \ncValve repair whenever possible.   \nESC Guidelines                                                                                                                                                                                          4687 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "keywords": [
        "valve replacement",
        "valve repair",
        "echocardiography",
        "hypertension",
        "pacemaker",
        "should be considered",
        "recommended",
        "aortic",
        "pulmonary hypertension",
        "may be considered",
        "tricuspid",
        "stenosis"
      ],
      "tables": [
        {
          "title": "Table on page 53",
          "page_number": 52,
          "content": " | Patients with tricuspid regurgitation and left-sided valvular\nheart disease requiring surgery |  |  | \nConcomitant TV surgeryc is recommended in\npatients with severe primary or secondary\nTR.725,731,743,744 |  | I | B | \nConcomitant TV repair should be considered in\npatients with moderate primary or secondary TR, to\navoid progression of TR and RV\nremodelling.723,724,726,731 |  | IIa | B | \nConcomitant TV repair may be considered\nin selected patients with mild secondary TR\nand tricuspid annulus dilatation (≥40 mm or\n>21 mm/m2), to avoid progression of TR and RV\nremodelling.723–726,731,743 |  | IIb | B | \n | Patients with severe tricuspid regurgitation without left-sided\nvalvular heart disease requiring surgery |  |  | \nTV surgeryc is recommended in symptomatic\npatients with severe primary TR without severe RV\ndysfunction or severe PH. |  | I | C | \nTV surgeryc should be considered in asymptomatic\npatients with severe primary TR who have RV\ndilatation/RV function deterioration, but without\nsevere LV/RV dysfunction or severe PH. |  | IIa | C | \nTV surgeryc should be considered in patients with\nsevere secondary TR who are symptomatic or have\nRV dilatation/RV function deterioration, but without\nsevere LV/RV dysfunction or PH.685,720,745–747 |  | IIa | B | \nTranscatheter TV treatment should be considered to\nimprove quality of life and RV remodelling in high-risk\npatients with symptomatic severe TR despite optimal\nmedical therapy in the absence of severe RV\ndysfunction or pre-capillary PH.713,733,735,738,748–751 |  | IIa | A | ",
          "bbox": [
            309.47198486328125,
            60.2,
            558.4249877929688,
            456.99798583984375
          ],
          "function_potential": "raw"
        },
        {
          "title": "©  ESC / EACTS 2025",
          "page_number": 52,
          "content": "Recommendations | Classa | Levelb\nCareful evaluation of TR aetiology, stage of the\ndisease (i.e. degree of TR severity, RV and LV\ndysfunction, and PH), patient operative risk, and\nlikelihood of recovery by a multidisciplinary Heart\nTeam is recommended in patients with severe TR\nprior to intervention.691,742 | I | C",
          "bbox": [
            42.51969909667969,
            631.697998046875,
            291.47198486328125,
            727.29736328125
          ],
          "function_potential": "raw"
        },
        {
          "title": "Recommendation Table 10  — Recommendations on  indications for intervention in tricuspid stenosis",
          "page_number": 53,
          "content": "Recommendations | Classa | Levelb\nSurgeryc is recommended in symptomatic patients\nwith severe TS.d | I | C\nSurgeryc is recommended in patients with severe TS\nundergoing left-sided valve intervention.e | I | C",
          "bbox": [
            36.850399017333984,
            407.7569885253906,
            285.8030090332031,
            479.7569885253906
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "13. Multiple and mixed valvular heart disease",
      "start_page": 53,
      "end_page": 54,
      "content": "commissural fusions are pathognomonic findings of rheumatic involve-\nment. A mean diastolic transvalvular gradient of >5 mmHg at a normal \nheart rate indicates severe TS.649 \n12.3. Medical therapy \nMedical therapy is a bridge to surgical or transcatheter intervention. \nIntensive sodium restriction and concomitant diuretic therapy can \nlead to symptom improvement and diminish hepatic congestion. \n12.4. Indications for intervention \nAlthough valve repair is preferred in younger patients,752 valve replace-\nment is frequently required (see Recommendation Table 10). Biological \nheart valves have demonstrated adequate mid- and long-term results, \nand are preferred over MHVs because of high thrombogenicity in the \nlow-pressure system.753 In the case of BHV degeneration, transcatheter \nvalve-in-valve procedures are good alternatives to re-replacement.754 \nTranscatheter TV implantation is an emerging field, although limited ex-\nperience is available for the treatment of TS.749,755 In patients with car-\ncinoid disease, a stable oncological situation is a prerequisite for any \nvalve intervention to maximize survival and valve durability.756 \nAlthough data are very limited, TV balloon valvuloplasty can be an \noption in selected patients with TS (and no relevant TR), as well as in \nthose with concomitant mitral and tricuspid rheumatic pathology.757 \nHowever, in contrast to rheumatic MS, tricuspid rheumatic disease \nmore frequently presents as combined stenosis and regurgitation, \nwhich limits the applicability of balloon valvuloplasty. \n13. Multiple and mixed valvular \nheart disease \n13.1. Prevalence and undertreatment \nPatients frequently present with disease of more than one native heart \nvalve [multiple VHD (MVHD)], or coexisting stenosis and regurgitation \nof the same valve (mixed VHD).758 While the main cause of MVHD or \nmixed VHD has shifted to degeneration in high-income countries, the \nleading aetiology in low- and middle-income countries remains \nRHD.758,759 Regurgitation of atrioventricular valves secondary to cardio-\nmyopathy or long-standing primary valve disease, and late effects of radi-\nation therapy, are further causes of MVHD.758,760 Challenges in diagnostic \nevaluation coupled with limited data to guide clinical decisions contribute \nto late referral and undertreatment of patients with MVHD.758 \n13.2. Evaluation and diagnostic pitfalls \nIn view of the complex haemodynamic interplay of multiple and mixed \nvalve lesions, assessment by a Heart Team at a Heart Valve Centre and \nuse of an integrative multimodality approach is key to gain diagnostic \ncertainty, detect cardiac damage, and evaluate therapeutic op-\ntions.761,762 In the light of paucity of data on diagnostic and prognostic \nparameters in patients with MVHD, assessment largely focuses on \npathophysiological considerations and evidence derived from isolated \nvalve lesions. \nEchocardiography is the main tool to diagnose MVHD, assess mech-\nanism, severity, and associated cardiac damage, and monitor disease \nprogression.761 Haemodynamic interdependence between multiple \nvalve defects alters the loading and flow conditions, thereby limiting \nthe diagnostic validity of measures established to grade single valve de-\nfects (Table 9). In the presence of MVHD, low-flow states are frequent. \nThe continuity equation becomes erroneous if transvalvular flows are \nunequal, and pressure half-time (PHT)-derived methods are inaccurate \nif the ventricular compliance or filling is altered.761 In this context, \nTOE can provide important detailed anatomical and mechanistic \nflow-independent information.46,761 \nIf symptoms or echocardiographic findings are equivocal, multimod-\nality diagnostics should be considered on an individual basis to assess \nthe cumulative repercussions of MVHD. \nMeasures obtained during cardiopulmonary exercise testing reflect \nthe effect of MVHD on functional capacity.52,105,654,761,779 Levels of \nnatriuretic peptides such as NT-proBNP correlate with functional \nand echocardiographic parameters, and provide incremental prognos-\ntic value in patients with mixed aortic disease and MVHD.98,780 AV cal-\ncium scoring confirms the diagnosis of true severe AS under low-flow \nconditions, as described in Section 8.2.777 Cardiac magnetic resonance \nimaging enables the independent assessment of valvular regurgitation \nusing volumetric methods or direct flow quantification.45,46,522,762,781 \nImportantly, invasive cardiac output-derived measures based on \nthermodilution or the Fick equation using estimated oxygen uptake \nare inaccurate in low-flow conditions or severe TR, commonly pre-\nsent in MVHD.782 \n13.3. Indications for intervention \nGiven the heterogeneity of clinical scenarios and the lack of evidence on \noptimal treatment pathways, it is recommended that patients with \nMVHD are evaluated for intervention by a collaborative Heart Team \nat a Heart Valve Centre with experience in multimodality imaging \nand treatment of complex VHD.16,764 \nPatients presenting with a lesion fulfilling criteria for an intervention \nbased on recommendations for single VHD should be treated accord-\ningly. In the remaining patients, assessment of symptoms and functional \nstatus, as well as cardiac damage (which may be masked by the conse-\nquences of concomitant lesions and occur before symptoms manifest), \nis required. The risk–benefit ratio of intervention needs to take into \naccount diagnostic (un)certainty, the mechanisms and severity of \nMVHD, and patient-specific factors, as well as procedural options and \nrisks to determine the mode, timing, and sequence of valve treatment. \n13.3.1. Multiple valvular heart disease \nMultiple VHD with primary (as opposed to secondary) valvular disease \nusually requires surgical treatment of all relevant valvular lesions. \nSimultaneous treatment of concomitant severe valve defects is recom-\nmended and treatment of concomitant moderate AS, or moderate TR, \nshould be considered (Recommendation Table 11). \nRecommendation Table 10 — Recommendations on \nindications for intervention in tricuspid stenosis \nRecommendations \nClassa \nLevelb  \nSurgeryc is recommended in symptomatic patients \nwith severe TS.d \nI \nC \nSurgeryc is recommended in patients with severe TS \nundergoing left-sided valve intervention.e \nI \nC \n© ESC/EACTS 2025\nMV, mitral valve; PMC, percutaneous mitral commissurotomy; TS, tricuspid stenosis; TV, \ntricuspid valve. \naClass of recommendation. \nbLevel of evidence. \ncUsually TV replacement. \ndPercutaneous balloon valvuloplasty can be attempted as a first approach if TS is isolated. \nePercutaneous balloon valvuloplasty can be attempted if PMC can be performed on the MV.   \n4688                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "keywords": [
        "diastolic",
        "disease",
        "valve repair",
        "echocardiography",
        "diuretic",
        "multiple",
        "heart",
        "valvular",
        "nt-probnp",
        "recommended",
        "should be considered",
        "aortic",
        "mixed",
        "tricuspid",
        "stenosis",
        "exercise"
      ],
      "tables": [
        {
          "title": "Table on page 55",
          "page_number": 54,
          "content": " |  | Valve lesion to be assessed |  |  | \n |  | AS | AR | MS | MR\nConcomitant\nvalve lesion | AS | — | PHT unreliable\nLV volume increase less\npronounced\n(hypertrophy,\ndisproportionate diastolic LV\npressure overload763) | PHT unreliable\n(LV compliance ↓ 764)\nLow gradient due to low\nfol w possible\n(low-flow state669) | Regurgitant volume ↑\nMR colour-flow jet area ↑\n(increased afterload and\ntransmitral systolic pressure\ngradient46)\n | AR | Simplified Bernoulli\nequation overestimates\ngradient if LVOT\nvelocity ↑ 765 | — | PHT unreliable\n(gradient ↓, altered LV\ncompliance766)\nMVA by continuity\nequation using aortic\nforward flow unreliable46 | Doppler volumetric\nmethod using net aortic\nforward flow invalid\nMitral-to-aortic VTI ratio\nunreliable\n(increased transaortic\nflow46)\n | MS | Low-flow low-gradient\npossible\n(low-flow state761) | LV volume increase less\npronounced\n(reduced preload761) | — | Mitral-to-aortic VTI ratio\nunreliable\n(increased mitral VTI due to\nstenosis767)\nCalcifications may shadow\njet area\n | MR | Low-flow low-gradient\n(MR-induced low-flow\nstate768)\nAS confused with MR jet | PHT unreliable\n(altered LV compliance763)\nDoppler volumetric\nmethod using net mitral\nforward flow invalid\n(increased flow46) | PHT unreliable\n(altered LA and LV\ncompliance769,770)\nContinuity equation\nunreliable\n(increased transmitral\nflow761) | —\n | TR | Low-fol w low-gradient\npossible\n(TR induced low-flow\nstate771) | — | Low gradient possible\n(low-flow state668)\nPHT may be less reliable\n(impaired LV filling due to\nventricular\ninterdependence772,773) | Regurgitant volume↓ in\nSMR possible\n(decreased preload774)\nRobust echocardiography\nmeasurements |  | AVA (continuity equation),\nDVI761\nIn mixed AR and AS: V\nmax\nand mean gradient reflect\ncombined burden765 | EROA (PISA), vena\ncontracta46,761 | Planimetry and 3D\nMVA (TOE)529,775\nIn mixed MR & MS:\nmean gradient reflects\ncombined burden674,776 | EROA (PISA), vena\ncontracta46,761\nAlternative imaging\nmodalities |  | CT: AV calcium\nscoring777 | CMR: regurgitant volume\nand fraction45,46 | — | CMR: regurgitant volume\nand fraction45,46",
          "bbox": [
            42.51969909667969,
            84.0,
            558.4249877929688,
            603.9970092773438
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "14. Management of patients with prosthetic valves or valve repair",
      "start_page": 55,
      "end_page": 56,
      "content": "(often TR > MR). While surgery aims to address all relevant valve lesions \nin a single procedure, a stepwise transcatheter strategy offers the possi-\nbility of reassessing the upstream valve(s) under altered loading condi-\ntions, usually 3 months after the initial intervention. In very selected \ncases simultaneous transcatheter valve treatment may be consid-\nered.788,789 However, evidence is limited and primarily derived from \nmodestly sized observational studies.786–789 \n13.3.2. Mixed aortic valve disease \nThe severity of mixed AV disease is often underestimated and patients \nwith balanced moderate AR and AS show adverse event rates compar-\nable to patients with severe isolated AS.790,791 \nTransvalvular gradients measured by Doppler reflect the overall \nhaemodynamic burden of both regurgitation and stenosis, and are strong-\nly associated with adverse outcomes.765,791–793 Therefore, the presence \nof high transvalvular gradients justifies valve intervention in patients \nwith moderate mixed AV disease, even if regurgitation is graded as mod-\nerate and the calculated or planimetric AVA is >1 cm2 (Recommendation \nTable 12). Patients presenting with mixed AV disease, but with gradients \nbelow thresholds for intervention, should undergo careful multimodality \ndiagnostics including assessment of cardiac damage to inform individual \ntreatment strategies. Global longitudinal strain and natriuretic peptides \nhave shown incremental prognostic value beyond symptom status and \nsingle lesion severity in patients with preserved LVEF.762,794–796 \n13.3.3. Mixed mitral valve disease \nMixed MV disease is usually present in patients with rheumatic valve dis-\nease or MAC. If MVA is ≤1.5 cm2, recommendations for isolated MS \napply. However, patients with an MVA of >1.5 cm2 and moderate \nMR may be evaluated for valve replacement based on symptoms, ana-\ntomical characteristics, transmitral gradient, and signs of cardiac damage \nsuch as LA dilatation, AF, or PH.529,674,776,797 \n13.4. Follow-up \nDue to the cumulative haemodynamic impact of MVHD or mixed \nVHD, progression of its severity and the development of cardiac dam-\nage may be faster than in single VHD.761 Therefore, follow-up intervals \nshould be adjusted according to individual patient characteristics. \n14. Management of patients with \nprosthetic valves or valve repair \n14.1. Choice of prosthetic valve \nWhen choosing between an MHV and a BHV prosthesis for an individual \npatient, age, life expectancy, lifestyle, bleeding and thromboembolic risks, \npossibility of pregnancy, and patient preference should be considered. \nLife expectancy is estimated according to age, sex, comorbidities, ethnicity, \nand geographical area.798 An MHV is preferred in younger patients with \nlonger life expectancy and in those with a pre-existing indication for long- \nterm OAC (Recommendation Table 13). Generally, a BHV is implanted in \npatients with shorter life expectancy, increased bleeding risk due to frailty \nor comorbidities, in women contemplating pregnancy, and in patients in \nwhom stable INRs with adequate times in therapeutic range are unlikely.799 \nImportantly, the performance of different BHV prostheses can vary consid-\nerably.800 The impact of the aetiology of the native valve disease, if any, on \nthe choice between an MHV and a BHV remains unexplored. \nSeveral large observational studies, smaller RCTs, and meta-analyses \nhave compared long-term mortality with BHV and MHV prostheses in \npatients aged 50–70 years.376,801–805 Some of the studies showed \nlower mortality with an MHV in AV patients <60 years and MV patients \n<65 years old,801,804 while others failed to show any differ-\nences.376,802,803 Most of these studies were limited by their observa-\ntional nature and missing information on the type of prostheses \nimplanted. RCTs with sufficient statistical power comparing biological \nand mechanical prostheses are warranted. \nReplacement of the AV using an autograft (Ross procedure) is an \nalternative to an MHV in young patients that should be performed \nat experienced centres by operators with dedicated expertise (see \nalso Section 8).806 General recommendations are summarized in  \nRecommendation Table 13. \nRecommendation Table 11 — Recommendations on \nindications for surgery of concomitant left-sided valvu-\nlar heart diseasea \nRecommendations \nClassb \nLevelc \nConcomitant aortic stenosis  \nSAVR is recommended in patients with severe AS \nundergoing surgery for another valve. \nI \nC \nSAVR should be considered in patients with \nmoderate ASd undergoing surgery for another valve. \nIIa \nC \nConcomitant aortic regurgitation \nAV surgery is recommended in patients with severe \nAR undergoing surgery for another valve. \nI \nC \nConcomitant mitral regurgitation \nMV surgery is recommended in patients with severe \nMR undergoing surgery for another valve. \nI \nC \n© ESC/EACTS 2025\nAR, aortic regurgitation; AS, aortic stenosis; AV, aortic valve; AVA, aortic valve area; MR, mitral \nregurgitation; MV, mitral valve; SAVR, surgical aortic valve replacement; TV, tricuspid valve. \naRecommendations for surgery of concomitant TV disease are listed in Section 11 and Section 12. \nbClass of recommendation. \ncLevel of evidence. \ndDefined as an AVA of 1.0–1.5 cm2 (or mean aortic gradient of 25–40 mmHg) in normal-flow \nconditions. Clinical assessment is essential to determine whether SAVR is appropriate for an \nindividual patient.  \nRecommendation Table 12 — Recommendations on \nindications for intervention in patients with mixed mod-\nerate aortic stenosis and moderate aortic regurgitation \n(see also Supplementary data online, Evidence Table 24) \nRecommendations \nClassa \nLevelb  \nIntervention is recommended in symptomatic \npatients with mixed moderate AV stenosisc and \nmoderate regurgitation, and a mean \ngradient ≥40 mmHg or Vmax ≥4.0 m/s.790–793 \nI \nB \nIntervention is recommended in asymptomatic \npatients with mixed moderate AV stenosisc and \nmoderate regurgitation with Vmax ≥4.0 m/s, and \nLVEF <50% not attributable to other cardiac \ndisease.791 \nI \nC \n© ESC/EACTS 2025\nAV, aortic valve; AVA, aortic valve area; LVEF, left ventricular ejection fraction; Vmax, peak \ntransvalvular velocity. \naClass of recommendation. \nbLevel of evidence. \ncAVA >1 cm2.   \n4690                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "keywords": [
        "aortic stenosis",
        "valves",
        "recommended",
        "indication",
        "repair",
        "valve repair",
        "lvef",
        "management",
        "ethnicity",
        "prosthetic valve",
        "should be considered",
        "patients",
        "mitral regurgitation",
        "aortic",
        "valve",
        "tricuspid",
        "aortic regurgitation",
        "sex",
        "savr",
        "prosthetic",
        "ejection fraction",
        "valve replacement",
        "age",
        "stenosis"
      ],
      "tables": [
        {
          "title": "Table on page 56",
          "page_number": 55,
          "content": "Recommendations | Classa | Levelb\nIntervention is recommended in symptomatic\npatients with mixed moderate AV stenosisc and\nmoderate regurgitation, and a mean\ngradient ≥40 mmHg or V ≥4.0 m/s.790–793\nmax | I | B\nIntervention is recommended in asymptomatic\npatients with mixed moderate AV stenosisc and\nmoderate regurgitation with V ≥4.0 m/s, and\nmax\nLVEF <50% not attributable to other cardiac\ndisease.791 | I | C",
          "bbox": [
            303.8030090332031,
            104.0009765625,
            552.7559814453125,
            236.0
          ],
          "function_potential": "raw"
        },
        {
          "title": "©  ESC / EACTS 2025",
          "page_number": 55,
          "content": "Recommendations |  | Classb | Levelc | \nConcomitant aortic stenosis |  |  |  | \nSAVR is recommended in patients with severe AS\nundergoing surgery for another valve. |  | I | C | \nSAVR should be considered in patients with\nmoderate ASd undergoing surgery for another valve. |  | IIa | C | \n | Concomitant aortic regurgitation |  |  | \nAV surgery is recommended in patients with severe\nAR undergoing surgery for another valve. |  | I | C | \n | Concomitant mitral regurgitation |  |  | \nMV surgery is recommended in patients with severe\nMR undergoing surgery for another valve. |  | I | C | ",
          "bbox": [
            36.850399017333984,
            491.2619934082031,
            285.8030090332031,
            668.260986328125
          ],
          "function_potential": "raw"
        },
        {
          "title": "Recommendation Table 13  — Recommendations for  prosthetic valve selection",
          "page_number": 56,
          "content": "Recommendations |  | Classa | Levelb | \nMechanical heart valve |  |  |  | \nAn MHV is recommended according to the desire of\nthe informed patient and if there is no\ncontraindication to long-term anticoagulation. |  | I | C | \nAn MHV should be considered in patients with an\nestimated long life expectancy,c if there are no\ncontraindications for long-term OAC.801,807–811 |  | IIa | B | \nAn MHV should be considered in patients aged\n<60 years for prostheses in the aortic position and\naged <65 years for prostheses in the mitral\nposition.801,807–811 |  | IIa | C | \nAn MHV should be considered in patients with a\npre-existing MHV in another position. |  | IIa | C | \nAn MHV may be considered in patients with a clear\nindication for long-term OAC. |  | IIb | C | \n | Biological heart valve |  |  | \nA BHV is recommended according to the desire of\nthe informed patient. |  | I | C | \nA BHV is recommended when an adequate quality of\nanticoagulation with VKA is unlikely, in patients at\nhigh bleeding risk, or with estimated short life\nexpectancy.c |  | I | C | \nA BHV should be considered in patients aged\n>65 years for prostheses in the aortic position or\naged >70 years for prostheses in the mitral position. |  | IIa | C | \nA BHV should be considered in women\ncontemplating pregnancy. |  | IIa | C | ",
          "bbox": [
            42.51969909667969,
            84.0,
            291.47198486328125,
            453.99798583984375
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "15. Management during non-cardiac surgery",
      "start_page": 65,
      "end_page": 66,
      "content": "15. Management during \nnon-cardiac surgery \nIn patients with significant VHD who undergo NCS, the risk of peri- \noperative cardiovascular complications is increased and related to \nboth the timing of the procedure (i.e. urgent vs non-urgent) and type \nof surgery (low, intermediate, or high risk), as well as patient-specific \nfactors (type and severity of VHD, LV function, etc.).194,957–959 \nDetailed recommendations related to NCS are available in the 2022 \nESC Guidelines on cardiovascular assessment and management of patients \nundergoing non-cardiac surgery.960 \n15.1. Pre-operative evaluation \nEchocardiography should be performed in all patients with VHD requiring \nNCS. Patient- and surgery-specific factors, along with risk calculators, can \nbe used to guide the treatment strategy. Determination of functional cap-\nacity is a pivotal step for pre-operative risk assessment, measured either by \nthe ability to perform activities in daily life or by exercise testing. Screening \nfor frailty using validated tools is advisable.90 Decisions on pre- and peri- \noperative management, surveillance, and continuation of chronic cardio-\nvascular medical treatment should be taken after multidisciplinary discus-\nsion involving cardiologists, surgeons, and cardiac anaesthesiologists, as \nwell as the team who will be in charge of the NCS. Patients receiving \nOAC treatment should be managed as described in Section 14. \n15.2. Specific valve lesions \n15.2.1. Aortic stenosis \nIn patients with severe symptomatic AS, the treatment depends on the \nurgency and risk of NCS. If life-saving time-sensitive NCS is needed, it \nshould be performed under careful haemodynamic monitoring avoiding \nrapid changes of volume status, with prompt treatment of arrhythmia re-\ngardless of AS severity. In cases of urgent high-risk NCS, TAVI or balloon \naortic valvuloplasty should be considered in patients with critical AS prior \nto surgery, considering the risk of developing severe acute AR after \nRecommendation Table 17 — Recommendations for the management of prosthetic valve dysfunction (see also  \nSupplementary data online, Evidence Table 25) \nRecommendations \nClassa \nLevelb \nHaemolysis and paravalvular leak  \nIt is recommended that the decision between transcatheter or surgical closure of clinically significant PVLs is based on Heart Team \nevaluation, including patient risk, leak morphology, and local expertise. \nI \nC \nReoperation is recommended if a PVL is related to endocarditis, or causes haemolysis requiring repeated blood transfusion or leading to HF \nsymptoms. \nI \nC \nTranscatheter closure should be considered for suitable PVLs with clinically significant regurgitation and/or haemolysis.940 \nIIa \nB \nMechanical heart valve failure \nReoperation is recommended in symptomatic patients with significant valve dysfunction not attributable to valve thrombosis. \nI \nC \nBiological heart valve failure \nReintervention is recommended in symptomatic patients with significant valve dysfunction not attributable to valve thrombosis. \nI \nC \nTranscatheter, transfemoral valve-in-valve implantation in the aortic position should be considered in patients with significant valve \ndysfunction who are at intermediate or high surgical risk, and have suitable anatomical and prosthesis features, as assessed by the Heart \nTeam.447,448,450,451,941 \nIIa \nB \nTranscatheter transvenous mitral or tricuspid valve-in-valve implantation should be considered in patients with significant valve dysfunction \nat intermediate or high surgical risk, if the anatomy is suitable.569,570,681,942–944 \nIIa \nB \nReoperation should be considered in asymptomatic patients with significant prosthetic dysfunction, if surgical risk is low. \nIIa \nC \nValve thrombosis \nTOE and/or 4D-CT are recommended in patients with suspected valve thrombosis to confirm the diagnosis.914,918,923,925,945–948 \nI \nC \nMechanical heart valve thrombosis \nHeart Team evaluation is recommended in patients with acute HF (NYHA class III or IV) due to obstructive MHV thrombosis to determine \nappropriate management (repeat valve replacement or low-dose slow infusion fibrinolysis).923,926–929,931,949–954 \nI \nB \nSurgery should be considered for large (>10 mm) prosthetic thrombus complicated by embolism.913,932,933 \nIIa \nC \nBiological heart valve thrombosis \nOAC using VKA is recommended in BHV thrombosis before considering reintervention.867,934–937,955,956 \nI \nB \nOAC should be considered in patients with leaflet thickening and reduced leaflet motion leading to elevated gradients at least until \nresolution.918,920–922 \nIIa \nB \n© ESC/EACTS 2025\n4D, four-dimensional; BHV, biological heart valve; CT, computed tomography; HF, heart failure; MHV, mechanical heart valve; NYHA, New York Heart Association; OAC, oral \nanticoagulation; PVL, paravalvular leak; TOE, transoesophageal echocardiography; VKA, vitamin K antagonist. \naClass of recommendation. \nbLevel of evidence.   \n4700                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "keywords": [
        "aortic stenosis",
        "heart failure",
        "recommended",
        "class iii",
        "surgery",
        "anticoagulation",
        "echocardiography",
        "should be considered",
        "management",
        "prosthetic valve",
        "during",
        "nyha",
        "aortic",
        "tricuspid",
        "arrhythmia",
        "valve replacement",
        "tavi",
        "cardiac",
        "stenosis",
        "exercise"
      ],
      "tables": [
        {
          "title": "Table on page 66",
          "page_number": 65,
          "content": "Recommendations |  | Classa | Levelb | \nHaemolysis and paravalvular leak |  |  |  | \nIt is recommended that the decision between transcatheter or surgical closure of clinically significant PVLs is based on Heart Team\nevaluation, including patient risk, leak morphology, and local expertise. |  | I | C | \nReoperation is recommended if a PVL is related to endocarditis, or causes haemolysis requiring repeated blood transfusion or leading to HF\nsymptoms. |  | I | C | \nTranscatheter closure should be considered for suitable PVLs with clinically significant regurgitation and/or haemolysis.940 |  | IIa | B | \n | Mechanical heart valve failure |  |  | \nReoperation is recommended in symptomatic patients with signifci ant valve dysfunction not attributable to valve thrombosis. |  | I | C | \n | Biological heart valve failure |  |  | \nReintervention is recommended in symptomatic patients with significant valve dysfunction not attributable to valve thrombosis. |  | I | C | \nTranscatheter, transfemoral valve-in-valve implantation in the aortic position should be considered in patients with significant valve\ndysfunction who are at intermediate or high surgical risk, and have suitable anatomical and prosthesis features, as assessed by the Heart\nTeam.447,448,450,451,941 |  | IIa | B | \nTranscatheter transvenous mitral or tricuspid valve-in-valve implantation should be considered in patients with significant valve dysfunction\nat intermediate or high surgical risk, if the anatomy is suitable.569,570,681,942–944 |  | IIa | B | \nReoperation should be considered in asymptomatic patients with significant prosthetic dysfunction, if surgical risk is low. |  | IIa | C | \n | Valve thrombosis |  |  | \nTOE and/or 4D-CT are recommended in patients with suspected valve thrombosis to confrim the diagnosis.914,918,923,925,945–948 |  | I | C | \n | Mechanical heart valve thrombosis |  |  | \nHeart Team evaluation is recommended in patients with acute HF (NYHA class III or IV) due to obstructive MHV thrombosis to determine\nappropriate management (repeat valve replacement or low-dose slow infusion fbi rinolysis).923,926–929,931,949–954 |  | I | B | \nSurgery should be considered for large (>10 mm) prosthetic thrombus complicated by embolism.913,932,933 |  | IIa | C | \n | Biological heart valve thrombosis |  |  | \nOAC using VKA is recommended in BHV thrombosis before considering reintervention.867,934–937,955,956 |  | I | B | \nOAC should be considered in patients with leaflet thickening and reduced leafel t motion leading to elevated gradients at least until\nresolution.918,920–922 |  | IIa | B | ",
          "bbox": [
            36.850399017333984,
            84.0,
            552.7559814453125,
            461.9989929199219
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "2",
      "title": "16. Management of valvular heart disease during pregnancy",
      "start_page": 67,
      "end_page": 68,
      "content": "and anatomical selection criteria.194,584 Valve treatment should be per-\nformed for patients with AR meeting the criteria for valve intervention \nbefore any elective intermediate- or high-risk NCS.966,967 \n15.3. Peri-operative monitoring \nHeart rate control (particularly in MS) and careful fluid management \n(particularly in AS and MR with reduced LVEF) are needed throughout \nthe procedure. The involvement of specialized cardiovascular anaesthe-\nsiologists should be considered in complex situations because TOE \nmonitoring may be considered. Pulmonary artery catheterization is \nnot routinely used. \n16. Management of valvular heart \ndisease during pregnancy \nSpecific ESC Guidelines on this topic are available (the 2025 ESC \nGuidelines on cardiovascular disease during pregnancy) and should be con-\nsulted for further details.968 Pregnancies in patients with VHD should \nbe considered high risk and managed under the close supervision of a \ncardiologist and a multidisciplinary Pregnancy Heart Team. The import-\nance of midwives and other specialized nursing personnel is increasingly \nrecognized for high-quality direct patient interactions. Shared decision- \nmaking is especially important when addressing the cardiovascular risk \nof pregnancy and the benefit–risk ratios of therapeutic options and \nmodes of delivery (Figure 22). \n16.1. Management before pregnancy \nIdeally, women should undergo a thorough physical examination by \ntheir general practitioner for VHD screening prior to pregnancy. A spe-\ncialized evaluation including TTE should be performed by a cardiologist \nin the case of clinical suspicion.968,969 \nIf VHD is diagnosed, pre-pregnancy counselling is imperative. \nUnplanned pregnancies in patients with VHD should be discouraged. \nContraception methods should be recommended after discussion \nwith the patient in the presence of a significant maternal and/or foetal \nrisk. In patients contemplating pregnancy, the maternal risk should be \nassessed using the modified WHO classification and other scores such \nas the CARPREG or DEVI risk score (see Supplementary data online,  \nTable S7).970 \n\u001f\u001e\u001d\u001c\u001b\u001c\u001a\u0019\u0018\u001d\n\u0017\u001a\u0019\u0016\u0015\u001a\u0014\u0013\u0018\u0015\u001a\u001b\n\u0012\u0019\u0011\u0010\u0019\u000f\u001b\u001d\u0013\u0015\u000e\u0011\n\r\u001c\f\u001b\u001a\u0013\u000e\u000b\u001a\u001d\u0019\u000e\n\u0013\t\u001b\u001a\u001d\r\u000e\u000e\u001b\b\n\u0007\u000e\u0015\u001b\u001d\u001c\f\u001b\u001d\u0019\r\b\r\n\u0019\u001d\u001c\u0013\u0015\u000e\u0011\n\r\u001c\f\u001b\u001a\u0013\u001d\t\u001b\u0018\u0019\u0015\b\u0019\u001d\u001c\u001d\n\u0006\u0015\u001a\u0011\u0019\r\b\r\n\u0014\n\u001f\n\u001e\n\u001d\n\u001c\n\u001b\n\u001a\n\u001b\n\u0019\n\u0018\n\u0017\n\u0016\n\u001d\n\u001a\n\u001e\n\u0015\u0017\n\u0014\n\u001d\n\u001a\n\u0013\n\u0017\n\u0005\n\f\n\u0015\n\u001a\n\u001b\n\u0011\n\u0013\n\u0011\n\u001b\n\u0018\n\u0019\u001d\n\u0019\n\r\n\u000e\n\u0004\n\u0016\n\u0015\n\u0003\u0019\n\u000e\n\n\u0013\n\u0010\n\u0019\u001c\n\f\n\u0013\u001c\n\f\n\u001b\n\u0013\n\t\n\u0015\n\u001c\u0019\n\u001b\n\u000e\n\u001c\n\u001f\u001e\u001d\u0012\u0019\u0011\u001b\u0019\u001d\u0010\u0015\u000f\u0011\u001b\u0017\u001a\u000e\u000e\u001d\u000e\u000e\u0013\u001d\u001b\u0015\n\u0006\b\u0019\u000e\u0019\u0018\u0015\b\u0013\u001d\u0018\u001a\u001b\u001b\u000e\u0019\u000e\n\u0002\u0013\f\u0019\u001d\u001c\r\u001a\u0014\u0001\u0013\t\f\u0014\u001d\u0019\u0018\u0015\b\u0013\n\u001b\u0015\u0016\u0019\u000e\u0015\u001c\u0019\r\u000e\u0001\u0013\u0006\n\u0013\u0018\b\u0019\u000e\u0019\u0018\u0015\b\u0013\u001d\u000b\u001d\t\u0019\u0018\u0019\r\u000e\u0013\r\u0013 ­\u0002\u0013\u0001\u0013\u001b\u001b\u001a\u0018\u0019\u001d\u001b\n\u0018\u0015\t\u0015\u0018\u0019\u001c\u0014\u0013\u0015\u001d\u001d\u001b\u001d\u001d\u0016\u001b\u000e\u001c\n\u000e\u0013\u0018\u0015\u001d\u001b\u0013\r\u0013\u0011\u001b\u000e\u0019\u001c\u001b\u0013 ­\u0002\u0013\u001a\u0019\u001d\u0003\u0013\u0015\u001d\u001d\u001b\u001d\u001d\u0016\u001b\u000e\u001c\n\u0016 \u001f\u0001\u0013\u0006\u0007\u0017\u0013\u0001\u0013­\n\u0006\r\u001a\u001a\u001b\u0018\u001c\u0019\r\u000e\u0013\r\u0013\u001d\u001b\u000f\u001b\u001a\u001b\u0013\u0012\u0005\u0001\u0013\u0007\u0005\u0001\u0013\u0015\r\u001a\u001c\u0019\u0018\u0013\u0011\u0019\b\u0015\u001c\u0015\u001c\u0019\r\u000e\n\u0010\u0019\u001c\f\u0013\f\u0019\n\f\u0013\u001a\u0019\u001d\u0003\u0013\r\u0013\u0015\r\u001a\u001c\u0019\u0018\u0013\u0011\u0019\u001d\u001d\u001b\u0018\u001c\u0019\r\u000e\n\r\u001d\f\u000f\u000b\u001d\u001e\u0018\n\u0010\u0011\u000e\u0015\u0012\u0010\u001a\u001e\u0015\t\u0013\n\u0015\n\u0019\u000e\u0015\b\u0013\u0011\u001b\b\u0019\u000f\u001b\u001a\u0014\u0013\u000b\u001d\u000b\u0015\b\b\u0014\u0013\t\u001a\u001b\u001b\u001a\u001a\u001b\u0011\n\u001b\n\u0019\r\u000e\u0015\b\u0013\u0015\u000e\u0015\u001b\u001d\u001c\f\u001b\u001d\u0019\u0015\n\u0012\r\u000e\u0019\u001c\r\u001a\u0019\u000e\n\u0013\u0011\u000b\u001a\u0019\u000e\n\u0013\u0011\u001b\b\u0019\u000f\u001b\u001a\u0014\u0013\u0015\u000e\u0011\u0013\u001b\u0015\u001a\b\u0014\n\t\r\u001d\u001c\u0004\u0011\u001b\b\u0019\u000f\u001b\u001a\u0014\n\u001c\u001b\u000e\u0011\u001b\u0011\u0013\u0019\u000e\u0004\f\r\u001d\t\u0019\u001c\u0015\b\u0013\u001d\u000b\u001a\u000f\u001b\u0019\b\b\u0015\u000e\u0018\u001b\u001c\u001a\u001b\u0015\u001c\u0016\u001b\u000e\u001c\n\b\u001a\u001b\u001a\u001c\u001d\u0013\u001d\u001b\u0015\u0017\u0007\t\u001e\u000f\u001b\u001c\u0017\u0010\u001e\u001d\u001c\u001b\u001a\u001b\u0019\u0018\n\u0005\u001b\u001a\u0019\u0015\b\u0013\u0016\r\u000e\u0019\u001c\r\u001a\u0019\u000e\n\u0013\u001d\u0014\u0016\t\u001c\r\u0016\u001d\u0001\u0013\u001e\u0019\r\u0016\u0015\u001a\u0003\u001b\u001a\u001d\u0001\u0013\n­\u001a\u000b\n\u0013\u001c\f\u001b\u001a\u0015\t\u0014\u0013\u0015\u000e\u001c\u0019\u0018\r\u0015\n\u000b\b\u0015\u001c\u0019\r\u000e\nFigure 22 The Pregnancy Heart Team model of care. AS, aortic stenosis; ECG, electrocardiogram; MS, mitral stenosis; TTE, transthoracic echocar-\ndiography; VHD, valvular heart disease.   \n4702                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "keywords": [
        "catheterization",
        "aortic stenosis",
        "cardiovascular risk",
        "disease",
        "electrocardiogram",
        "lvef",
        "heart",
        "valvular",
        "should be considered",
        "recommended",
        "management",
        "aortic",
        "pregnancy",
        "during",
        "mitral stenosis",
        "may be considered",
        "ecg",
        "stenosis"
      ],
      "tables": []
    },
    {
      "number": "2",
      "title": "17. Sex-specific considerations in patients with valvular heart disease",
      "start_page": 68,
      "end_page": 69,
      "content": "Before recommending pregnancy, the following conditions need to \nbe corrected: \n• MS with MVA <1.5 cm2, even when asymptomatic.971 \n• Severe AS with symptoms, or abnormal exercise test, or LV systolic \ndysfunction.972 \n• Heritable aortic disorders and high risk of aortic dissection: prophylactic \naortic repair is recommended prior to pregnancy in women with \nMarfan syndrome and an aortic diameter of >45 mm, and may be con-\nsidered in women with an aortic diameter between 40 and 45 mm \nwhen risk factors for dissection exist.973 Aneurysmal dilation in women \nwith BAV should be corrected when the aortic diameter is ≥50 mm.974 \nClose follow-up in dedicated units and beta-blocker therapy during \npregnancy and post-partum are recommended unless contraindicated, \nalthough strong evidence is only available for Marfan syndrome.  \nValvular regurgitant lesions are generally well tolerated during preg-\nnancy. Prophylactic intervention is therefore not recommended in the \nabsence of class I or IIa indications. \nThe first therapeutic option for MS in a woman considering preg-\nnancy should be PMC. When implantation of a prosthetic valve is ne-\ncessary, BHVs are recommended, although early SVD remains a \nserious concern.975 Mechanical heart valves must be avoided due to \nthe high risk of maternal and foetal complications linked to the potential \nteratogenic effects of VKAs, as well as the increased risk of bleeding.976 \nThe Ross procedure may be considered for the treatment of AV dis-\nease at centres with expertise. \n16.2. Management during pregnancy \n16.2.1. Patients with native valve disease \nPregnancy can worsen the clinical course of left-sided stenotic valvular \nlesions because increased cardiac output causes an increment of trans-\nvalvular gradient of ∼50%, mainly between the first and second trime-\nsters. Regurgitant lesions are less likely to cause complications, except \nin high-risk cases (LV systolic dysfunction, PH, and cardiac events before \npregnancy).977 \nMild MS is generally well tolerated.978 Heart failure occurs in \none-third of pregnant women with an MVA of <1.5 cm2 and in one-half \nof those with an MVA of <1.0 cm2, most often during the second tri-\nmester.971 Percutaneous mitral commissurotomy should be consid-\nered if symptoms or SPAP of >50 mmHg persist despite optimal \nmedical therapy (diuretics and beta-1-selective beta-blockers), prefer-\nably after the 20th week of pregnancy. \nRegarding AS, pregnancy is generally well tolerated if prior exercise \ntolerance was normal, even in severe AS, while HF has been reported \nto occur in up to 25% of symptomatic patients.972 In symptomatic \npatients despite medical therapy (i.e. diuretics), TAVI seems to be \nthe preferred option in very selected patients, although evidence is \nlacking. Percutaneous balloon valvuloplasty may be an alternative op-\ntion. Procedures should be performed in an experienced valve \ncentre.972,979,980 \nSurgery under cardiopulmonary bypass is associated with a high rate \nof foetal loss and should be restricted to conditions that threaten the \nmother’s life if transcatheter intervention is not possible or has failed. \nVaginal delivery is the first choice for the majority of patients. \nCaesarean section is preferred if there is an obstetric indication, \nand in the case of severe MS or AS, ascending aortic diameter of \n>45 mm, severe PH, or if delivery starts while the patient is being \ntreated with OAC. \n16.2.2. Patients with prosthetic valves \nPregnant patients with MHVs should be followed in a centre with cor-\nresponding expertise. In a cohort of 212 women with MHVs, valve \nthrombosis occurred in 10 (4.7%) pregnancies and haemorrhagic \nevents occurred in 49 (23.1%).976 Therapeutic OAC during pregnancy \nis essential to avoid thrombosis. The higher efficacy of VKAs compared \nwith LMWH to prevent thrombosis must be balanced against increased \nfoetal risks.981 \nIn patients requiring ≤5 mg/day of warfarin, OAC with warfarin \nthroughout pregnancy, changing to UFH before delivery, is advocated, \nin order to reduce the risk of thrombosis. In patients requiring higher \ndoses, switching to dose-adjusted LMWH at least twice per day with \nstrict anti-Xa monitoring during the first trimester is recommended \nto avoid the teratogenic effect of VKAs (for corresponding flowcharts \nsee the 2025 ESC Guidelines for the management of cardiovascular dis-\neases during pregnancy968). \nLifetime management of women with a BHV considering pregnancy \nis central and transcatheter valve-in-valve implantation may be consid-\nered as a bridge to MHV implantation.982 \n17. Sex-specific considerations \nin patients with valvular heart \ndisease \nAlthough men and women are equally likely to experience VHD, sex- \nspecific prevalence exists according to valve type and disease patho-\nphysiology.644,648,983 Women more frequently suffer from MV disease \nsuch as prolapse, RHD or TR, while men more often present with AS or \nAR, especially associated with BAV.984 Men also suffer from endocardi-\ntis of any valve more frequently.985 \nFemale sex is associated with higher mortality in the presence of vari-\nous VHDs,986 including early post-treatment,987 and is included as a \nrisk factor in surgical risk prediction tools such as the STS and \nEuroSCORE calculators. However, risk scores are often derived \nfrom populations including a majority of men.988 In addition, risk pre-\ndiction scores are susceptible to referral bias that results in a well- \nestablished higher risk of undertreatment or delayed treatment of \nVHD in women.983,984,986 \n17.1. Aortic valve disease \nFemale patients with severe AS present more often with shortness of \nbreath, whereas males more frequently have angina, presumably due to \nthe higher incidence of CAD.989 The pathophysiology of AS seems to \ndiffer according to sex, with women having less calcium and more fibro-\nsis.990 Concentric ventricular hypertrophy and remodelling are also \nmore frequently observed in women than in men, resulting in higher \nLVEF but smaller LV cavity and stroke volume.991 Consequently, para-\ndoxical low-flow, low-gradient constellations are frequent and may \nboth contribute to the underdiagnosis of severe AS in women and delay \nan intervention.992 The use of sex-specific thresholds to define flow \nlimitation (<40 mL/m2 for men and <32 mL/m2 for women) has there-\nfore been suggested,292 and the use of CCT to quantify the calcium \nscore should be performed in women with discordant echocardio-\ngraphic parameters.777 \nWomen are less likely to be referred to a cardiologist and \nundergo investigations. Surgical aortic valve replacement is per-\nformed less frequently in women, especially if echocardiographic \nparameters are discordant.993 In patients presenting with severe  \nESC Guidelines                                                                                                                                                                                          4703 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "keywords": [
        "class i",
        "considerations",
        "heart failure",
        "recommended",
        "systolic dysfunction",
        "indication",
        "female",
        "disease",
        "lvef",
        "heart",
        "prosthetic valve",
        "patients",
        "aortic",
        "may be considered",
        "valvular",
        "risk factor",
        "sex",
        "valve replacement",
        "systolic",
        "specific",
        "tavi",
        "exercise"
      ],
      "tables": []
    },
    {
      "number": "2",
      "title": "18. Key messages",
      "start_page": 69,
      "end_page": 71,
      "content": "AS and Class I indications for SAVR, a significantly higher proportion \nof men than women are referred for evaluation by a cardiac \nsurgeon.994,995 \nMale patients derive a clearer benefit from SAVR compared with wo-\nmen, who have higher in-hospital and long-term mortality and morbid-\nity,987,996 possibly explained by more severe concentric hypertrophy991 \nand a smaller aortic annulus predisposing to PPM.997 Conversely, in a \nrandomized trial (RHEIA) that compared TAVI with SAVR in 443 wo-\nmen with a mean age of 73 years, TAVI was superior in reducing the \nprimary endpoint composed of death, stroke, or rehospitalization at \n1 year, predominantly driven by a reduction in rehospitalization for \nvalve- or procedure-related symptoms or worsening HF.998 Several ob-\nservational studies suggest that elderly women have lower mortality \nafter TAVI,999 even if the rates of major vascular complications and \nbleeding tend to be higher.997 \nIndexed cut-offs to indicate treatment of AR are validated, but only \npartially account for sex differences. Newer studies using echocardio-\ngraphic volumes1000 and CMR1001 suggest that women may experience \nhigher event rates at lower cut-offs compared with men, but this re-\nquires further investigation. \n17.2. Mitral valve disease \nPatients with RHD are often young women and have a high prevalence \nof major cardiovascular complications with far-reaching impacts on re-\nproductive health and access to care.282 Although women experience \nfavourable outcomes compared with men when treated by percutan-\neous balloon valvuloplasty, access to these procedures is still limited \nin low-income countries.662 \nFibroelastic disease with MV prolapse is also more frequent in wo-\nmen, and may be accompanied by morphological abnormalities of \nthe MA associated with fibrosis of the papillary muscles or the infer-\nobasal LV that may act as the substrate for sudden cardiac death, \neven in the absence of severe MR.1002 Recent evidence has sup-\nported considering lower women-specific cut-offs for intervention \nwith regard to LVESD (36 mm; indexed LVESD, 1.8 cm/m2), while \nthe LVEF cut-off was similar to men (58%), albeit with higher \nmortality.548 \nVentricular SMR associated with low LVEF is more frequent in men \nwith HF,1003 while atrial SMR due to chronic AF and/or HFpEF affects \nmore women (58% vs 42% male).579 \nFemale sex is a risk factor for the development of MAC and was re-\nported to account for 68% of the patients included in a large-scale \ntranscatheter MV replacement in MAC registry.1004 Furthermore, wo-\nmen present with a faster disease progression.1005 \n17.3. Tricuspid valve disease \nTricuspid regurgitation is more prevalent in women,208 and female \nsex is associated with accelerated disease progression.1006–1008 \nHypotheses to explain these observations include the overall higher \nprevalence of HFpEF and AF in women.1009 Women are usually \ndiagnosed at an older age and the cause of TR is most frequently \na consequence of left valvular disease or annular dilatation attributable \nto RA dilatation.1010 No differences have been detected to date \nin terms of adverse events after surgery1011 or transcatheter TV \ninterventions.1012,1013 \n18. Key messages \nHeart Team and Heart Valve Centre \n• An integrated regional Heart Valve Network incorporating out-\npatient Heart Valve Clinics and specialist Heart Valve Centres allows \noptimal patient care. \n• Heart Valve Centres should fulfil institutional and local statutory re-\nquirements, and strive for high procedural volume and excellent clin-\nical outcomes. \n• Heart Team recommendations should be based upon these guideline \nrecommendations, relevant updated evidence, key medical consid-\nerations, and patient preferences. \n• Core members of the Heart Team include the primary clinical cardi-\nologist, cardiologists with subspecialty expertise in VHD, specialists in \nadvanced cardiovascular imaging and peri-procedural imaging guid-\nance, and surgeons and interventional cardiologists with training \nand expertise in valve interventions. \n• A network approach that distinguishes between higher- and \nlower-volume centres is appropriate, with more complex proce-\ndures focused in the most experienced (i.e. upper quartile) \ncentres. Information on the network organization should be com-\nmunicated to patients, as well as referring cardiologists and general \npractitioners.  \nAortic regurgitation \n• Assessment of AR severity with TTE remains challenging and current \ncut-offs for intervention are mostly based on 2D measurements, al-\nthough 3D echocardiography and CMR allow more accurate evalu-\nation of LV volumes and LVEF. \n• Mechanisms of AR may be closely related to the aortic diameters that \nshould be measured accurately at all levels of the aortic root (annulus, \nsinuses, and sinotubular junction). \n• Indication for operation is based on symptoms, LV volumes, LVEF, \nand aortic diameters. Although valve replacement remains the stand-\nard treatment, AV repair (or AV sparing when associated with root \naneurysm) is being increasingly used to avoid prosthesis-related com-\nplications, especially in experienced centres. \n• Current transcatheter options for AR are limited and applicable only \nin patients who are ineligible for surgery.  \nAortic stenosis \n• Diagnosis of severe AS requires integrative evaluation of pressure \ngradients (the most robust measurements), AVA, flow conditions, \nthe extent of valve calcification, and LV function. \n• Selection of the most appropriate mode of intervention should take \ninto account clinical characteristics (age and estimated life expect-\nancy, concomitant conditions), access and valve anatomy (particularly \nthe feasibility of transfemoral TAVI and calcification patterns), and \nsurgical risk, as well as repeat procedure options and risks (lifetime \nmanagement).  \nMitral regurgitation \n• The echocardiographic diagnostic workup of patients with MR in-\ncludes multiparametric assessment of MR severity, evaluation of  \n4704                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nMV anatomy (often with 3D TOE), identification of the mechanism \n(PMR, ventricular SMR, or atrial SMR), and evaluation of cardiac \ndamage. \n• Surgical MV repair is the preferred method of treatment in severe \nPMR. Transcatheter edge-to-edge repair is recommended in patients \nwho are inoperable or high risk according to the Heart Team. \n• Surgical MV repair is the procedure of choice for asymptomatic pa-\ntients with primary MR and signs of cardiac damage, including mod-\nerate or more TR. \n• In patients with ventricular SMR, GDMT (including CRT if indicated) \nis the initial and essential treatment step. In symptomatic patients \nwithout CAD needing revascularization, M-TEER is recommended. \nIn patients with concomitant complex CAD and those not suitable \nfor TEER, mitral surgery may be considered. \n• In patients with atrial SMR, MV surgery, AF ablation if indicated, and \nLAAO should be considered after optimization of medical therapy. \nTranscatheter edge-to-edge repair may be considered in patients at \nhigh surgical risk.  \nMitral stenosis \n• Most patients with severe rheumatic MS and favourable valve anat-\nomy should undergo PMC, which is the standard of care. Surgery \nis recommended for symptomatic patients with contraindications \nor unfavourable anatomical and clinical characteristics for PMC. \n• Decision-making in patients with unfavourable anatomy should take \ninto account local PMC experience. \n• In selected patients with clinically severe degenerative MS and MAC, \ntranscatheter intervention or surgery may improve symptoms.  \nTricuspid regurgitation \n• Concomitant TV repair is the preferred method for patients with \nleft-sided valve pathology and associated moderate or severe TR. \n• The use of risk scores for the assessment of RV and secondary organ \ndysfunction should be strongly encouraged in patients with isolated \nsevere TV disease. \n• In isolated severe TR without severe RV dysfunction, surgery should \nbe performed at an early stage in patients at low operative risk. \n• In isolated severe TR patients at increased surgical risk, tricuspid \nTEER or transcatheter replacement should be considered to im-\nprove quality of life and RV remodelling, in the absence of severe \nRV dysfunction or pre-capillary PH.  \nTricuspid stenosis \n• TS is a very rare manifestation of acquired VHD in high-income \ncountries. \n• TS is mainly associated with rheumatic valve disease, carcinoid syn-\ndrome, or enzymatic disorders such as Fabry’s or Whipple’s disease. \n• Treatment of symptomatic TS mainly involves surgical TV \nreplacement.  \nMultiple and mixed valvular heart disease \n• Transvalvular gradients and velocities reflect the combined burden of \nregurgitation and stenosis in mixed aortic and mitral disease. \n• Treatment decisions should be based on the assessment of symptom \nand functional status, cardiac damage, anatomical suitability, and the \nrisk–benefit ratio of intervention and lifetime management \nconsiderations. \n• Patients with mixed moderate AS and AR have similar detrimental \noutcomes compared with those with severe isolated AS. \n• In transcatheter procedures, which allow a sequential approach, \ndownstream lesions should be treated first to prevent potential \nhaemodynamic deterioration and allow improvement of upstream \nlesions due to changing loading conditions and reverse \nremodelling.  \nAntithrombotic treatment in patients with a mechanical \nheart valve \n• International normalized ratio therapeutic range should be balanced \nto the type and anatomical site of MHV, as well to the thrombotic risk \nprofile of the individual patient. \n• Patient training, self-monitoring, and education can increase INR sta-\nbility and TTR. \n• Minor or minimally invasive NCS procedures do not require VKA \ninterruption in patients with an MHV. \n• In patients with an MHV undergoing elective major NCS, bridging \nmay be omitted if the thromboembolic risk is low.  \nNon-cardiac surgery \n• The risk of peri-operative cardiovascular complications related to \nsurgery and to patient-specific factors should be evaluated and com-\nmunicated to the patient and surgical team. \n• In patients with symptomatic severe AS requiring urgent high-risk \nNCS, BAV or TAVI should be considered prior to surgery. In patients \nplanned for elective NCS, AV intervention is recommended prior to \nNCS.  \nPregnancy \n• In women with VHD, decisions regarding management before and dur-\ning pregnancy should be taken after discussion by the multidisciplinary \nPregnancy Heart Team. Unplanned pregnancies should be discouraged. \n• The following conditions should be corrected prior to considering \npregnancy: \n– clinically severe MS (MVA <1.5 cm2), even when asymptomatic \n– severe symptomatic AS, or asymptomatic patients with impaired \nLV function or a pathological exercise test \n– heritable aortic disorders and high risk of aortic dissection. \n• Vaginal delivery is the first choice for the majority of patients. \nIndications for Caesarean section include pre-term labour in patients \non OAC, severe MS or AS, aggressive aortic pathology, acute intract-\nable HF, and severe PH. \n• Women with MHVs should be managed in expert centres.  \n19. Gaps in evidence \nGeneral aspects \n• Patient-reported outcome measures are infrequently reported \nin VHD studies. Patient-reported outcome measure-oriented studies \nare required to improve quality of life and patient satisfaction. \n• Methods to address underdiagnosis and undertreatment of VHD \nneed to be identified and implemented.  \nESC Guidelines                                                                                                                                                                                          4705 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "keywords": [
        "aortic stenosis",
        "elderly",
        "class i",
        "recommended",
        "indication",
        "hfpef",
        "female",
        "echocardiography",
        "lvef",
        "crt",
        "aneurysm",
        "should be considered",
        "mitral stenosis",
        "mitral regurgitation",
        "aortic",
        "older",
        "may be considered",
        "tricuspid",
        "risk factor",
        "aortic regurgitation",
        "savr",
        "sex",
        "guideline",
        "messages",
        "valve replacement",
        "ablation",
        "tavi",
        "age",
        "male",
        "stenosis"
      ],
      "tables": []
    },
    {
      "number": "2",
      "title": "19. Gaps in evidence",
      "start_page": 70,
      "end_page": 73,
      "content": "MV anatomy (often with 3D TOE), identification of the mechanism \n(PMR, ventricular SMR, or atrial SMR), and evaluation of cardiac \ndamage. \n• Surgical MV repair is the preferred method of treatment in severe \nPMR. Transcatheter edge-to-edge repair is recommended in patients \nwho are inoperable or high risk according to the Heart Team. \n• Surgical MV repair is the procedure of choice for asymptomatic pa-\ntients with primary MR and signs of cardiac damage, including mod-\nerate or more TR. \n• In patients with ventricular SMR, GDMT (including CRT if indicated) \nis the initial and essential treatment step. In symptomatic patients \nwithout CAD needing revascularization, M-TEER is recommended. \nIn patients with concomitant complex CAD and those not suitable \nfor TEER, mitral surgery may be considered. \n• In patients with atrial SMR, MV surgery, AF ablation if indicated, and \nLAAO should be considered after optimization of medical therapy. \nTranscatheter edge-to-edge repair may be considered in patients at \nhigh surgical risk.  \nMitral stenosis \n• Most patients with severe rheumatic MS and favourable valve anat-\nomy should undergo PMC, which is the standard of care. Surgery \nis recommended for symptomatic patients with contraindications \nor unfavourable anatomical and clinical characteristics for PMC. \n• Decision-making in patients with unfavourable anatomy should take \ninto account local PMC experience. \n• In selected patients with clinically severe degenerative MS and MAC, \ntranscatheter intervention or surgery may improve symptoms.  \nTricuspid regurgitation \n• Concomitant TV repair is the preferred method for patients with \nleft-sided valve pathology and associated moderate or severe TR. \n• The use of risk scores for the assessment of RV and secondary organ \ndysfunction should be strongly encouraged in patients with isolated \nsevere TV disease. \n• In isolated severe TR without severe RV dysfunction, surgery should \nbe performed at an early stage in patients at low operative risk. \n• In isolated severe TR patients at increased surgical risk, tricuspid \nTEER or transcatheter replacement should be considered to im-\nprove quality of life and RV remodelling, in the absence of severe \nRV dysfunction or pre-capillary PH.  \nTricuspid stenosis \n• TS is a very rare manifestation of acquired VHD in high-income \ncountries. \n• TS is mainly associated with rheumatic valve disease, carcinoid syn-\ndrome, or enzymatic disorders such as Fabry’s or Whipple’s disease. \n• Treatment of symptomatic TS mainly involves surgical TV \nreplacement.  \nMultiple and mixed valvular heart disease \n• Transvalvular gradients and velocities reflect the combined burden of \nregurgitation and stenosis in mixed aortic and mitral disease. \n• Treatment decisions should be based on the assessment of symptom \nand functional status, cardiac damage, anatomical suitability, and the \nrisk–benefit ratio of intervention and lifetime management \nconsiderations. \n• Patients with mixed moderate AS and AR have similar detrimental \noutcomes compared with those with severe isolated AS. \n• In transcatheter procedures, which allow a sequential approach, \ndownstream lesions should be treated first to prevent potential \nhaemodynamic deterioration and allow improvement of upstream \nlesions due to changing loading conditions and reverse \nremodelling.  \nAntithrombotic treatment in patients with a mechanical \nheart valve \n• International normalized ratio therapeutic range should be balanced \nto the type and anatomical site of MHV, as well to the thrombotic risk \nprofile of the individual patient. \n• Patient training, self-monitoring, and education can increase INR sta-\nbility and TTR. \n• Minor or minimally invasive NCS procedures do not require VKA \ninterruption in patients with an MHV. \n• In patients with an MHV undergoing elective major NCS, bridging \nmay be omitted if the thromboembolic risk is low.  \nNon-cardiac surgery \n• The risk of peri-operative cardiovascular complications related to \nsurgery and to patient-specific factors should be evaluated and com-\nmunicated to the patient and surgical team. \n• In patients with symptomatic severe AS requiring urgent high-risk \nNCS, BAV or TAVI should be considered prior to surgery. In patients \nplanned for elective NCS, AV intervention is recommended prior to \nNCS.  \nPregnancy \n• In women with VHD, decisions regarding management before and dur-\ning pregnancy should be taken after discussion by the multidisciplinary \nPregnancy Heart Team. Unplanned pregnancies should be discouraged. \n• The following conditions should be corrected prior to considering \npregnancy: \n– clinically severe MS (MVA <1.5 cm2), even when asymptomatic \n– severe symptomatic AS, or asymptomatic patients with impaired \nLV function or a pathological exercise test \n– heritable aortic disorders and high risk of aortic dissection. \n• Vaginal delivery is the first choice for the majority of patients. \nIndications for Caesarean section include pre-term labour in patients \non OAC, severe MS or AS, aggressive aortic pathology, acute intract-\nable HF, and severe PH. \n• Women with MHVs should be managed in expert centres.  \n19. Gaps in evidence \nGeneral aspects \n• Patient-reported outcome measures are infrequently reported \nin VHD studies. Patient-reported outcome measure-oriented studies \nare required to improve quality of life and patient satisfaction. \n• Methods to address underdiagnosis and undertreatment of VHD \nneed to be identified and implemented.  \nESC Guidelines                                                                                                                                                                                          4705 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nHeart Team and Heart Valve Centre \n• Structured research is required to investigate the relationship be-\ntween procedural volume and clinical outcomes, in order to define \nminimum annual thresholds for individual operators and institutions \nundertaking surgical and transcatheter valve interventions. \n• There is a pressing need to ensure higher dispersion and adoption of \ninterventions for VHD, especially in middle- and low-income countries.  \nConditions associated with valvular heart disease \n• CAD: \n– The prognostic value of functional assessment of stable, moderate \ncoronary stenosis in VHD patients remains to be determined. \n– The optimal strategy (invasive vs non-invasive) for CAD assess-\nment in specific VHD populations remains to be elucidated. \n– The optimal timing of PCI in patients with CAD undergoing TAVI \nis yet to be determined. \n– The benefit of complete coronary revascularization with CABG in \npatients with combined VHD and CAD requires further research. \n• AF: \n– It is unclear which patients with chronic persistent AF and con-\ncomitant VHD are deemed to be suitable for rhythm control \ntherapy. \n– The protective effect against stroke of OAC with VKA or DOACs \nin patients after surgical or transcatheter LAAO remains to be \ndetermined. \n• Cardiogenic shock and acute HF: \n– The optimal treatment strategy in VHD patients presenting with \ncardiogenic shock and acute HF is unknown.  \nAortic regurgitation \n• Impact of early LV remodelling on prognosis in asymptomatic AR pa-\ntients is unknown. \n• Prognostic value of CMR-derived indices in asymptomatic patients \nneeds to be determined. \n• More data are required on long-term results of surgical AV repair for AR. \n• More evidence is required on transcatheter treatment options for \nAR, in particular using dedicated devices.  \nAortic stenosis \n• Better understanding of the pathophysiology of AS is needed to pro-\npose innovative medical therapy. \n• Further research is required on: \n– Refined prognostic markers to guide timing of intervention in \nasymptomatic patients. \n– The role of revascularization in patients with severe AS and asymp-\ntomatic concomitant CAD. \n– Further data on the long-term durability of transcatheter valves in \ncomparison with surgical BHVs in younger patients. \n– The role of TAVI in patients with BAV AS and patients <70 years \nof age. \n– Results of intervention (valve or coronary) after TAVI or SAVR. \n– Determining the optimal lifetime management strategy for AS \npatients.  \nMitral regurgitation \n• The association between primary MR and ventricular arrhythmias re-\nquires more investigation, including the impact of intervention on \nventricular arrhythmias. \n• More data are required on the role of TEER in patients with advanced HF. \n• Long-term results of TEER need to be further assessed, including the \nclinical relevance of transmitral gradients after treatment of both pri-\nmary and secondary MR. \n• Results of ongoing trials comparing MV surgery with TEER in non- \nhigh risk primary MR patients are awaited. \n• Data on the mid- and long-term clinical impacts of transcatheter MV \nreplacement are required. \n• More data on the clinical impacts of surgical and transcatheter treat-\nment of atrial SMR are required.  \nMitral stenosis \n• The potential role of TMVI using dedicated devices in high-risk \npatients is to be determined, particularly those with severe \nMAC.  \nTricuspid regurgitation \n• The long-term risks and benefits of concomitant TV surgery in pa-\ntients with less than moderate TR and annular dilatation undergoing \nleft-sided valve surgery need to be determined. \n• Further investigations are required on the outcomes of TV interven-\ntion in asymptomatic patients with severe TR and RV dysfunction or \nsignificant dilation. \n• The importance of addressing concomitant AF in patients with TR \nneeds to be investigated. \n• More data are required on the indications, timing, and long-term out-\ncomes of TV repair and replacement for TV disease. \n• Better understanding is required of the respective role of surgery vs \ntranscatheter TV therapy for TR treatment.  \nTricuspid stenosis \n• The role of transcatheter TV replacement remains unexplored in pa-\ntients with TS. The most efficient way to achieve ventricular pacing in \npatients after TV replacement needs to be investigated.  \nMultiple and mixed valvular heart disease \n• Further evaluation of the impact on outcomes and indication for \nintervention, as well as timing and modalities of intervention, is \nrequired.  \nProsthetic valves \n• Further development of current prosthetic valve devices is required \nto address their main complications (e.g. improved tissue processing \nto reduce degeneration of bioprostheses or new mechanical valve \ndesigns to reduce risk of thrombosis). \n• Antithrombotic drugs in MHV patients: \n– Whether UFH or LMWH should be preferred as bridging therapy \nafter MHV implantation, as well as their timing and dosage, remains \nto be established. \n– For patients with MHV undergoing major NCS, the optimal post- \noperative management and bridging of VKA needs further \ninvestigation. \n– The role of pharmacogenomics for VKORC1, CYP2C9, and \nCYP4F2 in patients with highly variable INR, and low TTR or major \nvascular complications despite good adherence, should be further \ninvestigated. \n– More data on the risks and benefits of slow thrombolysis for valve \nthrombosis are required.  \n4706                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nPregnancy \n• More data are required on optimal management of anticoagulation in \npregnant women with MHVs. Prospective studies comparing differ-\nent antithrombotic regimens are lacking.  \nNon-cardiac surgery \n• Clinical utility of scales for peri-operative risk evaluation needs to be \ndetermined.  \nSex-specific considerations \n• The development of sex-adjusted surgical risk prediction tools is required. \n• Additional data are needed to validate sex-specific cut-offs indicating \ninterventions. \n• Further research is needed to investigate sex-related differences in \nthe prognosis and treatment of specific valve diseases, especially \nTR.  \n20. ‘What to do’ and ‘What not \nto do’ messages from the \nGuidelines \nClass I and Class III recommendations from throughout the guideline \ndocument are summarized in Table 13. \nTable 13 ‘What to do’ and ‘what not to do’ \nRecommendations \nClassa \nLevelb  \nRecommendations for the management of coronary artery disease in patients with valvular heart disease \nCCTA is recommended before valve intervention in patients with moderate or lower (≤50%) pre-test likelihood of obstructive CAD. \nI \nB \nInvasive coronary angiography is recommended before valve intervention in patients with high and very high (>50%) pre-test likelihood of \nobstructive CAD. \nI \nC \nInvasive coronary angiography is recommended in the evaluation of CAD in patients with severe ventricular SMR. \nI \nC \nCABG is recommended in patients with a primary indication for valve surgery and coronary artery diameter stenosis ≥70%. \nI \nC \nRecommendations for the management of atrial fibrillation in patients with native valvular heart disease \nDOACs are recommended for stroke prevention in preference to VKAs in patients with AF and AS, AR, or MR who are eligible for OAC. \nI \nA \nConcomitant surgical ablation is recommended in patients undergoing MV surgery with AF suitable for a rhythm control strategy to prevent \nsymptoms and recurrence of AF, according to an experienced team of electrophysiologists and arrhythmia surgeons. \nI \nA \nSurgical closure of the LA appendage is recommended as an adjunct to OAC in patients with AF undergoing valve surgery to prevent \ncardioembolic stroke and systemic thromboembolism. \nI \nB \nThe use of DOACs is not recommended in patients with AF and rheumatic MS with an MVA ≤2.0 cm2. \nIII \nB \nRecommendations on indications for surgery in severe aortic regurgitation \nAV surgery is recommended in symptomatic patients with severe AR regardless of LV function. \nI \nB \nAV surgery is recommended in asymptomatic patients with severe AR and LVESD >50 mm or LVESDi >25 mm/m2 [especially in patients \nwith small body size (BSA <1.68 m2)] or resting LVEF ≤50%. \nI \nB \nValve-sparing aortic root replacement is recommended in young patients with aortic root dilatation at experienced centres when durable \nresults are expected. \nI \nB \nAV surgery is recommended in symptomatic and asymptomatic patients with severe AR undergoing CABG or surgery of the ascending \naorta. \nI \nC \nRecommendations for intervention and mode of intervention in severe aortic stenosis \nSymptomatic patients with severe aortic stenosis \nIntervention is recommended in symptomatic patients with severe, high-gradient AS [mean gradient ≥40 mmHg, Vmax ≥4.0 m/s, and \nAVA ≤1.0 cm2 (or ≤0.6 cm2/m2 BSA)]. \nI \nB \nIntervention is recommended in symptomatic patients with low-flow (SVi ≤35 mL/m2), low-gradient (<40 mmHg) AS with reduced LVEF \n(<50%) after careful confirmation that AS is severe. \nI \nB \nAsymptomatic patients with severe aortic stenosis \nIntervention is recommended in asymptomatic patients with severe AS and LVEF <50% without another cause. \nI \nB \nMode of intervention in patients with symptomatic severe aortic stenosis \nIt is recommended that AV interventions are performed in Heart Valve Centres that report their local expertise and outcome data, have \non-site interventional cardiology and cardiac surgical programmes, and a structured collaborative Heart Team. \nI \nC \nIt is recommended that the mode of intervention is based on Heart Team assessment of individual clinical, anatomical, and procedural \ncharacteristics, incorporating lifetime management considerations and estimated life expectancy. \nI \nC                       \nContinued  \nESC Guidelines                                                                                                                                                                                          4707 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "keywords": [
        "aortic stenosis",
        "class i",
        "angiography",
        "recommended",
        "indication",
        "evidence",
        "class iii",
        "anticoagulation",
        "lvef",
        "crt",
        "should be considered",
        "prosthetic valve",
        "coronary artery",
        "mitral stenosis",
        "mitral regurgitation",
        "aortic",
        "gaps",
        "may be considered",
        "tricuspid",
        "aortic regurgitation",
        "sex",
        "savr",
        "arrhythmia",
        "atrial fibrillation",
        "guideline",
        "ablation",
        "tavi",
        "age",
        "stenosis",
        "exercise"
      ],
      "tables": [
        {
          "title": "Table 13  ‘What to do’ and ‘what not to do’",
          "page_number": 72,
          "content": "Recommendations |  | Classa | Levelb | \n | Recommendations for the management of coronary artery disease in patients with valvular heart disease |  |  | \nCCTA is recommended before valve intervention in patients with moderate or lower (≤50%) pre-test likelihood of obstructive CAD. |  | I | B | \nInvasive coronary angiography is recommended before valve intervention in patients with high and very high (>50%) pre-test likelihood of\nobstructive CAD. |  | I | C | \nInvasive coronary angiography is recommended in the evaluation of CAD in patients with severe ventricular SMR. |  | I | C | \nCABG is recommended in patients with a primary indication for valve surgery and coronary artery diameter stenosis ≥70%. |  | I | C | \n | Recommendations for the management of atrial fibrillation in patients with native valvular heart disease |  |  | \nDOACs are recommended for stroke prevention in preference to VKAs in patients with AF and AS, AR, or MR who are eligible for OAC. |  | I | A | \nConcomitant surgical ablation is recommended in patients undergoing MV surgery with AF suitable for a rhythm control strategy to prevent\nsymptoms and recurrence of AF, according to an experienced team of electrophysiologists and arrhythmia surgeons. |  | I | A | \nSurgical closure of the LA appendage is recommended as an adjunct to OAC in patients with AF undergoing valve surgery to prevent\ncardioembolic stroke and systemic thromboembolism. |  | I | B | \nThe use of DOACs is not recommended in patients with AF and rheumatic MS with an MVA ≤2.0 cm2. |  | III | B | \n | Recommendations on indications for surgery in severe aortic regurgitation |  |  | \nAV surgery is recommended in symptomatic patients with severe AR regardless of LV function. |  | I | B | \nAV surgery is recommended in asymptomatic patients with severe AR and LVESD >50 mm or LVESDi >25 mm/m2 [especially in patients\nwith small body size (BSA <1.68 m2)] or resting LVEF ≤50%. |  | I | B | \nValve-sparing aortic root replacement is recommended in young patients with aortic root dilatation at experienced centres when durable\nresults are expected. |  | I | B | \nAV surgery is recommended in symptomatic and asymptomatic patients with severe AR undergoing CABG or surgery of the ascending\naorta. |  | I | C | \nRecommendations for intervention and mode of intervention in severe aortic stenosis |  |  |  | \nSymptomatic patients with severe aortic stenosis |  |  |  | \nIntervention is recommended in symptomatic patients with severe, high-gradient AS [mean gradient ≥40 mmHg, V ≥4.0 m/s, and\nmax\nAVA ≤1.0 cm2 (or ≤0.6 cm2/m2 BSA)]. |  | I | B | \nIntervention is recommended in symptomatic patients with low-flow (SVi ≤35 mL/m2), low-gradient (<40 mmHg) AS with reduced LVEF\n(<50%) after careful confrimation that AS is severe. |  | I | B | \n | Asymptomatic patients with severe aortic stenosis |  |  | \nIntervention is recommended in asymptomatic patients with severe AS and LVEF <50% without another cause. |  | I | B | \n | Mode of intervention in patients with symptomatic severe aortic stenosis |  |  | \nIt is recommended that AV interventions are performed in Heart Valve Centres that report their local expertise and outcome data, have\non-site interventional cardiology and cardiac surgical programmes, and a structured collaborative Heart Team. |  | I | C | \nIt is recommended that the mode of intervention is based on Heart Team assessment of individual clinical, anatomical, and procedural\ncharacteristics, incorporating lifetime management considerations and estimated life expectancy. |  | I | C | ",
          "bbox": [
            42.51969909667969,
            237.15399169921875,
            558.4249877929688,
            712.751953125
          ],
          "function_potential": "raw"
        },
        {
          "title": "Table on page 74",
          "page_number": 73,
          "content": "TAVI is recommended in patients ≥70 years of age with tricuspid AV stenosis, if the anatomy is suitable. |  | I | A | \nSAVR is recommended in patients <70 years of age, if the surgical risk is low. |  | I | B | \nSAVR or TAVI are recommended for all remaining candidates for an aortic BHV according to Heart Team assessment. |  | I | B | \n | Concomitant aortic valve surgery at the time of coronary artery bypass grafting or ascending aorta surgery |  |  | \nSAVR is recommended in symptomatic and asymptomatic patients with severe AS undergoing CABG or surgical intervention on the\nascending aorta. |  | I | C | \nRecommendations for intervention in severe mitral regurgitation |  |  |  | \nPrimary mitral regurgitation |  |  |  | \nMV repair is the recommended surgical technique to treat patients with severe PMR when the result is expected to be durable. |  | I | B | \nMV surgery is recommended in symptomatic patients with severe PMR considered operable by the Heart Team. |  | I | B | \nMV surgery is recommended in asymptomatic patients with severe PMR with LV dysfunction (LVESD ≥40 mm or LVESDi ≥20 mm/m2 or\nLVEF ≤60%). |  | I | B | \nSurgical MV repair is recommended in low-risk asymptomatic patients with severe PMR without LV dysfunction (LVESD <40 mm, LVESDi\n<20 mm/m2, and LVEF >60%) when a durable result is likely, if at least three of the following criteria are fulfliled:\n• AF\n• SPAP at rest >50 mmHg\n• LA dilatation (LAVI ≥60 mL/m2 or LA diameter ≥55 mm)\n• concomitant TR ≥ moderate. |  | I | B | \n | Ventricular secondary mitral regurgitation and concomitant coronary artery disease |  |  | \nMV surgery is recommended in patients with severe ventricular SMR undergoing CABG. |  | I | B | \n | Ventricular secondary mitral regurgitation without concomitant coronary artery disease |  |  | \nTEER is recommended to reduce HF hospitalizations and improve quality of life in haemodynamically stable, symptomatic patients with\nimpaired LVEF (<50%) and persistent severe ventricular SMR, despite optimized GDMT and CRT (if indicated), fulfilling specifci clinical and\nechocardiographic criteria. |  | I | A | \nRecommendations for mitral stenosis |  |  |  | \nIndications for mitral valve surgery and transcatheter intervention in clinically severe rheumatic and degenerative mitral stenosis |  |  |  | \nPMC is recommended in symptomatic patients in the absence of unfavourable characteristics for PMC. |  | I | B | \nPMC is recommended in any symptomatic patients with a contraindication or a high risk for surgery. |  | I | C | \nMV surgery is recommended in symptomatic patients who are not suitable for PMC. |  | I | C | \nRecommendations for tricuspid regurgitation |  |  |  | \nIndications for intervention in tricuspid regurgitation |  |  |  | \nCareful evaluation of TR aetiology, stage of the disease (i.e. degree of TR severity, RV and LV dysfunction, and PH), patient operative risk,\nand likelihood of recovery by a multidisciplinary Heart Team is recommended in patients with severe TR prior to intervention. |  | I | C | \n | Patients with left-sided valvular heart disease requiring tricuspid valve surgery |  |  | \nConcomitant TV surgery is recommended in patients with severe primary or secondary TR. |  | I | B | \n | Patients with severe tricuspid regurgitation (without left-sided valvular heart disease requiring surgery) |  |  | \nTV surgery is recommended in symptomatic patients with severe primary TR without severe RV dysfunction or severe PH. |  | I | C | \n | Recommendations on tricuspid stenosis |  |  | \nSurgery is recommended in symptomatic patients with severe TS. |  | I | C | \nSurgery is recommended in patients with severe TS undergoing left-sided valve intervention. |  | I | C | \nRecommendations for surgery of concomitant left-sided valvular heart disease |  |  |  | \nConcomitant aortic stenosis |  |  |  | \nSAVR is recommended in patients with severe AS undergoing surgery for another valve. |  | I | C | \n | Concomitant aortic regurgitation |  |  | \nAV surgery is recommended in patients with severe AR undergoing surgery for another valve. |  | I | C | \n | Concomitant mitral regurgitation |  |  | \nMV surgery is recommended in patients with severe MR undergoing surgery for another valve. |  | I | C | ",
          "bbox": [
            36.850399017333984,
            59.0,
            552.7559814453125,
            707.5965924944196
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "20. ‘What to do’ and ‘What not to do’ messages from the Guidelines",
      "start_page": 72,
      "end_page": 76,
      "content": "Pregnancy \n• More data are required on optimal management of anticoagulation in \npregnant women with MHVs. Prospective studies comparing differ-\nent antithrombotic regimens are lacking.  \nNon-cardiac surgery \n• Clinical utility of scales for peri-operative risk evaluation needs to be \ndetermined.  \nSex-specific considerations \n• The development of sex-adjusted surgical risk prediction tools is required. \n• Additional data are needed to validate sex-specific cut-offs indicating \ninterventions. \n• Further research is needed to investigate sex-related differences in \nthe prognosis and treatment of specific valve diseases, especially \nTR.  \n20. ‘What to do’ and ‘What not \nto do’ messages from the \nGuidelines \nClass I and Class III recommendations from throughout the guideline \ndocument are summarized in Table 13. \nTable 13 ‘What to do’ and ‘what not to do’ \nRecommendations \nClassa \nLevelb  \nRecommendations for the management of coronary artery disease in patients with valvular heart disease \nCCTA is recommended before valve intervention in patients with moderate or lower (≤50%) pre-test likelihood of obstructive CAD. \nI \nB \nInvasive coronary angiography is recommended before valve intervention in patients with high and very high (>50%) pre-test likelihood of \nobstructive CAD. \nI \nC \nInvasive coronary angiography is recommended in the evaluation of CAD in patients with severe ventricular SMR. \nI \nC \nCABG is recommended in patients with a primary indication for valve surgery and coronary artery diameter stenosis ≥70%. \nI \nC \nRecommendations for the management of atrial fibrillation in patients with native valvular heart disease \nDOACs are recommended for stroke prevention in preference to VKAs in patients with AF and AS, AR, or MR who are eligible for OAC. \nI \nA \nConcomitant surgical ablation is recommended in patients undergoing MV surgery with AF suitable for a rhythm control strategy to prevent \nsymptoms and recurrence of AF, according to an experienced team of electrophysiologists and arrhythmia surgeons. \nI \nA \nSurgical closure of the LA appendage is recommended as an adjunct to OAC in patients with AF undergoing valve surgery to prevent \ncardioembolic stroke and systemic thromboembolism. \nI \nB \nThe use of DOACs is not recommended in patients with AF and rheumatic MS with an MVA ≤2.0 cm2. \nIII \nB \nRecommendations on indications for surgery in severe aortic regurgitation \nAV surgery is recommended in symptomatic patients with severe AR regardless of LV function. \nI \nB \nAV surgery is recommended in asymptomatic patients with severe AR and LVESD >50 mm or LVESDi >25 mm/m2 [especially in patients \nwith small body size (BSA <1.68 m2)] or resting LVEF ≤50%. \nI \nB \nValve-sparing aortic root replacement is recommended in young patients with aortic root dilatation at experienced centres when durable \nresults are expected. \nI \nB \nAV surgery is recommended in symptomatic and asymptomatic patients with severe AR undergoing CABG or surgery of the ascending \naorta. \nI \nC \nRecommendations for intervention and mode of intervention in severe aortic stenosis \nSymptomatic patients with severe aortic stenosis \nIntervention is recommended in symptomatic patients with severe, high-gradient AS [mean gradient ≥40 mmHg, Vmax ≥4.0 m/s, and \nAVA ≤1.0 cm2 (or ≤0.6 cm2/m2 BSA)]. \nI \nB \nIntervention is recommended in symptomatic patients with low-flow (SVi ≤35 mL/m2), low-gradient (<40 mmHg) AS with reduced LVEF \n(<50%) after careful confirmation that AS is severe. \nI \nB \nAsymptomatic patients with severe aortic stenosis \nIntervention is recommended in asymptomatic patients with severe AS and LVEF <50% without another cause. \nI \nB \nMode of intervention in patients with symptomatic severe aortic stenosis \nIt is recommended that AV interventions are performed in Heart Valve Centres that report their local expertise and outcome data, have \non-site interventional cardiology and cardiac surgical programmes, and a structured collaborative Heart Team. \nI \nC \nIt is recommended that the mode of intervention is based on Heart Team assessment of individual clinical, anatomical, and procedural \ncharacteristics, incorporating lifetime management considerations and estimated life expectancy. \nI \nC                       \nContinued  \nESC Guidelines                                                                                                                                                                                          4707 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nTAVI is recommended in patients ≥70 years of age with tricuspid AV stenosis, if the anatomy is suitable. \nI \nA \nSAVR is recommended in patients <70 years of age, if the surgical risk is low. \nI \nB \nSAVR or TAVI are recommended for all remaining candidates for an aortic BHV according to Heart Team assessment. \nI \nB \nConcomitant aortic valve surgery at the time of coronary artery bypass grafting or ascending aorta surgery \nSAVR is recommended in symptomatic and asymptomatic patients with severe AS undergoing CABG or surgical intervention on the \nascending aorta. \nI \nC \nRecommendations for intervention in severe mitral regurgitation \nPrimary mitral regurgitation \nMV repair is the recommended surgical technique to treat patients with severe PMR when the result is expected to be durable. \nI \nB \nMV surgery is recommended in symptomatic patients with severe PMR considered operable by the Heart Team. \nI \nB \nMV surgery is recommended in asymptomatic patients with severe PMR with LV dysfunction (LVESD ≥40 mm or LVESDi ≥20 mm/m2 or \nLVEF ≤60%). \nI \nB \nSurgical MV repair is recommended in low-risk asymptomatic patients with severe PMR without LV dysfunction (LVESD <40 mm, LVESDi  \n<20 mm/m2, and LVEF >60%) when a durable result is likely, if at least three of the following criteria are fulfilled: \n• AF \n• SPAP at rest >50 mmHg \n• LA dilatation (LAVI ≥60 mL/m2 or LA diameter ≥55 mm) \n• concomitant TR ≥ moderate. \nI \nB \nVentricular secondary mitral regurgitation and concomitant coronary artery disease \nMV surgery is recommended in patients with severe ventricular SMR undergoing CABG. \nI \nB \nVentricular secondary mitral regurgitation without concomitant coronary artery disease \nTEER is recommended to reduce HF hospitalizations and improve quality of life in haemodynamically stable, symptomatic patients with \nimpaired LVEF (<50%) and persistent severe ventricular SMR, despite optimized GDMT and CRT (if indicated), fulfilling specific clinical and \nechocardiographic criteria. \nI \nA \nRecommendations for mitral stenosis \nIndications for mitral valve surgery and transcatheter intervention in clinically severe rheumatic and degenerative mitral stenosis \nPMC is recommended in symptomatic patients in the absence of unfavourable characteristics for PMC. \nI \nB \nPMC is recommended in any symptomatic patients with a contraindication or a high risk for surgery. \nI \nC \nMV surgery is recommended in symptomatic patients who are not suitable for PMC. \nI \nC \nRecommendations for tricuspid regurgitation \nIndications for intervention in tricuspid regurgitation \nCareful evaluation of TR aetiology, stage of the disease (i.e. degree of TR severity, RV and LV dysfunction, and PH), patient operative risk, \nand likelihood of recovery by a multidisciplinary Heart Team is recommended in patients with severe TR prior to intervention. \nI \nC \nPatients with left-sided valvular heart disease requiring tricuspid valve surgery \nConcomitant TV surgery is recommended in patients with severe primary or secondary TR. \nI \nB \nPatients with severe tricuspid regurgitation (without left-sided valvular heart disease requiring surgery) \nTV surgery is recommended in symptomatic patients with severe primary TR without severe RV dysfunction or severe PH. \nI \nC \nRecommendations on tricuspid stenosis \nSurgery is recommended in symptomatic patients with severe TS. \nI \nC \nSurgery is recommended in patients with severe TS undergoing left-sided valve intervention. \nI \nC \nRecommendations for surgery of concomitant left-sided valvular heart disease \nConcomitant aortic stenosis \nSAVR is recommended in patients with severe AS undergoing surgery for another valve. \nI \nC \nConcomitant aortic regurgitation \nAV surgery is recommended in patients with severe AR undergoing surgery for another valve. \nI \nC \nConcomitant mitral regurgitation \nMV surgery is recommended in patients with severe MR undergoing surgery for another valve. \nI \nC                         \nContinued  \n4708                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nRecommendations on indications for intervention in patients with mixed moderate aortic stenosis and moderate aortic regurgitation \nIntervention is recommended in symptomatic patients with mixed moderate AV stenosis and moderate regurgitation, and a mean \ngradient ≥40 mmHg or Vmax ≥4.0 m/s. \nI \nB \nIntervention is recommended in asymptomatic patients with mixed moderate AV stenosis and moderate regurgitation with Vmax ≥4.0 m/s, \nand LVEF <50% not attributable to other cardiac disease. \nI \nC \nRecommendations for prosthetic valve selection \nMechanical heart valves \nAn MHV is recommended according to the desire of the informed patient and if there is no contraindication to long-term anticoagulation. \nI \nC \nBiological heart valves \nA BHV is recommended according to the desire of the informed patient. \nI \nC \nA BHV is recommended when an adequate quality of anticoagulation with VKA is unlikely, in patients at high bleeding risk, or with estimated \nshort life expectancy. \nI \nC \nRecommendations for the management of antithrombotic therapy in patients with a mechanical heart valve replacement \nLifelong OAC with a VKA is recommended for all patients with MHVs to prevent thromboembolic complications. \nI \nA \nINR self-monitoring and self-management are recommended over standard monitoring in selected, trained patients to improve efficacy. \nI \nA \nIt is recommended that INR targets are based on the type and position of the MHV, and the patient’s risk factors and comorbidities. \nI \nA \nPatient education is recommended to improve the quality of OAC. \nI \nA \nFollowing cardiac surgery with MHV implantation, it is recommended to start UFH or LMWH bridging and VKA within 24 h, or as soon as \nconsidered safe. \nI \nB \nDOACs and/or DAPT are not recommended to prevent thrombosis in patients with an MHV. \nIII \nA \nRecommendations for the management of antithrombotic therapy in patients with mechanical heart valves undergoing elective \nnon-cardiac surgery or invasive procedures \nContinuing VKA treatment is recommended in patients with an MHV for minor or minimally invasive interventions associated with no or \nminimal bleeding. \nI \nA \nIt is recommended to discontinue VKA at least 4 days before major elective NCS, aiming for an INR <1.5, and to resume VKA treatment \nwithin 24 h after surgery, or as soon as considered safe. \nI \nB \nRecommendations for the management of antithrombotic therapy in patients with a biological heart valve or valve repair \nTranscatheter aortic valve implantation without indication for oral anticoagulation \nLow-dose ASA (75–100 mg/day) is recommended for 12 months after TAVI in patients without indication for OAC. \nI \nA \nDAPT is not recommended to prevent thrombosis after TAVI, unless there is a clear indication. \nIII \nA \nRoutine use of OAC is not recommended after TAVI in patients without baseline indication. \nIII \nA \nSurgical biological heart valve with indication for oral anticoagulation \nOAC continuation is recommended in patients with a clear indication for OAC undergoing surgical BHV implantation. \nI \nB \nTranscatheter biological heart valve with indication for oral anticoagulation \nOAC is recommended for TAVI patients who have other indications for OAC. \nI \nB \nRecommendations on management of prosthetic valve dysfunction \nHaemolysis and paravalvular leak \nIt is recommended that the decision between transcatheter or surgical closure of clinically significant PVLs is based on Heart Team \nevaluation, including patient risk, leak morphology, and local expertise. \nI \nC \nReoperation is recommended if a PVL is related to endocarditis, or causes haemolysis requiring repeated blood transfusion or leading to HF \nsymptoms. \nI \nC \nMechanical heart valve failure \nReoperation is recommended in symptomatic patients with significant valve dysfunction not attributable to valve thrombosis. \nI \nC \nBiological heart valve failure \nReintervention is recommended in symptomatic patients with significant valve dysfunction not attributable to valve thrombosis. \nI \nC \nValve thrombosis \nTOE and/or 4D-CT are recommended in patients with suspected valve thrombosis to confirm the diagnosis. \nI \nC                       \nContinued  \nESC Guidelines                                                                                                                                                                                          4709 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n21. Evidence tables \nEvidence tables are available at European Heart Journal online. \n22. Data availability statement \nNo new data were generated or analysed in support of this research. \n23. Author information \nJonas Lanz, Department of Cardiology, Bern University Hospital, \nBern, \nSwitzerland; \nMateo \nMarin-Cuartas, \nUniversity \nDepartment of Cardiac Surgery, Leipzig Heart Center, Leipzig, \nGermany; Ana Abreu, Faculdade de Medicina da Universidade de \nLisboa (FMUL), ISAMB, IMPSP, CCUL, CAML, Lisboa, Portugal; \nServiço Cardiologia, Unidade de Reabilitação Cardiovascular, ULS \nSanta Maria/FMUL, Lisboa, Portugal; Marianna Adamo, Institute \nof Cardiology, ASST Spedali Civili, Brescia, Italy; Department of \nmedical and surgical specialties, radiological sciences, and public \nhealth, University of Brescia, Italy; Nina Ajmone Marsan, \nDepartment of Cardiology, Leiden University Medical Center, \nLeiden, Netherlands; Fabio Barili, Department of Biomedical and \nClinical Sciences, Università Degli Studi Di Milano, Milan, Italy; \nUniversity Cardiac Surgery Unit, IRCCS Ospedale Galeazzi - \nSant’Ambrogio, Milan, Italy; Department of Epidemiology, Harvard \nT.H. Chan School of Public Health Boston, MA, United States of \nAmerica; Nikolaos Bonaros, Department of Cardiac Surgery, \nMedical University of Innsbruck, Innsbruck, Austria; University \nHospital Innsbruck, Innsbruck, Austria; Bernard Cosyns, \nCardiology department, Universitair Ziekenhuis Brussel, Brussels, \nBelgium; Ruggero De Paulis, Department of cardiac surgery, \nEuropean Hospital, Rome, Italy; Unicamillus University, Rome, \nItaly; Habib Gamra, Cardiology University of Monastir, Monastir, \nTunisia; Marjan Jahangiri, Cardiac Surgery, St George’s Hospital, \nLondon, United Kingdom; Anders Jeppsson, Cardiothoracic sur-\ngery, Sahlgrenska University Hospital, Gothenburg, Sweden; \nMolecular and clinical medicine, Institute of medicine, Sahlgrenska \nAcademy, University of Gothenburg, Gothenburg, Sweden; \nRobert J.M. Klautz, Department of Cardiothoracic Surgery, \nLeiden \nUniversity \nMedical \nCenter, \nLeiden, \nNetherlands; \nDepartment of Cardiothoracic Surgery, Amsterdam University \nMedical Center, Amsterdam, Netherlands; Benoit Mores, \n(Belgium), ESC Patient Forum, Sophia Antipolis, France; Esther \nPérez-David, Cardiology Department, Hospital Universitario La \nPaz, IdiPaz (Hospital la Paz Research Institute), Facultad de \nMedicina Universidad Europea de Madrid, Madrid, Spain; Janine \nPöss, Department of internal medicine/cardiology, Heart Centre \nLeipzig at University of Leipzig, Leipzig, Germany; Bernard \nD. Prendergast, Heart Vascular & Thoracic Institute, Cleveland \nClinic London, London, United Kingdom; Department of \nCardiology, St Thomas’ Hospital, London, United Kingdom; \nBianca Rocca, Department of Medicine and Surgery, LUM \nUniversity Casamassima (Ba), Italy; Xavier Rossello, Cardiology \nDepartment, Hospital Universitari Son Espases, Palma de Mallorca, \nSpain; Health Research Institute of the Balearic Islands (IdISBa), \nUniversitat de les Illes Balears (UIB), Palma de Mallorca, Spain; \nMikio Suzuki, (Serbia), ESC Patient Forum, Sophia Antipolis, \nFrance; Holger Thiele, Department of Internal Medicine/ \nCardiology, Heart Centre Leipzig at Leipzig University, Leipzig, \nGermany; Leipzig Heart Science, Leipzig, Germany; Christophe \nMichel Tribouilloy, Cardiology department, Amiens University \nHospital, Amiens, France; and Wojtek Wojakowski, Division of \nCardiology and Structural Heart Diseases, Medical University of \nSilesia, Katowice, Poland. \n24. Appendix \nESC/EACTS Scientific Document Group \nIncludes Document Reviewers, ESC National Cardiac Societies and \nEACTS Network of National Cardiac Surgery Societies \nDocument \nReviewers: \nAlec \nVahanian \n(ESC \nReview \nCo-ordinator) \n(France), \nCarlos-A. \nMestres \n(EACTS \nReview \nCo-ordinator) (South Africa), Leila Abid (Tunisia), Suleman Aktaa \n(United Kingdom), Elena Arbelo (Spain), Folkert W. Asselbergs \n(Netherlands), Emanuele Barbato (Italy), Giuseppe Boriani (Italy), \nMargarita Brida (Croatia), Sergio Buccheri (Sweden), Robert Byrne \n(Republic of Ireland), Ovidiu Chioncel (Romania), Lenard Conradi \n(Germany), Michele De Bonis (Italy), Victoria Delgado (Spain), Enoch \nF. Akowuah (United Kingdom), Anna Franzone (Italy), Kristina \nHermann Haugaa (Norway), Bettina Heidecker (Germany), Borja \nIbanez (Spain), Bernard Iung (France), Stefan James (Sweden), Lars \nKøber (Denmark), Konstantinos C. Koskinas (Switzerland), Ulf \nMechanical heart valve thrombosis \nHeart Team evaluation is recommended in patients with acute HF (NYHA class III or IV) due to obstructive MHV thrombosis to determine \nappropriate management (repeat valve replacement or low-dose slow infusion fibrinolysis). \nI \nB \nBiological heart valve thrombosis \nOAC using VKA is recommended in BHV thrombosis before considering reintervention. \nI \nB \n© ESC/EACTS 2025\n4D, four-dimensional; AF, atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; ASA, acetylsalicylic acid; AV, aortic valve; AVA, aortic valve area; BHV, biological heart valve; BSA, body \nsurface area; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCTA, coronary CT angiography; CRT, cardiac resynchronization therapy; CT, computed tomography; \nDAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulation; GDMT, guideline-directed medical therapy; h, hour; HF, heart failure; INR, international normalized ratio; LA, left atrium/ \nleft atrial; LAVI, left atrial volume index; LMWH, low-molecular-weight heparin; LV, left ventricle/left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic \ndiameter; LVESDi, left ventricular end-systolic diameter indexed to BSA; MHV, mechanical heart valve; MR, mitral regurgitation; MS, mitral stenosis; MV, mitral valve; MVA, mitral valve area; \nNCS, non-cardiac surgery; NYHA, New York Heart Association; OAC, oral anticoagulation; PH, pulmonary hypertension; PMC, percutaneous mitral commissurotomy; PMR, primary mitral \nregurgitation; PVL, paravalvular leak; RV, right ventricle/right ventricular; SAVR, surgical aortic valve replacement; SMR, secondary mitral regurgitation; SPAP, systolic pulmonary artery \npressure; SVi, stroke volume index; TAVI, transcatheter aortic valve implantation; TEER, transcatheter edge-to-edge repair; TOE, transoesophageal echocardiography; TR, tricuspid \nregurgitation; TS, tricuspid stenosis; TV, tricuspid valve; UFH, unfractionated heparin; VKA, vitamin K antagonist; Vmax, peak transvalvular velocity. \naClass of recommendation. \nbLevel of evidence.   \n4710                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "keywords": [
        "aortic stenosis",
        "class i",
        "angiography",
        "heart failure",
        "recommended",
        "what",
        "pulmonary hypertension",
        "indication",
        "contraindication",
        "class iii",
        "valve repair",
        "guidelines",
        "anticoagulation",
        "hypertension",
        "lvef",
        "echocardiography",
        "crt",
        "prosthetic valve",
        "mitral stenosis",
        "coronary artery",
        "mitral regurgitation",
        "nyha",
        "aortic",
        "weight",
        "tricuspid",
        "aortic regurgitation",
        "savr",
        "sex",
        "arrhythmia",
        "atrial fibrillation"
      ],
      "tables": [
        {
          "title": "Table on page 75",
          "page_number": 74,
          "content": " | Recommendations on indications for intervention in patients with mixed moderate aortic stenosis and moderate aortic regurgitation |  |  | \nIntervention is recommended in symptomatic patients with mixed moderate AV stenosis and moderate regurgitation, and a mean\ngradient ≥40 mmHg or V ≥4.0 m/s.\nmax |  | I | B | \nIntervention is recommended in asymptomatic patients with mixed moderate AV stenosis and moderate regurgitation with V ≥4.0 m/s,\nmax\nand LVEF <50% not attributable to other cardiac disease. |  | I | C | \nRecommendations for prosthetic valve selection |  |  |  | \nMechanical heart valves |  |  |  | \nAn MHV is recommended according to the desire of the informed patient and if there is no contraindication to long-term anticoagulation. |  | I | C | \n | Biological heart valves |  |  | \nA BHV is recommended according to the desire of the informed patient. |  | I | C | \nA BHV is recommended when an adequate quality of anticoagulation with VKA is unlikely, in patients at high bleeding risk, or with estimated\nshort life expectancy. |  | I | C | \n | Recommendations for the management of antithrombotic therapy in patients with a mechanical heart valve replacement |  |  | \nLifelong OAC with a VKA is recommended for all patients with MHVs to prevent thromboembolic complications. |  | I | A | \nINR self-monitoring and self-management are recommended over standard monitoring in selected, trained patients to improve effci acy. |  | I | A | \nIt is recommended that INR targets are based on the type and position of the MHV, and the patient’s risk factors and comorbidities. |  | I | A | \nPatient education is recommended to improve the quality of OAC. |  | I | A | \nFollowing cardiac surgery with MHV implantation, it is recommended to start UFH or LMWH bridging and VKA within 24 h, or as soon as\nconsidered safe. |  | I | B | \nDOACs and/or DAPT are not recommended to prevent thrombosis in patients with an MHV. |  | III | A | \n | Recommendations for the management of antithrombotic therapy in patients with mechanical heart valves undergoing elective\nnon-cardiac surgery or invasive procedures |  |  | \nContinuing VKA treatment is recommended in patients with an MHV for minor or minimally invasive interventions associated with no or\nminimal bleeding. |  | I | A | \nIt is recommended to discontinue VKA at least 4 days before major elective NCS, aiming for an INR <1.5, and to resume VKA treatment\nwithin 24 h after surgery, or as soon as considered safe. |  | I | B | \nRecommendations for the management of antithrombotic therapy in patients with a biological heart valve or valve repair |  |  |  | \nTranscatheter aortic valve implantation without indication for oral anticoagulation |  |  |  | \nLow-dose ASA (75–100 mg/day) is recommended for 12 months after TAVI in patients without indication for OAC. |  | I | A | \nDAPT is not recommended to prevent thrombosis after TAVI, unless there is a clear indication. |  | III | A | \nRoutine use of OAC is not recommended after TAVI in patients without baseline indication. |  | III | A | \n | Surgical biological heart valve with indication for oral anticoagulation |  |  | \nOAC continuation is recommended in patients with a clear indication for OAC undergoing surgical BHV implantation. |  | I | B | \n | Transcatheter biological heart valve with indication for oral anticoagulation |  |  | \nOAC is recommended for TAVI patients who have other indications for OAC. |  | I | B | \nRecommendations on management of prosthetic valve dysfunction |  |  |  | \nHaemolysis and paravalvular leak |  |  |  | \nIt is recommended that the decision between transcatheter or surgical closure of clinically signifci ant PVLs is based on Heart Team\nevaluation, including patient risk, leak morphology, and local expertise. |  | I | C | \nReoperation is recommended if a PVL is related to endocarditis, or causes haemolysis requiring repeated blood transfusion or leading to HF\nsymptoms. |  | I | C | \n | Mechanical heart valve failure |  |  | \nReoperation is recommended in symptomatic patients with signifci ant valve dysfunction not attributable to valve thrombosis. |  | I | C | \n | Biological heart valve failure |  |  | \nReintervention is recommended in symptomatic patients with signifci ant valve dysfunction not attributable to valve thrombosis. |  | I | C | \n | Valve thrombosis |  |  | \nTOE and/or 4D-CT are recommended in patients with suspected valve thrombosis to confirm the diagnosis. |  | I | C | ",
          "bbox": [
            42.51969909667969,
            60.2,
            558.4249877929688,
            705.5967538016183
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "Table on page 76",
          "page_number": 75,
          "content": " | Mechanical heart valve thrombosis |  |  | \nHeart Team evaluation is recommended in patients with acute HF (NYHA class III or IV) due to obstructive MHV thrombosis to determine\nappropriate management (repeat valve replacement or low-dose slow infusion fbi rinolysis). |  | I | B | \n | Biological heart valve thrombosis |  |  | \nOAC using VKA is recommended in BHV thrombosis before considering reintervention. |  | I | B | ",
          "bbox": [
            36.850399017333984,
            60.2,
            552.7559814453125,
            128.0
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "2",
      "title": "21. Evidence tables",
      "start_page": 75,
      "end_page": 76,
      "content": "21. Evidence tables \nEvidence tables are available at European Heart Journal online. \n22. Data availability statement \nNo new data were generated or analysed in support of this research. \n23. Author information \nJonas Lanz, Department of Cardiology, Bern University Hospital, \nBern, \nSwitzerland; \nMateo \nMarin-Cuartas, \nUniversity \nDepartment of Cardiac Surgery, Leipzig Heart Center, Leipzig, \nGermany; Ana Abreu, Faculdade de Medicina da Universidade de \nLisboa (FMUL), ISAMB, IMPSP, CCUL, CAML, Lisboa, Portugal; \nServiço Cardiologia, Unidade de Reabilitação Cardiovascular, ULS \nSanta Maria/FMUL, Lisboa, Portugal; Marianna Adamo, Institute \nof Cardiology, ASST Spedali Civili, Brescia, Italy; Department of \nmedical and surgical specialties, radiological sciences, and public \nhealth, University of Brescia, Italy; Nina Ajmone Marsan, \nDepartment of Cardiology, Leiden University Medical Center, \nLeiden, Netherlands; Fabio Barili, Department of Biomedical and \nClinical Sciences, Università Degli Studi Di Milano, Milan, Italy; \nUniversity Cardiac Surgery Unit, IRCCS Ospedale Galeazzi - \nSant’Ambrogio, Milan, Italy; Department of Epidemiology, Harvard \nT.H. Chan School of Public Health Boston, MA, United States of \nAmerica; Nikolaos Bonaros, Department of Cardiac Surgery, \nMedical University of Innsbruck, Innsbruck, Austria; University \nHospital Innsbruck, Innsbruck, Austria; Bernard Cosyns, \nCardiology department, Universitair Ziekenhuis Brussel, Brussels, \nBelgium; Ruggero De Paulis, Department of cardiac surgery, \nEuropean Hospital, Rome, Italy; Unicamillus University, Rome, \nItaly; Habib Gamra, Cardiology University of Monastir, Monastir, \nTunisia; Marjan Jahangiri, Cardiac Surgery, St George’s Hospital, \nLondon, United Kingdom; Anders Jeppsson, Cardiothoracic sur-\ngery, Sahlgrenska University Hospital, Gothenburg, Sweden; \nMolecular and clinical medicine, Institute of medicine, Sahlgrenska \nAcademy, University of Gothenburg, Gothenburg, Sweden; \nRobert J.M. Klautz, Department of Cardiothoracic Surgery, \nLeiden \nUniversity \nMedical \nCenter, \nLeiden, \nNetherlands; \nDepartment of Cardiothoracic Surgery, Amsterdam University \nMedical Center, Amsterdam, Netherlands; Benoit Mores, \n(Belgium), ESC Patient Forum, Sophia Antipolis, France; Esther \nPérez-David, Cardiology Department, Hospital Universitario La \nPaz, IdiPaz (Hospital la Paz Research Institute), Facultad de \nMedicina Universidad Europea de Madrid, Madrid, Spain; Janine \nPöss, Department of internal medicine/cardiology, Heart Centre \nLeipzig at University of Leipzig, Leipzig, Germany; Bernard \nD. Prendergast, Heart Vascular & Thoracic Institute, Cleveland \nClinic London, London, United Kingdom; Department of \nCardiology, St Thomas’ Hospital, London, United Kingdom; \nBianca Rocca, Department of Medicine and Surgery, LUM \nUniversity Casamassima (Ba), Italy; Xavier Rossello, Cardiology \nDepartment, Hospital Universitari Son Espases, Palma de Mallorca, \nSpain; Health Research Institute of the Balearic Islands (IdISBa), \nUniversitat de les Illes Balears (UIB), Palma de Mallorca, Spain; \nMikio Suzuki, (Serbia), ESC Patient Forum, Sophia Antipolis, \nFrance; Holger Thiele, Department of Internal Medicine/ \nCardiology, Heart Centre Leipzig at Leipzig University, Leipzig, \nGermany; Leipzig Heart Science, Leipzig, Germany; Christophe \nMichel Tribouilloy, Cardiology department, Amiens University \nHospital, Amiens, France; and Wojtek Wojakowski, Division of \nCardiology and Structural Heart Diseases, Medical University of \nSilesia, Katowice, Poland. \n24. Appendix \nESC/EACTS Scientific Document Group \nIncludes Document Reviewers, ESC National Cardiac Societies and \nEACTS Network of National Cardiac Surgery Societies \nDocument \nReviewers: \nAlec \nVahanian \n(ESC \nReview \nCo-ordinator) \n(France), \nCarlos-A. \nMestres \n(EACTS \nReview \nCo-ordinator) (South Africa), Leila Abid (Tunisia), Suleman Aktaa \n(United Kingdom), Elena Arbelo (Spain), Folkert W. Asselbergs \n(Netherlands), Emanuele Barbato (Italy), Giuseppe Boriani (Italy), \nMargarita Brida (Croatia), Sergio Buccheri (Sweden), Robert Byrne \n(Republic of Ireland), Ovidiu Chioncel (Romania), Lenard Conradi \n(Germany), Michele De Bonis (Italy), Victoria Delgado (Spain), Enoch \nF. Akowuah (United Kingdom), Anna Franzone (Italy), Kristina \nHermann Haugaa (Norway), Bettina Heidecker (Germany), Borja \nIbanez (Spain), Bernard Iung (France), Stefan James (Sweden), Lars \nKøber (Denmark), Konstantinos C. Koskinas (Switzerland), Ulf \nMechanical heart valve thrombosis \nHeart Team evaluation is recommended in patients with acute HF (NYHA class III or IV) due to obstructive MHV thrombosis to determine \nappropriate management (repeat valve replacement or low-dose slow infusion fibrinolysis). \nI \nB \nBiological heart valve thrombosis \nOAC using VKA is recommended in BHV thrombosis before considering reintervention. \nI \nB \n© ESC/EACTS 2025\n4D, four-dimensional; AF, atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; ASA, acetylsalicylic acid; AV, aortic valve; AVA, aortic valve area; BHV, biological heart valve; BSA, body \nsurface area; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCTA, coronary CT angiography; CRT, cardiac resynchronization therapy; CT, computed tomography; \nDAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulation; GDMT, guideline-directed medical therapy; h, hour; HF, heart failure; INR, international normalized ratio; LA, left atrium/ \nleft atrial; LAVI, left atrial volume index; LMWH, low-molecular-weight heparin; LV, left ventricle/left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic \ndiameter; LVESDi, left ventricular end-systolic diameter indexed to BSA; MHV, mechanical heart valve; MR, mitral regurgitation; MS, mitral stenosis; MV, mitral valve; MVA, mitral valve area; \nNCS, non-cardiac surgery; NYHA, New York Heart Association; OAC, oral anticoagulation; PH, pulmonary hypertension; PMC, percutaneous mitral commissurotomy; PMR, primary mitral \nregurgitation; PVL, paravalvular leak; RV, right ventricle/right ventricular; SAVR, surgical aortic valve replacement; SMR, secondary mitral regurgitation; SPAP, systolic pulmonary artery \npressure; SVi, stroke volume index; TAVI, transcatheter aortic valve implantation; TEER, transcatheter edge-to-edge repair; TOE, transoesophageal echocardiography; TR, tricuspid \nregurgitation; TS, tricuspid stenosis; TV, tricuspid valve; UFH, unfractionated heparin; VKA, vitamin K antagonist; Vmax, peak transvalvular velocity. \naClass of recommendation. \nbLevel of evidence.   \n4710                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "keywords": [
        "aortic stenosis",
        "angiography",
        "heart failure",
        "recommended",
        "pulmonary hypertension",
        "evidence",
        "class iii",
        "tables",
        "anticoagulation",
        "hypertension",
        "lvef",
        "echocardiography",
        "crt",
        "coronary artery",
        "mitral stenosis",
        "mitral regurgitation",
        "nyha",
        "aortic",
        "weight",
        "tricuspid",
        "aortic regurgitation",
        "savr",
        "guideline",
        "atrial fibrillation",
        "ejection fraction",
        "valve replacement",
        "systolic",
        "tavi",
        "stenosis"
      ],
      "tables": []
    },
    {
      "number": "2",
      "title": "22. Data availability statement",
      "start_page": 75,
      "end_page": 76,
      "content": "21. Evidence tables \nEvidence tables are available at European Heart Journal online. \n22. Data availability statement \nNo new data were generated or analysed in support of this research. \n23. Author information \nJonas Lanz, Department of Cardiology, Bern University Hospital, \nBern, \nSwitzerland; \nMateo \nMarin-Cuartas, \nUniversity \nDepartment of Cardiac Surgery, Leipzig Heart Center, Leipzig, \nGermany; Ana Abreu, Faculdade de Medicina da Universidade de \nLisboa (FMUL), ISAMB, IMPSP, CCUL, CAML, Lisboa, Portugal; \nServiço Cardiologia, Unidade de Reabilitação Cardiovascular, ULS \nSanta Maria/FMUL, Lisboa, Portugal; Marianna Adamo, Institute \nof Cardiology, ASST Spedali Civili, Brescia, Italy; Department of \nmedical and surgical specialties, radiological sciences, and public \nhealth, University of Brescia, Italy; Nina Ajmone Marsan, \nDepartment of Cardiology, Leiden University Medical Center, \nLeiden, Netherlands; Fabio Barili, Department of Biomedical and \nClinical Sciences, Università Degli Studi Di Milano, Milan, Italy; \nUniversity Cardiac Surgery Unit, IRCCS Ospedale Galeazzi - \nSant’Ambrogio, Milan, Italy; Department of Epidemiology, Harvard \nT.H. Chan School of Public Health Boston, MA, United States of \nAmerica; Nikolaos Bonaros, Department of Cardiac Surgery, \nMedical University of Innsbruck, Innsbruck, Austria; University \nHospital Innsbruck, Innsbruck, Austria; Bernard Cosyns, \nCardiology department, Universitair Ziekenhuis Brussel, Brussels, \nBelgium; Ruggero De Paulis, Department of cardiac surgery, \nEuropean Hospital, Rome, Italy; Unicamillus University, Rome, \nItaly; Habib Gamra, Cardiology University of Monastir, Monastir, \nTunisia; Marjan Jahangiri, Cardiac Surgery, St George’s Hospital, \nLondon, United Kingdom; Anders Jeppsson, Cardiothoracic sur-\ngery, Sahlgrenska University Hospital, Gothenburg, Sweden; \nMolecular and clinical medicine, Institute of medicine, Sahlgrenska \nAcademy, University of Gothenburg, Gothenburg, Sweden; \nRobert J.M. Klautz, Department of Cardiothoracic Surgery, \nLeiden \nUniversity \nMedical \nCenter, \nLeiden, \nNetherlands; \nDepartment of Cardiothoracic Surgery, Amsterdam University \nMedical Center, Amsterdam, Netherlands; Benoit Mores, \n(Belgium), ESC Patient Forum, Sophia Antipolis, France; Esther \nPérez-David, Cardiology Department, Hospital Universitario La \nPaz, IdiPaz (Hospital la Paz Research Institute), Facultad de \nMedicina Universidad Europea de Madrid, Madrid, Spain; Janine \nPöss, Department of internal medicine/cardiology, Heart Centre \nLeipzig at University of Leipzig, Leipzig, Germany; Bernard \nD. Prendergast, Heart Vascular & Thoracic Institute, Cleveland \nClinic London, London, United Kingdom; Department of \nCardiology, St Thomas’ Hospital, London, United Kingdom; \nBianca Rocca, Department of Medicine and Surgery, LUM \nUniversity Casamassima (Ba), Italy; Xavier Rossello, Cardiology \nDepartment, Hospital Universitari Son Espases, Palma de Mallorca, \nSpain; Health Research Institute of the Balearic Islands (IdISBa), \nUniversitat de les Illes Balears (UIB), Palma de Mallorca, Spain; \nMikio Suzuki, (Serbia), ESC Patient Forum, Sophia Antipolis, \nFrance; Holger Thiele, Department of Internal Medicine/ \nCardiology, Heart Centre Leipzig at Leipzig University, Leipzig, \nGermany; Leipzig Heart Science, Leipzig, Germany; Christophe \nMichel Tribouilloy, Cardiology department, Amiens University \nHospital, Amiens, France; and Wojtek Wojakowski, Division of \nCardiology and Structural Heart Diseases, Medical University of \nSilesia, Katowice, Poland. \n24. Appendix \nESC/EACTS Scientific Document Group \nIncludes Document Reviewers, ESC National Cardiac Societies and \nEACTS Network of National Cardiac Surgery Societies \nDocument \nReviewers: \nAlec \nVahanian \n(ESC \nReview \nCo-ordinator) \n(France), \nCarlos-A. \nMestres \n(EACTS \nReview \nCo-ordinator) (South Africa), Leila Abid (Tunisia), Suleman Aktaa \n(United Kingdom), Elena Arbelo (Spain), Folkert W. Asselbergs \n(Netherlands), Emanuele Barbato (Italy), Giuseppe Boriani (Italy), \nMargarita Brida (Croatia), Sergio Buccheri (Sweden), Robert Byrne \n(Republic of Ireland), Ovidiu Chioncel (Romania), Lenard Conradi \n(Germany), Michele De Bonis (Italy), Victoria Delgado (Spain), Enoch \nF. Akowuah (United Kingdom), Anna Franzone (Italy), Kristina \nHermann Haugaa (Norway), Bettina Heidecker (Germany), Borja \nIbanez (Spain), Bernard Iung (France), Stefan James (Sweden), Lars \nKøber (Denmark), Konstantinos C. Koskinas (Switzerland), Ulf \nMechanical heart valve thrombosis \nHeart Team evaluation is recommended in patients with acute HF (NYHA class III or IV) due to obstructive MHV thrombosis to determine \nappropriate management (repeat valve replacement or low-dose slow infusion fibrinolysis). \nI \nB \nBiological heart valve thrombosis \nOAC using VKA is recommended in BHV thrombosis before considering reintervention. \nI \nB \n© ESC/EACTS 2025\n4D, four-dimensional; AF, atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; ASA, acetylsalicylic acid; AV, aortic valve; AVA, aortic valve area; BHV, biological heart valve; BSA, body \nsurface area; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCTA, coronary CT angiography; CRT, cardiac resynchronization therapy; CT, computed tomography; \nDAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulation; GDMT, guideline-directed medical therapy; h, hour; HF, heart failure; INR, international normalized ratio; LA, left atrium/ \nleft atrial; LAVI, left atrial volume index; LMWH, low-molecular-weight heparin; LV, left ventricle/left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic \ndiameter; LVESDi, left ventricular end-systolic diameter indexed to BSA; MHV, mechanical heart valve; MR, mitral regurgitation; MS, mitral stenosis; MV, mitral valve; MVA, mitral valve area; \nNCS, non-cardiac surgery; NYHA, New York Heart Association; OAC, oral anticoagulation; PH, pulmonary hypertension; PMC, percutaneous mitral commissurotomy; PMR, primary mitral \nregurgitation; PVL, paravalvular leak; RV, right ventricle/right ventricular; SAVR, surgical aortic valve replacement; SMR, secondary mitral regurgitation; SPAP, systolic pulmonary artery \npressure; SVi, stroke volume index; TAVI, transcatheter aortic valve implantation; TEER, transcatheter edge-to-edge repair; TOE, transoesophageal echocardiography; TR, tricuspid \nregurgitation; TS, tricuspid stenosis; TV, tricuspid valve; UFH, unfractionated heparin; VKA, vitamin K antagonist; Vmax, peak transvalvular velocity. \naClass of recommendation. \nbLevel of evidence.   \n4710                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "keywords": [
        "data",
        "aortic stenosis",
        "angiography",
        "heart failure",
        "recommended",
        "pulmonary hypertension",
        "class iii",
        "anticoagulation",
        "hypertension",
        "lvef",
        "echocardiography",
        "crt",
        "coronary artery",
        "mitral stenosis",
        "availability",
        "statement",
        "mitral regurgitation",
        "nyha",
        "aortic",
        "weight",
        "tricuspid",
        "aortic regurgitation",
        "savr",
        "guideline",
        "atrial fibrillation",
        "ejection fraction",
        "valve replacement",
        "systolic",
        "tavi",
        "stenosis"
      ],
      "tables": []
    },
    {
      "number": "2",
      "title": "23. Author information",
      "start_page": 75,
      "end_page": 102,
      "content": "21. Evidence tables \nEvidence tables are available at European Heart Journal online. \n22. Data availability statement \nNo new data were generated or analysed in support of this research. \n23. Author information \nJonas Lanz, Department of Cardiology, Bern University Hospital, \nBern, \nSwitzerland; \nMateo \nMarin-Cuartas, \nUniversity \nDepartment of Cardiac Surgery, Leipzig Heart Center, Leipzig, \nGermany; Ana Abreu, Faculdade de Medicina da Universidade de \nLisboa (FMUL), ISAMB, IMPSP, CCUL, CAML, Lisboa, Portugal; \nServiço Cardiologia, Unidade de Reabilitação Cardiovascular, ULS \nSanta Maria/FMUL, Lisboa, Portugal; Marianna Adamo, Institute \nof Cardiology, ASST Spedali Civili, Brescia, Italy; Department of \nmedical and surgical specialties, radiological sciences, and public \nhealth, University of Brescia, Italy; Nina Ajmone Marsan, \nDepartment of Cardiology, Leiden University Medical Center, \nLeiden, Netherlands; Fabio Barili, Department of Biomedical and \nClinical Sciences, Università Degli Studi Di Milano, Milan, Italy; \nUniversity Cardiac Surgery Unit, IRCCS Ospedale Galeazzi - \nSant’Ambrogio, Milan, Italy; Department of Epidemiology, Harvard \nT.H. Chan School of Public Health Boston, MA, United States of \nAmerica; Nikolaos Bonaros, Department of Cardiac Surgery, \nMedical University of Innsbruck, Innsbruck, Austria; University \nHospital Innsbruck, Innsbruck, Austria; Bernard Cosyns, \nCardiology department, Universitair Ziekenhuis Brussel, Brussels, \nBelgium; Ruggero De Paulis, Department of cardiac surgery, \nEuropean Hospital, Rome, Italy; Unicamillus University, Rome, \nItaly; Habib Gamra, Cardiology University of Monastir, Monastir, \nTunisia; Marjan Jahangiri, Cardiac Surgery, St George’s Hospital, \nLondon, United Kingdom; Anders Jeppsson, Cardiothoracic sur-\ngery, Sahlgrenska University Hospital, Gothenburg, Sweden; \nMolecular and clinical medicine, Institute of medicine, Sahlgrenska \nAcademy, University of Gothenburg, Gothenburg, Sweden; \nRobert J.M. Klautz, Department of Cardiothoracic Surgery, \nLeiden \nUniversity \nMedical \nCenter, \nLeiden, \nNetherlands; \nDepartment of Cardiothoracic Surgery, Amsterdam University \nMedical Center, Amsterdam, Netherlands; Benoit Mores, \n(Belgium), ESC Patient Forum, Sophia Antipolis, France; Esther \nPérez-David, Cardiology Department, Hospital Universitario La \nPaz, IdiPaz (Hospital la Paz Research Institute), Facultad de \nMedicina Universidad Europea de Madrid, Madrid, Spain; Janine \nPöss, Department of internal medicine/cardiology, Heart Centre \nLeipzig at University of Leipzig, Leipzig, Germany; Bernard \nD. Prendergast, Heart Vascular & Thoracic Institute, Cleveland \nClinic London, London, United Kingdom; Department of \nCardiology, St Thomas’ Hospital, London, United Kingdom; \nBianca Rocca, Department of Medicine and Surgery, LUM \nUniversity Casamassima (Ba), Italy; Xavier Rossello, Cardiology \nDepartment, Hospital Universitari Son Espases, Palma de Mallorca, \nSpain; Health Research Institute of the Balearic Islands (IdISBa), \nUniversitat de les Illes Balears (UIB), Palma de Mallorca, Spain; \nMikio Suzuki, (Serbia), ESC Patient Forum, Sophia Antipolis, \nFrance; Holger Thiele, Department of Internal Medicine/ \nCardiology, Heart Centre Leipzig at Leipzig University, Leipzig, \nGermany; Leipzig Heart Science, Leipzig, Germany; Christophe \nMichel Tribouilloy, Cardiology department, Amiens University \nHospital, Amiens, France; and Wojtek Wojakowski, Division of \nCardiology and Structural Heart Diseases, Medical University of \nSilesia, Katowice, Poland. \n24. Appendix \nESC/EACTS Scientific Document Group \nIncludes Document Reviewers, ESC National Cardiac Societies and \nEACTS Network of National Cardiac Surgery Societies \nDocument \nReviewers: \nAlec \nVahanian \n(ESC \nReview \nCo-ordinator) \n(France), \nCarlos-A. \nMestres \n(EACTS \nReview \nCo-ordinator) (South Africa), Leila Abid (Tunisia), Suleman Aktaa \n(United Kingdom), Elena Arbelo (Spain), Folkert W. Asselbergs \n(Netherlands), Emanuele Barbato (Italy), Giuseppe Boriani (Italy), \nMargarita Brida (Croatia), Sergio Buccheri (Sweden), Robert Byrne \n(Republic of Ireland), Ovidiu Chioncel (Romania), Lenard Conradi \n(Germany), Michele De Bonis (Italy), Victoria Delgado (Spain), Enoch \nF. Akowuah (United Kingdom), Anna Franzone (Italy), Kristina \nHermann Haugaa (Norway), Bettina Heidecker (Germany), Borja \nIbanez (Spain), Bernard Iung (France), Stefan James (Sweden), Lars \nKøber (Denmark), Konstantinos C. Koskinas (Switzerland), Ulf \nMechanical heart valve thrombosis \nHeart Team evaluation is recommended in patients with acute HF (NYHA class III or IV) due to obstructive MHV thrombosis to determine \nappropriate management (repeat valve replacement or low-dose slow infusion fibrinolysis). \nI \nB \nBiological heart valve thrombosis \nOAC using VKA is recommended in BHV thrombosis before considering reintervention. \nI \nB \n© ESC/EACTS 2025\n4D, four-dimensional; AF, atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; ASA, acetylsalicylic acid; AV, aortic valve; AVA, aortic valve area; BHV, biological heart valve; BSA, body \nsurface area; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCTA, coronary CT angiography; CRT, cardiac resynchronization therapy; CT, computed tomography; \nDAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulation; GDMT, guideline-directed medical therapy; h, hour; HF, heart failure; INR, international normalized ratio; LA, left atrium/ \nleft atrial; LAVI, left atrial volume index; LMWH, low-molecular-weight heparin; LV, left ventricle/left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic \ndiameter; LVESDi, left ventricular end-systolic diameter indexed to BSA; MHV, mechanical heart valve; MR, mitral regurgitation; MS, mitral stenosis; MV, mitral valve; MVA, mitral valve area; \nNCS, non-cardiac surgery; NYHA, New York Heart Association; OAC, oral anticoagulation; PH, pulmonary hypertension; PMC, percutaneous mitral commissurotomy; PMR, primary mitral \nregurgitation; PVL, paravalvular leak; RV, right ventricle/right ventricular; SAVR, surgical aortic valve replacement; SMR, secondary mitral regurgitation; SPAP, systolic pulmonary artery \npressure; SVi, stroke volume index; TAVI, transcatheter aortic valve implantation; TEER, transcatheter edge-to-edge repair; TOE, transoesophageal echocardiography; TR, tricuspid \nregurgitation; TS, tricuspid stenosis; TV, tricuspid valve; UFH, unfractionated heparin; VKA, vitamin K antagonist; Vmax, peak transvalvular velocity. \naClass of recommendation. \nbLevel of evidence.   \n4710                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nLandmesser (Germany), Gregory Y.H. Lip (United Kingdom), John \nWilliam McEvoy (Ireland), Gil Meltzer (Israel), David Messika-Zeitoun \n(Canada), Borislava Mihaylova (United Kingdom), Richard Mindham \n(United Kingdom), Inge Moelgaard (Denmark), Jens Cosedis Nielsen \n(Denmark), Gareth Owens (United Kingdom), Agnes A. Pasquet \n(Belgium), Thomas Pilgrim (Switzerland), Eva Prescott (Denmark), \nEduard Quintana (Spain), Volker Rudolph (Germany), Rafael Sadaba \n(Spain), Anna Sannino (Germany), Felix C. Tanner (Switzerland), Marina \nUrena (France), Ilonca Vaartjes (Netherlands), Christiaan Vrints \n(Belgium), Alexander Wahba (Norway), Thomas Walther (Germany), \nAdam Witkowski (Poland), and Katja Zeppenfeld (Netherlands) \nContributor either withdrew or was engaged in only a part of the re-\nview process: Davide Capodanno \nESC National Cardiac Societies actively involved in the review \nprocess of the 2025 ESC/EACTS Guidelines for the management for \nvalvular heart disease: \nAlbania: Albanian Society of Cardiology, Naltin Shuka; Algeria: \nAlgerian Society of Cardiology, Brahim Kichou; Armenia: Armenian \nCardiologists Association, Aram L. Chilingaryan; Austria: Austrian \nSociety of Cardiology, Philipp Emanuel Bartko; Azerbaijan: \nAzerbaijan Society of Cardiology, Fuad Samadov; Belgium: Belgian \nSociety of Cardiology, Caroline M. Van de Heyning; Bosnia and \nHerzegovina: Association of Cardiologists of Bosnia and \nHerzegovina, Zumreta Kusljugic; Bulgaria: Bulgarian Society of \nCardiology, Elena Kinova; Croatia: Croatian Cardiac Society, Josko \nBulum; Cyprus: Cyprus Society of Cardiology, Christos Eftychiou; \nCzechia: Czech Society of Cardiology, Hana Linkova; Denmark: \nDanish Society of Cardiology, Emil Fosbøl; Egypt: Egyptian Society \nof Cardiology, Hesham Bahaa; Estonia: Estonian Society of \nCardiology, Jaagup Truusalu; Finland: Finnish Cardiac Society, Jarkko \nPiuhola; France: French Society of Cardiology, Erwan Donal; \nGeorgia: Georgian Society of Cardiology, Shalva Petriashvili; \nGermany: German Cardiac Society, Tanja Katharina Rudolph; \nGreece: Hellenic Society of Cardiology, Maria Drakopoulou; \nHungary: Hungarian Society of Cardiology, Attila Kertész; Iceland: \nIcelandic Society of Cardiology, Hjalti Guðmundsson; Ireland: Irish \nCardiac Society, Ben Cole; Israel: Israel Heart Society, Shemy \nCarasso; Italy: Italian Federation of Cardiology, Alessandro Navazio; \nKazakhstan: Association of Cardiologists of Kazakhstan, Madina \nSugralimova; Kosovo (Republic of): Kosovo Society of Cardiology, \nGani Bajraktari; Kyrgyzstan: Kyrgyz Society of Cardiology, Alina \nKerimkulova; Libya: Libyan Cardiac Society, Elham Omran Elgdhafi; \nLithuania: Lithuanian Society of Cardiology, Sigita Glaveckaite; \nLuxembourg: Luxembourg Society of Cardiology, Frederic Lebrun; \nMalta: Maltese Cardiac Society, Daniela Cassar Demarco; Moldova \n(Republic of): Moldavian Society of Cardiology, Dorin Mihail Lisii; \nNetherlands: Netherlands Society of Cardiology, Sebastian \nStreukens; North Macedonia: National Society of Cardiology of \nNorth Macedonia, Emilija Antova; Norway: Norwegian Society of \nCardiology, Håvard Dalen; Poland: Polish Cardiac Society, Tomasz \nKukulski; Portugal: Portuguese Society of Cardiology, Cristina \nGavina; Romania: Romanian Society of Cardiology, Bogdan \nA. Popescu; San Marino: San Marino Society of Cardiology, \nRoberto Bini; Serbia: Cardiology Society of Serbia, Igor Ivanov; \nSlovakia: Slovak Society of Cardiology, Martin Hudec; Slovenia: \nSlovenian Society of Cardiology, Matjaž Bunc; Spain: Spanish Society \nof Cardiology, Thomas Javier Bermejo; Sweden: Swedish Society of \nCardiology, Carl Johan Cronstedt Meurling; Switzerland: Swiss \nSociety of Cardiology, Raban Jeger; Tunisia: Tunisian Society of \nCardiology and Cardio-Vascular Surgery, Leila Abid; Türkiye: \nTurkish Society of Cardiology, Muzaffer M. Degertekin; Ukraine: \nUkrainian Association of Cardiology, Elena G. Nesukay; United \nKingdom of Great Britain and Northern Ireland: British \nCardiovascular Society, Madalina Garbi; Uzbekistan: Association of \nCardiologists of Uzbekistan, Guzal Mullabayeva. \nEACTS Network of National Cardiac Surgery Societies ac-\ntively involved in the review process of the 2025 ESC/EACTS \nGuidelines for the management for valvular heart disease: \nAustria: Austrian Society of Cardiac and Thoracic Vascular \nSurgery, Martin Grabenwoeger; Belgium: Belgian Association for \nCardio-Thoracic Surgery, Frederic Vanden Eynden; Czechia: The \nCzech Society for Cardiovascular Surgery, Jan Vojacek; France: The \nFrench Society for Thoracic and Cardiovascular Surgery; André \nVincentelli; \nGermany: \nGerman \nSociety \nfor \nThoracic \nand \nCardiovascular Surgery, Volkmar Falk; Greece: Hellenic Society of \nThoracic and Cardiovascular Surgeons, Panagiotis Dedeilias; Italy: Italian \nSociety for Cardiac Surgery, Alessandro Parolari; Netherlands: \nNetherlands Association for Cardio-thoracic surgery, Jerry Braun; \nNorth Macedonia: North Macedonian Society of Cardiac \nSurgery, Aleksandar Nikolic; Norway: Norwegian Association for \nCardiothoracic Surgery, Vegard S. Ellensen; Portugal: Sociedade \nPortuguesa de Cirurgia Cardíaca Torácica e Vascular, Miguel Sousa-Uva; \nSerbia: Serbian Society for Cardiovascular Surgery, Slobodan Micovic; \nSpain: Sociedad Española de Cirugía Cardiovascular y Endovascular, \nJuan J. Legarra; Switzerland: Swiss Society for Thoracic and \nCardiovascular Surgery, Enrico Ferrari; United Kingdom: The Society \nfor Cardiothoracic Surgery in Great Britain and Ireland, Narain Moorjani \nESC Clinical Practice Guidelines (CPG) Committee: \nUlf \nLandmesser \n(Chairperson) \n(Germany), \nStefan \nJames \n(Co-Chairperson) (Sweden), Marianna Adamo (Italy), Suleman Aktaa \n(United Kingdom), Folkert W. Asselbergs (Netherlands), Colin \nBaigent (United Kingdom), Michael A. Borger (Germany), Giuseppe \nBoriani (Italy), Margarita Brida (Croatia), Robert A. Byrne (Ireland), \nEstelle Gandjbakhch (France), Bettina Heidecker (Germany), Anja \nHennemuth (Germany), Borja Ibanez (Spain), Peter Jüni (United \nKingdom), Gregory Y.H. Lip (United Kingdom), John William McEvoy \n(Ireland), Borislava Mihaylova (United Kingdom), Inge Moelgaard \n(Denmark), Lis Neubeck (United Kingdom), Eva Prescott (Denmark), \nBianca Rocca (Italy), Xavier Rossello (Spain), Anna Sannino \n(Germany), Felix C. Tanner (Switzerland), Wojtek Wojakowski \n(Poland), and Katja Zeppenfeld (Netherlands) \nEACTS Council: Volkmar Falk (President) (Germany), Patrick \nMyers (Secretary General) (Switzerland), Joseph Bavaria (United \nStates of America), Korkut Bostanci (Türkiye), Filip Casselman \n(Belgium), Mario Gaudino (United States of America), Jurgen Hoerer \n(Germany), Nabil Hussein (United Kingdom), Virginia Litle (United \nStates of America), Franca Melfi (Italy), Rafael Sadaba (Spain), Florian \nSchoenhoff (Switzerland), Matthias Siepe (Switzerland), and Tanya \nWarburton (United Kingdom) \n25. References \n1. Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, et al. Transcatheter \naortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J \nMed 2019;380:1695–705. https://doi.org/10.1056/NEJMoa1814052 \n2. Mack MJ, Leon MB, Thourani VH, Pibarot P, Hahn RT, Genereux P, et al. Transcatheter \naortic-valve replacement in low-risk patients at five years. N Engl J Med 2023;389: \n1949–960. https://doi.org/10.1056/NEJMoa2307447 \n3. Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Sondergaard L, Mumtaz M, et al. \nSurgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl \nJ Med 2017;376:1321–31. https://doi.org/10.1056/NEJMoa1700456  \nESC Guidelines                                                                                                                                                                                          4711 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n4. Forrest JK, Deeb GM, Yakubov SJ, Gada H, Mumtaz MA, Ramlawi B, et al. 4-Year out-\ncomes of patients with aortic stenosis in the Evolut low risk trial. J Am Coll Cardiol 2023; \n82:2163–65. https://doi.org/10.1016/j.jacc.2023.09.813 \n5. Delgado V, Ajmone Marsan N, de Waha S, Bonaros N, Brida M, Burri H, et al. 2023 \nESC Guidelines for the management of endocarditis. Eur Heart J 2023;44: \n3948–4042. https://doi.org/10.1093/eurheartj/ehad193 \n6. Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC \nGuidelines for the management of chronic coronary syndromes: developed by the \ntask force for the management of chronic coronary syndromes of the European \nSociety of Cardiology (ESC) Endorsed by the European Association for \nCardio-Thoracic Surgery (EACTS). Eur Heart J 2024;45:3415–537. https://doi.org/ \n10.1093/eurheartj/ehae177 \n7. Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns H, et al. 2024 \nESC Guidelines for the management of atrial fibrillation developed in collaboration \nwith the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J \n2024;45:3314–414. https://doi.org/10.1093/eurheartj/ehae176 \n8. Mazzolai L, Teixido-Tura G, Lanzi S, Boc V, Bossone E, Brodmann M, et al. 2024 ESC \nGuidelines for the management of peripheral arterial and aortic diseases. Eur Heart J \n2024;45:3538–700. https://doi.org/10.1093/eurheartj/ehae179 \n9. Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller G-P, et al. \n2020 ESC Guidelines for the management of adult congenital heart disease: the Task \nForce for the management of adult congenital heart disease of the European Society of \nCardiology (ESC). Endorsed by: Association for European Paediatric and Congenital \nCardiology (AEPC), International Society for Adult Congenital Heart Disease \n(ISACHD). Eur Heart J 2020;42:563–645. https://doi.org/10.1093/eurheartj/ehaa554 \n10. Généreux P, Sharma RP, Cubeddu RJ, Aaron L, Abdelfattah OM, Koulogiannis KP, et al. \nThe mortality burden of untreated aortic stenosis. J Am Coll Cardiol 2023;82:2101–9.  \nhttps://doi.org/10.1016/j.jacc.2023.09.796 \n11. d’Arcy JL, Coffey S, Loudon MA, Kennedy A, Pearson-Stuttard J, Birks J, et al. \nLarge-scale community echocardiographic screening reveals a major burden of undiag-\nnosed valvular heart disease in older people: the OxVALVE Population Cohort Study. \nEur Heart J 2016;37:3515–22. https://doi.org/10.1093/eurheartj/ehw229 \n12. Iung B, Delgado V, Rosenhek R, Price S, Prendergast B, Wendler O, et al. \nContemporary presentation and management of valvular heart disease: the \nEURObservational research programme valvular heart disease II survey. Circulation \n2019;140:1156–69. https://doi.org/10.1161/CIRCULATIONAHA.119.041080 \n13. Gaede L, Di Bartolomeo R, van der Kley F, Elsässer A, Iung B, Möllmann H. Aortic valve \nstenosis: what do people know? A heart valve disease awareness survey of over 8,800 \npeople aged 60 or over. EuroIntervention 2016;12:883–9. https://doi.org/10.4244/ \neijy16m06_02 \n14. Lancellotti P, Magne J, Dulgheru R, Clavel MA, Donal E, Vannan MA, et al. Outcomes of \npatients with asymptomatic aortic stenosis followed up in heart valve clinics. JAMA \nCardiol 2018;3:1060–8. https://doi.org/10.1001/jamacardio.2018.3152 \n15. Lancellotti P, Rosenhek R, Pibarot P, Iung B, Otto CM, Tornos P, et al. ESC Working \nGroup on Valvular Heart Disease Position Paper—heart valve clinics: organization, \nstructure, and experiences. Eur Heart J 2013;34:1597–606. https://doi.org/10.1093/ \neurheartj/ehs443 \n16. Chambers JB, Prendergast B, Iung B, Rosenhek R, Zamorano JL, Pierard LA, et al. \nStandards defining a ‘Heart Valve Centre’: ESC Working Group on Valvular Heart \nDisease and European Association for Cardiothoracic Surgery Viewpoint. Eur Heart \nJ 2017;38:2177–83. https://doi.org/10.1093/eurheartj/ehx370 \n17. Nishimura RA, O’Gara PT, Bavaria JE, Brindis RG, Carroll JD, Kavinsky CJ, et al. 2019 \nAATS/ACC/ASE/SCAI/STS Expert Consensus Systems of Care document: a proposal \nto optimize care for patients with valvular heart disease: a joint report of the American \nAssociation for Thoracic Surgery, American College of Cardiology, American Society \nof Echocardiography, Society for Cardiovascular Angiography and Interventions, and \nSociety of Thoracic Surgeons. J Am Coll Cardiol 2019;73:2609–35. https://doi.org/10. \n1016/j.jacc.2018.10.007 \n18. Dreyfus G, Windecker S. How to shape the future of cardiology and cardiac surgery? \nEur Heart J 2020;41:3693–701. https://doi.org/10.1093/eurheartj/ehaa707 \n19. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/ \nEACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022;43: \n561–632. https://doi.org/10.1093/eurheartj/ehab395 \n20. Leonardi S, Capodanno D, Sousa-Uva M, Vrints C, Rex S, Guarracino F, et al. \nComposition, structure, and function of heart teams: a joint position paper of the \nACVC, EAPCI, EACTS, and EACTA focused on the management of patients with \ncomplex coronary artery disease requiring myocardial revascularization. Eur Heart J \nAcute Cardiovasc Care 2021;10:83–93. https://doi.org/10.1093/ehjacc/zuaa013 \n21. Agricola E, Ancona F, Brochet E, Donal E, Dweck M, Faletra F, et al. The structural \nheart disease interventional imager rationale, skills and training: a position paper of \nthe European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging \n2021;22:471–9. https://doi.org/10.1093/ehjci/jeab005 \n22. Hahn RT, Mahmood F, Kodali S, Lang R, Monaghan M, Gillam LD, et al. Core compe-\ntencies in echocardiography for imaging structural heart disease interventions: an ex-\npert consensus statement. JACC Cardiovasc Imaging 2019;12:2560–70. https://doi.org/ \n10.1016/j.jcmg.2019.10.008 \n23. Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon \nvolume and operative mortality in the United States. N Engl J Med 2003;349:2117–27.  \nhttps://doi.org/10.1056/NEJMsa035205 \n24. Khera R, Pandey A, Koshy T, Ayers C, Nallamothu BK, Das SR, et al. Role of hospital \nvolumes in identifying low-performing and high-performing aortic and mitral valve sur-\ngical centers in the United States. JAMA Cardiol 2017;2:1322–31. https://doi.org/10. \n1001/jamacardio.2017.4003 \n25. Gammie JS, O’Brien SM, Griffith BP, Ferguson TB, Peterson ED. Influence of hospital \nprocedural volume on care process and mortality for patients undergoing elective sur-\ngery for mitral regurgitation. Circulation 2007;115:881–7. https://doi.org/10.1161/ \nCIRCULATIONAHA.106.634436 \n26. Chikwe J, Toyoda N, Anyanwu AC, Itagaki S, Egorova NN, Boateng P, et al. Relation of \nmitral valve surgery volume to repair rate, durability, and survival. J Am Coll Cardiol \n2017;69:2397–406. https://doi.org/10.1016/j.jacc.2017.02.026 \n27. Chhatriwalla AK, Vemulapalli S, Szerlip M, Kodali S, Hahn RT, Saxon JT, et al. Operator \nexperience and outcomes of transcatheter mitral valve repair in the United States. J Am \nColl Cardiol 2019;74:2955–65. https://doi.org/10.1016/j.jacc.2019.09.014 \n28. Bonow RO, O’Gara PT, Adams DH, Badhwar V, Bavaria JE, Elmariah S, et al. 2019 \nAATS/ACC/SCAI/STS Expert Consensus Systems of Care document: operator and \ninstitutional recommendations and requirements for transcatheter mitral valve inter-\nvention: a joint report of the American Association for Thoracic Surgery, the \nAmerican College of Cardiology, the Society for Cardiovascular Angiography and \nInterventions, and The Society of Thoracic Surgeons. J Am Coll Cardiol 2020;76: \n96–117. https://doi.org/10.1016/j.jacc.2019.12.002 \n29. Grayburn PA, Mack MJ, Manandhar P, Kosinski AS, Sannino A, Smith RL 2nd, et al. \nComparison of transcatheter edge-to-edge mitral valve repair for primary mitral regur-\ngitation outcomes to hospital volumes of surgical mitral valve repair. Circ Cardiovasc Interv \n2024;17:e013581. https://doi.org/10.1161/circinterventions.123.013581 \n30. Wild MG, Stolz L, Rosch S, Rudolph F, Goebel B, Köll B, et al. Transcatheter valve re-\npair for tricuspid regurgitation: 1-year results from a large European real-world regis-\ntry. J Am Coll Cardiol 2025;85:220–31. https://doi.org/10.1016/j.jacc.2024.10.068 \n31. Carroll JD, Vemulapalli S, Dai D, Matsouaka R, Blackstone E, Edwards F, et al. \nProcedural experience for transcatheter aortic valve replacement and relation to out-\ncomes: the STS/ACC TVT registry. J Am Coll Cardiol 2017;70:29–41. https://doi.org/10. \n1016/j.jacc.2017.04.056 \n32. Mao J, Redberg RF, Carroll JD, Marinac-Dabic D, Laschinger J, Thourani V, et al. \nAssociation between hospital surgical aortic valve replacement volume and transcath-\neter aortic valve replacement outcomes. JAMA Cardiol 2018;3:1070–8. https://doi.org/ \n10.1001/jamacardio.2018.3562 \n33. Vemulapalli S, Carroll JD, Mack MJ, Li Z, Dai D, Kosinski AS, et al. Procedural volume \nand outcomes for transcatheter aortic-valve replacement. N Engl J Med 2019;380: \n2541–50. https://doi.org/10.1056/NEJMsa1901109 \n34. Edwards FH, Ferraris VA, Kurlansky PA, Lobdell KW, He X, O’Brien SM, et al. Failure \nto rescue rates after coronary artery bypass grafting: an analysis from the Society of \nThoracic Surgeons adult cardiac surgery database. Ann Thorac Surg 2016;102: \n458–64. https://doi.org/10.1016/j.athoracsur.2016.04.051 \n35. Wallen T, Habertheuer A, Bavaria JE, Hughes GC, Badhwar V, Jacobs JP, et al. Elective \naortic root replacement in North America: analysis of STS adult cardiac surgery data-\nbase. Ann Thorac Surg 2019;107:1307–12. https://doi.org/10.1016/j.athoracsur.2018. \n12.039 \n36. Geirsson A, Ahlsson A, Franco-Cereceda A, Fuglsang S, Gunn J, Hansson EC, et al. \nHospital volumes and later year of operation correlates with better outcomes in acute \nType A aortic dissection. Eur J Cardiothorac Surg 2018;53:276–81. https://doi.org/10. \n1093/ejcts/ezx231 \n37. Gonzalez AA, Dimick JB, Birkmeyer JD, Ghaferi AA. Understanding the \nvolume-outcome effect in cardiovascular surgery: the role of failure to rescue. JAMA \nSurg 2014;149:119–23. https://doi.org/10.1001/jamasurg.2013.3649 \n38. Wakeam E, Asafu-Adjei D, Ashley SW, Cooper Z, Weissman JS. The association of \nintensivists with failure-to-rescue rates in outlier hospitals: results of a national survey \nof intensive care unit organizational characteristics. J Crit Care 2014;29:930–5. https:// \ndoi.org/10.1016/j.jcrc.2014.06.010 \n39. Ward ST, Dimick JB, Zhang W, Campbell DA, Ghaferi AA. Association between hos-\npital staffing models and failure to rescue. Ann Surg 2019;270:91–4. https://doi.org/10. \n1097/sla.0000000000002744 \n40. Timmis A, Townsend N, Gale CP, Torbica A, Lettino M, Petersen SE, et al. European \nSociety of Cardiology: cardiovascular disease statistics 2019. Eur Heart J 2020;41: \n12–85. https://doi.org/10.1093/eurheartj/ehz859 \n41. Ali N, Aktaa S, Younsi T, Beska B, Batra G, Blackman DJ, et al. European Society of \nCardiology quality indicators for the care and outcomes of adults undergoing trans-\ncatheter aortic valve implantation. Eur Heart J Qual Care Clin Outcomes 2024;10: \n723–36. https://doi.org/10.1093/ehjqcco/qcae006 \n42. Messika-Zeitoun D, Baumgartner H, Burwash IG, Vahanian A, Bax J, Pibarot P, et al. \nUnmet needs in valvular heart disease. Eur Heart J 2023;44:1862–73. https://doi.org/ \n10.1093/eurheartj/ehad121  \n4712                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n43. van Dijk WB, Schuit E, van der Graaf R, Groenwold RHH, Laurijssen S, Casadei B, et al. \nApplicability of European Society of Cardiology guidelines according to gross national \nincome. Eur Heart J 2022;44:598–607. https://doi.org/10.1093/eurheartj/ehac606 \n44. Sengupta PP, Kluin J, Lee SP, Oh JK, Smits A. The future of valvular heart disease as-\nsessment and therapy. Lancet 2024;403:1590–602. https://doi.org/10.1016/s0140- \n6736(23)02754-x \n45. Lancellotti P, Pibarot P, Chambers J, La Canna G, Pepi M, Dulgheru R, et al. \nMulti-modality imaging assessment of native valvular regurgitation: an EACVI and \nESC council of valvular heart disease position paper. Eur Heart J Cardiovasc Imaging \n2022;23:e171–232. https://doi.org/10.1093/ehjci/jeab253 \n46. Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, et al. \nRecommendations for noninvasive evaluation of native valvular regurgitation: a report \nfrom the American Society of Echocardiography developed in collaboration with the \nSociety for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 2017;30: \n303–71. https://doi.org/10.1016/j.echo.2017.01.007 \n47. Popescu BA, Andrade MJ, Badano LP, Fox KF, Flachskampf FA, Lancellotti P, et al. \nEuropean Association of Echocardiography recommendations for training, compe-\ntence, and quality improvement in echocardiography. Eur J Echocardiogr 2009;10: \n893–905. https://doi.org/10.1093/ejechocard/jep151 \n48. Chambers JB, Garbi M, Nieman K, Myerson S, Pierard LA, Habib G, et al. \nAppropriateness criteria for the use of cardiovascular imaging in heart valve disease \nin adults: a European Association of Cardiovascular Imaging report of literature review \nand current practice. Eur Heart J Cardiovasc Imaging 2017;18:489–98. https://doi.org/ \n10.1093/ehjci/jew309 \n49. Agricola E, Ancona F, Bartel T, Brochet E, Dweck M, Faletra F, et al. Multimodality im-\naging for patient selection, procedural guidance, and follow-up of transcatheter inter-\nventions for structural heart disease: a consensus document of the EACVI Task Force \non Interventional Cardiovascular Imaging: part 1: access routes, transcatheter aortic \nvalve implantation, and transcatheter mitral valve interventions. Eur Heart J \nCardiovasc Imaging 2023;24:e209–68. https://doi.org/10.1093/ehjci/jead096 \n50. Zoghbi WA, Jone PN, Chamsi-Pasha MA, Chen T, Collins KA, Desai MY, et al. \nGuidelines for the evaluation of prosthetic valve function with cardiovascular imaging: \na report from the American Society of Echocardiography developed in collaboration \nwith the Society for Cardiovascular Magnetic Resonance and the Society of \nCardiovascular Computed Tomography. J Am Soc Echocardiogr 2024;37:2–63.  \nhttps://doi.org/10.1016/j.echo.2023.10.004 \n51. Faletra FF, Agricola E, Flachskampf FA, Hahn R, Pepi M, Ajmone Marsan N, et al. \nThree-dimensional transoesophageal echocardiography: how to use and when to \nuse—a clinical consensus statement from the European Association of \nCardiovascular Imaging of the European Society of Cardiology. Eur Heart J \nCardiovasc Imaging 2023;24:e119–97. https://doi.org/10.1093/ehjci/jead090 \n52. Picano E, Pibarot P, Lancellotti P, Monin JL, Bonow RO. The emerging role of exercise \ntesting and stress echocardiography in valvular heart disease. J Am Coll Cardiol 2009;54: \n2251–60. https://doi.org/10.1016/j.jacc.2009.07.046 \n53. Genereux P, Pibarot P, Redfors B, Mack MJ, Makkar RR, Jaber WA, et al. Staging clas-\nsification of aortic stenosis based on the extent of cardiac damage. Eur Heart J 2017;38: \n3351–8. https://doi.org/10.1093/eurheartj/ehx381 \n54. Stolz L, Doldi PM, Orban M, Karam N, Puscas T, Wild MG, et al. Staging heart failure \npatients with secondary mitral regurgitation undergoing transcatheter edge-to-edge \nrepair. JACC Cardiovasc Interv 2023;16:140–51. https://doi.org/10.1016/j.jcin.2022.10. \n032 \n55. Dietz MF, Prihadi EA, van der Bijl P, Ajmone Marsan N, Delgado V, Bax JJ. Prognostic \nimplications of staging right heart failure in patients with significant secondary tricuspid \nregurgitation. JACC Heart Fail 2020;8:627–36. https://doi.org/10.1016/j.jchf.2020.02. \n008 \n56. Généreux P, Pibarot P, Redfors B, Bax JJ, Zhao Y, Makkar RR, et al. Evolution and prog-\nnostic impact of cardiac damage after aortic valve replacement. J Am Coll Cardiol 2022; \n80:783–800. https://doi.org/10.1016/j.jacc.2022.05.006 \n57. Genereux P, Cohen DJ, Pibarot P, Redfors B, Bax JJ, Zhao Y, et al. Cardiac damage and \nquality of life after aortic valve replacement in the PARTNER trials. J Am Coll Cardiol \n2023;81:743–52. https://doi.org/10.1016/j.jacc.2022.11.059 \n58. Kwak S, Everett RJ, Treibel TA, Yang S, Hwang D, Ko T, et al. Markers of myocardial \ndamage predict mortality in patients with aortic stenosis. J Am Coll Cardiol 2021;78: \n545–58. https://doi.org/10.1016/j.jacc.2021.05.047 \n59. Magne J, Cosyns B, Popescu BA, Carstensen HG, Dahl J, Desai MY, et al. Distribution \nand prognostic significance of left ventricular global longitudinal strain in asymptomatic \nsignificant aortic stenosis: an individual participant data meta-analysis. JACC Cardiovasc \nImaging 2019;12:84–92. https://doi.org/10.1016/j.jcmg.2018.11.005 \n60. Prihadi EA, van der Bijl P, Dietz M, Abou R, Vollema EM, Marsan NA, et al. Prognostic \nimplications of right ventricular free wall longitudinal strain in patients with significant \nfunctional tricuspid regurgitation. Circ Cardiovasc Imaging 2019;12:e008666. https://doi. \norg/10.1161/CIRCIMAGING.118.008666 \n61. Little SH, Rigolin VH, Garcia-Sayan E, Hahn RT, Hung J, Mackensen GB, et al. \nRecommendations for special competency in echocardiographic guidance of structural \nheart disease interventions: from the American Society of Echocardiography. J Am Soc \nEchocardiogr 2023;36:350–65. https://doi.org/10.1016/j.echo.2023.01.014 \n62. Hahn RT, Saric M, Faletra FF, Garg R, Gillam LD, Horton K, et al. Recommended stan-\ndards for the performance of transesophageal echocardiographic screening for struc-\ntural heart intervention: from the American Society of Echocardiography. J Am Soc \nEchocardiogr 2022;35:1–76. https://doi.org/10.1016/j.echo.2021.07.006 \n63. Nicoara A, Skubas N, Ad N, Finley A, Hahn RT, Mahmood F, et al. Guidelines for the \nuse of transesophageal echocardiography to assist with surgical decision-making in the \noperating room: a surgery-based approach: from the American Society of \nEchocardiography \nin \ncollaboration \nwith \nthe \nSociety \nof \nCardiovascular \nAnesthesiologists and the Society of Thoracic Surgeons. J Am Soc Echocardiogr 2020; \n33:692–734. https://doi.org/10.1016/j.echo.2020.03.002 \n64. Popescu BA, Stefanidis A, Fox KF, Cosyns B, Delgado V, Di Salvo GD, et al. Training, \ncompetence, and quality improvement in echocardiography: the European Association \nof Cardiovascular Imaging Recommendations: update 2020. Eur Heart J Cardiovasc \nImaging 2020;21:1305–19. https://doi.org/10.1093/ehjci/jeaa266 \n65. Iung B, Delgado V, Lazure P, Murray S, Sirnes PA, Rosenhek R, et al. Educational needs \nand application of guidelines in the management of patients with mitral regurgitation. A \nEuropean mixed-methods study. Eur Heart J 2018;39:1295–303. https://doi.org/10. \n1093/eurheartj/ehx763 \n66. Nashef SAM, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, et al. \nEuroSCORE II. Eur J Cardiothorac Surg 2012;41:734–44; discussion 744–735. https:// \ndoi.org/10.1093/ejcts/ezs043 \n67. Ad N, Holmes SD, Patel J, Pritchard G, Shuman DJ, Halpin L. Comparison of \nEuroSCORE II, original EuroSCORE, and the Society of Thoracic Surgeons Risk \nScore in Cardiac Surgery Patients. Ann Thorac Surg 2016;102:573–9. https://doi.org/ \n10.1016/j.athoracsur.2016.01.105 \n68. O’Brien SM, Shahian DM, Filardo G, Ferraris VA, Haan CK, Rich JB, et al. The Society of \nThoracic Surgeons 2008 cardiac surgery risk models: part 2—isolated valve surgery. \nAnn Thorac Surg 2009;88:S23–42. https://doi.org/10.1016/j.athoracsur.2009.05.056 \n69. Duchnowski P, Hryniewiecki T, Kuśmierczyk M, Szymanski P. Performance of the \nEuroSCORE II and the Society of Thoracic Surgeons score in patients undergoing aor-\ntic valve replacement for aortic stenosis. J Thorac Dis 2019;11:2076–81. https://doi.org/ \n10.21037/jtd.2019.04.48 \n70. Provenchere S, Chevalier A, Ghodbane W, Bouleti C, Montravers P, Longrois D, et al. \nIs the EuroSCORE II reliable to estimate operative mortality among octogenarians? \nPLoS One 2017;12:e0187056. https://doi.org/10.1371/journal.pone.0187056 \n71. Taleb Bendiab T, Brusset A, Estagnasié P, Squara P, Nguyen LS. Performance of \nEuroSCORE II and Society of Thoracic Surgeons risk scores in elderly patients under-\ngoing aortic valve replacement surgery. Arch Cardiovasc Dis 2021;114:474–81. https:// \ndoi.org/10.1016/j.acvd.2020.12.004 \n72. Roques F, Michel P, Goldstone AR, Nashef SAM. The logistic EuroSCORE. Eur Heart J \n2003;24:882–3. https://doi.org/10.1016/S0195-668X(02)00799-6 \n73. Al-Azizi K, Shih E, DiMaio JM, Squiers JJ, Moubarak G, Kluis A, et al. Assessment of TVT \nand STS risk score performances in patients undergoing transcatheter aortic valve re-\nplacement. JSCAI 2023;2:100600. https://doi.org/10.1016/j.jscai.2023.100600 \n74. Compagnone M, Moretti C, Marcelli C, Taglieri N, Ghetti G, Corsini A, et al. Surgical \nrisk scores applied to transcatheter aortic valve implantation: friends or foes? \nShort-term and long-term outcomes from a single-center registry. J Invasive Cardiol \n2019;31:E282–88. \n75. Tarantini G, Lefèvre T, Terkelsen CJ, Frerker C, Ohlmann P, Mojoli M, et al. One-year \noutcomes of a European transcatheter aortic valve implantation cohort according to \nsurgical risk. Circ Cardiovasc Interv 2019;12:e006724. https://doi.org/10.1161/ \nCIRCINTERVENTIONS.118.006724 \n76. Arnold SV, Reynolds MR, Lei Y, Magnuson EA, Kirtane AJ, Kodali SK, et al. Predictors of \npoor outcomes after transcatheter aortic valve replacement: results from the \nPARTNER (Placement of Aortic Transcatheter Valve) trial. Circulation 2014;129: \n2682–90. https://doi.org/10.1161/circulationaha.113.007477 \n77. Edwards FH, Cohen DJ, O’Brien SM, Peterson ED, Mack MJ, Shahian DM, et al. \nDevelopment and validation of a risk prediction model for in-hospital mortality after \ntranscatheter aortic valve replacement. JAMA Cardiol 2016;1:46–52. https://doi.org/10. \n1001/jamacardio.2015.0326 \n78. Iung B, Laouénan C, Himbert D, Eltchaninoff H, Chevreul K, Donzeau-Gouge P, et al. \nPredictive factors of early mortality after transcatheter aortic valve implantation: indi-\nvidual risk assessment using a simple score. Heart 2014;100:1016–23. https://doi.org/ \n10.1136/heartjnl-2013-305314 \n79. Arnold SV, Afilalo J, Spertus JA, Tang Y, Baron SJ, Jones PG, et al. Prediction of poor \noutcome after transcatheter aortic valve replacement. J Am Coll Cardiol 2016;68: \n1868–77. https://doi.org/10.1016/j.jacc.2016.07.762 \n80. Raposeiras-Roubin S, Adamo M, Freixa X, Arzamendi D, Benito-González T, \nMontefusco A, et al. A score to assess mortality after percutaneous mitral valve repair. \nJ Am Coll Cardiol 2022;79:562–73. https://doi.org/10.1016/j.jacc.2021.11.041 \n81. Shah N, Madhavan MV, Gray WA, Brener SJ, Ahmad Y, Lindenfeld J, et al. Prediction of \ndeath or HF hospitalization in patients with severe FMR: the COAPT risk score. JACC \nCardiovasc Interv 2022;15:1893–905. https://doi.org/10.1016/j.jcin.2022.08.005 \n82. Hausleiter J, Lachmann M, Stolz L, Bedogni F, Rubbio AP, Estévez-Loureiro R, et al. \nArtificial intelligence-derived risk score for mortality in secondary mitral regurgitation  \nESC Guidelines                                                                                                                                                                                          4713 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\ntreated by transcatheter edge-to-edge repair: the EuroSMR risk score. Eur Heart J \n2024;45:922–36. https://doi.org/10.1093/eurheartj/ehad871 \n83. Adamo M, Rubbio AP, Zaccone G, Pighi M, Massussi M, Tomasoni D, et al. Prediction \nof mortality and heart failure hospitalisations in patients undergoing M-TEER: external \nvalidation of the COAPT risk score. EuroIntervention 2023;18:1408–17. https://doi.org/ \n10.4244/EIJ-D-22-00992 \n84. Dreyfus J, Audureau E, Bohbot Y, Coisne A, Lavie-Badie Y, Bouchery M, et al. \nTRI-SCORE: a new risk score for in-hospital mortality prediction after isolated tricus-\npid valve surgery. Eur Heart J 2022;43:654–62. https://doi.org/10.1093/eurheartj/ \nehab679 \n85. Dreyfus J, Bohbot Y, Coisne A, Lavie-Badie Y, Flagiello M, Bazire B, et al. Predictive va-\nlue of the TRI-SCORE for in-hospital mortality after redo isolated tricuspid valve sur-\ngery. Heart 2023;109:951–8. https://doi.org/10.1136/heartjnl-2022-322167 \n86. Lantelme P, Aubry M, Peng JC, Riche B, Souteyrand G, Jaafar P, et al. Comorbidities \nmay offset expected improved survival after transcatheter aortic valve replacement. \nEur Heart J Open 2022;2:oeac029. https://doi.org/10.1093/ehjopen/oeac029 \n87. Piankova P, Afilalo J. Prevalence and prognostic implications of frailty in transcatheter aortic \nvalve replacement. Cardiol Clin 2020;38:75–87. https://doi.org/10.1016/j.ccl.2019.09.011 \n88. Kim DH, Afilalo J, Shi SM, Popma JJ, Khabbaz KR, Laham RJ, et al. Evaluation of changes \nin functional status in the year after aortic valve replacement. JAMA Intern Med 2019; \n179:383–91. https://doi.org/10.1001/jamainternmed.2018.6738 \n89. Scotti A, Coisne A, Granada JF, Driggin E, Madhavan MV, Zhou Z, et al. Impact of mal-\nnutrition in patients with heart failure and secondary mitral regurgitation: the COAPT \nTrial. J Am Coll Cardiol 2023;82:128–38. https://doi.org/10.1016/j.jacc.2023.04.047 \n89a. Pagnesi M, Adamo M, Stolz L, Pancaldi E, Kresoja KP, von Stein J, et al. Malnutrition \nand outcomes in patients with tricuspid regurgitation undergoing transcatheter \ntricuspid valve repair. Eur J Heart Fail 2025. https://doi.org/10.1002/ejhf.3623. Epub \nahead of print. PMID: 39980251. \n90. Sündermann SH, Bäck C, Bischoff-Ferrari HA, Dehbi HM, Szekely A, Völler H, et al. \nPreinterventional frailty assessment in patients scheduled for cardiac surgery or trans-\ncatheter aortic valve implantation: a consensus statement of the European Association \nfor Cardio-Thoracic Surgery (EACTS) and the European Association of Preventive \nCardiology (EAPC) of the European Society of Cardiology (ESC). Eur J Cardiothorac \nSurg 2023;64:ezad181. https://doi.org/10.1093/ejcts/ezad181 \n91. Richter D, Guasti L, Walker D, Lambrinou E, Lionis C, Abreu A, et al. Frailty in cardi-\nology: definition, assessment and clinical implications for general cardiology. A consen-\nsus document of the Council for Cardiology Practice (CCP), Association for Acute \nCardio Vascular Care (ACVC), Association of Cardiovascular Nursing and Allied \nProfessions (ACNAP), European Association of Preventive Cardiology (EAPC), \nEuropean Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases \n(VHD), Council on Hypertension (CHT), Council of Cardio-Oncology (CCO), \nWorking Group (WG) Aorta and Peripheral Vascular Diseases, WG e-Cardiology, \nWG Thrombosis, of the European Society of Cardiology, European Primary Care \nCardiology Society (EPCCS). Eur J Prev Cardiol 2022;29:216–27. https://doi.org/10. \n1093/eurjpc/zwaa167 \n92. Kundi H, Popma JJ, Reynolds MR, Strom JB, Pinto DS, Valsdottir LR, et al. Frailty and \nrelated outcomes in patients undergoing transcatheter valve therapies in a nationwide \ncohort. Eur Heart J 2019;40:2231–9. https://doi.org/10.1093/eurheartj/ehz187 \n93. Brusco NK, Atkinson V, Woods J, Myles PS, Hodge A, Jones C, et al. Implementing \nPROMS for elective surgery patients: feasibility, response rate, degree of recovery \nand patient acceptability. J Patient Rep Outcomes 2022;6:73. https://doi.org/10.1186/ \ns41687-022-00483-6 \n94. Arnold SV, Spertus JA, Lei Y, Allen KB, Chhatriwalla AK, Leon MB, et al. Use of the Kansas \nCity Cardiomyopathy Questionnaire for monitoring health status in patients with aortic \nstenosis. Circ Heart Fail 2013;6:61–7. https://doi.org/10.1161/circheartfailure.112.970053 \n95. Arnold SV, Spertus JA, Gosch K, Dunlay SM, Olds DM, Jones PG, et al. Validation of the \nKansas City Cardiomyopathy Questionnaire in patients with tricuspid regurgitation. \nJAMA Cardiol 2025;10:117–25 https://doi.org/10.1001/jamacardio.2024.4266 \n96. Clavel MA, Tribouilloy C, Vanoverschelde JL, Pizarro R, Suri RM, Szymanski C, et al. \nAssociation of B-type natriuretic peptide with survival in patients with degenerative \nmitral regurgitation. J Am Coll Cardiol 2016;68:1297–307. https://doi.org/10.1016/j. \njacc.2016.06.047 \n97. Clavel MA, Malouf J, Michelena HI, Suri RM, Jaffe AS, Mahoney DW, et al. B-type natri-\nuretic peptide clinical activation in aortic stenosis: impact on long-term survival. J Am \nColl Cardiol 2014;63:2016–25. https://doi.org/10.1016/j.jacc.2014.02.581 \n98. Zhang B, Xu H, Zhang H, Liu Q, Ye Y, Hao J, et al. Prognostic value of N-terminal pro– \nB-type natriuretic peptide in elderly patients with valvular heart disease. J Am Coll \nCardiol 2020;75:1659–72. https://doi.org/10.1016/j.jacc.2020.02.031 \n99. Lindman BR, Breyley JG, Schilling JD, Vatterott AM, Zajarias A, Maniar HS, et al. \nPrognostic utility of novel biomarkers of cardiovascular stress in patients with aortic \nstenosis undergoing valve replacement. Heart 2015;101:1382–8. https://doi.org/10. \n1136/heartjnl-2015-307742 \n100. Lindman BR, Clavel MA, Abu-Alhayja’a R, Cote N, Dagenais F, Novak E, et al. \nMultimarker approach to identify patients with higher mortality and rehospitalization \nrate after surgical aortic valve replacement for aortic stenosis. JACC Cardiovasc Interv \n2018;11:2172–81. https://doi.org/10.1016/j.jcin.2018.07.039 \n101. Henri C, Piérard LA, Lancellotti P, Mongeon F-P, Pibarot P, Basmadjian AJ. Exercise \ntesting and stress imaging in valvular heart disease. Can J Cardiol 2014;30:1012–26.  \nhttps://doi.org/10.1016/j.cjca.2014.03.013 \n102. Das P, Rimington H, Chambers J. Exercise testing to stratify risk in aortic stenosis. Eur \nHeart J 2005;26:1309–13. https://doi.org/10.1093/eurheartj/ehi250 \n103. Redfors B, Pibarot P, Gillam LD, Burkhoff D, Bax JJ, Lindman BR, et al. Stress testing in \nasymptomatic aortic stenosis. Circulation 2017;135:1956–76. https://doi.org/10.1161/ \nCIRCULATIONAHA.116.025457 \n104. Lund O, Nielsen TT, Emmertsen K, Flø C, Rasmussen B, Jensen FT, et al. Mortality and \nworsening of prognostic profile during waiting time for valve replacement in aortic \nstenosis. Thorac Cardiovasc Surg 1996;44:289–95. https://doi.org/10.1055/s-2007- \n1012039 \n105. Guazzi M, Arena R, Halle M, Piepoli MF, Myers J, Lavie CJ. 2016 focused update: clinical \nrecommendations for cardiopulmonary exercise testing data assessment in specific pa-\ntient populations. Eur Heart J 2018;39:1144–61. https://doi.org/10.1093/eurheartj/ \nehw180 \n106. Hoedemakers S, Pugliese NR, Stassen J, Vanoppen A, Claessens J, Gojevic T, et al. \nmPAP/CO slope and oxygen uptake add prognostic value in aortic stenosis. \nCirculation \n2024;149:1172–82. \nhttps://doi.org/10.1161/CIRCULATIONAHA.123. \n067130 \n107. Lancellotti P, Dulgheru R, Go YY, Sugimoto T, Marchetta S, Oury C, et al. Stress echo-\ncardiography in patients with native valvular heart disease. Heart 2018;104:807–13.  \nhttps://doi.org/10.1136/heartjnl-2017-311682 \n108. Gentry JL III, Phelan D, Desai MY, Griffin BP. The role of stress echocardiography in \nvalvular heart disease: a current appraisal. Cardiology 2017;137:137–50. https://doi. \norg/10.1159/000460274 \n109. Lancellotti P, Magne J. Stress echocardiography in regurgitant valve disease. Circ \nCardiovasc Imaging 2013;6:840–9. https://doi.org/10.1161/CIRCIMAGING.113.000474 \n110. Lancellotti P, Magne J, Donal E, O’Connor K, Dulgheru R, Rosca M, et al. Determinants \nand prognostic significance of exercise pulmonary hypertension in asymptomatic se-\nvere \naortic \nstenosis. \nCirculation \n2012;126:851–9. \nhttps://doi.org/10.1161/ \nCIRCULATIONAHA.111.088427 \n111. Coisne A, Aghezzaf S, Galli E, Mouton S, Richardson M, Dubois D, et al. Prognostic va-\nlues of exercise echocardiography and cardiopulmonary exercise testing in patients \nwith primary mitral regurgitation. Eur Heart J Cardiovasc Imaging 2022;23:1552–61.  \nhttps://doi.org/10.1093/ehjci/jeab231 \n112. Saeed S, Rajani R, Seifert R, Parkin D, Chambers JB. Exercise testing in patients with \nasymptomatic moderate or severe aortic stenosis. Heart 2018;104:1836–42. https:// \ndoi.org/10.1136/heartjnl-2018-312939 \n113. Saeed S, Chambers JB. Exercise testing in aortic stenosis: safety, tolerability, clinical \nbenefits and prognostic value. J Clin Med 2022;11:4983. https://doi.org/10.3390/ \njcm11174983 \n114. Scarsini R, Pesarini G, Zivelonghi C, Piccoli A, Ferrero V, Lunardi M, et al. Physiologic \nevaluation of coronary lesions using instantaneous wave-free ratio (iFR) in patients \nwith severe aortic stenosis undergoing transcatheter aortic valve implantation. \nEuroIntervention 2018;13:1512–9. https://doi.org/10.4244/EIJ-D-17-00542 \n115. Pesarini G, Scarsini R, Zivelonghi C, Piccoli A, Gambaro A, Gottin L, et al. Functional \nassessment of coronary artery disease in patients undergoing transcatheter aortic \nvalve implantation: influence of pressure overload on the evaluation of lesions severity. \nCirc Cardiovasc Interv 2016;9:e004088. https://doi.org/10.1161/circinterventions.116. \n004088 \n116. Ahmad Y, Götberg M, Cook C, Howard JP, Malik I, Mikhail G, et al. Coronary hemo-\ndynamics in patients with severe aortic stenosis and coronary artery disease undergo-\ning transcatheter aortic valve replacement: implications for clinical indices of coronary \nstenosis severity. JACC Cardiovasc Interv 2018;11:2019–31. https://doi.org/10.1016/j. \njcin.2018.07.019 \n117. Ardehali A, Segal J, Cheitlin MD. Coronary blood flow reserve in acute aortic regurgi-\ntation. \nJ \nAm \nColl \nCardiol \n1995;25:1387–92. \nhttps://doi.org/10.1016/0735- \n1097(95)00018-Y \n118. Akasaka T, Yoshida K, Hozumi T, Takagi T, Kaji S, Kawamoto T, et al. Restricted cor-\nonary flow reserve in patients with mitral regurgitation improves after mitral recon-\nstructive surgery. J Am Coll Cardiol 1998;32:1923–30. https://doi.org/10.1016/S0735- \n1097(98)00490-2 \n119. D’Alto M, Dimopoulos K, Coghlan JG, Kovacs G, Rosenkranz S, Naeije R. Right heart \ncatheterization for the diagnosis of pulmonary hypertension: controversies and prac-\ntical issues. Heart Fail Clin 2018;14:467–77. https://doi.org/10.1016/j.hfc.2018.03.011 \n120. Lindman BR, Arnold SV, Bagur R, Clarke L, Coylewright M, Evans F, et al. Priorities for \npatient-centered research in valvular heart disease: a report from the National Heart, \nLung, and Blood Institute Working Group. J Am Heart Assoc 2020;9:e015975. https:// \ndoi.org/10.1161/JAHA.119.015975 \n121. Dharmarajan K, Foster J, Coylewright M, Green P, Vavalle JP, Faheem O, et al. The \nmedically managed patient with severe symptomatic aortic stenosis in the TAVR \nera: patient characteristics, reasons for medical management, and quality of shared de-\ncision making at heart valve treatment centers. PLoS One 2017;12:e0175926. https:// \ndoi.org/10.1371/journal.pone.0175926  \n4714                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n122. Ren X, Liu K, Zhang H, Meng Y, Li H, Sun X, et al. Coronary evaluation before heart \nvalvular surgery by using coronary computed tomographic angiography versus invasive \ncoronary angiography. J Am Heart Assoc 2021;10:e019531. https://doi.org/10.1161/ \njaha.120.019531 \n123. Opolski MP, Staruch AD, Jakubczyk M, Min James K, Gransar H, Staruch M, et al. CT \nangiography for the detection of coronary artery stenoses in patients referred for car-\ndiac valve surgery. JACC Cardiovasc Imaging 2016;9:1059–70. https://doi.org/10.1016/j. \njcmg.2015.09.028 \n124. Meijboom Willem B, Mollet Nico R, Van Mieghem Carlos AG, Kluin J, Weustink Annick \nC, Pugliese F, et al. Pre-operative computed tomography coronary angiography to de-\ntect significant coronary artery disease in patients referred for cardiac valve surgery. J \nAm Coll Cardiol 2006;48:1658–65. https://doi.org/10.1016/j.jacc.2006.06.054 \n125. Gatti M, Gallone G, Poggi V, Bruno F, Serafini A, Depaoli A, et al. Diagnostic accuracy of \ncoronary computed tomography angiography for the evaluation of obstructive coron-\nary artery disease in patients referred for transcatheter aortic valve implantation: a sys-\ntematic review and meta-analysis. Eur Radiol 2022;32:5189–200. https://doi.org/10. \n1007/s00330-022-08603-y \n126. Diller GP, Gerwing M, Boroni Grazioli S, De-Torres-Alba F, Radke RM, Vormbrock J, \net al. Utility of coronary computed tomography angiography in patients undergoing \ntranscatheter aortic valve implantation: a meta-analysis and meta-regression based \non published data from 7458 patients. J Clin Med 2024;13:631. https://doi.org/10. \n3390/jcm13020631 \n127. Kondoleon NP, Layoun H, Spilias N, Sipko J, Kanaan C, Harb S, et al. Effectiveness of \npre-TAVR CTA as a screening tool for significant CAD before TAVR. JACC Cardiovasc \nInterv 2023;16:1990–2000. https://doi.org/10.1016/j.jcin.2023.05.030 \n128. Malebranche D, Hoffner MKM, Huber AT, Cicovic A, Spano G, Bernhard B, et al. \nDiagnostic performance of quantitative coronary artery disease assessment using \ncomputed tomography in patients with aortic stenosis undergoing transcatheter \naortic-valve implantation. BMC Cardiovasc Disord 2022;22:178. https://doi.org/10. \n1186/s12872-022-02623-8 \n129. Chieffo A, Giustino G, Spagnolo P, Panoulas VF, Montorfano M, Latib A, et al. Routine \nscreening of coronary artery disease with computed tomographic coronary angiog-\nraphy in place of invasive coronary angiography in patients undergoing transcatheter \naortic valve replacement. Circ Cardiovasc Interv 2015;8:e002025. https://doi.org/10. \n1161/circinterventions.114.002025 \n130. Patel KP, Michail M, Treibel TA, Rathod K, Jones DA, Ozkor M, et al. Coronary revas-\ncularization in patients undergoing aortic valve replacement for severe aortic stenosis. \nJACC Cardiovasc Interv 2021;14:2083–96. https://doi.org/10.1016/j.jcin.2021.07.058 \n131. Miyagawa S, Masai T, Fukuda H, Yamauchi T, Iwakura K, Itoh H, et al. Coronary micro-\ncirculatory dysfunction in aortic stenosis: myocardial contrast echocardiography study. \nAnn Thorac Surg 2009;87:715–9. https://doi.org/10.1016/j.athoracsur.2008.11.078 \n132. Beach JM, Mihaljevic T, Svensson LG, Rajeswaran J, Marwick T, Griffin B, et al. Coronary \nartery disease and outcomes of aortic valve replacement for severe aortic stenosis. J \nAm Coll Cardiol 2013;61:837–48. https://doi.org/10.1016/j.jacc.2012.10.049 \n133. Thalji NM, Suri RM, Daly RC, Greason KL, Dearani JA, Stulak JM, et al. The prognostic \nimpact of concomitant coronary artery bypass grafting during aortic valve surgery: im-\nplications for revascularization in the transcatheter era. J Thorac Cardiovasc Surg 2015; \n149:451–60. https://doi.org/10.1016/j.jtcvs.2014.08.073 \n134. Lønborg J, Jabbari R, Sabbah M, Veien KT, Niemelä M, Freeman P, et al. PCI in patients \nundergoing transcatheter aortic-valve implantation. N Engl J Med 2024;391:2189–200.  \nhttps://doi.org/10.1056/NEJMoa2401513 \n135. Patterson T, Clayton T, Dodd M, Khawaja Z, Morice MC, Wilson K, et al. \nACTIVATION (PercutAneous Coronary inTervention prIor to transcatheter aortic \nVAlve implantaTION): a randomized clinical trial. JACC Cardiovasc Interv 2021;14: \n1965–74. https://doi.org/10.1016/j.jcin.2021.06.041 \n136. Okuno T, Demirel C, Tomii D, Heg D, Häner J, Siontis GCM, et al. Long-term risk of \nunplanned percutaneous coronary intervention after transcatheter aortic valve re-\nplacement. EuroIntervention 2022;18:797–803. https://doi.org/10.4244/eij-d-22-00342 \n137. Persits I, Layoun H, Kondoleon NP, Spilias N, Badwan O, Sipko J, et al. Impact of un-\ntreated chronic obstructive coronary artery disease on outcomes after transcatheter \naortic valve replacement. Eur Heart J 2024;45:1890–900. https://doi.org/10.1093/ \neurheartj/ehae019 \n138. Ogami T, Kliner DE, Toma C, Sanon S, Smith AJC, Serna-Gallegos D, et al. Acute cor-\nonary syndrome after transcatheter aortic valve implantation (results from over \n40,000 patients). Am J Cardiol 2023;193:126–32. https://doi.org/10.1016/j.amjcard. \n2023.02.003 \n139. Mentias A, Desai MY, Saad M, Horwitz PA, Rossen JD, Panaich S, et al. Incidence and \noutcomes of acute coronary syndrome after transcatheter aortic valve replacement. \nJACC Cardiovasc Interv 2020;13:938–50. https://doi.org/10.1016/j.jcin.2019.11.027 \n140. Yassen M, Moustafa A, Venkataramany B, Schodowski E, Royfman R, Eltahawy E. \nClinical outcomes of transcatheter aortic valve replacement with and without percu-\ntaneous coronary intervention—an updated meta-analysis and systematic review. Curr \nProbl Cardiol 2023;48:101980. https://doi.org/10.1016/j.cpcardiol.2023.101980 \n141. Altibi AM, Ghanem F, Hammad F, Patel J, Song HK, Golwala H, et al. Clinical outcomes \nof revascularization with percutaneous coronary intervention prior to transcatheter \naortic valve replacement: a comprehensive meta-analysis. Curr Probl Cardiol 2022;47: \n101339. https://doi.org/10.1016/j.cpcardiol.2022.101339 \n142. Tomii D, Pilgrim T, Borger MA, De Backer O, Lanz J, Reineke D, et al. Aortic stenosis \nand coronary artery disease: decision-making between surgical and transcatheter man-\nagement. Circulation 2024;150:2046–69. https://doi.org/10.1161/circulationaha.124. \n070502 \n143. Tarantini G, Tang G, Nai Fovino L, Blackman D, Van Mieghem NM, Kim WK, et al. \nManagement of coronary artery disease in patients undergoing transcatheter aortic \nvalve implantation. A clinical consensus statement from the European Association of \nPercutaneous Cardiovascular Interventions in collaboration with the ESC Working \nGroup on Cardiovascular Surgery. EuroIntervention 2023;19:37–52. https://doi.org/ \n10.4244/eij-d-22-00958 \n144. Barbanti M, Costa G, Picci A, Criscione E, Reddavid C, Valvo R, et al. Coronary cannu-\nlation after transcatheter aortic valve replacement: the RE-ACCESS study. JACC \nCardiovasc Interv 2020;13:2542–55. https://doi.org/10.1016/j.jcin.2020.07.006 \n145. Costa G, Sammartino S, Strazzieri O, Motta S, Frittitta V, Dipietro E, et al. Coronary \ncannulation following TAVR using self-expanding devices with commissural alignment: \nthe RE-ACCESS 2 study. JACC Cardiovasc Interv 2024;17:727–37. https://doi.org/10. \n1016/j.jcin.2023.12.015 \n146. Tang GHL, Amat-Santos IJ, Backer OD, Avvedimento M, Redondo A, Barbanti M, et al. \nRationale, definitions, techniques, and outcomes of commissural alignment in TAVR. \nJACC Cardiovasc Interv 2022;15:1497–518. https://doi.org/10.1016/j.jcin.2022.06.001 \n147. Campwala SZ, Bansal RC, Wang N, Razzouk A, Pai RG. Factors affecting regression of \nmitral regurgitation following isolated coronary artery bypass surgery. Eur J \nCardiothorac Surg 2005;28:783–7. https://doi.org/10.1016/j.ejcts.2005.10.010 \n148. Castleberry AW, Williams JB, Daneshmand MA, Honeycutt E, Shaw LK, Samad Z, et al. \nSurgical revascularization is associated with maximal survival in patients with ischemic \nmitral regurgitation: a 20-year experience. Circulation 2014;129:2547–56. https://doi. \norg/10.1161/CIRCULATIONAHA.113.005223 \n149. Samad Z, Shaw LK, Phelan M, Ersboll M, Risum N, Al-Khalidi HR, et al. Management and \noutcomes in patients with moderate or severe functional mitral regurgitation and se-\nvere left ventricular dysfunction. Eur Heart J 2015;36:2733–41. https://doi.org/10.1093/ \neurheartj/ehv343 \n150. Yousefzai R, Bajaj N, Krishnaswamy A, Goel SS, Agarwal S, Aksoy O, et al. Outcomes of \npatients with ischemic mitral regurgitation undergoing percutaneous coronary inter-\nvention. Am J Cardiol 2014;114:1011–7. https://doi.org/10.1016/j.amjcard.2014.07.012 \n151. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC \nGuidelines for the management of acute coronary syndromes. Eur Heart J 2023;44: \n3720–826. https://doi.org/10.1093/eurheartj/ehad191 \n152. Thomas KL, Jackson LR 2nd, Shrader P, Ansell J, Fonarow GC, Gersh B, et al. \nPrevalence, characteristics, and outcomes of valvular heart disease in patients with at-\nrial fibrillation: insights from the ORBIT-AF (outcomes registry for better informed \ntreatment for atrial fibrillation). J Am Heart Assoc 2017;6:e006475. https://doi.org/10. \n1161/jaha.117.006475 \n153. Naser JA, Castrichini M, Ibrahim HH, Scott CG, Lin G, Lee E, et al. Secondary tricuspid \nregurgitation: incidence, types, and outcomes in atrial fibrillation vs. sinus rhythm. Eur \nHeart J 2024;45:2878–90. https://doi.org/10.1093/eurheartj/ehae346 \n154. Naser JA, Pislaru C, Roslan A, Ciobanu AO, Jouni H, Nkomo VT, et al. Unfavorable \ntricuspid annulus dynamics: a novel concept to explain development of tricuspid regur-\ngitation in atrial fibrillation. J Am Soc Echocardiogr 2022;35:664–6. https://doi.org/10. \n1016/j.echo.2022.02.009 \n155. Vinereanu D, Wang A, Mulder H, Lopes RD, Jansky P, Lewis BS, et al. Outcomes in \nanticoagulated patients with atrial fibrillation and with mitral or aortic valve disease. \nHeart 2018;104:1292–9. https://doi.org/10.1136/heartjnl-2017-312272 \n156. Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, et al. Apixaban in com-\nparison with warfarin in patients with atrial fibrillation and valvular heart disease: find-\nings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in \nAtrial Fibrillation (ARISTOTLE) trial. Circulation 2015;132:624–32. https://doi.org/10. \n1161/CIRCULATIONAHA.114.014807 \n157. Ezekowitz MD, Nagarakanti R, Noack H, Brueckmann M, Litherland C, Jacobs M, et al. \nComparison of dabigatran and warfarin in patients with atrial fibrillation and valvular \nheart disease: the RE-LY trial (randomized evaluation of long-term anticoagulant ther-\napy). Circulation 2016;134:589–98. https://doi.org/10.1161/CIRCULATIONAHA.115. \n020950 \n158. De Caterina R, Renda G, Carnicelli AP, Nordio F, Trevisan M, Mercuri MF, et al. \nValvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI \n48 trial. J Am Coll Cardiol 2017;69:1372–82. https://doi.org/10.1016/j.jacc.2016.12.031 \n159. Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Stevens SR, et al. \nClinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with \nnon-valvular atrial fibrillation but underlying native mitral and aortic valve disease par-\nticipating in the ROCKET AF trial. Eur Heart J 2014;35:3377–85. https://doi.org/10. \n1093/eurheartj/ehu305 \n160. Whitlock RP, Belley-Cote EP, Paparella D, Healey JS, Brady K, Sharma M, et al. Left at-\nrial appendage occlusion during cardiac surgery to prevent stroke. N Engl J Med 2021; \n384:2081–91. https://doi.org/10.1056/NEJMoa2101897  \nESC Guidelines                                                                                                                                                                                          4715 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n161. Martín Gutiérrez E, Castaño M, Gualis J, Martinez-Comendador JM, Maiorano P, \nCastillo L, et al. Beneficial effect of left atrial appendage closure during cardiac surgery: \na meta-analysis of 280 585 patients. Eur J Cardiothorac Surg 2020;57:252–62. https://doi. \norg/10.1093/ejcts/ezz289 \n162. Connolly SJ, Healey JS, Belley-Cote EP, Balasubramanian K, Paparella D, Brady K, et al. \nOral anticoagulation use and left atrial appendage occlusion in LAAOS III. Circulation \n2023;148:1298–304. https://doi.org/10.1161/CIRCULATIONAHA.122.060315 \n163. Kapadia SR, Krishnaswamy A, Whisenant B, Potluri S, Iyer V, Aragon J, et al. \nConcomitant left atrial appendage occlusion and transcatheter aortic valve replace-\nment among patients with atrial fibrillation. Circulation 2024;149:734–43. https://doi. \norg/10.1161/circulationaha.123.067312 \n164. Dawwas GK, Dietrich E, Cuker A, Barnes GD, Leonard CE, Lewis JD. Effectiveness and \nsafety of direct oral anticoagulants versus warfarin in patients with valvular atrial fibril-\nlation: a population-based cohort study. Ann Intern Med 2021;174:910–9. https://doi. \norg/10.7326/m20-6194 \n165. Connolly SJ, Karthikeyan G, Ntsekhe M, Haileamlak A, El Sayed A, El Ghamrawy A, \net al. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. N Engl J \nMed 2022;387:978–88. https://doi.org/10.1056/NEJMoa2209051 \n166. Rankin JS, Grau-Sepulveda MV, Ad N, Damiano RJ Jr, Gillinov AM, Brennan JM, et al. \nAssociations between surgical ablation and operative mortality after mitral valve pro-\ncedures. Ann Thorac Surg 2018;105:1790–6. https://doi.org/10.1016/j.athoracsur.2017. \n12.035 \n167. Badhwar V, Rankin JS, Ad N, Grau-Sepulveda M, Damiano RJ, Gillinov AM, et al. \nSurgical ablation of atrial fibrillation in the United States: trends and propensity \nmatched outcomes. Ann Thorac Surg 2017;104:493–500. https://doi.org/10.1016/j. \nathoracsur.2017.05.016 \n168. Gillinov AM, Gelijns AC, Parides MK, DeRose JJ Jr, Moskowitz AJ, Voisine P, et al. \nSurgical ablation of atrial fibrillation during mitral-valve surgery. N Engl J Med 2015; \n372:1399–409. https://doi.org/10.1056/NEJMoa1500528 \n169. Huffman MD, Karmali KN, Berendsen MA, Andrei AC, Kruse J, McCarthy PM, et al. \nConcomitant atrial fibrillation surgery for people undergoing cardiac surgery. \nCochrane Database Syst Rev 2016;2016:CD011814. https://doi.org/10.1002/ \n14651858.CD011814.pub2 \n170. Wang H, Han J, Wang Z, Yin Z, Liu Z, Jin Y, et al. A prospective randomized trial of the \ncut-and-sew Maze procedure in patients undergoing surgery for rheumatic mitral valve \ndisease. J Thorac Cardiovasc Surg 2018;155:608–17. https://doi.org/10.1016/j.jtcvs.2017. \n07.084 \n171. Lawrance CP, Henn MC, Miller JR, Sinn LA, Schuessler RB, Maniar HS, et al. A minimally \ninvasive Cox maze IV procedure is as effective as sternotomy while decreasing major \nmorbidity and hospital stay. J Thorac Cardiovasc Surg 2014;148:955–61; discussion \n962–952. https://doi.org/10.1016/j.jtcvs.2014.05.064 \n172. Cheng DC, Ad N, Martin J, Berglin EE, Chang BC, Doukas G, et al. Surgical ablation for \natrial fibrillation in cardiac surgery: a meta-analysis and systematic review. Innovations \n(Phila) 2010;5:84–96. https://doi.org/10.1097/IMI.0b013e3181d9199b \n173. McClure GR, Belley-Cote EP, Jaffer IH, Dvirnik N, An KR, Fortin G, et al. Surgical ab-\nlation of atrial fibrillation: a systematic review and meta-analysis of randomized con-\ntrolled trials. Europace 2018;20:1442–50. https://doi.org/10.1093/europace/eux336 \n174. Yoo JS, Kim JB, Ro SK, Jung Y, Jung SH, Choo SJ, et al. Impact of concomitant surgical \natrial fibrillation ablation in patients undergoing aortic valve replacement. Circ J 2014; \n78:1364–71. https://doi.org/10.1253/circj.cj-13-1533 \n175. Malaisrie SC, Lee R, Kruse J, Lapin B, Wang EC, Bonow RO, et al. Atrial fibrillation ab-\nlation in patients undergoing aortic valve replacement. J Heart Valve Dis 2012;21: \n350–7. \n176. Gujral DM, Lloyd G, Bhattacharyya S. Radiation-induced valvular heart disease. Heart \n2016;102:269–76. https://doi.org/10.1136/heartjnl-2015-308765 \n177. Lee C, Hahn RT. Valvular heart disease associated with radiation therapy: a contem-\nporary review. Struct Heart 2023;7:100104. https://doi.org/10.1016/j.shj.2022.100104 \n178. Lancellotti P, Nkomo VT, Badano LP, Bergler-Klein J, Bogaert J, Davin L, et al. Expert \nconsensus for multi-modality imaging evaluation of cardiovascular complications of \nradiotherapy in adults: a report from the European Association of Cardiovascular \nImaging and the American Society of Echocardiography. J Am Soc Echocardiogr 2013; \n26:1013–32. https://doi.org/10.1016/j.echo.2013.07.005 \n179. Wu W, Masri A, Popovic ZB, Smedira NG, Lytle BW, Marwick TH, et al. Long-term \nsurvival of patients with radiation heart disease undergoing cardiac surgery: a cohort \nstudy. Circulation 2013;127:1476–85. https://doi.org/10.1161/CIRCULATIONAHA. \n113.001435 \n180. Donnellan E, Masri A, Johnston DR, Pettersson GB, Rodriguez LL, Popovic ZB, et al. \nLong-term outcomes of patients with mediastinal radiation-associated severe aortic \nstenosis and subsequent surgical aortic valve replacement: a matched cohort study. J \nAm Heart Assoc 2017;6:e005396. https://doi.org/10.1161/JAHA.116.005396 \n181. Donnellan E, Alashi A, Johnston DR, Gillinov AM, Pettersson GB, Svensson LG, et al. \nOutcomes of patients with mediastinal radiation-associated mitral valve disease under-\ngoing cardiac surgery. Circulation 2019;140:1288–90. https://doi.org/10.1161/ \nCIRCULATIONAHA.119.040546 \n182. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. \n2022 ESC Guidelines on cardio-oncology developed in collaboration with the \nEuropean Hematology Association (EHA), the European Society for Therapeutic \nRadiology and Oncology (ESTRO) and the International Cardio-Oncology Society \n(IC-OS). Eur Heart J 2022;43:4229–361. https://doi.org/10.1093/eurheartj/ehac244 \n183. Yazdchi F, Hirji SA, Nohria A, Percy E, Harloff M, Malarczyk A, et al. Transcatheter \ncompared with surgical aortic valve replacement in patients with previous chest- \ndirected radiation therapy. JACC CardioOncol 2021;3:397–407. https://doi.org/10. \n1016/j.jaccao.2021.07.005 \n184. Zafar MR, Mustafa SF, Miller TW, Alkhawlani T, Sharma UC. Outcomes after trans-\ncatheter aortic valve replacement in cancer survivors with prior chest radiation ther-\napy: a systematic review and meta-analysis. Cardiooncology 2020;6:8. https://doi.org/10. \n1186/s40959-020-00062-y \n185. Ullah W, Thalambedu N, Zahid S, Muhammadzai Hamza Zahid U, Sandhyavenu H, \nKumar A, et al. Trends and outcomes of TAVI and SAVR in cancer and noncancer pa-\ntients. JACC Adv 2023;2:100167. https://doi.org/10.1016/j.jacadv.2022.100167 \n186. Lind A, Totzeck M, Mahabadi AA, Janosi RA, El Gabry M, Ruhparwar A, et al. Impact of \ncancer in patients undergoing transcatheter aortic valve replacement: a single-center \nstudy. JACC CardioOncol 2020;2:735–43. https://doi.org/10.1016/j.jaccao.2020.11.008 \n187. Yadgir S, Johnson CO, Aboyans V, Adebayo OM, Adedoyin RA, Afarideh M, et al. \nGlobal, regional, and national burden of calcific aortic valve and degenerative mitral \nvalve diseases, 1990–2017. Circulation 2020;141:1670–80. https://doi.org/10.1161/ \nCIRCULATIONAHA.119.043391 \n188. Rwebembera J, Marangou J, Mwita JC, Mocumbi AO, Mota C, Okello E, et al. 2023 \nWorld Heart Federation guidelines for the echocardiographic diagnosis of rheumatic \nheart disease. Nat Rev Cardiol 2023;21:250–63. https://doi.org/10.1038/s41569-023- \n00940-9 \n189. Karki P, Uranw S, Bastola S, Mahato R, Shrestha NR, Sherpa K, et al. Effectiveness of \nsystematic echocardiographic screening for rheumatic heart disease in Nepalese \nschoolchildren: a cluster randomized clinical trial. JAMA Cardiol 2021;6:420–26.  \nhttps://doi.org/10.1001/jamacardio.2020.7050 \n190. Beaton A, Okello E, Rwebembera J, Grobler A, Engelman D, Alepere J, et al. Secondary \nantibiotic prophylaxis for latent rheumatic heart disease. N Engl J Med 2022;386: \n230–40. https://doi.org/10.1056/NEJMoa2102074 \n191. Kumar RK, Antunes MJ, Beaton A, Mirabel M, Nkomo VT, Okello E, et al. \nContemporary diagnosis and management of rheumatic heart disease: implications \nfor closing the gap: a scientific statement from the American Heart Association. \nCirculation 2020;142:e337–57. https://doi.org/10.1161/cir.0000000000000921 \n192. World Health Organization. WHO Guideline on the Prevention and Diagnosis of \nRheumatic Fever and Rheumatic Heart Disease. https://www.who.int/publications/i/ \nitem/9789240100077 (28 March 2025, date last accessed). \n193. Chioncel O, Adamo M, Nikolaou M, Parissis J, Mebazaa A, Yilmaz MB, et al. Acute heart \nfailure and valvular heart disease: a scientific statement of the Heart Failure \nAssociation, the Association for Acute CardioVascular Care and the European \nAssociation of Percutaneous Cardiovascular Interventions of the European Society \nof Cardiology. Eur J Heart Fail 2023;25:1025–48. https://doi.org/10.1002/ejhf.2918 \n194. Lüsebrink E, Lanz H, Kellnar A, Karam N, Kapadia S, Makkar R, et al. (December 11, \n2024) Management of acute decompensated valvular heart disease. Eur J Heart Fail,  \nhttps://doi.org/10.1002/ejhf.3549 \n195. Kolte D, Khera S, Vemulapalli S, Dai D, Heo S, Goldsweig AM, et al. Outcomes follow-\ning urgent/emergent transcatheter aortic valve replacement: insights from the STS/ \nACC TVT registry. JACC Cardiovasc Interv 2018;11:1175–85. https://doi.org/10.1016/ \nj.jcin.2018.03.002 \n196. Elbadawi A, Elgendy IY, Mentias A, Saad M, Mohamed AH, Choudhry MW, et al. \nOutcomes of urgent versus nonurgent transcatheter aortic valve replacement. \nCatheter Cardiovasc Interv 2020;96:189–95. https://doi.org/10.1002/ccd.28563 \n197. Masha L, Vemulapalli S, Manandhar P, Balan P, Shah P, Kosinski AS, et al. Demographics, \nprocedural characteristics, and clinical outcomes when cardiogenic shock precedes \nTAVR in the United States. JACC Cardiovasc Interv 2020;13:1314–25. https://doi.org/ \n10.1016/j.jcin.2020.02.033 \n198. Goel K, Shah P, Jones BM, Korngold E, Bhardwaj A, Kar B, et al. Outcomes of trans-\ncatheter aortic valve replacement in patients with cardiogenic shock. Eur Heart J \n2023;44:3181–95. https://doi.org/10.1093/eurheartj/ehad387 \n199. Buchwald AB, Meyer T, Scholz K, Schorn B, Unterberg C. Efficacy of balloon valvulo-\nplasty in patients with critical aortic stenosis and cardiogenic shock—the role of shock \nduration. Clin Cardiol 2001;24:214–8. https://doi.org/10.1002/clc.4960240308 \n200. Moreno PR, Jang IK, Newell JB, Block PC, Palacios IF. The role of percutaneous aortic \nballoon valvuloplasty in patients with cardiogenic shock and critical aortic stenosis. J Am \nColl Cardiol 1994;23:1071–5. https://doi.org/10.1016/0735-1097(94)90592-4 \n201. Llah ST, Sharif S, Ullah S, Sheikh SA, Shah MA, Shafi OM, et al. TAVR vs balloon aortic \nvalvotomy for severe aortic stenosis and cardiogenic shock: an insight from the nation-\nal inpatient sample database. Cardiovasc Revasc Med 2023;55:1–7. https://doi.org/10. \n1016/j.carrev.2023.05.006 \n202. Tang GHL, Estevez-Loureiro R, Yu Y, Prillinger JB, Zaid S, Psotka MA. Survival following \nedge-to-edge transcatheter mitral valve repair in patients with cardiogenic shock: a na-\ntionwide analysis. J Am Heart Assoc 2021;10:e019882. https://doi.org/10.1161/jaha.120. \n019882  \n4716                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n203. Haberman D, Estevez-Loureiro R, Benito-Gonzalez T, Denti P, Arzamendi D, Adamo \nM, et al. Conservative, surgical, and percutaneous treatment for mitral regurgitation \nshortly after acute myocardial infarction. Eur Heart J 2021;43:641–50. https://doi. \norg/10.1093/eurheartj/ehab496 \n204. Hill L, Prager Geller T, Baruah R, Beattie JM, Boyne J, de Stoutz N, et al. Integration of a \npalliative approach into heart failure care: a European Society of Cardiology Heart \nFailure Association position paper. Eur J Heart Fail 2020;22:2327–39. https://doi.org/ \n10.1002/ejhf.1994 \n205. Kyriakou M, Middleton N, Ktisti S, Philippou K, Lambrinou E. Supportive care interven-\ntions to promote health-related quality of life in patients living with heart failure: a sys-\ntematic review and meta-analysis. Heart Lung Circ 2020;29:1633–47. https://doi.org/10. \n1016/j.hlc.2020.04.019 \n206. Fendler TJ, Swetz KM, Allen LA. Team-based palliative and end-of-life care for heart \nfailure. Heart Fail Clin 2015;11:479–98. https://doi.org/10.1016/j.hfc.2015.03.010 \n207. Brännström M, Boman K. Effects of person-centred and integrated chronic heart fail-\nure and palliative home care. PREFER: a randomized controlled study. Eur J Heart Fail \n2014;16:1142–51. https://doi.org/10.1002/ejhf.151 \n208. Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL, et al. Prevalence and clinical \ndeterminants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart \nStudy). Am J Cardiol 1999;83:897–902. https://doi.org/10.1016/s0002-9149(98) \n01064-9 \n209. Lee JKT, Franzone A, Lanz J, Siontis GCM, Stortecky S, Gräni C, et al. Early detection of \nsubclinical myocardial damage in chronic aortic regurgitation and strategies for timely \ntreatment of asymptomatic patients. Circulation 2018;137:184–96. https://doi.org/10. \n1161/circulationaha.117.029858 \n210. Alashi A, Khullar T, Mentias A, Gillinov AM, Roselli EE, Svensson LG, et al. Long-term \noutcomes after aortic valve surgery in patients with asymptomatic chronic aortic re-\ngurgitation and preserved LVEF: impact of baseline and follow-up global longitudinal \nstrain. JACC Cardiovasc Imaging 2020;13:12–21. https://doi.org/10.1016/j.jcmg.2018. \n12.021 \n211. deCampos D, Teixeira R, Saleiro C, Botelho A, Gonçalve L. Global longitudinal strain in \nchronic asymptomatic aortic regurgitation: systematic review. Echo Res Pract 2020;7: \n39–48. https://doi.org/10.1530/erp-20-0024 \n212. Lee SY, Park SJ, Kim EK, Chang SA, Lee SC, Ahn JH, et al. Predictive value of exercise \nstress echocardiography in asymptomatic patients with severe aortic regurgitation and \npreserved left ventricular systolic function without LV dilatation. Int J Cardiovasc \nImaging 2019;35:1241–7. https://doi.org/10.1007/s10554-019-01565-1 \n213. Pizarro R, Bazzino OO, Oberti PF, Falconi ML, Arias AM, Krauss JG, et al. Prospective \nvalidation of the prognostic usefulness of B-type natriuretic peptide in asymptomatic \npatients with chronic severe aortic regurgitation. J Am Coll Cardiol 2011;58:1705–14.  \nhttps://doi.org/10.1016/j.jacc.2011.07.016 \n214. Kočková R, Línková H, Hlubocká Z, Mědílek K, Tuna M, Vojáček J, et al. Multiparametric \nstrategy to predict early disease decompensation in asymptomatic severe aortic regur-\ngitation. Circ Cardiovasc Imaging 2022;15:e014901. https://doi.org/10.1161/circimaging. \n122.014901 \n215. Goldstein SA, Evangelista A, Abbara S, Arai A, Asch FM, Badano LP, et al. Multimodality \nimaging of diseases of the thoracic aorta in adults: from the American Society of \nEchocardiography and the European Association of Cardiovascular Imaging: endorsed \nby the Society of Cardiovascular Computed Tomography and Society for \nCardiovascular Magnetic Resonance. J Am Soc Echocardiogr 2015;28:119–82. https:// \ndoi.org/10.1016/j.echo.2014.11.015 \n216. Czerny M, Grabenwöger M, Berger T, Aboyans V, Della Corte A, Chen EP, et al. \nEACTS/STS Guidelines for diagnosing and treating acute and chronic syndromes of \nthe aortic organ. Eur J Cardiothorac Surg 2024;65:ezad426. https://doi.org/10.1093/ \nejcts/ezad426 \n217. le Polain de Waroux JB, Pouleur AC, Goffinet C, Vancraeynest D, Van Dyck M, Robert \nA, et al. Functional anatomy of aortic regurgitation: accuracy, prediction of surgical re-\npairability, and outcome implications of transesophageal echocardiography. Circulation \n2007;116:I264–9. https://doi.org/10.1161/CIRCULATIONAHA.106.680074 \n218. Lansac E, Di Centa I, Raoux F, Al Attar N, Acar C, Joudinaud T, et al. A lesional clas-\nsification to standardize surgical management of aortic insufficiency towards valve re-\npair. Eur J Cardiothorac Surg 2008;33:872–8; discussion 878–880. https://doi.org/10. \n1016/j.ejcts.2007.12.033 \n219. Michelena HI, Della Corte A, Evangelista A, Maleszewski JJ, Edwards WD, Roman MJ, \net al. International consensus statement on nomenclature and classification of the con-\ngenital bicuspid aortic valve and its aortopathy, for clinical, surgical, interventional and \nresearch purposes. Eur J Cardiothorac Surg 2021;60:448–76. https://doi.org/10.1093/ \nejcts/ezab038 \n220. Ehrlich T, de Kerchove L, Vojacek J, Boodhwani M, El-Hamamsy I, De Paulis R, et al. \nState-of-the art bicuspid aortic valve repair in 2020. Prog Cardiovasc Dis 2020;63: \n457–64. https://doi.org/10.1016/j.pcad.2020.04.010 \n221. Evangelista Masip A, Galian-Gay L, Guala A, Lopez-Sainz A, Teixido-Turà G, Ruiz \nMuñoz A, et al. Unraveling bicuspid aortic valve enigmas by multimodality imaging: clin-\nical implications. J Clin Med 2022;11:456. https://doi.org/10.3390/jcm11020456 \n222. Elder DHJ, Wei L, Szwejkowski BR, Libianto R, Nadir A, Pauriah M, et al. The impact of \nrenin-angiotensin-aldosterone system blockade on heart failure outcomes and \nmortality in patients identified to have aortic regurgitation: a large population cohort \nstudy. J Am Coll Cardiol 2011;58:2084–91. https://doi.org/10.1016/j.jacc.2011.07.043 \n223. Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JGF, et al. \nClinical practice update on heart failure 2019: pharmacotherapy, procedures, devices \nand patient management. An expert consensus meeting report of the Heart Failure \nAssociation of the European Society of Cardiology. Eur J Heart Fail 2019;21: \n1169–86. https://doi.org/10.1002/ejhf.1531 \n224. Chaliki HP, Mohty D, Avierinos JF, Scott CG, Schaff HV, Tajik AJ, et al. Outcomes after \naortic valve replacement in patients with severe aortic regurgitation and markedly re-\nduced left ventricular function. Circulation 2002;106:2687–93. https://doi.org/10.1161/ \n01.cir.0000038498.59829.38 \n225. Kaneko T, Ejiofor JI, Neely RC, McGurk S, Ivkovic V, Stevenson LW, et al. Aortic re-\ngurgitation with markedly reduced left ventricular function is not a contraindication \nfor aortic valve replacement. Ann Thorac Surg 2016;102:41–7. https://doi.org/10. \n1016/j.athoracsur.2015.12.068 \n226. Tornos P, Sambola A, Permanyer-Miralda G, Evangelista A, Gomez Z, Soler-Soler J. \nLong-term outcome of surgically treated aortic regurgitation: influence of guideline ad-\nherence toward early surgery. J Am Coll Cardiol 2006;47:1012–7. https://doi.org/10. \n1016/j.jacc.2005.10.049 \n227. Klodas E, Enriquez-Sarano M, Tajik AJ, Mullany CJ, Bailey KR, Seward JB. Optimizing \ntiming of surgical correction in patients with severe aortic regurgitation: role of symp-\ntoms. J Am Coll Cardiol 1997;30:746–52. https://doi.org/10.1016/s0735-1097(97) \n00205-2 \n228. Dujardin KS, Enriquez-Sarano M, Schaff HV, Bailey KR, Seward JB, Tajik AJ. Mortality \nand morbidity of aortic regurgitation in clinical practice. A long-term follow-up study. \nCirculation 1999;99:1851–7. https://doi.org/10.1161/01.cir.99.14.1851 \n229. Fiedler AG, Bhambhani V, Laikhter E, Picard MH, Wasfy MM, Tolis G, et al. Aortic valve \nreplacement associated with survival in severe regurgitation and low ejection fraction. \nHeart 2018;104:835–40. https://doi.org/10.1136/heartjnl-2017-312024 \n230. Tribouilloy CM, Enriquez-Sarano M, Schaff HV, Orszulak TA, Fett SL, Bailey KR, et al. \nExcess mortality due to coronary artery disease after valve surgery. Secular trends in \nvalvular regurgitation and effect of internal mammary artery bypass. Circulation 1998; \n98:II108–15. \n231. Forman R, Firth BG, Barnard MS. Prognostic significance of preoperative left ventricu-\nlar ejection fraction and valve lesion in patients with aortic valve replacement. Am J \nCardiol 1980;45:1120–5. https://doi.org/10.1016/0002-9149(80)90468-3 \n232. Bonow RO, Lakatos E, Maron BJ, Epstein SE. Serial long-term assessment of the natural \nhistory of asymptomatic patients with chronic aortic regurgitation and normal left ven-\ntricular systolic function. Circulation 1991;84:1625–35. https://doi.org/10.1161/01.cir. \n84.4.1625 \n233. Bhudia SK, McCarthy PM, Kumpati GS, Helou J, Hoercher KJ, Rajeswaran J, et al. \nImproved outcomes after aortic valve surgery for chronic aortic regurgitation with se-\nvere left ventricular dysfunction. J Am Coll Cardiol 2007;49:1465–71. https://doi.org/10. \n1016/j.jacc.2007.01.026 \n234. Sambola A, Tornos P, Ferreira-Gonzalez I, Evangelista A. Prognostic value of preopera-\ntive indexed end-systolic left ventricle diameter in the outcome after surgery in pa-\ntients with chronic aortic regurgitation. Am Heart J 2008;155:1114–20. https://doi. \norg/10.1016/j.ahj.2007.12.025 \n235. Yang LT, Michelena HI, Scott CG, Enriquez-Sarano M, Pislaru SV, Schaff HV, et al. \nOutcomes in chronic hemodynamically significant aortic regurgitation and limitations \nof current guidelines. J Am Coll Cardiol 2019;73:1741–52. https://doi.org/10.1016/j.jacc. \n2019.01.024 \n236. Mentias A, Feng K, Alashi A, Rodriguez LL, Gillinov AM, Johnston DR, et al. Long-term \noutcomes in patients with aortic regurgitation and preserved left ventricular ejection \nfraction. J Am Coll Cardiol 2016;68:2144–53. https://doi.org/10.1016/j.jacc.2016.08.045 \n237. de Meester C, Gerber BL, Vancraeynest D, Pouleur AC, Noirhomme P, Pasquet A, \net al. Do guideline-based indications result in an outcome penalty for patients with se-\nvere aortic regurgitation? JACC Cardiovasc Imaging 2019;12:2126–38. https://doi.org/ \n10.1016/j.jcmg.2018.11.022 \n238. Yang LT, Anand V, Zambito EI, Pellikka PA, Scott CG, Thapa P, et al. Association of \nechocardiographic left ventricular end-systolic volume and volume-derived ejection \nfraction with outcome in asymptomatic chronic aortic regurgitation. JAMA Cardiol \n2021;6:189–98. https://doi.org/10.1001/jamacardio.2020.5268 \n239. Yang LT, Lee CC, Su CH, Amano M, Nabeshima Y, Kitano T, et al. Analysis of left ven-\ntricular indexes and mortality among Asian adults with hemodynamically significant \nchronic aortic regurgitation. JAMA Netw Open 2023;6:e234632. https://doi.org/10. \n1001/jamanetworkopen.2023.4632 \n240. Hashimoto G, Enriquez-Sarano M, Stanberry LI, Oh F, Wang M, Acosta K, et al. \nAssociation of left ventricular remodeling assessment by cardiac magnetic resonance \nwith outcomes in patients with chronic aortic regurgitation. JAMA Cardiol 2022;7: \n924–33. https://doi.org/10.1001/jamacardio.2022.2108 \n241. Malahfji M, Crudo V, Kaolawanich Y, Nguyen DT, Telmesani A, Saeed M, et al. Influence \nof cardiac remodeling on clinical outcomes in patients with aortic regurgitation. J Am \nColl Cardiol 2023;81:1885–98. https://doi.org/10.1016/j.jacc.2023.03.001 \n242. Vermes E, Iacuzio L, Levy F, Bohbot Y, Renard C, Gerber B, et al. Role of cardiovascular \nmagnetic resonance in native valvular regurgitation: a comprehensive review of  \nESC Guidelines                                                                                                                                                                                          4717 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nprotocols, grading of severity, and prediction of valve surgery. Front Cardiovasc Med \n2022;9:881141. https://doi.org/10.3389/fcvm.2022.881141 \n243. Flynn CD, Tian DH, Wilson-Smith A, David T, Matalanis G, Misfeld M, et al. Systematic \nreview and meta-analysis of surgical outcomes in Marfan patients undergoing aortic \nroot surgery by composite-valve graft or valve sparing root replacement. Ann \nCardiothorac Surg 2017;6:570–81. https://doi.org/10.21037/acs.2017.11.06 \n244. Chauvette V, Kluin J, de Kerchove L, El Khoury G, Schäfers HJ, Lansac E, et al. \nOutcomes of valve-sparing surgery in heritable aortic disorders: results from the \nAVIATOR registry. Eur J Cardiothorac Surg 2022;62:ezac366. https://doi.org/10.1093/ \nejcts/ezac366 \n245. Wilson-Smith AR, Wilson-Smith CJ, Strode Smith J, Ng D, Muston BT, Eranki A, et al. \nThe outcomes of three decades of the David and Yacoub procedures in bicuspid aortic \nvalve patients—a systematic review and meta-analysis. Ann Cardiothorac Surg 2023;12: \n286–94. https://doi.org/10.21037/acs-2023-avs2-19 \n246. Zuo Y, Tan R, Qin C. Outcomes of valve-sparing aortic root replacement in patients \nwith bicuspid aortic valve and tricuspid aortic valve: a systematic review and \nmeta-analysis. J Cardiothorac Surg 2023;18:206. https://doi.org/10.1186/s13019-023- \n02329-8 \n247. Mastrobuoni S, Govers PJ, Veen KM, Jahanyar J, van Saane S, Segreto A, et al. \nValve-sparing aortic root replacement using the reimplantation (David) technique: a \nsystematic review and meta-analysis on survival and clinical outcome. Ann \nCardiothorac Surg 2023;12:149–58. https://doi.org/10.21037/acs-2023-avs1-0038 \n248. Aicher D, Fries R, Rodionycheva S, Schmidt K, Langer F, Schafers HJ. Aortic valve repair \nleads to a low incidence of valve-related complications. Eur J Cardiothorac Surg 2010;37: \n127–32. https://doi.org/10.1016/j.ejcts.2009.06.021 \n249. de Meester C, Pasquet A, Gerber BL, Vancraeynest D, Noirhomme P, El Khoury G, \net al. Valve repair improves the outcome of surgery for chronic severe aortic regurgi-\ntation: a propensity score analysis. J Thorac Cardiovasc Surg 2014;148:1913–20. https:// \ndoi.org/10.1016/j.jtcvs.2014.02.010 \n250. Klotz S, Stock S, Sievers HH, Diwoky M, Petersen M, Stierle U, et al. Survival and re-\noperation pattern after 20 years of experience with aortic valve-sparing root replace-\nment in patients with tricuspid and bicuspid valves. J Thorac Cardiovasc Surg 2018;155: \n1403–11.e1401. https://doi.org/10.1016/j.jtcvs.2017.12.039 \n251. Elbatarny M, Tam DY, Edelman JJ, Rocha RV, Chu MWA, Peterson MD, et al. \nValve-sparing root replacement versus composite valve grafting in aortic root dilation: \na meta-analysis. Ann Thorac Surg 2020;110:296–306. https://doi.org/10.1016/j. \nathoracsur.2019.11.054 \n252. Leontyev S, Schamberger L, Davierwala PM, Von Aspern K, Etz C, Lehmann S, et al. \nEarly and late results after David vs Bentall procedure: a propensity matched analysis. \nAnn Thorac Surg 2019;110:120–6. https://doi.org/10.1016/j.athoracsur.2019.10.020 \n253. Mastrobuoni S, de Kerchove L, Navarra E, Watremez C, Vancraeynest D, Rubay J, et al. \nLong-term experience with valve-sparing reimplantation technique for the treatment \nof aortic aneurysm and aortic regurgitation. J Thorac Cardiovasc Surg 2019;158:14–23.  \nhttps://doi.org/10.1016/j.jtcvs.2018.10.155 \n254. Lansac E, Di Centa I, Sleilaty G, Lejeune S, Khelil N, Berrebi A, et al. Long-term results \nof external aortic ring annuloplasty for aortic valve repair. Eur J Cardiothorac Surg 2016; \n50:350–60. https://doi.org/10.1093/ejcts/ezw070 \n255. Lee H, Cho YH, Sung K, Kim WS, Park KH, Jeong DS, et al. Clinical outcomes of root \nreimplantation and Bentall procedure: propensity score matching analysis. Ann Thorac \nSurg 2018;106:539–47. https://doi.org/10.1016/j.athoracsur.2018.02.057 \n256. Norton EL, Patel PM, Levine D, Wei JW, Binongo JN, Leshnower BG, et al. Bentall ver-\nsus valve-sparing aortic root replacement for root pathology with moderate-to-severe \naortic insufficiency: a propensity-matched analysis. Eur J Cardiothorac Surg 2023;64: \nezad231. https://doi.org/10.1093/ejcts/ezad231 \n257. Arabkhani B, Klautz RJM, de Heer F, De Kerchove L, El Khoury G, Lansac E, et al. A \nmulticentre, propensity score matched analysis comparing a valve-sparing approach \nto valve replacement in aortic root aneurysm: insight from the AVIATOR database. \nEur J Cardiothorac Surg 2023;63:ezac514. https://doi.org/10.1093/ejcts/ezac514 \n258. Levine D, Patel P, Zhao Y, Chung M, Singh S, Childress P, et al. Valve-sparing aortic root \nreplacement versus composite valve graft with bioprosthesis in patients under age 50. J \nThorac Cardiovasc Surg 2023;168:992–1002.e1. https://doi.org/10.1016/j.jtcvs.2023.07. \n016 \n259. Schneider U, Hofmann C, Schöpe J, Niewald AK, Giebels C, Karliova I, et al. Long-term \nresults of differentiated anatomic reconstruction of bicuspid aortic valves. JAMA Cardiol \n2020;5:1366–73. https://doi.org/10.1001/jamacardio.2020.3749 \n260. Mazine A, Rocha RV, El-Hamamsy I, Ouzounian M, Yanagawa B, Bhatt DL, et al. Ross \nprocedure vs mechanical aortic valve replacement in adults: a systematic review and \nmeta-analysis. JAMA Cardiol 2018;3:978–87. https://doi.org/10.1001/jamacardio.2018. \n2946 \n261. Takkenberg JJM, Klieverik LMA, Schoof PH, van Suylen RJ, van Herwerden LA, \nZondervan PE, et al. The Ross procedure: a systematic review and meta-analysis. \nCirculation \n2009;119:222–8. \nhttps://doi.org/10.1161/CIRCULATIONAHA.107. \n726349 \n262. Yokoyama Y, Kuno T, Toyoda N, Fujisaki T, Takagi H, Itagaki S, et al. Ross procedure \nversus mechanical versus bioprosthetic aortic valve replacement: a network \nmeta-analysis. J Am Heart Assoc 2023;12:e8066. https://doi.org/10.1161/jaha.122. \n027715 \n263. El-Hamamsy I, Toyoda N, Itagaki S, Stelzer P, Varghese R, Williams EE, et al. \nPropensity-matched comparison of the Ross procedure and prosthetic aortic valve re-\nplacement in adults. J Am Coll Cardiol 2022;79:805–15. https://doi.org/10.1016/j.jacc. \n2021.11.057 \n264. Sawaya FJ, Deutsch MA, Seiffert M, Yoon SH, Codner P, Wickramarachchi U, et al. \nSafety and efficacy of transcatheter aortic valve replacement in the treatment of \npure aortic regurgitation in native valves and failing surgical bioprostheses: results \nfrom an international registry study. JACC Cardiovasc Interv 2017;10:1048–56. https:// \ndoi.org/10.1016/j.jcin.2017.03.004 \n265. Yoon SH, Schmidt T, Bleiziffer S, Schofer N, Fiorina C, Munoz-Garcia AJ, et al. \nTranscatheter aortic valve replacement in pure native aortic valve regurgitation. J \nAm Coll Cardiol 2017;70:2752–63. https://doi.org/10.1016/j.jacc.2017.10.006 \n266. Poletti E, De Backer O, Scotti A, Costa G, Bruno F, Fiorina C, et al. Transcatheter aor-\ntic valve replacement for pure native aortic valve regurgitation: the PANTHEON inter-\nnational project. JACC Cardiovasc Interv 2023;16:1974–85. https://doi.org/10.1016/j.jcin. \n2023.07.026 \n267. Garcia S, Ye J, Webb J, Reardon M, Kleiman N, Goel S, et al. Transcatheter treatment \nof native aortic valve regurgitation: the North American experience with a novel de-\nvice. JACC Cardiovasc Interv 2023;16:1953–60. https://doi.org/10.1016/j.jcin.2023.05. \n018 \n268. Adam M, Tamm AR, Wienemann H, Unbehaun A, Klein C, Arnold M, et al. \nTranscatheter aortic valve replacement for isolated aortic regurgitation using a new \nself-expanding TAVR system. JACC Cardiovasc Interv 2023;16:1965–73. https://doi. \norg/10.1016/j.jcin.2023.07.038 \n269. Vahl TP, Thourani VH, Makkar RR, Hamid N, Khalique OK, Daniels D, et al. \nTranscatheter aortic valve implantation in patients with high-risk symptomatic native \naortic regurgitation (ALIGN-AR): a prospective, multicentre, single-arm study. Lancet \n2024;403:1451–9. https://doi.org/10.1016/s0140-6736(23)02806-4 \n270. Borger MA, Preston M, Ivanov J, Fedak PW, Davierwala P, Armstrong S, et al. Should \nthe ascending aorta be replaced more frequently in patients with bicuspid aortic valve \ndisease? J Thorac Cardiovasc Surg 2004;128:677–83. https://doi.org/10.1016/j.jtcvs. \n2004.07.009 \n271. Coady MA, Rizzo JA, Hammond GL, Mandapati D, Darr U, Kopf GS, et al. What is the \nappropriate size criterion for resection of thoracic aortic aneurysms? J Thorac \nCardiovasc Surg 1997;113:476–91; discussion 489–491. https://doi.org/10.1016/ \nS0022-5223(97)70360-X \n272. Davies RR, Goldstein LJ, Coady MA, Tittle SL, Rizzo JA, Kopf GS, et al. Yearly rupture \nor dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann \nThorac Surg 2002;73:17–27; discussion 27–18. https://doi.org/10.1016/s0003- \n4975(01)03236-2 \n273. Zafar MA, Li Y, Rizzo JA, Charilaou P, Saeyeldin A, Velasquez CA, et al. Height alone, \nrather than body surface area, suffices for risk estimation in ascending aortic aneurysm. \nJ Thorac Cardiovasc Surg 2018;155:1938–50. https://doi.org/10.1016/j.jtcvs.2017.10.140 \n274. Popović ZB, Desai MY, Griffin BP. Decision making with imaging in asymptomatic aor-\ntic regurgitation. JACC Cardiovasc Imaging 2018;11:1499–513. https://doi.org/10.1016/j. \njcmg.2018.05.027 \n275. Evangelista A, Sitges M, Jondeau G, Nijveldt R, Pepi M, Cuellar H, et al. Multimodality \nimaging in thoracic aortic diseases: a clinical consensus statement from the European \nAssociation of Cardiovascular Imaging and the European Society of Cardiology work-\ning group on aorta and peripheral vascular diseases. Eur Heart J Cardiovasc Imaging \n2023;24:e65–85. https://doi.org/10.1093/ehjci/jead024 \n276. Weisenberg D, Omelchenko A, Shapira Y, Vaturi M, Monakier D, Bental T, et al. \nMid-term echocardiographic progression of patients with moderate aortic regurgita-\ntion: implications for aortic valve surgery. J Heart Valve Dis 2013;22:192–4. \n277. Budts W, Pieles GE, Roos-Hesselink JW, Sanz de la Garza M, D’Ascenzi F, \nGiannakoulas G, et al. Recommendations for participation in competitive sport in ado-\nlescent and adult athletes with Congenital Heart Disease (CHD): position statement of \nthe Sports Cardiology & Exercise Section of the European Association of Preventive \nCardiology (EAPC), the European Society of Cardiology (ESC) Working Group on \nAdult Congenital Heart Disease and the Sports Cardiology, Physical Activity and \nPrevention Working Group of the Association for European Paediatric and \nCongenital Cardiology (AEPC). Eur Heart J 2020;41:4191–9. https://doi.org/10.1093/ \neurheartj/ehaa501 \n278. Robertson EN, van der Linde D, Sherrah AG, Vallely MP, Wilson M, Bannon PG, et al. \nFamilial non-syndromal thoracic aortic aneurysms and dissections—incidence and \nfamily screening outcomes. Int J Cardiol 2016;220:43–51. https://doi.org/10.1016/j. \nijcard.2016.06.086 \n279. Bray JJH, Freer R, Pitcher A, Kharbanda R. Family screening for bicuspid aortic valve and \naortic dilatation: a meta-analysis. Eur Heart J 2023;44:3152–64. https://doi.org/10.1093/ \neurheartj/ehad320 \n280. Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic \nvalves in adults having isolated aortic valve replacement for aortic stenosis, with or \nwithout associated aortic regurgitation. Circulation 2005;111:920–5. https://doi.org/ \n10.1161/01.Cir.0000155623.48408.C5  \n4718                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n281. Verma S, Siu SC. Aortic dilatation in patients with bicuspid aortic valve. N Engl J Med \n2014;370:1920–9. https://doi.org/10.1056/NEJMra1207059 \n282. Zühlke L, Engel ME, Karthikeyan G, Rangarajan S, Mackie P, Cupido B, et al. \nCharacteristics, complications, and gaps in evidence-based interventions in rheumatic \nheart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). Eur \nHeart J 2015;36:1115–22a. https://doi.org/10.1093/eurheartj/ehu449 \n283. Willner N, Prosperi-Porta G, Lau L, Nam Fu AY, Boczar K, Poulin A, et al. Aortic sten-\nosis progression: a systematic review and meta-analysis. JACC Cardiovasc Imaging 2023; \n16:314–28. https://doi.org/10.1016/j.jcmg.2022.10.009 \n284. Dweck MR, Loganath K, Bing R, Treibel TA, McCann GP, Newby DE, et al. \nMulti-modality imaging in aortic stenosis: an EACVI clinical consensus document. Eur \nHeart J Cardiovasc Imaging 2023;24:1430–43. https://doi.org/10.1093/ehjci/jead153 \n285. Jaiswal V, Agrawal V, Khulbe Y, Hanif M, Huang H, Hameed M, et al. Cardiac amyloid-\nosis and aortic stenosis: a state-of-the-art review. Eur Heart J Open 2023;3:oead106.  \nhttps://doi.org/10.1093/ehjopen/oead106 \n286. Desai MY, Alashi A, Popovic ZB, Wierup P, Griffin BP, Thamilarasan M, et al. \nOutcomes in patients with obstructive hypertrophic cardiomyopathy and concomi-\ntant aortic stenosis undergoing surgical myectomy and aortic valve replacement. J \nAm Heart Assoc 2021;10:e018435. https://doi.org/10.1161/JAHA.120.018435 \n287. Baumgartner H, Hung J, Bermejo J, Chambers JB, Edvardsen T, Goldstein S, et al. \nRecommendations on the echocardiographic assessment of aortic valve stenosis: a fo-\ncused update from the European Association of Cardiovascular Imaging and the \nAmerican Society of Echocardiography. J Am Soc Echocardiogr 2017;30:372–92.  \nhttps://doi.org/10.1016/j.echo.2017.02.009 \n288. Rusinaru D, Bohbot Y, Djelaili F, Delpierre Q, Altes A, Serbout S, et al. Normative ref-\nerence values of cardiac output by pulsed-wave Doppler echocardiography in adults. \nAm J Cardiol 2021;140:128–33. https://doi.org/10.1016/j.amjcard.2020.10.046 \n289. Annabi MS, Touboul E, Dahou A, Burwash IG, Bergler-Klein J, Enriquez-Sarano M, et al. \nDobutamine stress echocardiography for management of low-flow, low-gradient aor-\ntic stenosis. J Am Coll Cardiol 2018;71:475–85. https://doi.org/10.1016/j.jacc.2017.11. \n052 \n290. Clavel MA, Burwash IG, Mundigler G, Dumesnil JG, Baumgartner H, Bergler-Klein J, \net al. Validation of conventional and simplified methods to calculate projected valve \narea at normal flow rate in patients with low flow, low gradient aortic stenosis: the \nmulticenter TOPAS (True or Pseudo Severe Aortic Stenosis) study. J Am Soc \nEchocardiogr 2010;23:380–6. https://doi.org/10.1016/j.echo.2010.02.002 \n291. Ash J, Sandhu GS, Arriola-Montenegro J, Agakishiev D, Clavel MA, Pibarot P, et al. \nPerformance of computed tomographic angiography-based aortic valve area for as-\nsessment of aortic stenosis. J Am Heart Assoc 2023;12:e029973. https://doi.org/10. \n1161/jaha.123.029973 \n292. Guzzetti E, Poulin A, Annabi MS, Zhang B, Kalavrouziotis D, Couture C, et al. \nTransvalvular flow, sex, and survival after valve replacement surgery in patients with \nsevere aortic stenosis. J Am Coll Cardiol 2020;75:1897–909. https://doi.org/10.1016/j. \njacc.2020.02.065 \n293. Mehrotra P, Jansen K, Flynn AW, Tan TC, Elmariah S, Picard MH, et al. Differential left \nventricular remodelling and longitudinal function distinguishes low flow from normal- \nflow preserved ejection fraction low-gradient severe aortic stenosis. Eur Heart J 2013; \n34:1906–14. https://doi.org/10.1093/eurheartj/eht094 \n294. Tribouilloy C, Rusinaru D, Marechaux S, Castel AL, Debry N, Maizel J, et al. \nLow-gradient, low-flow severe aortic stenosis with preserved left ventricular ejection \nfraction: characteristics, outcome, and implications for surgery. J Am Coll Cardiol 2015; \n65:55–66. https://doi.org/10.1016/j.jacc.2014.09.080 \n295. Jander N, Minners J, Holme I, Gerdts E, Boman K, Brudi P, et al. Outcome of patients \nwith low-gradient “severe” aortic stenosis and preserved ejection fraction. Circulation \n2011;123:887–95. https://doi.org/10.1161/CIRCULATIONAHA.110.983510 \n296. Bohbot Y, Kubala M, Rusinaru D, Maréchaux S, Vanoverschelde JL, Tribouilloy C. \nSurvival and management of patients with discordant high-gradient aortic stenosis: a \npropensity-matched study. JACC Cardiovasc Imaging 2021;14:1672–4. https://doi.org/ \n10.1016/j.jcmg.2021.02.010 \n297. Unger P, Powers A, Le Nezet E, Lacasse-Rioux E, Galloo X, Clavel MA. Prevalence and \noutcomes of patients with discordant high-gradient aortic stenosis. J Am Coll Cardiol \n2024;83:1109–19. https://doi.org/10.1016/j.jacc.2024.01.025 \n298. Ito S, Oh JK, Michelena HI, Egbe AC, Connolly HM, Pellikka PA, et al. High-gradient \naortic stenosis with valve area >1.0 cm2: the “forgotten” discordant hemodynamic \nphenotype. JACC Cardiovasc Imaging 2025;18:166–76. https://doi.org/10.1016/j.jcmg. \n2024.07.025 \n299. Ribeiro HB, Lerakis S, Gilard M, Cavalcante JL, Makkar R, Herrmann HC, et al. \nTranscatheter aortic valve replacement in patients with low-flow, low-gradient aortic \nstenosis: the TOPAS-TAVI registry. J Am Coll Cardiol 2018;71:1297–308. https://doi. \norg/10.1016/j.jacc.2018.01.054 \n300. Clavel MA, Pibarot P, Messika-Zeitoun D, Capoulade R, Malouf J, Aggarval S, et al. \nImpact of aortic valve calcification, as measured by MDCT, on survival in patients \nwith aortic stenosis: results of an international registry study. J Am Coll Cardiol 2014; \n64:1202–13. https://doi.org/10.1016/j.jacc.2014.05.066 \n301. Tastet L, Enriquez-Sarano M, Capoulade R, Malouf J, Araoz PA, Shen M, et al. Impact of \naortic valve calcification and sex on hemodynamic progression and clinical outcomes in \nAS. J Am Coll Cardiol 2017;69:2096–8. https://doi.org/10.1016/j.jacc.2017.02.037 \n302. Clavel MA, Messika-Zeitoun D, Pibarot P, Aggarwal SR, Malouf J, Araoz PA, et al. The \ncomplex nature of discordant severe calcified aortic valve disease grading: new insights \nfrom combined Doppler echocardiographic and computed tomographic study. J Am \nColl Cardiol 2013;62:2329–38. https://doi.org/10.1016/j.jacc.2013.08.1621 \n303. Pawade T, Clavel MA, Tribouilloy C, Dreyfus J, Mathieu T, Tastet L, et al. Computed \ntomography aortic valve calcium scoring in patients with aortic stenosis. Circ Cardiovasc \nImaging 2018;11:e007146. https://doi.org/10.1161/CIRCIMAGING.117.007146 \n304. Shen M, Oh JK, Guzzetti E, Singh GK, Pawade T, Tastet L, et al. Computed tomography \naortic valve calcium scoring in patients with bicuspid aortic valve stenosis. Struct Heart \n2022;6:100027. https://doi.org/10.1016/j.shj.2022.100027 \n305. Shen M, Tastet L, Capoulade R, Larose É, Bédard É, Arsenault M, et al. Effect of age and \naortic valve anatomy on calcification and haemodynamic severity of aortic stenosis. \nHeart 2017;103:32–9. https://doi.org/10.1136/heartjnl-2016-309665 \n306. Wanchaitanawong W, Kanjanavanit R, Srisuwan T, Wongcharoen W, Phrommintikul \nA. Diagnostic role of aortic valve calcium scoring in various etiologies of aortic stenosis. \nSci Rep 2023;13:8019. https://doi.org/10.1038/s41598-023-34118-7 \n307. Ye Z, Clavel MA, Foley TA, Pibarot P, Enriquez-Sarano M, Michelena HI. Computed \ntomography calcium scoring in aortic stenosis: bicuspid versus tricuspid morphology. \nHeart 2024;110:594–602. https://doi.org/10.1136/heartjnl-2023-323281 \n308. Maznyczka A, Tomii D, Angellotti D, Baekke PS, Nakase M, Samim D, et al. Fibrotic vs \ncalcific aortic stenosis: characteristics and outcomes in patients undergoing transcath-\neter aortic valve replacement. JACC Cardiovasc Interv 2024;17:2969–71. https://doi.org/ \n10.1016/j.jcin.2024.09.041 \n309. Rusinaru D, Malaquin D, Marechaux S, Debry N, Tribouilloy C. Relation of dimension-\nless index to long-term outcome in aortic stenosis with preserved LVEF. JACC \nCardiovasc Imaging 2015;8:766–75. https://doi.org/10.1016/j.jcmg.2015.01.023 \n310. Thellier N, Altes A, Rietz M, Menet A, Layec J, Outteryck F, et al. Additive prognostic \nvalue of left ventricular dispersion and deformation in patients with severe aortic sten-\nosis. JACC Cardiovasc Imaging 2023;17:235–45. https://doi.org/10.1016/j.jcmg.2023.09. \n010 \n311. Vollema EM, Amanullah MR, Prihadi EA, Ng ACT, van der Bijl P, Sin YK, et al. \nIncremental value of left ventricular global longitudinal strain in a newly proposed sta-\nging classification based on cardiac damage in patients with severe aortic stenosis. Eur \nHeart J Cardiovasc Imaging 2020;21:1248–58. https://doi.org/10.1093/ehjci/jeaa220 \n312. Ternacle J, Bodez D, Guellich A, Audureau E, Rappeneau S, Lim P, et al. Causes and \nconsequences of longitudinal LV dysfunction assessed by 2D strain echocardiography \nin cardiac amyloidosis. JACC Cardiovasc Imaging 2016;9:126–38. https://doi.org/10. \n1016/j.jcmg.2015.05.014 \n313. Harada K, Saitoh T, Tanaka J, Shibayama K, Berdejo J, Shiota T. Valvuloarterial imped-\nance, but not aortic stenosis severity, predicts syncope in patients with aortic stenosis. \nCirc Cardiovasc Imaging 2013;6:1024–31. https://doi.org/10.1161/circimaging.113. \n000584 \n314. Hachicha Z, Dumesnil JG, Pibarot P. Usefulness of the valvuloarterial impedance to \npredict adverse outcome in asymptomatic aortic stenosis. J Am Coll Cardiol 2009;54: \n1003–11. https://doi.org/10.1016/j.jacc.2009.04.079 \n315. Pibarot P, Salaun E, Dahou A, Avenatti E, Guzzetti E, Annabi MS, et al. \nEchocardiographic results of transcatheter versus surgical aortic valve replacement \nin low-risk patients: the PARTNER 3 trial. Circulation 2020;141:1527–37. https://doi. \norg/10.1161/circulationaha.119.044574 \n316. Zamorano JL, Badano LP, Bruce C, Chan KL, Goncalves A, Hahn RT, et al. EAE/ASE \nrecommendations for the use of echocardiography in new transcatheter interventions \nfor valvular heart disease. Eur Heart J 2011;32:2189–214. https://doi.org/10.1093/ \neurheartj/ehr259 \n317. Bergler-Klein J, Klaar U, Heger M, Rosenhek R, Mundigler G, Gabriel H, et al. \nNatriuretic peptides predict symptom-free survival and postoperative outcome in se-\nvere aortic stenosis. Circulation 2004;109:2302–8. https://doi.org/10.1161/01.CIR. \n0000126825.50903.18 \n318. Rafique AM, Biner S, Ray I, Forrester JS, Tolstrup K, Siegel RJ. Meta-analysis of prognos-\ntic value of stress testing in patients with asymptomatic severe aortic stenosis. Am J \nCardiol 2009;104:972–7. https://doi.org/10.1016/j.amjcard.2009.05.044 \n319. Lancellotti P, Lebois F, Simon M, Tombeux C, Chauvel C, Pierard LA. Prognostic im-\nportance of quantitative exercise Doppler echocardiography in asymptomatic valvular \naortic stenosis. Circulation 2005;112:I377–82. https://doi.org/10.1161/circulationaha. \n104.523274 \n320. Le VD, Jensen GV, Kjøller-Hansen L. Prognostic usefulness of cardiopulmonary exer-\ncise testing for managing patients with severe aortic stenosis. Am J Cardiol 2017;120: \n844–9. https://doi.org/10.1016/j.amjcard.2017.05.047 \n321. Hoedemakers S, Verwerft J, Reddy YNV, Delvaux R, Stroobants S, Jogani S, et al. \nCardiac dysfunction rather than aortic valve stenosis severity drives exercise intoler-\nance and adverse hemodynamics. Eur Heart J Cardiovasc Imaging 2023;25:302–12.  \nhttps://doi.org/10.1093/ehjci/jead276  \nESC Guidelines                                                                                                                                                                                          4719 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n322. Bing R, Cavalcante JL, Everett RJ, Clavel MA, Newby DE, Dweck MR. Imaging and im-\npact of myocardial fibrosis in aortic stenosis. JACC Cardiovasc Imaging 2019;12:283–96.  \nhttps://doi.org/10.1016/j.jcmg.2018.11.026 \n323. Everett RJ, Treibel TA, Fukui M, Lee H, Rigolli M, Singh A, et al. Extracellular myocardial \nvolume in patients with aortic stenosis. J Am Coll Cardiol 2020;75:304–16. https://doi. \norg/10.1016/j.jacc.2019.11.032 \n324. Thornton GD, Vassiliou VS, Musa TA, Aziminia N, Craig N, Dattani A, et al. Myocardial \nscar and remodelling predict long-term mortality in severe aortic stenosis beyond 10 \nyears. Eur Heart J 2024;45:2019–22. https://doi.org/10.1093/eurheartj/ehae067 \n325. Nitsche C, Scully PR, Patel KP, Kammerlander AA, Koschutnik M, Dona C, et al. \nPrevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. J \nAm Coll Cardiol 2021;77:128–39. https://doi.org/10.1016/j.jacc.2020.11.006 \n326. Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, et al. Expert \nconsensus recommendations for the suspicion and diagnosis of transthyretin cardiac \namyloidosis. Circ Heart Fail 2019;12:e006075. https://doi.org/10.1161/circheartfailure. \n119.006075 \n327. Cannata F, Chiarito M, Pinto G, Villaschi A, Sanz-Sánchez J, Fazzari F, et al. \nTranscatheter aortic valve replacement in aortic stenosis and cardiac amyloidosis: a \nsystematic review and meta-analysis. ESC Heart Fail 2022;9:3188–97. https://doi.org/ \n10.1002/ehf2.13876 \n328. Blanke P, Weir-McCall JR, Achenbach S, Delgado V, Hausleiter J, Jilaihawi H, et al. \nComputed tomography imaging in the context of Transcatheter Aortic Valve \nImplantation (TAVI)/Transcatheter Aortic Valve Replacement (TAVR). JACC \nCardiovasc Imaging 2019;12:1–24. https://doi.org/10.1016/j.jcmg.2018.12.003 \n329. Khan JM, Kamioka N, Lisko JC, Perdoncin E, Zhang C, Maini A, et al. Coronary obstruc-\ntion from TAVR in native aortic stenosis: development and validation of multivariate \nprediction model. JACC Cardiovasc Interv 2023;16:415–25. https://doi.org/10.1016/j. \njcin.2022.11.018 \n330. Reindl M, Lechner I, Holzknecht M, Tiller C, Fink P, Oberhollenzer F, et al. Cardiac mag-\nnetic resonance imaging versus computed tomography to guide transcatheter aortic \nvalve replacement: a randomized, open-label, noninferiority trial. Circulation 2023; \n148:1220–30. https://doi.org/10.1161/CIRCULATIONAHA.123.066498 \n331. Gleitman S, Elbaz-Greener G, Ghanim D, Kusniec F, Rabin A, Sudarsky D, et al. Similar \nprocedural success of transcutaneous aortic valve replacement with prosthesis valve \nsizing by either three-dimensional transesophageal echocardiography modeling or \ncomputed tomography. J Am Soc Echocardiogr 2020;33:1149–51. https://doi.org/10. \n1016/j.echo.2020.05.026 \n332. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al. Intensive \nlipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359: \n1343–56. https://doi.org/10.1056/NEJMoa0804602 \n333. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, et al. A ran-\ndomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med \n2005;352:2389–97. https://doi.org/10.1056/NEJMoa043876 \n334. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J. Effect of lipid lowering with rosuvastatin on \nprogression of aortic stenosis: results of the aortic stenosis progression observation: \nmeasuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2010;121: \n306–14. https://doi.org/10.1161/CIRCULATIONAHA.109.900027 \n335. Pawade TA, Doris MK, Bing R, White AC, Forsyth L, Evans E, et al. Effect of denosumab \nor alendronic acid on the progression of aortic stenosis: a double-blind randomized \ncontrolled trial. Circulation 2021;143:2418–27. https://doi.org/10.1161/CIRCU \nLATIONAHA.121.053708 \n336. Diederichsen ACP, Lindholt JS, Möller S, Øvrehus KA, Auscher S, Lambrechtsen J, et al. \nVitamin K2 and D in patients with aortic valve calcification: a randomized double- \nblinded \nclinical \ntrial. \nCirculation \n2022;145:1387–97. \nhttps://doi.org/10.1161/ \nCIRCULATIONAHA.121.057008 \n337. McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 \nESC Guidelines for the management of elevated blood pressure and hypertension. Eur \nHeart J 2024;45:3912–4018. https://doi.org/10.1093/eurheartj/ehae178 \n338. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC \nGuidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; \n42:3227–337. https://doi.org/10.1093/eurheartj/ehab484 \n339. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 \nESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: de-\nveloped by the Task Force for the diagnosis and treatment of acute and chronic heart \nfailure of the European Society of Cardiology (ESC) with the special contribution of \nthe Heart Failure Association (HFA) of the ESC. Eur Heart J 2021;42:3599–726.  \nhttps://doi.org/10.1093/eurheartj/ehab368 \n340. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 \nFocused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute \nand chronic heart failure: developed by the Task Force for the diagnosis and treatment \nof acute and chronic heart failure of the European Society of Cardiology (ESC) with \nthe special contribution of the Heart Failure Association (HFA) of the ESC. Eur \nHeart J 2023;44:3627–39. https://doi.org/10.1093/eurheartj/ehad195 \n341. Monin JL, Quéré JP, Monchi M, Petit H, Baleynaud S, Chauvel C, et al. Low-gradient \naortic stenosis: operative risk stratification and predictors for long-term outcome: a \nmulticenter study using dobutamine stress hemodynamics. Circulation 2003;108: \n319–24. https://doi.org/10.1161/01.CIR.0000079171.43055.46 \n342. Tribouilloy C, Levy F, Rusinaru D, Gueret P, Petit-Eisenmann H, Baleynaud S, et al. \nOutcome after aortic valve replacement for low-flow/low-gradient aortic stenosis \nwithout contractile reserve on dobutamine stress echocardiography. J Am Coll \nCardiol 2009;53:1865–73. https://doi.org/10.1016/j.jacc.2009.02.026 \n343. Quere JP, Monin JL, Levy F, Petit H, Baleynaud S, Chauvel C, et al. Influence of pre-\noperative left ventricular contractile reserve on postoperative ejection fraction in low- \ngradient aortic stenosis. Circulation 2006;113:1738–44. https://doi.org/10.1161/ \ncirculationaha.105.568824 \n344. Fougeres E, Tribouilloy C, Monchi M, Petit-Eisenmann H, Baleynaud S, Pasquet A, et al. \nOutcomes of pseudo-severe aortic stenosis under conservative treatment. Eur Heart J \n2012;33:2426–33. https://doi.org/10.1093/eurheartj/ehs176 \n345. Levy F, Laurent M, Monin JL, Maillet JM, Pasquet A, Le Tourneau T, et al. Aortic valve \nreplacement for low-flow/low-gradient aortic stenosis operative risk stratification and \nlong-term outcome: a European multicenter study. J Am Coll Cardiol 2008;51:1466–72.  \nhttps://doi.org/10.1016/j.jacc.2007.10.067 \n346. Maes F, Lerakis S, Barbosa Ribeiro H, Gilard M, Cavalcante JL, Makkar R, et al. \nOutcomes from transcatheter aortic valve replacement in patients with low-flow, low- \ngradient aortic stenosis and left ventricular ejection fraction less than 30%: a substudy \nfrom the TOPAS-TAVI registry. JAMA Cardiol 2019;4:64–70. https://doi.org/10.1001/ \njamacardio.2018.4320 \n347. Sato K, Sankaramangalam K, Kandregula K, Bullen JA, Kapadia SR, Krishnaswamy A, \net al. Contemporary outcomes in low-gradient aortic stenosis patients who under-\nwent dobutamine stress echocardiography. J Am Heart Assoc 2019;8:e011168.  \nhttps://doi.org/10.1161/JAHA.118.011168 \n348. Ueyama H, Kuno T, Harrington M, Takagi H, Krishnamoorthy P, Sharma SK, et al. \nImpact of surgical and transcatheter aortic valve replacement in low-gradient aortic \nstenosis: a meta-analysis. JACC Cardiovasc Interv 2021;14:1481–92. https://doi.org/10. \n1016/j.jcin.2021.04.038 \n349. Clavel MA, Dumesnil JG, Capoulade R, Mathieu P, Senechal M, Pibarot P. Outcome of \npatients with aortic stenosis, small valve area, and low-flow, low-gradient despite pre-\nserved left ventricular ejection fraction. J Am Coll Cardiol 2012;60:1259–67. https://doi. \norg/10.1016/j.jacc.2011.12.054 \n350. Chadha G, Bohbot Y, Rusinaru D, Marechaux S, Tribouilloy C. Outcome of normal- \nflow low-gradient severe aortic stenosis with preserved left ventricular ejection frac-\ntion: a propensity-matched study. J Am Heart Assoc 2019;8:e012301. https://doi.org/10. \n1161/JAHA.119.012301 \n351. Pellikka PA, Sarano ME, Nishimura RA, Malouf JF, Bailey KR, Scott CG, et al. Outcome \nof 622 adults with asymptomatic, hemodynamically significant aortic stenosis during \nprolonged \nfollow-up. \nCirculation \n2005;111:3290–5. \nhttps://doi.org/10.1161/ \ncirculationaha.104.495903 \n352. Heuvelman HJ, van Geldorp MW, Kappetein AP, Geleijnse ML, Galema TW, Bogers AJ, \net al. Clinical course of patients diagnosed with severe aortic stenosis in the Rotterdam \narea: insights from the AVARIJN study. Neth Heart J 2012;20:487–93. https://doi.org/ \n10.1007/s12471-012-0309-3 \n353. Otto CM, Burwash IG, Legget ME, Munt BI, Fujioka M, Healy NL, et al. Prospective \nstudy of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exer-\ncise predictors of outcome. Circulation 1997;95:2262–70. https://doi.org/10.1161/01. \ncir.95.9.2262 \n354. Bohbot Y, de Meester de Ravenstein C, Chadha G, Rusinaru D, Belkhir K, Trouillet C, \net al. Relationship between left ventricular ejection fraction and mortality in asymp-\ntomatic and minimally symptomatic patients with severe aortic stenosis. JACC \nCardiovasc Imaging 2019;12:38–48. https://doi.org/10.1016/j.jcmg.2018.07.029 \n355. Capoulade R, Le Ven F, Clavel MA, Dumesnil JG, Dahou A, Thebault C, et al. \nEchocardiographic predictors of outcomes in adults with aortic stenosis. Heart \n2016;102:934–42. https://doi.org/10.1136/heartjnl-2015-308742 \n356. Dahl JS, Eleid MF, Michelena HI, Scott CG, Suri RM, Schaff HV, et al. Effect of left ven-\ntricular ejection fraction on postoperative outcome in patients with severe aortic sten-\nosis undergoing aortic valve replacement. Circ Cardiovasc Imaging 2015;8:e002917.  \nhttps://doi.org/10.1161/CIRCIMAGING.114.002917 \n357. Taniguchi T, Morimoto T, Shiomi H, Ando K, Kanamori N, Murata K, et al. Prognostic \nimpact of left ventricular ejection fraction in patients with severe aortic stenosis. JACC \nCardiovasc Interv 2018;11:145–57. https://doi.org/10.1016/j.jcin.2017.08.036 \n358. Ito S, Miranda WR, Nkomo VT, Connolly HM, Pislaru SV, Greason KL, et al. Reduced \nleft ventricular ejection fraction in patients with aortic stenosis. J Am Coll Cardiol 2018; \n71:1313–21. https://doi.org/10.1016/j.jacc.2018.01.045 \n359. De Azevedo D, Boute M, Tribouilloy C, Maréchaux S, Pouleur AC, Bohbot Y, et al. \nQuantifying the survival loss linked to late therapeutic indication in high-gradient se-\nvere aortic stenosis. JACC Adv 2024;3:100830. https://doi.org/10.1016/j.jacadv.2024. \n100830 \n360. Généreux P, Schwartz A, Oldemeyer JB, Pibarot P, Cohen DJ, Blanke P, et al. \nTranscatheter aortic-valve replacement for asymptomatic severe aortic stenosis. N \nEngl J Med 2024;392:217–27. https://doi.org/10.1056/NEJMoa2405880 \n361. Loganath K, Craig NJ, Everett RJ, Bing R, Tsampasian V, Molek P, et al. Early interven-\ntion in patients with asymptomatic severe aortic stenosis and myocardial fibrosis: the  \n4720                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nEVOLVED randomized clinical trial. JAMA 2024;333:213–21. https://doi.org/10.1001/ \njama.2024.22730 \n362. Kang DH, Park SJ, Lee SA, Lee S, Kim DH, Kim HK, et al. Early surgery or conservative \ncare for asymptomatic aortic stenosis. N Engl J Med 2020;382:111–9. https://doi.org/ \n10.1056/NEJMoa1912846 \n363. Banovic M, Putnik S, Penicka M, Doros G, Deja MA, Kockova R, et al. Aortic valve re-\nplacement versus conservative treatment in asymptomatic severe aortic stenosis: the \nAVATAR \nTrial. \nCirculation \n2022;145:648–58. \nhttps://doi.org/10.1161/ \nCIRCULATIONAHA.121.057639 \n364. Rosenhek R, Binder T, Porenta G, Lang I, Christ G, Schemper M, et al. Predictors of \noutcome in severe, asymptomatic aortic stenosis. N Engl J Med 2000;343:611–7.  \nhttps://doi.org/10.1056/NEJM200008313430903 \n365. Nakatsuma K, Taniguchi T, Morimoto T, Shiomi H, Ando K, Kanamori N, et al. B-type \nnatriuretic peptide in patients with asymptomatic severe aortic stenosis. Heart 2019; \n105:384–90. https://doi.org/10.1136/heartjnl-2018-313746 \n366. Parikh V, Kim C, Siegel RJ, Arsanjani R, Rader F. Natriuretic peptides for risk stratifica-\ntion of patients with valvular aortic stenosis. Circ Heart Fail 2015;8:373–80. https://doi. \norg/10.1161/CIRCHEARTFAILURE.114.001649 \n367. Banovic M, Putnik S, Da Costa BR, Penicka M, Deja MA, Kotrc M, et al. Aortic valve \nreplacement versus conservative treatment in asymptomatic severe aortic stenosis: \nlong-term follow-up of the AVATAR trial. Eur Heart J 2024;45:4526–35. https://doi. \norg/10.1093/eurheartj/ehae585 \n368. Généreux P, Banovic M, Kang DH, Giustino G, Prendergast BD, Lindman BR, et al. \nAortic valve replacement vs clinical surveillance in asymptomatic severe aortic stenosis: \na systematic review and meta-analysis. J Am Coll Cardiol 2024;85:912–22. https://doi. \norg/10.1016/j.jacc.2024.11.006 \n369. Smith WTI, Ferguson TBJ, Ryan T, Landolfo CK, Peterson ED. Should coronary artery \nbypass graft surgery patients with mild or moderate aortic stenosis undergo concomi-\ntant aortic valve replacement? A decision analysis approach to the surgical dilemma. J \nAm Coll Cardiol 2004;44:1241–7. https://doi.org/10.1016/j.jacc.2004.06.031 \n370. Jean G, Van Mieghem NM, Gegenava T, van Gils L, Bernard J, Geleijnse ML, et al. \nModerate aortic stenosis in patients with heart failure and reduced ejection fraction. \nJ Am Coll Cardiol 2021;77:2796–803. https://doi.org/10.1016/j.jacc.2021.04.014 \n371. Jacquemyn X, Strom JB, Strange G, Playford D, Stewart S, Kutty S, et al. Moderate aor-\ntic valve stenosis is associated with increased mortality rate and lifetime loss: system-\natic review and meta-analysis of reconstructed time-to-event data of 409 680 patients. \nJ Am Heart Assoc 2024;13:e033872. https://doi.org/10.1161/jaha.123.033872 \n372. Amanullah MR, Pio SM, Ng ACT, Sin KYK, Marsan NA, Ding ZP, et al. Prognostic im-\nplications of associated cardiac abnormalities detected on echocardiography in pa-\ntients with moderate aortic stenosis. JACC Cardiovasc Imaging 2021;14:1724–37.  \nhttps://doi.org/10.1016/j.jcmg.2021.04.009 \n373. Van Mieghem NM, Elmariah S, Spitzer E, Pibarot P, Nazif TM, Bax JJ, et al. \nTranscatheter aortic valve replacement in patients with systolic heart failure and mod-\nerate aortic stenosis: TAVR UNLOAD. J Am Coll Cardiol 2024;85:878–90. https://doi. \norg/10.1016/j.jacc.2024.10.070 \n374. Graversen PL, Butt JH, Østergaard L, Jensen AD, Warming PE, Strange JE, et al. \nChanges in aortic valve replacement procedures in Denmark from 2008 to 2020. \nHeart 2023;109:557–63. https://doi.org/10.1136/heartjnl-2022-321594 \n375. Johnston DR, Soltesz EG, Vakil N, Rajeswaran J, Roselli EE, Sabik JF 3rd, et al. Long-term \ndurability of bioprosthetic aortic valves: implications from 12,569 implants. Ann Thorac \nSurg 2015;99:1239–47. https://doi.org/10.1016/j.athoracsur.2014.10.070 \n376. Goldstone AB, Chiu P, Baiocchi M, Lingala B, Patrick WL, Fischbein MP, et al. \nMechanical or biologic prostheses for aortic-valve and mitral-valve replacement. N \nEngl J Med 2017;377:1847–57. https://doi.org/10.1056/NEJMoa1613792 \n377. Mazine A, David TE, Stoklosa K, Chung J, Lafreniere-Roula M, Ouzounian M. Improved \noutcomes following the Ross procedure compared with bioprosthetic aortic valve re-\nplacement. J Am Coll Cardiol 2022;79:993–1005. https://doi.org/10.1016/j.jacc.2021.12. \n026 \n378. Notenboom ML, Melina G, Veen KM, De Robertis F, Coppola G, De Siena P, et al. \nLong-term clinical and echocardiographic outcomes following the Ross procedure: a \npost hoc analysis of a randomized clinical trial. JAMA Cardiology 2023;9:6–14. https:// \ndoi.org/10.1001/jamacardio.2023.4090 \n379. Alkhouli M, Zack CJ, Sarraf M, Bashir R, Nishimura RA, Eleid MF, et al. Morbidity and \nmortality associated with balloon aortic valvuloplasty: a national perspective. Circ \nCardiovasc Interv 2017;10:e004481. https://doi.org/10.1161/CIRCINTERVENTIONS. \n116.004481 \n380. Sharma T, Krishnan AM, Lahoud R, Polomsky M, Dauerman HL. National trends in \nTAVR and SAVR for patients with severe isolated aortic stenosis. J Am Coll Cardiol \n2022;80:2054–6. https://doi.org/10.1016/j.jacc.2022.08.787 \n381. Gaede L, Blumenstein J, Eckel C, Grothusen C, Tiyerili V, Sötemann D, et al. \nTranscatheter-based aortic valve replacement vs. isolated surgical aortic valve replace-\nment in 2020. Clin Res Cardiol 2022;111:924–33. https://doi.org/10.1007/s00392-022- \n02006-1 \n382. Nguyen V, Willner N, Eltchaninoff H, Burwash IG, Michel M, Durand E, et al. Trends in \naortic valve replacement for aortic stenosis: a French nationwide study. Eur Heart J \n2022;43:666–79. https://doi.org/10.1093/eurheartj/ehab773 \n383. Mori M, Gupta A, Wang Y, Vahl T, Nazif T, Kirtane AJ, et al. Trends in transcatheter \nand surgical aortic valve replacement among older adults in the United States. J Am Coll \nCardiol 2021;78:2161–72. https://doi.org/10.1016/j.jacc.2021.09.855 \n384. Pilgrim T, Windecker S. Expansion of transcatheter aortic valve implantation: new in-\ndications and socio-economic considerations. Eur Heart J 2018;39:2643–45. https:// \ndoi.org/10.1093/eurheartj/ehy228 \n385. Durko AP, Osnabrugge RL, Van Mieghem NM, Milojevic M, Mylotte D, Nkomo VT, \net al. Annual number of candidates for transcatheter aortic valve implantation per \ncountry: current estimates and future projections. Eur Heart J 2018;39:2635–42.  \nhttps://doi.org/10.1093/eurheartj/ehy107 \n386. Barbato E, Noc M, Baumbach A, Dudek D, Bunc M, Skalidis E, et al. Mapping interven-\ntional cardiology in Europe: the European Association of Percutaneous Cardiovascular \nInterventions (EAPCI) Atlas project. Eur Heart J 2020;41:2579–88. https://doi.org/10. \n1093/eurheartj/ehaa475 \n387. Benfari G, Essayagh B, Michelena HI, Ye Z, Inojosa JM, Ribichini FL, et al. Severe aortic \nstenosis: secular trends of incidence and outcomes. Eur Heart J 2024;45:1877–86.  \nhttps://doi.org/10.1093/eurheartj/ehad887 \n388. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter \naortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N \nEngl J Med 2010;363:1597–607. https://doi.org/10.1056/NEJMoa1008232 \n389. Gleason TG, Reardon MJ, Popma JJ, Deeb GM, Yakubov SJ, Lee JS, et al. 5-Year out-\ncomes of self-expanding transcatheter versus surgical aortic valve replacement in high- \nrisk patients. J Am Coll Cardiol 2018;72:2687–96. https://doi.org/10.1016/j.jacc.2018.08. \n2146 \n390. Mack MJ, Leon MB, Smith CR, Miller DC, Moses JW, Tuzcu EM, et al. 5-Year outcomes \nof transcatheter aortic valve replacement or surgical aortic valve replacement for high \nsurgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. \nLancet 2015;385:2477–84. https://doi.org/10.1016/S0140-6736(15)60308-7 \n391. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter \nversus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011;364: \n2187–98. https://doi.org/10.1056/NEJMoa1103510 \n392. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, et al. Transcatheter \nor surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016; \n374:1609–20. https://doi.org/10.1056/NEJMoa1514616 \n393. Toff WD, Hildick-Smith D, Kovac J, Mullen MJ, Wendler O, Mansouri A, et al. Effect of \ntranscatheter aortic valve implantation vs surgical aortic valve replacement on all-cause \nmortality in patients with aortic stenosis: a randomized clinical trial. JAMA 2022;327: \n1875–87. https://doi.org/10.1001/jama.2022.5776 \n394. Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O’Hair D, et al. Transcatheter \naortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J \nMed 2019;380:1706–15. https://doi.org/10.1056/NEJMoa1816885 \n395. Blankenberg S, Seiffert M, Vonthein R, Baumgartner H, Bleiziffer S, Borger MA, et al. \nTranscatheter or surgical treatment of aortic-valve stenosis. N Engl J Med 2024;390: \n1572–83. https://doi.org/10.1056/NEJMoa2400685 \n396. Makkar RR, Thourani VH, Mack MJ, Kodali SK, Kapadia S, Webb JG, et al. Five-year out-\ncomes of transcatheter or surgical aortic-valve replacement. N Engl J Med 2020;382: \n799–809. https://doi.org/10.1056/NEJMoa1910555 \n397. Van Mieghem NM, Deeb GM, Søndergaard L, Grube E, Windecker S, Gada H, et al. \nSelf-expanding transcatheter vs surgical aortic valve replacement in intermediate-risk \npatients: 5-year outcomes of the SURTAVI randomized clinical trial. JAMA Cardiol \n2022;7:1000–8. https://doi.org/10.1001/jamacardio.2022.2695 \n398. Thyregod HGH, Jørgensen TH, Ihlemann N, Steinbrüchel DA, Nissen H, Kjeldsen BJ, \net al. Transcatheter or surgical aortic valve implantation: 10-year outcomes of the \nNOTION trial. Eur Heart J 2024;45:1116–24. https://doi.org/10.1093/eurheartj/ \nehae043 \n399. Ahmad Y, Howard JP, Arnold AD, Madhavan MV, Cook CM, Alu M, et al. \nTranscatheter versus surgical aortic valve replacement in lower-risk and higher-risk pa-\ntients: a meta-analysis of randomized trials. Eur Heart J 2023;44:836–52. https://doi. \norg/10.1093/eurheartj/ehac642 \n400. Barili F, Brophy JM, Ronco D, Myers PO, Uva MS, Almeida RMS, et al. Risk of bias in \nrandomized clinical trials comparing transcatheter and surgical aortic valve replace-\nment: a systematic review and meta-analysis. JAMA Netw Open 2023;6:e2249321.  \nhttps://doi.org/10.1001/jamanetworkopen.2022.49321 \n401. Siontis GCM, Overtchouk P, Cahill TJ, Modine T, Prendergast B, Praz F, et al. \nTranscatheter aortic valve implantation vs. surgical aortic valve replacement for treat-\nment of symptomatic severe aortic stenosis: an updated meta-analysis. Eur Heart J \n2019;40:3143–53. https://doi.org/10.1093/eurheartj/ehz275 \n402. Pibarot P, Hahn RT, Weissman NJ, Arsenault M, Beaudoin J, Bernier M, et al. \nAssociation of paravalvular regurgitation with 1-year outcomes after transcatheter \naortic valve replacement with the SAPIEN 3 valve. JAMA Cardiol 2017;2:1208–16.  \nhttps://doi.org/10.1001/jamacardio.2017.3425 \n403. Kodali S, Pibarot P, Douglas PS, Williams M, Xu K, Thourani V, et al. Paravalvular re-\ngurgitation after transcatheter aortic valve replacement with the Edwards sapien valve \nin the PARTNER trial: characterizing patients and impact on outcomes. Eur Heart J \n2015;36:449–56. https://doi.org/10.1093/eurheartj/ehu384  \nESC Guidelines                                                                                                                                                                                          4721 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n404. Lerman TT, Levi A, Kornowski R. Meta-analysis of short- and long-term clinical out-\ncomes of the self-expanding Evolut R/pro valve versus the balloon-expandable \nSapien 3 valve for transcatheter aortic valve implantation. Int J Cardiol 2023;371: \n100–8. https://doi.org/10.1016/j.ijcard.2022.09.035 \n405. Faroux L, Chen S, Muntané-Carol G, Regueiro A, Philippon F, Sondergaard L, et al. \nClinical impact of conduction disturbances in transcatheter aortic valve replacement \nrecipients: a systematic review and meta-analysis. Eur Heart J 2020;41:2771–81.  \nhttps://doi.org/10.1093/eurheartj/ehz924 \n406. Greason KL, Lahr BD, Stulak JM, Cha YM, Rea RF, Schaff HV, et al. Long-term mortality \neffect of early pacemaker implantation after surgical aortic valve replacement. Ann \nThorac Surg 2017;104:1259–64. https://doi.org/10.1016/j.athoracsur.2017.01.083 \n407. Rück A, Saleh N, Glaser N. Outcomes following permanent pacemaker implantation \nafter transcatheter aortic valve replacement: SWEDEHEART observational study. \nJACC Cardiovasc Interv 2021;14:2173–81. https://doi.org/10.1016/j.jcin.2021.07.043 \n408. Baron SJ, Wang K, House JA, Magnuson EA, Reynolds MR, Makkar R, et al. \nCost-effectiveness of transcatheter versus surgical aortic valve replacement in patients \nwith severe aortic stenosis at intermediate risk. Circulation 2019;139:877–88. https:// \ndoi.org/10.1161/CIRCULATIONAHA.118.035236 \n409. Tam DY, Azizi PM, Fremes SE, Chikwe J, Gaudino M, Wijeysundera HC. The cost- \neffectiveness of transcatheter aortic valve replacement in low surgical risk patients \nwith severe aortic stenosis. Eur Heart J Qual Care Clin Outcomes 2021;7:556–63.  \nhttps://doi.org/10.1093/ehjqcco/qcaa058 \n410. Pibarot P, Ternacle J, Jaber WA, Salaun E, Dahou A, Asch FM, et al. Structural deteri-\noration of transcatheter versus surgical aortic valve bioprostheses in the PARTNER-2 \ntrial. J Am Coll Cardiol 2020;76:1830–43. https://doi.org/10.1016/j.jacc.2020.08.049 \n411. Fatima B, Mohananey D, Khan FW, Jobanputra Y, Tummala R, Banerjee K, et al. \nDurability data for bioprosthetic surgical aortic valve: a systematic review. JAMA \nCardiol 2019;4:71–80. https://doi.org/10.1001/jamacardio.2018.4045 \n412. Kedhi E, Hermanides RS, Dambrink JE, Singh SK, Ten Berg JM, van Ginkel D, et al. \nTransCatheter aortic valve implantation and fractional flow reserve-guided percutan-\neous coronary intervention versus conventional surgical aortic valve replacement and \ncoronary bypass grafting for treatment of patients with aortic valve stenosis and com-\nplex or multivessel coronary disease (TCW): an international, multicentre, prospect-\nive, open-label, non-inferiority, randomised controlled trial. Lancet 2025;404: \n2593–602. https://doi.org/10.1016/s0140-6736(24)02100-7 \n413. Martinsson A, Nielsen SJ, Milojevic M, Redfors B, Omerovic E, Tonnessen T, et al. Life \nexpectancy after surgical aortic valve replacement. J Am Coll Cardiol 2021;78:2147–57.  \nhttps://doi.org/10.1016/j.jacc.2021.09.861 \n414. Glaser N, Persson M, Jackson V, Holzmann MJ, Franco-Cereceda A, Sartipy U. Loss in \nlife expectancy after surgical aortic valve replacement: SWEDEHEART study. J Am Coll \nCardiol 2019;74:26–33. https://doi.org/10.1016/j.jacc.2019.04.053 \n415. Attinger-Toller A, Ferrari E, Tueller D, Templin C, Muller O, Nietlispach F, et al. \nAge-related outcomes after transcatheter aortic valve replacement: insights from \nthe SwissTAVI registry. JACC Cardiovasc Interv 2021;14:952–60. https://doi.org/10. \n1016/j.jcin.2021.01.042 \n416. Jørgensen TH, Thyregod HGH, Savontaus M, Willemen Y, Bleie Ø, Tang M, et al. \nTranscatheter aortic valve implantation in low-risk tricuspid or bicuspid aortic sten-\nosis: the NOTION-2 trial. Eur Heart J 2024;45:3804–14. https://doi.org/10.1093/ \neurheartj/ehae331 \n417. Dahle TG, Kaneko T, McCabe JM. Outcomes following subclavian and axillary artery \naccess for transcatheter aortic valve replacement: Society of the Thoracic Surgeons/ \nAmerican College of Cardiology TVT registry report. JACC Cardiovasc Interv 2019; \n12:662–9. https://doi.org/10.1016/j.jcin.2019.01.219 \n418. Gleason TG, Schindler JT, Hagberg RC, Deeb GM, Adams DH, Conte JV, et al. \nSubclavian/axillary access for self-expanding transcatheter aortic valve replacement \nrenders equivalent outcomes as transfemoral. Ann Thorac Surg 2018;105:477–83.  \nhttps://doi.org/10.1016/j.athoracsur.2017.07.017 \n419. Kirker E, Korngold E, Hodson RW, Jones BM, McKay R, Cheema M, et al. Transcarotid \nversus subclavian/axillary access for transcatheter aortic valve replacement with \nSAPIEN 3. Ann Thorac Surg 2020;110:1892–7. https://doi.org/10.1016/j.athoracsur. \n2020.05.141 \n420. Debry N, Trimech TR, Gandet T, Vincent F, Hysi I, Delhaye C, et al. Transaxillary com-\npared with transcarotid access for TAVR: a propensity-matched comparison from a \nFrench multicentre registry. EuroIntervention 2020;16:842–9. https://doi.org/10.4244/ \neij-d-20-00117 \n421. Beurtheret S, Karam N, Resseguier N, Houel R, Modine T, Folliguet T, et al. Femoral \nversus nonfemoral peripheral access for transcatheter aortic valve replacement. J Am \nColl Cardiol 2019;74:2728–39. https://doi.org/10.1016/j.jacc.2019.09.054 \n422. Greenbaum AB, Babaliaros VC, Chen MY, Stine AM, Rogers T, O’Neill WW, et al. \nTranscaval access and closure for transcatheter aortic valve replacement: a prospect-\nive investigation. J Am Coll Cardiol 2017;69:511–21. https://doi.org/10.1016/j.jacc.2016. \n10.024 \n423. Lederman RJ, Babaliaros VC, Lisko JC, Rogers T, Mahoney P, Foerst JR, et al. Transcaval \nversus transaxillary TAVR in contemporary practice: a propensity-weighted analysis. \nJACC Cardiovasc Interv 2022;15:965–75. https://doi.org/10.1016/j.jcin.2022.03.014 \n424. Okuno T, Asami M, Heg D, Lanz J, Praz F, Hagemeyer D, et al. Impact of left ventricular \noutflow tract calcification on procedural outcomes after transcatheter aortic valve re-\nplacement. JACC Cardiovasc Interv 2020;13:1789–99. https://doi.org/10.1016/j.jcin. \n2020.04.015 \n425. Barbanti M, Yang TH, Rodès Cabau J, Tamburino C, Wood DA, Jilaihawi H, et al. \nAnatomical and procedural features associated with aortic root rupture during \nballoon-expandable transcatheter aortic valve replacement. Circulation 2013;128: \n244–53. https://doi.org/10.1161/circulationaha.113.002947 \n426. Kirmani BH, Jones SG, Muir A, Malaisrie SC, Chung DA, Williams RJ, et al. Limited ver-\nsus full sternotomy for aortic valve replacement. Cochrane Database Syst Rev 2023;12: \nCD011793. https://doi.org/10.1002/14651858.CD011793.pub3 \n427. Paparella D, Malvindi PG, Santarpino G, Moscarelli M, Guida P, Fattouch K, et al. Full \nsternotomy and minimal access approaches for surgical aortic valve replacement: a \nmulticentre propensity-matched study. Eur J Cardiothorac Surg 2020;57:709–16.  \nhttps://doi.org/10.1093/ejcts/ezz286 \n428. Vincent F, Ternacle J, Denimal T, Shen M, Redfors B, Delhaye C, et al. Transcatheter \naortic valve replacement in bicuspid aortic valve stenosis. Circulation 2021;143: \n1043–61. https://doi.org/10.1161/CIRCULATIONAHA.120.048048 \n429. Alperi A, Voisine P, Kalavrouziotis D, Dumont E, Dagenais F, Perron J, et al. Aortic \nvalve replacement in low-risk patients with severe aortic stenosis outside randomized \ntrials. J Am Coll Cardiol 2021;77:111–23. https://doi.org/10.1016/j.jacc.2020.10.056 \n430. Makkar RR, Yoon SH, Leon MB, Chakravarty T, Rinaldi M, Shah PB, et al. Association \nbetween transcatheter aortic valve replacement for bicuspid vs tricuspid aortic sten-\nosis and mortality or stroke. JAMA 2019;321:2193–202. https://doi.org/10.1001/jama. \n2019.7108 \n431. Halim SA, Edwards FH, Dai D, Li Z, Mack MJ, Holmes DR, et al. Outcomes of trans-\ncatheter aortic valve replacement in patients with bicuspid aortic valve disease: a re-\nport from the Society of Thoracic Surgeons/American College of Cardiology \nTranscatheter Valve Therapy Registry. Circulation 2020;141:1071–9. https://doi.org/ \n10.1161/CIRCULATIONAHA.119.040333 \n432. Forrest JK, Kaple RK, Ramlawi B, Gleason TG, Meduri CU, Yakubov SJ, et al. \nTranscatheter aortic valve replacement in bicuspid versus tricuspid aortic valves \nfrom the STS/ACC TVT registry. JACC Cardiovasc Interv 2020;13:1749–59. https:// \ndoi.org/10.1016/j.jcin.2020.03.022 \n433. Montalto C, Sticchi A, Crimi G, Laricchia A, Khokhar AA, Giannini F, et al. Outcomes \nafter transcatheter aortic valve replacement in bicuspid versus tricuspid anatomy: a \nsystematic review and meta-analysis. JACC Cardiovasc Interv 2021;14:2144–55.  \nhttps://doi.org/10.1016/j.jcin.2021.07.052 \n434. Yoon SH, Bleiziffer S, De Backer O, Delgado V, Arai T, Ziegelmueller J, et al. Outcomes \nin transcatheter aortic valve replacement for bicuspid versus tricuspid aortic valve \nstenosis. J Am Coll Cardiol 2017;69:2579–89. https://doi.org/10.1016/j.jacc.2017.03.017 \n435. Jilaihawi H, Chen M, Webb J, Himbert D, Ruiz CE, Rodés-Cabau J, et al. A bicuspid aor-\ntic valve imaging classification for the TAVR era. JACC Cardiovasc Imaging 2016;9: \n1145–58. https://doi.org/10.1016/j.jcmg.2015.12.022 \n436. Sá MPBO, Zhigalov K, Cavalcanti LRP, Escorel Neto AC, Rayol SC, Weymann A, et al. \nImpact of aortic annulus enlargement on the outcomes of aortic valve replacement: a \nmeta-analysis. Semin Thorac Cardiovasc Surg 2021;33:316–25. https://doi.org/10.1053/j. \nsemtcvs.2020.06.046 \n437. Head SJ, Reardon MJ, Deeb GM, Van Mieghem NM, Popma JJ, Gleason TG, et al. \nComputed tomography-based indexed aortic annulus size to predict prosthesis- \npatient mismatch. Circ Cardiovasc Interv 2019;12:e007396. https://doi.org/10.1161/ \ncircinterventions.118.007396 \n438. Herrmann HC, Mehran R, Blackman DJ, Bailey S, Möllmann H, Abdel-Wahab M, et al. \nSelf-expanding or balloon-expandable TAVR in patients with a small aortic annulus. N \nEngl J Med 2024;390:1959–71. https://doi.org/10.1056/NEJMoa2312573 \n439. Yokoyama Y, Kuno T, Zaid S, Kaneko T, Takagi H, Tang GHL, et al. Surgical explant-\nation of transcatheter aortic bioprosthesis: a systematic review and meta-analysis. \nJTCVS Open 2021;8:207–27. https://doi.org/10.1016/j.xjon.2021.09.023 \n440. Marin-Cuartas M, Tang GHL, Kiefer P, Fukuhara S, Lange R, Harrington KB, et al. \nTranscatheter heart valve explant with infective endocarditis-associated prosthesis \nfailure and outcomes: the EXPLANT-TAVR international registry. Eur Heart J 2024; \n45:2519–32. https://doi.org/10.1093/eurheartj/ehae292 \n441. Hirji SA, Percy ED, McGurk S, Malarczyk A, Harloff MT, Yazdchi F, et al. Incidence, \ncharacteristics, predictors, and outcomes of surgical explantation after transcatheter \naortic valve replacement. J Am Coll Cardiol 2020;76:1848–59. https://doi.org/10.1016/ \nj.jacc.2020.08.048 \n442. Jawitz OK, Gulack BC, Grau-Sepulveda MV, Matsouaka RA, Mack MJ, Holmes DR Jr, \net al. Reoperation after transcatheter aortic valve replacement: an analysis of the \nSociety of Thoracic Surgeons database. JACC Cardiovasc Interv 2020;13:1515–25.  \nhttps://doi.org/10.1016/j.jcin.2020.04.029 \n443. Hawkins RB, Deeb GM, Sukul D, Patel HJ, Gualano SK, Chetcuti SJ, et al. Redo surgical \naortic valve replacement after prior transcatheter versus surgical aortic valve replace-\nment. JACC Cardiovasc Interv 2023;16:942–53. https://doi.org/10.1016/j.jcin.2023.03. \n015 \n444. Bapat VN, Zaid S, Fukuhara S, Saha S, Vitanova K, Kiefer P, et al. Surgical explantation \nafter TAVR failure: mid-term outcomes from the EXPLANT-TAVR international  \n4722                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nregistry. JACC Cardiovasc Interv 2021;14:1978–91. https://doi.org/10.1016/j.jcin.2021. \n07.015 \n445. Bowdish ME, Habib RH, Kaneko T, Thourani VH, Badhwar V. Cardiac surgery after \ntranscatheter aortic valve replacement: trends and outcomes. Ann Thorac Surg 2024; \n118:155–62. https://doi.org/10.1016/j.athoracsur.2024.03.024 \n446. Landes U, Webb JG, De Backer O, Sondergaard L, Abdel-Wahab M, Crusius L, et al. \nRepeat transcatheter aortic valve replacement for transcatheter prosthesis dysfunc-\ntion. J Am Coll Cardiol 2020;75:1882–93. https://doi.org/10.1016/j.jacc.2020.02.051 \n447. Tam DY, Dharma C, Rocha RV, Ouzounian M, Wijeysundera HC, Austin PC, et al. \nTranscatheter ViV versus redo surgical AVR for the management of failed biological \nprosthesis: early and late outcomes in a propensity-matched cohort. JACC Cardiovasc \nInterv 2020;13:765–74. https://doi.org/10.1016/j.jcin.2019.10.030 \n448. Sá MBPO, Van den Eynde J, Simonato M, Cavalcanti LRP, Doulamis IP, Weixler V, et al. \nValve-in-valve transcatheter aortic valve replacement versus redo surgical aortic valve \nreplacement: an updated meta-analysis. JACC Cardiovasc Interv 2021;14:211–20. https:// \ndoi.org/10.1016/j.jcin.2020.10.020 \n449. Percy ED, Harloff MT, Hirji S, McGurk S, Yazdchi F, Newell P, et al. Nationally repre-\nsentative repeat transcatheter aortic valve replacement outcomes: report from the \ncenters for Medicare and Medicaid services. JACC Cardiovasc Interv 2021;14: \n1717–26. https://doi.org/10.1016/j.jcin.2021.06.011 \n450. Makkar RR, Kapadia S, Chakravarty T, Cubeddu RJ, Kaneko T, Mahoney P, et al. \nOutcomes of repeat transcatheter aortic valve replacement with balloon-expandable \nvalves: a registry study. Lancet 2023;402:1529–40. https://doi.org/10.1016/s0140- \n6736(23)01636-7 \n451. Deharo P, Bisson A, Herbert J, Lacour T, Etienne CS, Porto A, et al. Transcatheter \nvalve-in-valve aortic valve replacement as an alternative to surgical re-replacement. J \nAm Coll Cardiol 2020;76:489–99. https://doi.org/10.1016/j.jacc.2020.06.010 \n452. Dismorr M, Glaser N, Franco-Cereceda A, Sartipy U. Effect of prosthesis-patient mis-\nmatch on long-term clinical outcomes after bioprosthetic aortic valve replacement. J \nAm Coll Cardiol 2023;81:964–75. https://doi.org/10.1016/j.jacc.2022.12.023 \n453. Head SJ, Mokhles MM, Osnabrugge RL, Pibarot P, Mack MJ, Takkenberg JJ, et al. The \nimpact of prosthesis-patient mismatch on long-term survival after aortic valve replace-\nment: a systematic review and meta-analysis of 34 observational studies comprising 27 \n186 patients with 133 141 patient-years. Eur Heart J 2012;33:1518–29. https://doi.org/ \n10.1093/eurheartj/ehs003 \n454. Herrmann HC, Daneshvar SA, Fonarow GC, Stebbins A, Vemulapalli S, Desai ND, \net al. Prosthesis–patient mismatch in patients undergoing transcatheter aortic valve re-\nplacement: from the STS/ACC TVT registry. J Am Coll Cardiol 2018;72:2701–11.  \nhttps://doi.org/10.1016/j.jacc.2018.09.001 \n455. Ternacle J, Pibarot P, Herrmann HC, Kodali S, Leipsic J, Blanke P, et al. \nProsthesis-patient mismatch after aortic valve replacement in the PARTNER 2 trial \nand registry. JACC Cardiovasc Interv 2021;14:1466–77. https://doi.org/10.1016/j.jcin. \n2021.03.069 \n456. Akodad M, Sellers S, Landes U, Meier D, Tang Gilbert HL, Gada H, et al. \nBalloon-expandable valve for treatment of Evolut valve failure. JACC Cardiovasc Interv \n2022;15:368–77. https://doi.org/10.1016/j.jcin.2021.12.021 \n457. Ribeiro HB, Rodés-Cabau J, Blanke P, Leipsic J, Kwan Park J, Bapat V, et al. Incidence, \npredictors, and clinical outcomes of coronary obstruction following transcatheter aor-\ntic valve replacement for degenerative bioprosthetic surgical valves: insights from the \nVIVID registry. Eur Heart J 2018;39:687–95. https://doi.org/10.1093/eurheartj/ehx455 \n458. Ochiai T, Oakley L, Sekhon N, Komatsu I, Flint N, Kaewkes D, et al. Risk of coronary \nobstruction due to sinus sequestration in redo transcatheter aortic valve replacement. \nJACC Cardiovasc Interv 2020;13:2617–27. https://doi.org/10.1016/j.jcin.2020.09.022 \n459. Akodad M, Sellers S, Gulsin GS, Tzimas G, Landes U, Chatfield Andrew G, et al. Leaflet \nand neoskirt height in transcatheter heart valves. JACC Cardiovasc Interv 2021;14: \n2298–300. https://doi.org/10.1016/j.jcin.2021.07.034 \n460. Tang GH, Spencer J, Rogers T, Grubb KJ, Gleason P, Gada H, et al. Feasibility of cor-\nonary access following redo-TAVR for Evolut failure: a computed tomography simu-\nlation study. Circ Cardiovasc Interv 2023;16:e013238. https://doi.org/10.1161/ \nCIRCINTERVENTIONS.123.013238 \n461. De Backer O, Landes U, Fuchs A, Yoon SH, Mathiassen ON, Sedaghat A, et al. \nCoronary access after TAVR-in-TAVR as evaluated by multidetector computed tom-\nography. JACC Cardiovasc Interv 2020;13:2528–38. https://doi.org/10.1016/j.jcin.2020. \n06.016 \n462. Fukui M, Okada A, Thao KR, Burns MR, Koike H, Wang C, et al. Feasibility of redo- \ntranscatheter aortic valve replacement in Sapien valves based on in vivo computed \ntomography assessment. Circ Cardiovasc Interv 2023;16:e013497. https://doi.org/10. \n1161/CIRCINTERVENTIONS.123.013497 \n463. Chhatriwalla AK, Allen KB, Depta JP, Rodriguez E, Thourani VH, Whisenant BK, et al. \nOutcomes of bioprosthetic valve fracture in patients undergoing valve-in-valve TAVR. \nJACC Cardiovasc Interv 2023;16:530–9. https://doi.org/10.1016/j.jcin.2022.12.019 \n464. Khan JM, Babaliaros VC, Greenbaum AB, Spies C, Daniels D, Depta JP, et al. Preventing \ncoronary obstruction during transcatheter aortic valve replacement: results from the \nmulticenter international BASILICA registry. JACC Cardiovasc Interv 2021;14:941–8.  \nhttps://doi.org/10.1016/j.jcin.2021.02.035 \n465. Jørgensen TH, Thyregod HGH, Ihlemann N, Nissen H, Petursson P, Kjeldsen BJ, et al. \nEight-year outcomes for patients with aortic valve stenosis at low surgical risk rando-\nmized to transcatheter vs. surgical aortic valve replacement. Eur Heart J 2021;42: \n2912–9. https://doi.org/10.1093/eurheartj/ehab375 \n466. O’Hair D, Yakubov SJ, Grubb KJ, Oh JK, Ito S, Deeb GM, et al. Structural valve deteri-\noration after self-expanding transcatheter or surgical aortic valve implantation in pa-\ntients at intermediate or high risk. JAMA Cardiol 2023;8:111–9. https://doi.org/10. \n1001/jamacardio.2022.4627 \n467. Rodriguez-Gabella T, Voisine P, Puri R, Pibarot P, Rodés-Cabau J. Aortic bioprosthetic \nvalve durability: incidence, mechanisms, predictors, and management of surgical and \ntranscatheter valve degeneration. J Am Coll Cardiol 2017;70:1013–28. https://doi.org/ \n10.1016/j.jacc.2017.07.715 \n468. Pibarot P, Magne J, Leipsic J, Cote N, Blanke P, Thourani VH, et al. Imaging for predict-\ning and assessing prosthesis-patient mismatch after aortic valve replacement. JACC \nCardiovasc Imaging 2019;12:149–62. https://doi.org/10.1016/j.jcmg.2018.10.020 \n469. Freitas-Ferraz Afonso B, Tirado-Conte G, Dagenais F, Ruel M, Al-Atassi T, Dumont E, \net al. Aortic stenosis and small aortic annulus. Circulation 2019;139:2685–702. https:// \ndoi.org/10.1161/CIRCULATIONAHA.118.038408 \n470. Tang GHL, Zaid S, Fuchs A, Yamabe T, Yazdchi F, Gupta E, et al. Alignment of trans-\ncatheter aortic-valve neo-commissures (ALIGN TAVR): impact on final valve orienta-\ntion and coronary artery overlap. JACC Cardiovasc Interv 2020;13:1030–42. https://doi. \norg/10.1016/j.jcin.2020.02.005 \n471. Kapadia SR, Leon MB, Makkar RR, Tuzcu EM, Svensson LG, Kodali S, et al. 5-Year out-\ncomes of transcatheter aortic valve replacement compared with standard treatment \nfor patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled \ntrial. Lancet 2015;385:2485–91. https://doi.org/10.1016/S0140-6736(15)60290-2 \n472. Makkar RR, Fontana GP, Jilaihawi H, Kapadia S, Pichard AD, Douglas PS, et al. \nTranscatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl \nJ Med 2012;366:1696–704. https://doi.org/10.1056/NEJMoa1202277 \n473. Turina J, Hess O, Sepulcri F, Krayenbuehl HP. Spontaneous course of aortic valve dis-\nease. Eur Heart J 1987;8:471–83. https://doi.org/10.1093/oxfordjournals.eurheartj. \na062307 \n474. Pellikka PA, Nishimura RA, Bailey KR, Tajik AJ. The natural history of adults with \nasymptomatic, hemodynamically significant aortic stenosis. J Am Coll Cardiol 1990;15: \n1012–7. https://doi.org/10.1016/0735-1097(90)90234-g \n475. Mangner N, Stachel G, Woitek F, Haussig S, Schlotter F, Hollriegel R, et al. Predictors of \nmortality and symptomatic outcome of patients with low-flow severe aortic stenosis \nundergoing transcatheter aortic valve replacement. J Am Heart Assoc 2018;7:e007977.  \nhttps://doi.org/10.1161/JAHA.117.007977 \n476. Eleid MF, Padang R, Al-Hijji M, Pislaru SV, Greason KL, Maltais S, et al. Hemodynamic \nresponse in low-flow low-gradient aortic stenosis with preserved ejection fraction \nafter TAVR. J Am Coll Cardiol 2019;73:1731–2. https://doi.org/10.1016/j.jacc.2019.01. \n034 \n477. Rusinaru D, Bohbot Y, Ringle A, Marechaux S, Diouf M, Tribouilloy C. Impact of low \nstroke volume on mortality in patients with severe aortic stenosis and preserved left \nventricular ejection fraction. Eur Heart J 2018;39:1992–9. https://doi.org/10.1093/ \neurheartj/ehy123 \n478. Zheng Q, Djohan AH, Lim E, Ding ZP, Ling LH, Shi L, et al. Effects of aortic valve re-\nplacement on severe aortic stenosis and preserved systolic function: systematic review \nand network meta-analysis. Sci Rep 2017;7:5092. https://doi.org/10.1038/s41598-017- \n05021-9 \n479. Salaun E, Clavel MA, Hahn RT, Jaber WA, Asch FM, Rodriguez L, et al. Outcome of \nflow-gradient patterns of aortic stenosis after aortic valve replacement: an analysis \nof the PARTNER 2 trial and registry. Circ Cardiovasc Interv 2020;13:e008792. https:// \ndoi.org/10.1161/CIRCINTERVENTIONS.119.008792 \n480. Annabi MS, Côté N, Dahou A, Bartko PE, Bergler-Klein J, Burwash IG, et al. \nComparison of early surgical or transcatheter aortic valve replacement versus conser-\nvative management in low-flow, low-gradient aortic stenosis using inverse probability \nof treatment weighting: results from the TOPAS prospective observational cohort \nstudy. J Am Heart Assoc 2020;9:e017870. https://doi.org/10.1161/jaha.120.017870 \n481. Mosleh W, Amer MR, Ding Y, Megaly M, Mather JF, McMahon S, et al. Benefit of trans-\ncatheter aortic valve replacement in patients with paradoxical low-flow low-gradient \nversus high-gradient aortic stenosis and preserved left ventricular function. Circ \nCardiovasc Interv 2021;14:e010042. https://doi.org/10.1161/circinterventions.120. \n010042 \n482. Bohbot Y, Kowalski C, Rusinaru D, Ringle A, Marechaux S, Tribouilloy C. Impact of \nmean transaortic pressure gradient on long-term outcome in patients with severe aor-\ntic stenosis and preserved left ventricular ejection fraction. J Am Heart Assoc 2017;6: \ne005850. https://doi.org/10.1161/JAHA.117.005850 \n483. Costa GNF, Cardoso JFL, Oliveiros B, Gonçalves L, Teixeira R. Early surgical interven-\ntion versus conservative management of asymptomatic severe aortic stenosis: a sys-\ntematic review and meta-analysis. Heart 2023;109:314–21. https://doi.org/10.1136/ \nheartjnl-2022-321411 \n484. Bohbot Y, Rusinaru D, Delpierre Q, Marechaux S, Tribouilloy C. Risk stratification of \nsevere aortic stenosis with preserved left ventricular ejection fraction using peak aortic  \nESC Guidelines                                                                                                                                                                                          4723 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\njet velocity: an outcome study. Circ Cardiovasc Imaging 2017;10:e006760. https://doi. \norg/10.1161/CIRCIMAGING.117.006760 \n485. Adams DH, Popma JJ, Reardon MJ. Transcatheter aortic-valve replacement with a self- \nexpanding prosthesis. N Engl J Med 2014;371:967–8. https://doi.org/10.1056/ \nNEJMc1408396 \n486. Thyregod HGH, Steinbrüchel DA, Ihlemann N, Nissen H, Kjeldsen BJ, Petursson P, \net al. Transcatheter versus surgical aortic valve replacement in patients with severe \naortic valve stenosis: 1-year results from the all-comers NOTION randomized clinical \ntrial. J Am Coll Cardiol 2015;65:2184–94. https://doi.org/10.1016/j.jacc.2015.03.014 \n487. Thourani VH, Suri RM, Gunter RL, Sheng S, O’Brien SM, Ailawadi G, et al. \nContemporary real-world outcomes of surgical aortic valve replacement in 141,905 \nlow-risk, intermediate-risk, and high-risk patients. Ann Thorac Surg 2015;99:55–61.  \nhttps://doi.org/10.1016/j.athoracsur.2014.06.050 \n488. Thourani VH, Kodali S, Makkar RR, Herrmann HC, Williams M, Babaliaros V, et al. \nTranscatheter aortic valve replacement versus surgical valve replacement in \nintermediate-risk patients: a propensity score analysis. Lancet 2016;387:2218–25.  \nhttps://doi.org/10.1016/s0140-6736(16)30073-3 \n489. Coylewright M, Grubb KJ, Arnold SV, Batchelor W, Dhoble A, Horne A Jr, et al. \nOutcomes of balloon-expandable transcatheter aortic valve replacement in younger \npatients in the low-risk era. JAMA Cardiol 2025;10:127–35. https://doi.org/10.1001/ \njamacardio.2024.4237 \n490. Ullah W, DiMeglio M, Sana MK, Muhammadzai HZU, Kochar K, Zahid S, et al. \nOutcomes after transcatheter aortic valve implantation in patients excluded from clin-\nical trials. JACC Adv 2023;2:100271. https://doi.org/10.1016/j.jacadv.2023.100271 \n491. Reents W, Barth S, Griese DP, Winkler S, Babin-Ebell J, Kerber S, et al. Transfemoral \nversus transapical transcatheter aortic valve implantation: a single-centre experience. \nEur J Cardiothorac Surg 2019;55:744–50. https://doi.org/10.1093/ejcts/ezy363 \n492. Allen KB, Chhatriwalla AK, Cohen D, Saxon J, Hawa Z, Kennedy KF, et al. Transcarotid \nversus transapical and transaortic access for transcatheter aortic valve replacement. \nAnn Thorac Surg 2019;108:715–22. https://doi.org/10.1016/j.athoracsur.2019.02.007 \n493. Overtchouk P, Folliguet T, Pinaud F, Fouquet O, Pernot M, Bonnet G, et al. \nTranscarotid approach for transcatheter aortic valve replacement with the Sapien 3 \nprosthesis. JACC Cardiovasc Interv 2019;12:413–9. https://doi.org/10.1016/j.jcin.2018. \n11.014 \n494. Kumar N, Khera R, Fonarow GC, Bhatt DL. Comparison of outcomes of transfemoral \nversus transapical approach for transcatheter aortic valve implantation. Am J Cardiol \n2018;122:1520–6. https://doi.org/10.1016/j.amjcard.2018.07.025 \n495. van Wely M, van Nieuwkerk AC, Rooijakkers M, van der Wulp K, Gehlmann H, \nVerkroost M, et al. Transaxillary versus transfemoral access as default access in \nTAVI: a propensity matched analysis. Int J Cardiol 2024;394:131353. https://doi.org/ \n10.1016/j.ijcard.2023.131353 \n496. Allen KB, Watson D, Vora AN, Mahoney P, Chhatriwalla AK, Schwartz JG, et al. \nTranscarotid versus transaxillary access for transcatheter aortic valve replacement \nwith a self-expanding valve: a propensity-matched analysis. JTCVS Tech 2023;21: \n45–55. https://doi.org/10.1016/j.xjtc.2023.07.019 \n497. Salihu A, Ferlay C, Kirsch M, Shah PB, Skali H, Fournier S, et al. Outcomes and safety of \ntranscaval transcatheter aortic valve replacement: a systematic review and \nmeta-analysis. Can J Cardiol 2024;40:2054–62. https://doi.org/10.1016/j.cjca.2024.05. \n016 \n498. Abraham B, Sous M, Sedhom R, Megaly M, Roman S, Sweeney J, et al. Meta-analysis on \ntranscarotid versus transfemoral and other alternate accesses for transcatheter aortic \nvalve implantation. Am J Cardiol 2023;192:196–205. https://doi.org/10.1016/j.amjcard. \n2023.01.023 \n499. Williams MR, Jilaihawi H, Makkar R, O’Neill WW, Guyton R, Malaisrie SC, et al. The \nPARTNER 3 bicuspid registry for transcatheter aortic valve replacement in \nlow-surgical-risk patients. JACC Cardiovasc Interv 2022;15:523–32. https://doi.org/10. \n1016/j.jcin.2022.01.279 \n500. Waksman R, Craig PE, Torguson R, Asch FM, Weissman G, Ruiz D, et al. Transcatheter \naortic valve replacement in low-risk patients with symptomatic severe bicuspid aortic \nvalve stenosis. JACC Cardiovasc Interv 2020;13:1019–27. https://doi.org/10.1016/j.jcin. \n2020.02.008 \n501. Elbadawi A, Saad M, Elgendy IY, Barssoum K, Omer MA, Soliman A, et al. Temporal \ntrends and outcomes of transcatheter versus surgical aortic valve replacement for bi-\ncuspid aortic valve stenosis. JACC Cardiovasc Interv 2019;12:1811–22. https://doi.org/ \n10.1016/j.jcin.2019.06.037 \n502. Tchétché D, Ziviello F, De Biase C, De Backer O, Hovasse T, Leroux L, et al. \nTranscatheter aortic valve implantation with the Evolut platform for bicuspid aortic \nvalve stenosis: the international, multicentre, prospective BIVOLUTX registry. \nEuroIntervention 2023;19:502–11. https://doi.org/10.4244/eij-d-23-00021 \n503. Yang L-T, Boler A, Medina-Inojosa Jose R, Scott Christopher G, Maurer Matthew J, \nEleid Mackram F, et al. Aortic stenosis progression, cardiac damage, and survival. \nJACC Cardiovasc Imaging 2021;14:1113–26. https://doi.org/10.1016/j.jcmg.2021.01.017 \n504. Strange G, Stewart S, Celermajer D, Prior D, Scalia GM, Marwick T, et al. Poor long- \nterm survival in patients with moderate aortic stenosis. J Am Coll Cardiol 2019;74: \n1851–63. https://doi.org/10.1016/j.jacc.2019.08.004 \n505. Samad Z, Vora AN, Dunning A, Schulte PJ, Shaw LK, Al-Enezi F, et al. Aortic valve sur-\ngery and survival in patients with moderate or severe aortic stenosis and left ventricu-\nlar dysfunction. Eur Heart J 2016;37:2276–86. https://doi.org/10.1093/eurheartj/ \nehv701 \n506. Oz A, Tsoumas I, Lampropoulos K, Xanthos T, Karpettas N, Papadopoulos D. Cardiac \nrehabilitation after TAVI—a systematic review and meta-analysis. Curr Probl Cardiol \n2023;48:101531. https://doi.org/10.1016/j.cpcardiol.2022.101531 \n507. Monteagudo Ruiz JM, Galderisi M, Buonauro A, Badano L, Aruta P, Swaans MJ, et al. \nOverview of mitral regurgitation in Europe: results from the European Registry of mi-\ntral regurgitation (EuMiClip). Eur Heart J Cardiovasc Imaging 2018;19:503–7. https://doi. \norg/10.1093/ehjci/jey011 \n508. Nalliah CJ, Mahajan R, Elliott AD, Haqqani H, Lau DH, Vohra JK, et al. Mitral valve pro-\nlapse and sudden cardiac death: a systematic review and meta-analysis. Heart 2019; \n105:144–51. https://doi.org/10.1136/heartjnl-2017-312932 \n509. Van der Bijl P, Stassen J, Haugaa KH, Essayagh B, Basso C, Thiene G, et al. Mitral annular \ndisjunction in the context of mitral valve prolapse: identifying the at-risk patient. JACC \nCardiovasc Imaging 2024;17:1229–45. https://doi.org/10.1016/j.jcmg.2024.03.006 \n510. Antoine C, Benfari G, Michelena HI, Maalouf JF, Nkomo VT, Thapa P, et al. Clinical out-\ncome of degenerative mitral regurgitation. Circulation 2018;138:1317–26. https://doi. \norg/10.1161/CIRCULATIONAHA.117.033173 \n511. Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, Detaint D, Capps M, Nkomo V, \net al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. \nN Engl J Med 2005;352:875–83. https://doi.org/10.1056/NEJMoa041451 \n512. O’Gara PT, Grayburn PA, Badhwar V, Afonso LC, Carroll JD, Elmariah S, et al. 2017 \nACC Expert Consensus Decision Pathway on the management of mitral regurgitation: \na report of the American College of Cardiology Task Force on Expert Consensus \nDecision Pathways. J Am Coll Cardiol 2017;70:2421–49. https://doi.org/10.1016/j.jacc. \n2017.09.019 \n513. Dziadzko V, Dziadzko M, Medina-Inojosa JR, Benfari G, Michelena HI, Crestanello JA, \net al. Causes and mechanisms of isolated mitral regurgitation in the community: clinical \ncontext and outcome. Eur Heart J 2019;40:2194–202. https://doi.org/10.1093/ \neurheartj/ehz314 \n514. Samad Z, Shaw LK, Phelan M, Glower DD, Ersboll M, Toptine JH, et al. Long-term out-\ncomes of mitral regurgitation by type and severity. Am Heart J 2018;203:39–48. https:// \ndoi.org/10.1016/j.ahj.2018.05.001 \n515. Bakkestrom R, Banke A, Christensen NL, Pecini R, Irmukhamedov A, Andersen M, \net al. Hemodynamic characteristics in significant symptomatic and asymptomatic pri-\nmary mitral valve regurgitation at rest and during exercise. Circ Cardiovasc Imaging \n2018;11:e007171. https://doi.org/10.1161/CIRCIMAGING.117.007171 \n516. Utsunomiya H, Hidaka T, Susawa H, Izumi K, Harada Y, Kinoshita M, et al. \nExercise-stress echocardiography and effort intolerance in asymptomatic/minimally \nsymptomatic patients with degenerative mitral regurgitation combined invasive- \nnoninvasive hemodynamic monitoring. Circ Cardiovasc Imaging 2018;11:e007282.  \nhttps://doi.org/10.1161/CIRCIMAGING.117.007282 \n517. Butcher SC, Essayagh B, Steyerberg EW, Benfari G, Antoine C, Grigioni F, et al. Factors \ninfluencing post-surgical survival in degenerative mitral regurgitation. Eur Heart J 2023; \n44:871–81. https://doi.org/10.1093/eurheartj/ehad004 \n518. Grigioni F, Clavel MA, Vanoverschelde JL, Tribouilloy C, Pizarro R, Huebner M, et al. \nThe MIDA mortality risk score: development and external validation of a prognostic \nmodel for early and late death in degenerative mitral regurgitation. Eur Heart J 2018; \n39:1281–91. https://doi.org/10.1093/eurheartj/ehx465 \n519. Del Rio-Pertuz G, Nugent K, Argueta-Sosa E. Right heart catheterization in clinical \npractice: a review of basic physiology and important issues relevant to interpretation. \nAm J Cardiovasc Dis 2023;13:122–37. \n520. Mentias A, Patel K, Patel H, Gillinov AM, Rodriguez LL, Svensson LG, et al. Prognostic \nutility of brain natriuretic peptide in asymptomatic patients with significant mitral re-\ngurgitation and preserved left ventricular ejection fraction. Am J Cardiol 2016;117: \n258–63. https://doi.org/10.1016/j.amjcard.2015.10.040 \n521. Cawley PJ, Hamilton-Craig C, Owens DS, Krieger EV, Strugnell WE, Mitsumori L, et al. \nProspective comparison of valve regurgitation quantitation by cardiac magnetic reson-\nance imaging and transthoracic echocardiography. Circ Cardiovasc Imaging 2013;6: \n48–57. https://doi.org/10.1161/CIRCIMAGING.112.975623 \n522. Penicka M, Vecera J, Mirica DC, Kotrc M, Kockova R, Van Camp G. Prognostic implica-\ntions of magnetic resonance-derived quantification in asymptomatic patients with or-\nganic mitral regurgitation: comparison with Doppler echocardiography-derived \nintegrative \napproach. \nCirculation \n2018;137:1349–60. \nhttps://doi.org/10.1161/ \nCIRCULATIONAHA.117.029332 \n523. Naoum C, Blanke P, Cavalcante JL, Leipsic J. Cardiac computed tomography and mag-\nnetic resonance imaging in the evaluation of mitral and tricuspid valve disease. Circ \nCardiovasc Imaging 2017;10:e005331. https://doi.org/10.1161/CIRCIMAGING.116. \n005331 \n524. Kitkungvan D, Nabi F, Kim RJ, Bonow RO, Khan MA, Xu J, et al. Myocardial fibrosis in \npatients with primary mitral regurgitation with and without prolapse. J Am Coll Cardiol \n2018;72:823–34. https://doi.org/10.1016/j.jacc.2018.06.048  \n4724                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n525. Garg P, Swift AJ, Zhong L, Carlhall CJ, Ebbers T, Westenberg J, et al. Assessment of \nmitral valve regurgitation by cardiovascular magnetic resonance imaging. Nat Rev \nCardiol 2020;17:298–312. https://doi.org/10.1038/s41569-019-0305-z \n526. Feuchtner GM, Alkadhi H, Karlo C, Sarwar A, Meier A, Dichtl W, et al. Cardiac CT \nangiography for the diagnosis of mitral valve prolapse: comparison with echocardiog-\nraphy. Radiology 2010;254:374–83. https://doi.org/10.1148/radiol.2541090393 \n527. Gollmann-Tepeköylü C, Nägele F, Höfer D, Holfeld J, Hirsch J, Oezpeker CU, et al. A \nqualitative improvement program for minimally invasive mitral surgery: technical ad-\nvancements ameliorate outcome and operative times. Interdiscip Cardiovasc Thorac \nSurg 2023;36:ivad030. https://doi.org/10.1093/icvts/ivad030 \n528. Tarzia P, Ciampi P, Lanza O, Canali E, Canestrelli S, Calò L. Multi-modality imaging for \npre-procedural planning of transcatheter mitral valve interventions. Eur Heart J Suppl \n2023;25:C205–11. https://doi.org/10.1093/eurheartjsupp/suad021 \n529. Eleid MF, Foley TA, Said SM, Pislaru SV, Rihal CS. Severe mitral annular calcification: \nmultimodality imaging for therapeutic strategies and interventions. JACC Cardiovasc \nImaging 2016;9:1318–37. https://doi.org/10.1016/j.jcmg.2016.09.001 \n530. Roselli C, Yu M, Nauffal V, Georges A, Yang Q, Love K, et al. Genome-wide association \nstudy reveals novel genetic loci: a new polygenic risk score for mitral valve prolapse. Eur \nHeart J 2022;43:1668–80. https://doi.org/10.1093/eurheartj/ehac049 \n531. Badhwar V, Chikwe J, Gillinov AM, Vemulapalli S, O’Gara PT, Mehaffey JH, et al. Risk of \nsurgical mitral valve repair for primary mitral regurgitation. J Am Coll Cardiol 2023;81: \n636–48. https://doi.org/10.1016/j.jacc.2022.11.017 \n532. Lazam S, Vanoverschelde JL, Tribouilloy C, Grigioni F, Suri RM, Avierinos JF, et al. \nTwenty-year outcome after mitral repair versus replacement for severe degenerative \nmitral regurgitation: analysis of a large, prospective, multicenter, international registry. \nCirculation \n2017;135:410–22. \nhttps://doi.org/10.1161/CIRCULATIONAHA.116. \n023340 \n533. David TE, David CM, Tsang W, Lafreniere-Roula M, Manlhiot C. Long-term results of \nmitral valve repair for regurgitation due to leaflet prolapse. J Am Coll Cardiol 2019;74: \n1044–53. https://doi.org/10.1016/j.jacc.2019.06.052 \n534. Deja MA, Malinowski M, Widenka K, Stozynski N, Bartus K, Kapelak B, et al. \nComparison of repair vs replacement in calcific and rheumatic mitral disease. Ann \nThorac Surg 2023;116:954–61. https://doi.org/10.1016/j.athoracsur.2023.04.048 \n535. Brescia AA, Watt TMF, Murray SL, Rosenbloom LM, Kleeman KC, Allgeyer H, et al. \nRheumatic mitral valve repair or replacement in the valve-in-valve era. J Thorac \nCardiovasc Surg 2022;163:591–602.e1. https://doi.org/10.1016/j.jtcvs.2020.04.118 \n536. Chen SW, Chen CY, Chien-Chia Wu V, Chou AH, Cheng YT, Chang SH, et al. Mitral \nvalve repair versus replacement in patients with rheumatic heart disease. J Thorac \nCardiovasc Surg 2022;164:57–67.e11. https://doi.org/10.1016/j.jtcvs.2020.07.117 \n537. Yun KL, Sintek CF, Miller DC, Pfeffer TA, Kochamba GS, Khonsari S, et al. Randomized \ntrial comparing partial versus complete chordal-sparing mitral valve replacement: ef-\nfects on left ventricular volume and function. J Thorac Cardiovasc Surg 2002;123: \n707–14. https://doi.org/10.1067/mtc.2002.121048 \n538. Makkar RR, Chikwe J, Chakravarty T, Chen Q, O’Gara PT, Gillinov M, et al. \nTranscatheter mitral valve repair for degenerative mitral regurgitation. JAMA 2023; \n329:1778–88. https://doi.org/10.1001/jama.2023.7089 \n539. von Bardeleben RS, Mahoney P, Morse MA, Price MJ, Denti P, Maisano F, et al. 1-Year \noutcomes with fourth-generation mitral valve transcatheter edge-to-edge repair from \nthe EXPAND G4 study. JACC Cardiovasc Interv 2023;16:2600–10. https://doi.org/10. \n1016/j.jcin.2023.09.029 \n540. Zahr F, Smith RL, Gillam LD, Chadderdon S, Makkar R, von Bardeleben RS, et al. \nOne-year outcomes from the CLASP IID randomized trial for degenerative mitral re-\ngurgitation. JACC Cardiovasc Interv 2023;15:2803–16. https://doi.org/10.1016/j.jcin. \n2023.10.002 \n541. Kaneko T, Hirji S, Zaid S, Lange R, Kempfert J, Conradi L, et al. Mitral valve surgery after \ntranscatheter edge-to-edge repair: mid-term outcomes from the CUTTING-EDGE \ninternational registry. JACC Cardiovasc Interv 2021;14:2010–21. https://doi.org/10. \n1016/j.jcin.2021.07.029 \n542. Wild MG, Kreidel F, Hell MM, Praz F, Mach M, Adam M, et al. Transapical mitral valve \nimplantation for treatment of symptomatic mitral valve disease: a real-world multicen-\ntre experience. Eur J Heart Fail 2022;24:899–907. https://doi.org/10.1002/ejhf.2434 \n543. Ludwig S, Perrin N, Coisne A, Ben Ali W, Weimann J, Duncan A, et al. Clinical out-\ncomes of transcatheter mitral valve replacement: two-year results of the \nCHOICE-MI Registry. EuroIntervention 2023;19:512–25. https://doi.org/10.4244/EIJ- \nD-22-01037 \n544. Suri RM, Vanoverschelde JL, Grigioni F, Schaff HV, Tribouilloy C, Avierinos J-F, et al. \nAssociation between early surgical intervention vs watchful waiting and outcomes \nfor mitral regurgitation due to flail mitral valve leaflets. JAMA 2013;310:609–16.  \nhttps://doi.org/10.1001/jama.2013.8643 \n545. Tribouilloy C, Grigioni F, Avierinos JF, Barbieri A, Rusinaru D, Szymanski C, et al. \nSurvival implication of left ventricular end-systolic diameter in mitral regurgitation \ndue to flail leaflets a long-term follow-up multicenter study. J Am Coll Cardiol 2009; \n54:1961–68. https://doi.org/10.1016/j.jacc.2009.06.047 \n546. Tribouilloy C, Rusinaru D, Grigioni F, Avierinos JF, Vanoverschelde JL, Benfari G, et al. \nIndexing left ventricular end-systolic dimension to body size: association with mortality \nin patients with degenerative mitral regurgitation. Eur J Heart Fail 2024;26:2563–9.  \nhttps://doi.org/10.1002/ejhf.3393 \n547. Essayagh B, Antoine C, Benfari G, Messika-Zeitoun D, Michelena H, Le Tourneau T, \net al. Prognostic implications of left atrial enlargement in degenerative mitral regurgi-\ntation. J Am Coll Cardiol 2019;74:858–70. https://doi.org/10.1016/j.jacc.2019.06.032 \n548. Abadie BQ, Cremer PC, Vakamudi S, Gillinov AM, Svensson LG, Cho L. Sex-specific \nprognosis of left ventricular size and function following repair of degenerative mitral \nregurgitation. J Am Coll Cardiol 2024;83:303–12. https://doi.org/10.1016/j.jacc.2023. \n10.033 \n549. Dejgaard LA, Skjolsvik ET, Lie OH, Ribe M, Stokke MK, Hegbom F, et al. The mitral \nannulus disjunction arrhythmic syndrome. J Am Coll Cardiol 2018;72:1600–9. https:// \ndoi.org/10.1016/j.jacc.2018.07.070 \n550. Essayagh B, Sabbag A, Antoine C, Benfari G, Batista R, Yang LT, et al. The mitral annular \ndisjunction of mitral valve prolapse: presentation and outcome. JACC Cardiovasc \nImaging 2021;14:2073–87. https://doi.org/10.1016/j.jcmg.2021.04.029 \n551. Essayagh B, Sabbag A, Antoine C, Benfari G, Yang LT, Maalouf J, et al. Presentation and \noutcome of arrhythmic mitral valve prolapse. J Am Coll Cardiol 2020;76:637–49. https:// \ndoi.org/10.1016/j.jacc.2020.06.029 \n552. Weiner MM, Boateng P, Pandis D, Miller MA, Adams DH. Impact of mitral valve repair \non the Pickelhaube sign. Eur Heart J 2019;40:2267. https://doi.org/10.1093/eurheartj/ \nehy458 \n553. Pandis D, David N, Ei-Eshmawi A, Miller MA, Boateng P, Costa AC, et al. Noncomplex \nventricular arrhythmia associated with greater freedom from recurrent ectopy at 1 \nyear after mitral repair surgery. JTCVS Open 2024;19:94–113. https://doi.org/10. \n1016/j.xjon.2024.04.005 \n554. Bonaros N, Hoefer D, Oezpeker C, Gollmann-Tepekoylu C, Holfeld J, Dumfarth J, \net al. Predictors of safety and success in minimally invasive surgery for degenerative mi-\ntral disease. Eur J Cardiothorac Surg 2022;61:637–44. https://doi.org/10.1093/ejcts/ \nezab438 \n555. Berretta P, Kempfert J, Van Praet F, Salvador L, Lamelas J, Nguyen TC, et al. \nRisk-related clinical outcomes after minimally invasive mitral valve surgery: insights \nfrom the Mini-Mitral International Registry. Eur J Cardiothorac Surg 2023;63:ezad090.  \nhttps://doi.org/10.1093/ejcts/ezad090 \n556. Pfannmueller B, Misfeld M, Verevkin A, Garbade J, Holzhey DM, Davierwala P, et al. \nLoop neochord versus leaflet resection techniques for minimally invasive mitral valve \nrepair: long-term results. Eur J Cardiothorac Surg 2021;59:180–6. https://doi.org/10. \n1093/ejcts/ezaa255 \n557. Akowuah EF, Maier RH, Hancock HC, Kharatikoopaei E, Vale L, Fernandez-Garcia C, \net al. Minithoracotomy vs conventional sternotomy for mitral valve repair: a rando-\nmized clinical trial. JAMA 2023;329:1957–66. https://doi.org/10.1001/jama.2023.7800 \n558. Olsthoorn JR, Heuts S, Houterman S, Maessen JG, Sardari Nia P. Effect of minimally \ninvasive mitral valve surgery compared to sternotomy on short- and long-term out-\ncomes: a retrospective multicentre interventional cohort study based on \nNetherlands Heart Registration. Eur J Cardiothorac Surg 2022;61:1099–106. https:// \ndoi.org/10.1093/ejcts/ezab507 \n559. Lang M, Vitanova K, Voss B, Feirer N, Rheude T, Krane M, et al. Beyond the 10-year \nhorizon: mitral valve repair solely with chordal replacement and annuloplasty. Ann \nThorac Surg 2023;115:96–103. https://doi.org/10.1016/j.athoracsur.2022.05.036 \n560. Newell P, Percy E, Hirji S, Harloff M, McGurk S, Malarczyk A, et al. Outcomes of mitral \nvalve repair among high- and low-volume surgeons within a high-volume institution. \nAnn Thorac Surg 2023;115:412–19. https://doi.org/10.1016/j.athoracsur.2022.05.057 \n561. Rosenhek R, Rader F, Klaar U, Gabriel H, Krejc M, Kalbeck D, et al. Outcome of watch-\nful waiting in asymptomatic severe mitral regurgitation. Circulation 2006;113:2238–44.  \nhttps://doi.org/10.1161/CIRCULATIONAHA.105.599175 \n562. Grigioni F, Benfari G, Vanoverschelde JL, Tribouilloy C, Avierinos JF, Bursi F, et al. \nLong-term implications of atrial fibrillation in patients with degenerative mitral regur-\ngitation. J Am Coll Cardiol 2019;73:264–74. https://doi.org/10.1016/j.jacc.2018.10.067 \n563. Ratwatte S, Strange G, Playford D, Stewart S, Celermajer DS. Prevalence of pulmonary \nhypertension in mitral regurgitation and its influence on outcomes. Open Heart 2023; \n10:e002268. https://doi.org/10.1136/openhrt-2023-002268 \n564. Essayagh B, Antoine C, Benfari G, Maalouf J, Michelena HI, Crestanello JA, et al. \nFunctional tricuspid regurgitation of degenerative mitral valve disease: a crucial deter-\nminant of survival. Eur Heart J 2020;41:1918–29. https://doi.org/10.1093/eurheartj/ \nehaa192 \n565. Essayagh B, Benfari G, Antoine C, Grigioni F, Le Tourneau T, Roussel JC, et al. The \nMIDA-Q mortality risk score: a quantitative prognostic tool for the mitral valve pro-\nlapse spectrum. Circulation 2023;147:798–811. https://doi.org/10.1161/CIRCULA \nTIONAHA.122.062612 \n566. Benfari G, Sorajja P, Pedrazzini G, Taramasso M, Gavazzoni M, Biasco L, et al. \nAssociation of transcatheter edge-to-edge repair with improved survival in older pa-\ntients with severe, symptomatic degenerative mitral regurgitation. Eur Heart J 2022; \n43:1626–35. https://doi.org/10.1093/eurheartj/ehab910 \n567. Speziale G, Nasso G, Esposito G, Conte M, Greco E, Fattouch K, et al. Results of mitral \nvalve repair for Barlow disease (bileaflet prolapse) via right minithoracotomy versus \nconventional median sternotomy: a randomized trial. J Thorac Cardiovasc Surg 2011; \n142:77–83. https://doi.org/10.1016/j.jtcvs.2010.08.033  \nESC Guidelines                                                                                                                                                                                          4725 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n568. Zilberszac R, Heinze G, Binder T, Laufer G, Gabriel H, Rosenhek R. Long-term out-\ncome of active surveillance in severe but asymptomatic primary mitral regurgitation. \nJACC Cardiovasc Imaging 2018;11:1213–21. https://doi.org/10.1016/j.jcmg.2018.05.014 \n569. Sengupta A, Yazdchi F, Alexis SL, Percy E, Premkumar A, Hirji S, et al. Reoperative mi-\ntral surgery versus transcatheter mitral valve replacement: a systematic review. J Am \nHeart Assoc 2021;10:e019854. https://doi.org/10.1161/JAHA.120.019854 \n570. Simonato M, Whisenant B, Ribeiro HB, Webb JG, Kornowski R, Guerrero M, et al. \nTranscatheter mitral valve replacement after surgical repair or replacement: compre-\nhensive midterm evaluation of valve-in-valve and valve-in-ring implantation from the \nVIVID \nregistry. \nCirculation \n2021;143:104–16. \nhttps://doi.org/10.1161/ \nCIRCULATIONAHA.120.049088 \n571. Sugiura A, Kavsur R, Spieker M, Iliadis C, Goto T, Öztürk C, et al. Recurrent mitral re-\ngurgitation after MitraClip: predictive factors, morphology, and clinical implication. Circ \nCardiovasc Interv 2022;15:e010895. https://doi.org/10.1161/CIRCINTERVENTIONS. \n121.010895 \n572. Zaid S, Avvedimento M, Vitanova K, Akansel S, Bhadra OD, Ascione G, et al. Impact of \nmitral regurgitation etiology on mitral surgery after transcatheter edge-to-edge repair: \nfrom the CUTTING-EDGE registry. JACC Cardiovasc Interv 2023;16:1176–88. https:// \ndoi.org/10.1016/j.jcin.2023.02.029 \n573. Bartkowiak J, Reineke D, Tomii D, Brugger N, Pilgrim T, Terbeck S, et al. Electrosurgical \nlaceration and stabilization of MitraClip followed by valve implantation for iatrogenic \nmitral stenosis. JACC Cardiovasc Interv 2022;15:110–12. https://doi.org/10.1016/j.jcin. \n2021.10.011 \n574. Lisko JC, Greenbaum AB, Guyton RA, Kamioka N, Grubb KJ, Gleason PT, et al. \nElectrosurgical detachment of MitraClips from the anterior mitral leaflet prior to \ntranscatheter mitral valve implantation. JACC Cardiovasc Interv 2020;13:2361–70.  \nhttps://doi.org/10.1016/j.jcin.2020.06.047 \n575. Huang AL, Dal-Bianco JP, Levine RA, Hung JW. Secondary mitral regurgitation: cardiac \nremodeling, diagnosis, and management. Struct Heart 2022;7:100129. https://doi.org/ \n10.1016/j.shj.2022.100129 \n576. Bartko PE, Heitzinger G, Pavo N, Heitzinger M, Spinka G, Prausmüller S, et al. Burden, \ntreatment use, and outcome of secondary mitral regurgitation across the spectrum of \nheart failure: observational cohort study. BMJ 2021;373:n1421. https://doi.org/10. \n1136/bmj.n1421 \n577. Deferm S, Bertrand PB, Verbrugge FH, Verhaert D, Rega F, Thomas JD, et al. Atrial \nfunctional mitral regurgitation: JACC review topic of the week. J Am Coll Cardiol \n2019;73:2465–76. https://doi.org/10.1016/j.jacc.2019.02.061 \n578. Mori M, Zogg CK, Amabile A, Fereydooni S, Agarwal R, Weininger G, et al. Impact of \nsecondary mitral regurgitation on survival in atrial and ventricular dysfunction. PLoS \nOne 2022;17:e0277385. https://doi.org/10.1371/journal.pone.0277385 \n579. Moonen A, Ng MKC, Playford D, Strange G, Scalia GM, Celermajer DS. Atrial function-\nal mitral regurgitation: prevalence, characteristics and outcomes from the National \nEcho Database of Australia. Open Heart 2023;10:e002180. https://doi.org/10.1136/ \nopenhrt-2022-002180 \n580. Okamoto C, Okada A, Nishimura K, Moriuchi K, Amano M, Takahama H, et al. \nPrognostic comparison of atrial and ventricular functional mitral regurgitation. Open \nHeart 2021;8:e001574. https://doi.org/10.1136/openhrt-2021-001574 \n581. Farhan S, Silbiger JJ, Halperin JL, Zhang L, Dukkipati SR, Vogel B, et al. Pathophysiology, \nechocardiographic diagnosis, and treatment of atrial functional mitral regurgitation: \nJACC state-of-the-art review. J Am Coll Cardiol 2022;80:2314–30. https://doi.org/10. \n1016/j.jacc.2022.09.046 \n582. Naser JA, Michelena HI, Lin G, Scott CG, Lee E, Kennedy AM, et al. Incidence, risk fac-\ntors, and outcomes of atrial functional mitral regurgitation in patients with atrial fibril-\nlation or sinus rhythm. Eur Heart J Cardiovasc Imaging 2023;24:1450–7. https://doi.org/ \n10.1093/ehjci/jead199 \n583. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, et al. Transcatheter \nmitral-valve repair in patients with heart failure. N Engl J Med 2018;379:2307–18.  \nhttps://doi.org/10.1056/NEJMoa1806640 \n584. Stone GW, Abraham WT, Lindenfeld J, Kar S, Grayburn PA, Lim DS, et al. Five-year \nfollow-up after transcatheter repair of secondary mitral regurgitation. N Engl J Med \n2023;388:2037–48. https://doi.org/10.1056/NEJMoa2300213 \n585. Cavalcante JL, Kusunose K, Obuchowski NA, Jellis C, Griffin BP, Flamm SD, et al. \nPrognostic impact of ischemic mitral regurgitation severity and myocardial infarct \nquantification by cardiovascular magnetic resonance. JACC Cardiovasc Imaging 2020; \n13:1489–501. https://doi.org/10.1016/j.jcmg.2019.11.008 \n586. Kim K, Kitai T, Kaji S, Pak M, Toyota T, Sasaki Y, et al. Outcomes and predictors of \ncardiac events in medically treated patients with atrial functional mitral regurgitation. \nInt J Cardiol 2020;316:195–202. https://doi.org/10.1016/j.ijcard.2020.06.042 \n587. Mesi O, Gad MM, Crane AD, Ramchand J, Puri R, Layoun H, et al. Severe atrial func-\ntional mitral regurgitation: clinical and echocardiographic characteristics, management \nand outcomes. JACC Cardiovasc Imaging 2021;14:797–808. https://doi.org/10.1016/j. \njcmg.2021.02.008 \n588. Doldi P, Stolz L, Orban M, Karam N, Praz F, Kalbacher D, et al. Transcatheter mitral \nvalve repair in patients with atrial functional mitral regurgitation. JACC Cardiovasc \nImaging 2022;15:1843–51. https://doi.org/10.1016/j.jcmg.2022.05.009 \n589. Masiero G, Montonati C, Rubbio AP, Adamo M, Grasso C, Denti P, et al. Impact of \ntranscatheter edge-to-edge mitral valve repair on atrial functional mitral regurgitation \nfrom the GIOTTO registry. Am J Cardiol 2024;211:219–27. https://doi.org/10.1016/j. \namjcard.2023.11.007 \n590. Yoon SH, Makar M, Kar S, Chakravarty T, Oakley L, Sekhon N, et al. Outcomes after \ntranscatheter edge-to-edge mitral valve repair according to mitral regurgitation eti-\nology and cardiac remodeling. JACC Cardiovasc Interv 2022;15:1711–22. https://doi. \norg/10.1016/j.jcin.2022.07.004 \n591. Chen QF, Zhou X, Katsouras CS, Ni C, Zhu H, Liu C, et al. Atrial and ventricular func-\ntional mitral regurgitation: prevalence, characteristics, outcomes, and disease progres-\nsion. Eur Heart J Cardiovasc Imaging 2024;26:545–56. https://doi.org/10.1093/ehjci/ \njeae309 \n592. von Stein P, von Stein J, Hohmann C, Wienemann H, Guthoff H, Körber MI, et al. Atrial \nfunctional mitral regurgitation subtypes undergoing transcatheter edge-to-edge repair: \nsuboptimal outcomes in atriogenic hamstringing. JACC Cardiovasc Imaging 2025;18: \n16–29. https://doi.org/10.1016/j.jcmg.2024.06.019 \n593. Rosano GMC, Moura B, Metra M, Böhm M, Bauersachs J, Ben Gal T, et al. Patient pro-\nfiling in heart failure for tailoring medical therapy. A consensus document of the Heart \nFailure Association of the European Society of Cardiology. Eur J Heart Fail 2021;23: \n872–81. https://doi.org/10.1002/ejhf.2206 \n594. Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al. Safety, \ntolerability and efficacy of up-titration of guideline-directed medical therapies for acute \nheart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet \n2022;400:1938–52. https://doi.org/10.1016/s0140-6736(22)02076-1 \n595. Spinka G, Bartko PE, Heitzinger G, Prausmuller S, Winter MP, Arfsten H, et al. \nGuideline directed medical therapy and reduction of secondary mitral regurgitation. \nEur Heart J Cardiovasc Imaging 2022;23:755–64. https://doi.org/10.1093/ehjci/jeac068 \n596. Pagnesi M, Adamo M, Sama IE, Anker SD, Cleland JG, Dickstein K, et al. Clinical im-\npact of changes in mitral regurgitation severity after medical therapy optimization in \nheart failure. Clin Res Cardiol 2022;111:912–23. https://doi.org/10.1007/s00392- \n022-01991-7 \n597. Di Biase L, Auricchio A, Mohanty P, Bai R, Kautzner J, Pieragnoli P, et al. Impact of car-\ndiac resynchronization therapy on the severity of mitral regurgitation. Europace 2011; \n13:829–38. https://doi.org/10.1093/europace/eur047 \n598. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 \nESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J \n2021;42:3427–520. https://doi.org/10.1093/eurheartj/ehab364 \n599. Michalski B, Stankovic I, Pagourelias E, Ciarka A, Aarones M, Winter S, et al. \nRelationship of mechanical dyssynchrony and LV remodeling with improvement of mi-\ntral regurgitation after CRT. JACC Cardiovasc Imaging 2022;15:212–20. https://doi.org/ \n10.1016/j.jcmg.2021.08.010 \n600. Ypenburg C, Lancellotti P, Tops LF, Bleeker GB, Holman ER, Pierard LA, et al. Acute \neffects of initiation and withdrawal of cardiac resynchronization therapy on papillary \nmuscle dyssynchrony and mitral regurgitation. J Am Coll Cardiol 2007;50:2071–7.  \nhttps://doi.org/10.1016/j.jacc.2007.08.019 \n601. Obadia JF, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, et al. \nPercutaneous repair or medical treatment for secondary mitral regurgitation. N Engl \nJ Med 2018;379:2297–306. https://doi.org/10.1056/NEJMoa1805374 \n602. Iung B, Armoiry X, Vahanian A, Boutitie F, Mewton N, Trochu JN, et al. Percutaneous \nrepair or medical treatment for secondary mitral regurgitation: outcomes at 2 years. \nEur J Heart Fail 2019;21:1619–27. https://doi.org/10.1002/EJHF.1616 \n603. Grayburn PA, Sannino A, Packer M. Proportionate and disproportionate functional \nmitral regurgitation: a new conceptual framework that reconciles the results of the \nMITRA-FR and COAPT trials. JACC Cardiovasc Imaging 2019;12:353–62. https://doi. \norg/10.1016/j.jcmg.2018.11.006 \n604. Senni M, Adamo M, Metra M, Alfieri O, Vahanian A. Treatment of functional mitral re-\ngurgitation in chronic heart failure: can we get a ‘proof of concept’ from the MITRA-FR \nand COAPT trials? Eur J Heart Fail 2019;21:852–61. https://doi.org/10.1002/EJHF.1491 \n605. Pibarot P, Delgado V, Bax JJ. MITRA-FR vs. COAPT: lessons from two trials with dia-\nmetrically opposed results. Eur Heart J Cardiovasc Imaging 2019;20:620–24. https://doi. \norg/10.1093/ehjci/jez073 \n606. Anker SD, Friede T, von Bardeleben RS, Butler J, Khan MS, Diek M, et al. Transcatheter \nvalve repair in heart failure with moderate to severe mitral regurgitation. N Engl J Med \n2024;391:1799–809. https://doi.org/10.1056/NEJMoa2314328 \n607. Anker MS, Porthun J, Bonnet G, Schulze PC, Rassaf T, Landmesser U. Percutaneous \ntranscatheter edge-to-edge repair for functional mitral regurgitation in heart failure: \na meta-analysis of 3 randomized controlled trials. J Am Coll Cardiol 2024;84: \n2364–68. https://doi.org/10.1016/j.jacc.2024.08.026 \n608. Koell B, Orban M, Weimann J, Kassar M, Karam N, Neuss M, et al. Outcomes stratified \nby adapted inclusion criteria after mitral edge-to-edge repair. J Am Coll Cardiol 2021;78: \n2408–21. https://doi.org/10.1016/j.jacc.2021.10.011 \n609. Scotti A, Latib A, Rubbio AP, Testa L, Adamo M, Denti P, et al. Derivation and valid-\nation of a clinical risk score for COAPT-ineligible patients who underwent transcath-\neter edge-to-edge repair. Am J Cardiol 2023;186:100–8. https://doi.org/10.1016/j. \namjcard.2022.10.024  \n4726                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n610. Godino C, Munafò A, Scotti A, Estevez-Loureiro R, Portoles Hernandez A, Arzamendi \nD, et al. MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: \n1-year outcomes from the International MitraBridge registry. J Heart Lung Transplant \n2020;39:1353–62. https://doi.org/10.1016/j.healun.2020.09.005 \n611. Ailawadi G, Lim DS, Mack MJ, Trento A, Kar S, Grayburn PA, et al. One-year outcomes \nafter MitraClip for functional mitral regurgitation. Circulation 2019;139:37–47. https:// \ndoi.org/10.1161/CIRCULATIONAHA.117.031733 \n612. Goel K, Lindenfeld J, Makkar R, Naik H, Atmakuri S, Mahoney P, et al. Transcatheter \nedge-to-edge repair in 5,000 patients with secondary mitral regurgitation: COAPT \npost-approval study. J Am Coll Cardiol 2023;82:1281–97. https://doi.org/10.1016/j. \njacc.2023.07.015 \n613. Adamo M, Tomasoni D, Stolz L, Stocker TJ, Pancaldi E, Koell B, et al. Impact of trans-\ncatheter edge-to-edge mitral valve repair on guideline-directed medical therapy upti-\ntration. JACC Cardiovasc Interv 2023;16:896–905. https://doi.org/10.1016/j.jcin.2023.01. \n362 \n614. Witte KK, Lipiecki J, Siminiak T, Meredith IT, Malkin CJ, Goldberg SL, et al. The \nREDUCE FMR trial: a randomized sham-controlled study of percutaneous mitral an-\nnuloplasty in functional mitral regurgitation. JACC Heart Fail 2019;7:945–55. https:// \ndoi.org/10.1016/j.jchf.2019.06.011 \n615. Anker SD, Starling RC, Khan MS, Friede T, Filippatos G, Lindenfeld J, et al. \nPercutaneous mitral valve annuloplasty in patients with secondary mitral regurgitation \nand severe left ventricular enlargement. JACC Heart Fail 2021;9:453–62. https://doi.org/ \n10.1016/j.jchf.2021.03.002 \n616. Wu AH, Aaronson KD, Bolling SF, Pagani FD, Welch K, Koelling TM. Impact of mitral \nvalve annuloplasty on mortality risk in patients with mitral regurgitation and left ven-\ntricular systolic dysfunction. J Am Coll Cardiol 2005;45:381–7. https://doi.org/10.1016/j. \njacc.2004.09.073 \n617. Baldus S, Doenst T, Pfister R, Gummert J, Kessler M, Boekstegers P, et al. \nTranscatheter repair versus mitral-valve surgery for secondary mitral regurgitation. \nN Engl J Med 2024;391:1787–98. https://doi.org/10.1056/NEJMoa2408739 \n618. Acker MA, Parides MK, Perrault LP, Moskowitz AJ, Gelijns AC, Voisine P, et al. \nMitral-valve repair versus replacement for severe ischemic mitral regurgitation. N \nEngl J Med 2014;370:23–32. https://doi.org/10.1056/NEJMoa1312808 \n619. von Stumm M, Dudde F, Holst T, Sequeira-Gross T, Pausch J, Muller L, et al. Predicting \nclinical outcome by indexed mitral valve tenting in functional mitral valve regurgitation. \nOpen Heart 2021;8:e001483. https://doi.org/10.1136/openhrt-2020-001483 \n620. Girdauskas E, Pausch J, Reichenspurner H, Kempfert J, Kuntze T, Owais T, et al. \nSubannular repair for functional mitral regurgitation with reduced systolic ventricle \nfunction: rationale and design of REFORM-MR registry. J Cardiothorac Surg 2022;17: \n343. https://doi.org/10.1186/s13019-022-02045-9 \n621. Pausch J, Sequeira Gross T, Müller L, von Stumm M, Kloth B, Reichenspurner H, et al. \nSubannular repair for functional mitral regurgitation type IIIb in patients with ischaemic \nversus dilated cardiomyopathy. Eur J Cardiothorac Surg 2021;60:122–30. https://doi.org/ \n10.1093/ejcts/ezab048 \n622. Kopjar T, Gasparovic H, Mestres CA, Milicic D, Biocina B. Meta-analysis of concomi-\ntant mitral valve repair and coronary artery bypass surgery versus isolated coronary \nartery bypass surgery in patients with moderate ischaemic mitral regurgitation. Eur J \nCardiothorac Surg 2016;50:212–22. https://doi.org/10.1093/ejcts/ezw022 \n623. Altarabsheh SE, Deo SV, Dunlay SM, Erwin PJ, Obeidat YM, Navale S, et al. \nMeta-analysis of usefulness of concomitant mitral valve repair or replacement for \nmoderate ischemic mitral regurgitation with coronary artery bypass grafting. Am J \nCardiol 2017;119:734–41. https://doi.org/10.1016/j.amjcard.2016.11.024 \n624. Michler RE, Smith PK, Parides MK, Ailawadi G, Thourani V, Moskowitz AJ, et al. \nTwo-year outcomes of surgical treatment of moderate ischemic mitral regurgitation. \nN Engl J Med 2016;374:1932–41. https://doi.org/10.1056/NEJMoa1602003 \n625. Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, \net al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis \nof five randomised controlled trials. Lancet 2022;400:757–67. https://doi.org/10. \n1016/S0140-6736(22)01429-5 \n626. Soulat-Dufour L, Lang S, Addetia K, Ederhy S, Adavane-Scheuble S, Chauvet-Droit M, \net al. Restoring sinus rhythm reverses cardiac remodeling and reduces valvular regur-\ngitation in patients with atrial fibrillation. J Am Coll Cardiol 2022;79:951–61. https://doi. \norg/10.1016/j.jacc.2021.12.029 \n627. Kagiyama N, Kaneko T, Amano M, Sato Y, Ohno Y, Obokata M, et al. Clinical outcomes \nof mitral valve surgery in atrial functional mitral regurgitation in the REVEAL-AFMR \nregistry. \nJAMA \nNetw \nOpen \n2024;7:e2428032. \nhttps://doi.org/10.1001/ \njamanetworkopen.2024.28032 \n628. Wagner CM, Brescia AA, Watt TMF, Bergquist C, Rosenbloom LM, Ceniza NN, et al. \nSurgical strategy and outcomes for atrial functional mitral regurgitation: all functional \nmitral regurgitation is not the same! J Thorac Cardiovasc Surg 2024;167:647–55. https:// \ndoi.org/10.1016/j.jtcvs.2022.02.056 \n629. Balogh Z, Mizukami T, Bartunek J, Collet C, Beles M, Albano M, et al. Mitral valve repair \nof atrial functional mitral regurgitation in heart failure with preserved ejection fraction. \nJ Clin Med 2020;9:3432. https://doi.org/10.3390/jcm9113432 \n630. Ye Q, Li Y, Zhang W, Zhao Y, Zhao C, Li Z, et al. Catheter ablation or surgical therapy \nin severe atrial functional mitral regurgitation caused by long-standing persistent atrial \nfibrillation-propensity score analysis. J Am Heart Assoc 2024;13:e035695. https://doi. \norg/10.1161/jaha.124.035695 \n631. Chen J, Wang Y, Lv M, Yang Z, Zhu S, Wei L, et al. Mitral valve repair and surgical ab-\nlation for atrial functional mitral regurgitation. Ann Transl Med 2020;8:1420. https://doi. \norg/10.21037/atm-20-2958 \n632. Benito-González T, Carrasco-Chinchilla F, Estévez-Loureiro R, Pascual I, Arzamendi D, \nGarrote-Coloma C, et al. Clinical and echocardiographic outcomes of transcatheter \nmitral valve repair in atrial functional mitral regurgitation. Int J Cardiol 2021;345: \n29–35. https://doi.org/10.1016/j.ijcard.2021.09.056 \n633. Popolo Rubbio A, Testa L, Grasso C, Sisinni A, Tusa M, Agricola E, et al. Transcatheter \nedge-to-edge mitral valve repair in atrial functional mitral regurgitation: insights from \nthe multi-center MITRA-TUNE registry. Int J Cardiol 2022;349:39–45. https://doi. \norg/10.1016/j.ijcard.2021.11.027 \n634. Rudolph F, Geyer M, Baldus S, De Luca VM, Doenst T, Pfister R, et al. Transcatheter \nrepair versus surgery for atrial versus ventricular functional mitral regurgitation: a post \nhoc analysis of the MATTERHORN trial. Circulation 2024;151:418–20. https://doi.org/ \n10.1161/circulationaha.124.072648 \n635. Tanaka T, Sugiura A, Vogelhuber J, Öztürk C, Böhm L, Wilde N, et al. Outcomes of \ntranscatheter edge-to-edge repair for atrial functional mitral regurgitation. \nEuroIntervention 2024;20:e250–60. https://doi.org/10.4244/eij-d-23-00819 \n636. Gemelli M, Gallo M, Addonizio M, Van den Eynde J, Pradegan N, Danesi TH, et al. \nSurgical ablation for atrial fibrillation during mitral valve surgery: a systematic review \nand meta-analysis of randomized controlled trials. Am J Cardiol 2023;209:104–13.  \nhttps://doi.org/10.1016/j.amjcard.2023.09.088 \n637. Suwalski P, Kowalewski M, Jasiński M, Staromlynski J, Zembala M, Widenka K, et al. \nSurvival after surgical ablation for atrial fibrillation in mitral valve surgery: analysis \nfrom the Polish National Registry of Cardiac Surgery Procedures (KROK). J \nThorac Cardiovasc Surg 2019;157:1007–18.e1004. https://doi.org/10.1016/j.jtcvs. \n2018.07.099 \n638. Hamada S, Ueyama H, Aikawa T, Kampaktsis PN, Misumida N, Takagi H, et al. \nOutcomes of transcatheter edge-to-edge repair for atrial functional mitral regurgita-\ntion: a meta-analysis of observational studies. Catheter Cardiovasc Interv 2023;102: \n751–60. https://doi.org/10.1002/ccd.30806 \n639. Sodhi N, Asch FM, Ruf T, Petrescu A, von Bardeleben S, Lim DS, et al. Clinical out-\ncomes with transcatheter edge-to-edge repair in atrial functional MR from the \nEXPAND study. JACC Cardiovasc Interv 2022;15:1723–30. https://doi.org/10.1016/j. \njcin.2022.07.023 \n640. Deja MA, Grayburn PA, Sun B, Rao V, She L, Krejca M, et al. Influence of mitral regur-\ngitation repair on survival in the surgical treatment for ischemic heart failure trial. \nCirculation \n2012;125:2639–48. \nhttps://doi.org/10.1161/CIRCULATIONAHA.111. \n072256 \n641. Chan KM, Punjabi PP, Flather M, Wage R, Symmonds K, Roussin I, et al. Coronary ar-\ntery bypass surgery with or without mitral valve annuloplasty in moderate functional \nischemic mitral regurgitation: final results of the Randomized Ischemic Mitral \nEvaluation (RIME) trial. Circulation 2012;126:2502–10. https://doi.org/10.1161/ \ncirculationaha.112.143818 \n642. Virk SA, Tian DH, Sriravindrarajah A, Dunn D, Wolfenden HD, Suri RM, et al. \nMitral valve surgery and coronary artery bypass grafting for moderate-to-severe \nischemic mitral regurgitation: meta-analysis of clinical and echocardiographic out-\ncomes. J Thorac Cardiovasc Surg 2017;154:127–36. https://doi.org/10.1016/j.jtcvs. \n2017.03.039 \n643. Adamo M, Fiorelli F, Melica B, D’Ortona R, Lupi L, Giannini C, et al. COAPT-like profile \npredicts long-term outcomes in patients with secondary mitral regurgitation undergo-\ning MitraClip implantation. JACC Cardiovasc Interv 2021;14:15–25. https://doi.org/10. \n1016/J.JCIN.2020.09.050 \n644. Coffey S, Roberts-Thomson R, Brown A, Carapetis J, Chen M, Enriquez-Sarano M, \net al. Global epidemiology of valvular heart disease. Nat Rev Cardiol 2021;18:853–64.  \nhttps://doi.org/10.1038/s41569-021-00570-z \n645. Kingue S, Ba SA, Balde D, Diarra MB, Anzouan-Kacou JB, Anisubia B, et al. The \nVALVAFRIC study: a registry of rheumatic heart disease in Western and Central \nAfrica. Arch Cardiovasc Dis 2016;109:321–9. https://doi.org/10.1016/j.acvd.2015. \n12.004 \n646. Timmis A, Vardas P, Townsend N, Torbica A, Katus H, De Smedt D, et al. European \nSociety of Cardiology: cardiovascular disease statistics 2021. Eur Heart J 2022;43: \n716–99. https://doi.org/10.1093/eurheartj/ehab892 \n647. Churchill TW, Yucel E, Deferm S, Levine RA, Hung J, Bertrand PB. Mitral valve dysfunc-\ntion in patients with annular calcification: JACC review topic of the week. J Am Coll \nCardiol 2022;80:739–51. https://doi.org/10.1016/j.jacc.2022.05.032 \n648. Andell P, Li X, Martinsson A, Andersson C, Stagmo M, Zoller B, et al. Epidemiology of \nvalvular heart disease in a Swedish nationwide hospital-based register study. Heart \n2017;103:1696–703. https://doi.org/10.1136/heartjnl-2016-310894 \n649. Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, et al. \nEchocardiographic assessment of valve stenosis: EAE/ASE recommendations for clin-\nical practice. J Am Soc Echocardiogr 2009;22:1–23; quiz 101–102. https://doi.org/10. \n1016/j.echo.2008.11.029  \nESC Guidelines                                                                                                                                                                                          4727 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n650. Otto CM, Davis KB, Reid CL, Slater JN, Kronzon I, Kisslo KB, et al. Relation between \npulmonary artery pressure and mitral stenosis severity in patients undergoing balloon \nmitral commissurotomy. Am J Cardiol 1993;71:874–8. https://doi.org/10.1016/0002- \n9149(93)90844-3 \n651. Bouleti C, Iung B, Laouenan C, Himbert D, Brochet E, Messika-Zeitoun D, et al. Late \nresults of percutaneous mitral commissurotomy up to 20 years: development and val-\nidation of a risk score predicting late functional results from a series of 912 patients. \nCirculation \n2012;125:2119–27. \nhttps://doi.org/10.1161/CIRCULATIONAHA.111. \n055905 \n652. Nunes MC, Tan TC, Elmariah S, do Lago R, Margey R, Cruz-Gonzalez I, et al. The echo \nscore revisited: impact of incorporating commissural morphology and leaflet displace-\nment to the prediction of outcome for patients undergoing percutaneous mitral val-\nvuloplasty. Circulation 2014;129:886–95. https://doi.org/10.1161/CIRCULATION \nAHA.113.001252 \n653. Wilkins GT, Weyman AE, Abascal VM, Block PC, Palacios IF. Percutaneous balloon \ndilatation of the mitral valve: an analysis of echocardiographic variables related to out-\ncome and the mechanism of dilatation. Br Heart J 1988;60:299–308. https://doi.org/10. \n1136/hrt.60.4.299 \n654. Lancellotti P, Pellikka PA, Budts W, Chaudhry FA, Donal E, Dulgheru R, et al. The clin-\nical use of stress echocardiography in non-ischaemic heart disease: recommendations \nfrom the European Association of Cardiovascular Imaging and the American Society of \nEchocardiography. Eur Heart J Cardiovasc Imaging 2016;17:1191–229. https://doi.org/ \n10.1093/ehjci/jew190 \n655. Brochet E, Détaint D, Fondard O, Tazi-Mezalek A, Messika-Zeitoun D, Iung B, et al. \nEarly hemodynamic changes versus peak values: what is more useful to predict occur-\nrence of dyspnea during stress echocardiography in patients with asymptomatic mitral \nstenosis? J Am Soc Echocardiogr 2011;24:392–8. https://doi.org/10.1016/j.echo.2011.01. \n006 \n656. Al Rawahi MN, Al-Maqbali JS, Al Noumani J, Al Alawi AM, Essebag V. Novel oral antic-\noagulants in patients with atrial fibrillation and moderate to severe mitral stenosis: a \nsystematic review. Cureus 2023;15:e33222. https://doi.org/10.7759/cureus.33222 \n657. Kim JY, Kim SH, Myong JP, Kim YR, Kim TS, Kim JH, et al. Outcomes of direct oral an-\nticoagulants in patients with mitral stenosis. J Am Coll Cardiol 2019;73:1123–31. https:// \ndoi.org/10.1016/j.jacc.2018.12.047 \n658. Vilvanathan VK, Srinivas Prabhavathi Bhat BC, Nanjappa MC, Pandian B, Bagi V, Kasturi \nS, et al. A randomized placebo-controlled trial with amiodarone for persistent atrial \nfibrillation in rheumatic mitral stenosis after successful balloon mitral valvuloplasty. \nIndian Heart J 2016;68:671–7. https://doi.org/10.1016/j.ihj.2016.02.013 \n659. Sharma G, Anantha Krishnan R, Bohra V, Ramakrishnan S, Naik N, Seth S, et al. \nEvaluation of early direct current cardioversion for maintenance of sinus rhythm in \nrheumatic atrial fibrillation following successful balloon mitral valvotomy. Indian \nHeart J 2016;68:486–92. https://doi.org/10.1016/j.ihj.2015.11.013 \n660. Keenan NG, Cueff C, Cimadevilla C, Brochet E, Lepage L, Detaint D, et al. Usefulness \nof left atrial volume versus diameter to assess thromboembolic risk in mitral stenosis. \nAm J Cardiol 2010;106:1152–6. https://doi.org/10.1016/j.amjcard.2010.06.024 \n661. Badheka AO, Shah N, Ghatak A, Patel NJ, Chothani A, Mehta K, et al. Balloon mitral \nvalvuloplasty in the United States: a 13-year perspective. Am J Med 2014;127: \n1126.e1121–1126.e1112. https://doi.org/10.1016/j.amjmed.2014.05.015 \n662. Tomai F, Gaspardone A, Versaci F, Ghini AS, Altamura L, De Luca L, et al. Twenty year \nfollow-up after successful percutaneous balloon mitral valvuloplasty in a large contem-\nporary series of patients with mitral stenosis. Int J Cardiol 2014;177:881–5. https://doi. \norg/10.1016/j.ijcard.2014.10.040 \n663. Bouleti C, Iung B, Himbert D, Messika-Zeitoun D, Brochet E, Garbarz E, et al. \nRelationship between valve calcification and long-term results of percutaneous mitral \ncommissurotomy for rheumatic mitral stenosis. Circ Cardiovasc Interv 2014;7:381–9.  \nhttps://doi.org/10.1161/CIRCINTERVENTIONS.113.000858 \n664. Bouleti C, Iung B, Himbert D, Brochet E, Messika-Zeitoun D, Detaint D, et al. \nReinterventions after percutaneous mitral commissurotomy during long-term follow- \nup, up to 20 years: the role of repeat percutaneous mitral commissurotomy. Eur Heart \nJ 2013;34:1923–30. https://doi.org/10.1093/eurheartj/eht097 \n665. Desnos C, Iung B, Himbert D, Ducrocq G, Urena M, Cormier B, et al. Temporal trends \non percutaneous mitral commissurotomy: 30 years of experience. J Am Heart Assoc \n2019;8:e012031. https://doi.org/10.1161/JAHA.119.012031 \n666. Ambari AM, Setianto B, Santoso A, Dwiputra B, Radi B, Alkatiri AA, et al. Survival ana-\nlysis of patients with rheumatic MS after PBMV compared with MVS in a \nlow-to-middle-income country. Neth Heart J 2019;27:559–64. https://doi.org/10. \n1007/s12471-019-01315-x \n667. Song H, Kang DH, Kim JH, Park KM, Song JM, Choi KJ, et al. Percutaneous mitral val-\nvuloplasty versus surgical treatment in mitral stenosis with severe tricuspid regurgita-\ntion. Circulation 2007;116:I246–50. https://doi.org/10.1161/CIRCULATIONAHA.107. \n678151 \n668. Soesanto AM, Roeswita D, Atmosudigdo IS, Adiarto S, Sahara E. Clinical and hemo-\ndynamic factors associated with low gradient severe rheumatic mitral stenosis. Int J \nAngiol 2022;32:43–7. https://doi.org/10.1055/s-0042-1751231 \n669. El Sabbagh A, Reddy YNV, Barros-Gomes S, Borlaug BA, Miranda WR, Pislaru SV, et al. \nLow-gradient severe mitral stenosis: hemodynamic profiles, clinical characteristics, and \noutcomes. J Am Heart Assoc 2019;8:e010736. https://doi.org/10.1161/JAHA.118. \n010736 \n670. Okura H, Nakada Y, Nogi M, Ishihara S, Okamura A, Okayama S, et al. Prevalence of \nmitral annular calcification and its association with mitral valvular disease. \nEchocardiography 2021;38:1907–12. https://doi.org/10.1111/echo.15236 \n671. Kato N, Padang R, Scott CG, Guerrero M, Pislaru SV, Pellikka PA. The natural history \nof severe calcific mitral stenosis. J Am Coll Cardiol 2020;75:3048–57. https://doi.org/10. \n1016/j.jacc.2020.04.049 \n672. Chehab O, Roberts-Thomson R, Bivona A, Gill H, Patterson T, Pursnani A, et al. \nManagement of patients with severe mitral annular calcification: JACC state-of-the-art \nreview. J Am Coll Cardiol 2022;80:722–38. https://doi.org/10.1016/j.jacc.2022.06.009 \n673. Okuno T, Brugger N, Asami M, Heg D, Siontis GCM, Winkel MG, et al. Clinical impact \nof mitral calcium volume in patients undergoing transcatheter aortic valve implant-\nation. J Cardiovasc Comput Tomogr 2021;15:356–65. https://doi.org/10.1016/j.jcct. \n2020.10.003 \n674. Bertrand PB, Churchill TW, Yucel E, Namasivayam M, Bernard S, Nagata Y, et al. \nPrognostic importance of the transmitral pressure gradient in mitral annular calcifica-\ntion with associated mitral valve dysfunction. Eur Heart J 2020;41:4321–8. https://doi. \norg/10.1093/eurheartj/ehaa819 \n675. Urena M, Himbert D, Brochet E, Carrasco JL, Iung B, Nataf P, et al. Transseptal trans-\ncatheter mitral valve replacement using balloon-expandable transcatheter heart valves: \na step-by-step approach. JACC Cardiovasc Interv 2017;10:1905–19. https://doi.org/10. \n1016/j.jcin.2017.06.069 \n676. Guerrero ME, Grayburn P, Smith RLI, Sorajja P, Wang DD, Ahmad Y, et al. Diagnosis, \nclassification, and management strategies for mitral annular calcification. JACC \nCardiovasc Interv 2023;16:2195–210. https://doi.org/10.1016/j.jcin.2023.06.044 \n677. Uchimuro T, Fukui T, Shimizu A, Takanashi S. Mitral valve surgery in patients with se-\nvere mitral annular calcification. Ann Thorac Surg 2016;101:889–95. https://doi.org/10. \n1016/j.athoracsur.2015.08.071 \n678. Fukui M, Cavalcante JL, Ahmed A, Bae R, Bapat VN, Gössl M, et al. Clinical outcomes of \nmitral valve disease with mitral annular calcification. Am J Cardiol 2022;174:107–13.  \nhttps://doi.org/10.1016/j.amjcard.2022.03.041 \n679. Kato N, Pellikka PA, Scott CG, Lee AT, Jain V, Eleid MF, et al. Impact of mitral inter-\nvention on outcomes of patients with mitral valve dysfunction and annulus calcification. \nCatheter Cardiovasc Interv 2022;99:1807–16. https://doi.org/10.1002/ccd.30093 \n680. Brener MI, Hamandi M, Hong E, Pizano A, Harloff MT, Garner EF, et al. Early outcomes \nfollowing transatrial transcatheter mitral valve replacement in patients with severe mi-\ntral annular calcification. J Thorac Cardiovasc Surg 2024;167:1263–1275.e3. https://doi. \norg/10.1016/j.jtcvs.2022.07.038 \n681. Guerrero ME, Eleid MF, Wang DD, Pursnani A, Kodali SK, George I, et al. 5-Year pro-\nspective evaluation of mitral valve-in-valve, valve-in-ring, and valve-in-MAC outcomes: \nMITRAL trial final results. JACC Cardiovasc Interv 2023;16:2211–27. https://doi.org/10. \n1016/j.jcin.2023.06.041 \n682. Topilsky Y, Maltais S, Medina Inojosa J, Oguz D, Michelena H, Maalouf J, et al. Burden of \ntricuspid regurgitation in patients diagnosed in the community setting. JACC Cardiovasc \nImaging 2019;12:433–42. https://doi.org/10.1016/j.jcmg.2018.06.014 \n683. Chorin E, Rozenbaum Z, Topilsky Y, Konigstein M, Ziv-Baran T, Richert E, et al. \nTricuspid regurgitation and long-term clinical outcomes. Eur Heart J Cardiovasc \nImaging 2020;21:157–65. https://doi.org/10.1093/ehjci/jez216 \n684. Topilsky Y, Inojosa JM, Benfari G, Vaturi O, Maltais S, Michelena H, et al. Clinical pres-\nentation and outcome of tricuspid regurgitation in patients with systolic dysfunction. \nEur Heart J 2018;39:3584–92. https://doi.org/10.1093/eurheartj/ehy434 \n685. Kadri AN, Menon V, Sammour YM, Gajulapalli RD, Meenakshisundaram C, Nusairat L, \net al. Outcomes of patients with severe tricuspid regurgitation and congestive heart \nfailure. Heart 2019;105:1813–7. https://doi.org/10.1136/heartjnl-2019-315004 \n686. Dreyfus J, Ghalem N, Garbarz E, Cimadevilla C, Nataf P, Vahanian A, et al. Timing of \nreferral of patients with severe isolated tricuspid valve regurgitation to surgeons \n(from a French nationwide database). Am J Cardiol 2018;122:323–6. https://doi.org/ \n10.1016/j.amjcard.2018.04.003 \n687. Hoke U, Auger D, Thijssen J, Wolterbeek R, van der Velde ET, Holman ER, et al. \nSignificant lead-induced tricuspid regurgitation is associated with poor prognosis at \nlong-term follow-up. Heart 2014;100:960–8. https://doi.org/10.1136/heartjnl-2013- \n304673 \n688. Andreas M, Burri H, Praz F, Soliman O, Badano L, Barreiro M, et al. Tricuspid valve dis-\nease and cardiac implantable electronic devices. Eur Heart J 2024;45:346–65. https:// \ndoi.org/10.1093/eurheartj/ehad783 \n689. Praz F, Muraru D, Kreidel F, Lurz P, Hahn RT, Delgado V, et al. Transcatheter treat-\nment for tricuspid valve disease. EuroIntervention 2021;17:791–808. https://doi.org/ \n10.4244/EIJ-D-21-00695 \n690. Song H, Kim MJ, Chung CH, Choo SJ, Song MG, Song JM, et al. Factors associated with \ndevelopment of late significant tricuspid regurgitation after successful left-sided valve \nsurgery. Heart 2009;95:931–6. https://doi.org/10.1136/hrt.2008.152793 \n691. Galloo X, Dietz MF, Fortuni F, Prihadi EA, Cosyns B, Delgado V, et al. Prognostic im-\nplications of atrial vs. ventricular functional tricuspid regurgitation. Eur Heart J \nCardiovasc Imaging 2023;24:733–41. https://doi.org/10.1093/ehjci/jead016  \n4728                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n692. Schlotter F, Dietz MF, Stolz L, Kresoja KP, Besler C, Sannino A, et al. Atrial functional \ntricuspid regurgitation: novel definition and impact on prognosis. Circ Cardiovasc Interv \n2022;15:e011958. https://doi.org/10.1161/CIRCINTERVENTIONS.122.011958 \n693. Adamo M, Chioncel O, Pagnesi M, Bayes-Genis A, Abdelhamid M, Anker SD, et al. \nEpidemiology, pathophysiology, diagnosis and management of chronic right-sided \nheart failure and tricuspid regurgitation. A clinical consensus statement of the Heart \nFailure Association (HFA) and the European Association of Percutaneous \nCardiovascular Interventions (EAPCI) of the ESC. Eur J Heart Fail 2024;26:18–33.  \nhttps://doi.org/10.1002/ejhf.3106 \n694. Fortuni F, Dietz MF, Prihadi EA, van der Bijl P, De Ferrari GM, Knuuti J, et al. Prognostic \nimplications of a novel algorithm to grade secondary tricuspid regurgitation. JACC \nCardiovasc Imaging 2021;14:1085–95. https://doi.org/10.1016/j.jcmg.2020.12.011 \n695. Peri Y, Sadeh B, Sherez C, Hochstadt A, Biner S, Aviram G, et al. Quantitative assess-\nment of effective regurgitant orifice: impact on risk stratification, and cut-off for severe \nand torrential tricuspid regurgitation grade. Eur Heart J Cardiovasc Imaging 2020;21: \n768–76. https://doi.org/10.1093/ehjci/jez267 \n696. Dreyfus J, Galloo X, Taramasso M, Heitzinger G, Benfari G, Kresoja KP, et al. \nTRI-SCORE and benefit of intervention in patients with severe tricuspid regurgitation. \nEur Heart J 2024;45:586–97. https://doi.org/10.1093/eurheartj/ehad585 \n697. Hahn RT, Lawlor MK, Davidson CJ, Badhwar V, Sannino A, Spitzer E, et al. Tricuspid \nValve Academic Research Consortium definitions for tricuspid regurgitation and trial \nendpoints. Eur Heart J 2023;44:4508–32. https://doi.org/10.1093/eurheartj/ehad653 \n698. Petersen SE, Khanji MY, Plein S, Lancellotti P, Bucciarelli-Ducci C. European \nAssociation of Cardiovascular Imaging expert consensus paper: a comprehensive re-\nview of cardiovascular magnetic resonance normal values of cardiac chamber size \nand aortic root in adults and recommendations for grading severity. Eur Heart J \nCardiovasc Imaging 2019;20:1321–31. https://doi.org/10.1093/ehjci/jez232 \n699. Kawel-Boehm N, Hetzel SJ, Ambale-Venkatesh B, Captur G, Francois CJ, \nJerosch-Herold M, et al. Reference ranges (“normal values”) for cardiovascular mag-\nnetic resonance (CMR) in adults and children: 2020 update. J Cardiovasc Magn Reson \n2020;22:87. https://doi.org/10.1186/s12968-020-00683-3 \n700. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. \nRecommendations for cardiac chamber quantification by echocardiography in adults: \nan update from the American Society of Echocardiography and the European \nAssociation of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16: \n233–70. https://doi.org/10.1093/ehjci/jev014 \n701. Addetia K, Miyoshi T, Citro R, Daimon M, Gutierrez Fajardo P, Kasliwal RR, et al. \nTwo-dimensional echocardiographic right ventricular size and systolic function mea-\nsurements stratified by sex, age, and ethnicity: results of the World Alliance of \nSocieties of Echocardiography study. J Am Soc Echocardiogr 2021;34:1148–1157.e1.  \nhttps://doi.org/10.1016/j.echo.2021.06.013 \n702. Addetia K, Miyoshi T, Amuthan V, Citro R, Daimon M, Gutierrez Fajardo P, et al. \nNormal values of three-dimensional right ventricular size and function measurements: \nresults of the World Alliance Societies of Echocardiography study. J Am Soc \nEchocardiogr 2023;36:858–866.e1. https://doi.org/10.1016/j.echo.2023.04.011 \n703. Dietz MF, Prihadi EA, van der Bijl P, Goedemans L, Mertens BJA, Gursoy E, et al. \nPrognostic implications of right ventricular remodeling and function in patients with \nsignificant secondary tricuspid regurgitation. Circulation 2019;140:836–45. https:// \ndoi.org/10.1161/CIRCULATIONAHA.119.039630 \n704. Eriksen-Volnes T, Grue JF, Hellum Olaisen S, Letnes JM, Nes B, Løvstakken L, et al. \nNormalized echocardiographic values from guideline-directed dedicated views for car-\ndiac dimensions and left ventricular function. JACC Cardiovasc Imaging 2023;16: \n1501–15. https://doi.org/10.1016/j.jcmg.2022.12.020 \n705. Lurz P, Orban M, Besler C, Braun D, Schlotter F, Noack T, et al. Clinical characteristics, \ndiagnosis, and risk stratification of pulmonary hypertension in severe tricuspid regur-\ngitation and implications for transcatheter tricuspid valve repair. Eur Heart J 2020;41: \n2785–95. https://doi.org/10.1093/eurheartj/ehaa138 \n706. Stocker TJ, Hertell H, Orban M, Braun D, Rommel KP, Ruf T, et al. Cardiopulmonary \nhemodynamic profile predicts mortality after transcatheter tricuspid valve repair in \nchronic heart failure. JACC Cardiovasc Interv 2021;14:29–38. https://doi.org/10.1016/j. \njcin.2020.09.033 \n707. Brener MI, Lurz P, Hausleiter J, Rodés-Cabau J, Fam N, Kodali SK, et al. Right \nventricular-pulmonary arterial coupling and afterload reserve in patients undergoing \ntranscatheter tricuspid valve repair. J Am Coll Cardiol 2022;79:448–61. https://doi. \norg/10.1016/j.jacc.2021.11.031 \n708. Stolz L, Weckbach LT, Karam N, Kalbacher D, Praz F, Lurz P, et al. Invasive right ven-\ntricular to pulmonary artery coupling in patients undergoing transcatheter \nedge-to-edge tricuspid valve repair. JACC Cardiovasc Imaging 2023;16:564–6. https:// \ndoi.org/10.1016/j.jcmg.2022.10.004 \n709. Dreyfus J, Juarez-Casso F, Sala A, Carnero-Alcazar M, Eixerés-Esteve A, Bohbot Y, et al. \nBenefit of isolated surgical valve repair or replacement for functional tricuspid regur-\ngitation and long-term outcomes stratified by the TRI-SCORE. Eur Heart J 2024;45: \n4512–22. https://doi.org/10.1093/eurheartj/ehae578 \n710. Thourani VH, Bonnell L, Wyler von Ballmoos MC, Mehaffey JH, Bowdish M, Kurlansky \nP, et al. Outcomes of isolated tricuspid valve surgery: a Society of Thoracic Surgeons \nanalysis and risk model. Ann Thorac Surg 2024;118:873–81. https://doi.org/10.1016/j. \nathoracsur.2024.04.014 \n711. Anguita-Gámez M, Giraldo MA, Nombela-Franco L, Eixeres Esteve A, Cuerpo G, \nLopez-Menendez J, et al. Validation of the TRI-SCORE in patients undergoing surgery \nfor isolated tricuspid regurgitation. Heart 2023;109:1401–6. https://doi.org/10.1136/ \nheartjnl-2022-322067 \n712. Nassif ME, Qintar M, Windsor SL, Jermyn R, Shavelle DM, Tang F, et al. Empagliflozin \neffects on pulmonary artery pressure in patients with heart failure: results from the \nEMBRACE-HF \ntrial. \nCirculation \n2021;143:1673–86. \nhttps://doi.org/10.1161/ \ncirculationaha.120.052503 \n713. Sorajja P, Whisenant B, Hamid N, Naik H, Makkar R, Tadros P, et al. Transcatheter re-\npair for patients with tricuspid regurgitation. N Engl J Med 2023;388:1833–42. https:// \ndoi.org/10.1056/NEJMoa2300525 \n714. Dreyfus J, Flagiello M, Bazire B, Eggenspieler F, Viau F, Riant E, et al. Isolated tricuspid \nvalve surgery: impact of aetiology and clinical presentation on outcomes. Eur Heart J \n2020;41:4304–17. https://doi.org/10.1093/eurheartj/ehaa643 \n715. Scotti A, Sturla M, Granada JF, Kodali SK, Coisne A, Mangieri A, et al. Outcomes of iso-\nlated tricuspid valve replacement: a systematic review and meta-analysis of 5,316 pa-\ntients from 35 studies. EuroIntervention 2022;18:840–51. https://doi.org/10.4244/EIJ-D- \n22-00442 \n716. Chen Q, Bowdish ME, Malas J, Roach A, Gill G, Rowe G, et al. Isolated tricuspid opera-\ntions: the Society of Thoracic Surgeons adult cardiac surgery database analysis. Ann \nThorac Surg 2023;115:1162–70. https://doi.org/10.1016/j.athoracsur.2022.12.041 \n717. Hahn RT, Wilkoff BL, Kodali S, Birgersdotter-Green UM, Ailawadi G, Addetia K, et al. \nManaging implanted cardiac electronic devices in patients with severe tricuspid regur-\ngitation: JACC state-of-the-art review. J Am Coll Cardiol 2024;83:2002–14. https://doi. \norg/10.1016/j.jacc.2024.02.045 \n718. Taramasso M, Gavazzoni M, Pozzoli A, Dreyfus GD, Bolling SF, George I, et al. \nTricuspid regurgitation: predicting the need for intervention, procedural success, \nand recurrence of disease. JACC Cardiovasc Imaging 2019;12:605–21. https://doi.org/ \n10.1016/j.jcmg.2018.11.034 \n719. Bannehr M, Edlinger CR, Kahn U, Liebchen J, Okamoto M, Hähnel V, et al. Natural \ncourse of tricuspid regurgitation and prognostic implications. Open Heart 2021;8: \ne001529. https://doi.org/10.1136/openhrt-2020-001529 \n720. Park SJ, Oh JK, Kim SO, Lee SA, Kim HJ, Lee S, et al. Determinants of clinical outcomes \nof surgery for isolated severe tricuspid regurgitation. Heart 2021;107:403–10. https:// \ndoi.org/10.1136/heartjnl-2020-317715 \n721. McCarthy PM, Bhudia SK, Rajeswaran J, Hoercher KJ, Lytle BW, Cosgrove DM, et al. \nTricuspid valve repair: durability and risk factors for failure. J Thorac Cardiovasc Surg \n2004;127:674–85. https://doi.org/10.1016/j.jtcvs.2003.11.019 \n722. Kwak JJ, Kim YJ, Kim MK, Kim HK, Park JS, Kim KH, et al. Development of tricuspid \nregurgitation late after left-sided valve surgery: a single-center experience with long- \nterm echocardiographic examinations. Am Heart J 2008;155:732–7. https://doi.org/ \n10.1016/j.ahj.2007.11.010 \n723. Dreyfus GD, Corbi PJ, Chan KM, Bahrami T. Secondary tricuspid regurgitation or dila-\ntation: which should be the criteria for surgical repair? Ann Thorac Surg 2005;79: \n127–32. https://doi.org/10.1016/j.athoracsur.2004.06.057 \n724. Dreyfus GD, Essayagh B, Benfari G, Dulguerov F, Haley SR, Dommerc C, et al. \nOutcome of consistent guideline-based tricuspid management in patients undergoing \ndegenerative mitral regurgitation correction. JTCVS Open 2021;7:125–38. https://doi. \norg/10.1016/j.xjon.2021.07.010 \n725. Gammie JS, Chu MWA, Falk V, Overbey JR, Moskowitz AJ, Gillinov M, et al. \nConcomitant tricuspid repair in patients with degenerative mitral regurgitation. N \nEngl J Med 2022;386:327–39. https://doi.org/10.1056/NEJMoa2115961 \n726. Pettinari M, De Kerchove L, Lazam S, Pasquet A, Gerber B, Vanoverschelde JL, et al. \nMid-term results of a randomized trial of tricuspid annuloplasty for less-than-severe \nfunctional tricuspid regurgitation at the time of mitral valve surgery. Eur J \nCardiothorac Surg 2019;55:851–8. https://doi.org/10.1093/ejcts/ezy378 \n727. Ailawadi G, Voisine P, Raymond S, Gelijns AC, Moskowitz AJ, Falk V, et al. Pacemaker \nimplantation associated with tricuspid repair in the setting of mitral valve surgery: in-\nsights from a Cardiothoracic Surgical Trials Network randomized trial. J Thorac \nCardiovasc Surg 2022;167:2104–16.e5. https://doi.org/10.1016/j.jtcvs.2022.11.031 \n728. Ragnarsson S, Taha A, Nielsen SJ, Amabile A, Geirsson A, Krane M, et al. Pacemaker \nimplantation following tricuspid valve annuloplasty. JTCVS Open 2023;16:276–89.  \nhttps://doi.org/10.1016/j.xjon.2023.08.017 \n729. Iribarne A, Alabbadi SH, Moskowitz AJ, Ailawadi G, Badhwar V, Gillinov M, et al. \nPermanent pacemaker implantation and long-term outcomes of patients undergoing \nconcomitant mitral and tricuspid valve surgery. J Am Coll Cardiol 2024;83:1656–68.  \nhttps://doi.org/10.1016/j.jacc.2024.02.042 \n730. Kassab J, Harb SC, Desai MY, Gillinov AM, Layoun H, El Dahdah J, et al. Incidence, risk \nfactors, and outcomes associated with permanent pacemaker implantation following \ntricuspid valve surgery. J Am Heart Assoc 2024;13:e032760. https://doi.org/10.1161/ \njaha.123.032760 \n731. Chikwe J, Itagaki S, Anyanwu A, Adams DH. Impact of concomitant tricuspid annulo-\nplasty on tricuspid regurgitation, right ventricular function, and pulmonary artery  \nESC Guidelines                                                                                                                                                                                          4729 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nhypertension after repair of mitral valve prolapse. J Am Coll Cardiol 2015;65:1931–8.  \nhttps://doi.org/10.1016/j.jacc.2015.01.059 \n732. Chang JD, Manning WJ, Ebrille E, Zimetbaum PJ. Tricuspid valve dysfunction following \npacemaker or cardioverter-defibrillator implantation. J Am Coll Cardiol 2017;69: \n2331–41. https://doi.org/10.1016/j.jacc.2017.02.055 \n733. von Bardeleben RS, Lurz P, Sorajja P, Ruf T, Hausleiter J, Sitges M, et al. Two-year out-\ncomes for tricuspid repair with a transcatheter edge-to-edge valve repair from the \ntransatlantic TRILUMINATE trial. Circ Cardiovasc Interv 2023;16:e012888. https://doi. \norg/10.1161/CIRCINTERVENTIONS.122.012888 \n734. Lurz P, Besler C, Schmitz T, Bekeredjian R, Nickenig G, Möllmann H, et al. Short-term \noutcomes of tricuspid edge-to-edge repair in clinical practice. J Am Coll Cardiol 2023;82: \n281–91. https://doi.org/10.1016/j.jacc.2023.05.008 \n735. Kodali SK, Hahn RT, Davidson CJ, Narang A, Greenbaum A, Gleason P, et al. 1-Year \noutcomes of transcatheter tricuspid valve repair. J Am Coll Cardiol 2023;81:1766–76.  \nhttps://doi.org/10.1016/j.jacc.2023.02.049 \n736. Kar S, Makkar RR, Whisenant BK, Hamid N, Naik H, Tadros P, et al. (March 30, 2025) \nTwo-year outcomes of transcatheter edge-to-edge repair for severe tricuspid regur-\ngitation: the TRILUMINATE pivotal randomized trial. Circulation, https://doi.org/10. \n1161/CIRCULATIONAHA.125.074536 \n737. Donal E, Dreyfus J, Leurent G, Coisne A, Leroux PY, Ganivet A, et al. Transcatheter \nedge-to-edge repair for severe isolated tricuspid regurgitation: the Tri.Fr randomized \nclinical trial. JAMA 2025;333:124–32. https://doi.org/10.1001/jama.2024.21189 \n738. Hahn RT, Makkar R, Thourani VH, Makar M, Sharma RP, Haeffele C, et al. \nTranscatheter valve replacement in severe tricuspid regurgitation. N Engl J Med \n2024;392:115–26. https://doi.org/10.1056/NEJMoa2401918 \n739. Park SJ, Gentry JLI, Varma N, Wazni O, Tarakji KG, Mehta A, et al. Transvenous extrac-\ntion of pacemaker and defibrillator leads and the risk of tricuspid valve regurgitation. \nJACC Clin Electrophysiol 2018;4:1421–8. https://doi.org/10.1016/j.jacep.2018.07.011 \n740. Aboulhosn J, Cabalka AK, Levi DS, Himbert D, Testa L, Latib A, et al. Transcatheter \nvalve-in-ring implantation for the treatment of residual or recurrent tricuspid valve \ndysfunction after prior surgical repair. JACC Cardiovasc Interv 2017;10:53–63. https:// \ndoi.org/10.1016/j.jcin.2016.10.036 \n741. Chen S, Dershowitz L, George I. Transcatheter valve implantation for degenerated tri-\ncuspid bioprosthesis and failed tricuspid ring. Ann Cardiothorac Surg 2021;10:651–7.  \nhttps://doi.org/10.21037/acs-2021-tviv-11 \n742. Rao VN, Giczewska A, Chiswell K, Felker GM, Wang A, Glower DD, et al. Long-term \noutcomes of phenoclusters in severe tricuspid regurgitation. Eur Heart J 2023;44: \n1910–23. https://doi.org/10.1093/eurheartj/ehad133 \n743. Van de Veire NR, Braun J, Delgado V, Versteegh MI, Dion RA, Klautz RJ, et al. Tricuspid \nannuloplasty prevents right ventricular dilatation and progression of tricuspid regurgi-\ntation in patients with tricuspid annular dilatation undergoing mitral valve repair. J \nThorac Cardiovasc Surg 2011;141:1431–9. https://doi.org/10.1016/j.jtcvs.2010.05.050 \n744. Brescia AA, Ward ST, Watt TMF, Rosenbloom LM, Baker M, Khan S, et al. Outcomes \nof guideline-directed concomitant annuloplasty for functional tricuspid regurgitation. \nAnn Thorac Surg 2020;109:1227–32. https://doi.org/10.1016/j.athoracsur.2019.07.035 \n745. Hamandi M, Smith RL, Ryan WH, Grayburn PA, Vasudevan A, George TJ, et al. \nOutcomes of isolated tricuspid valve surgery have improved in the modern era. Ann \nThorac Surg 2019;108:11–5. https://doi.org/10.1016/j.athoracsur.2019.03.004 \n746. Russo M, Di Mauro M, Saitto G, Lio A, Berretta P, Taramasso M, et al. Outcome of \npatients undergoing isolated tricuspid repair or replacement surgery. Eur J \nCardiothorac Surg 2022;62:ezac230. https://doi.org/10.1093/ejcts/ezac230 \n747. Abdelbar A, Kenawy A, Zacharias J. Minimally invasive tricuspid valve surgery. J Thorac \nDis 2021;13:1982–92. https://doi.org/10.21037/jtd-20-1331 \n748. Taramasso M, Benfari G, van der Bijl P, Alessandrini H, Attinger-Toller A, Biasco L, et al. \nTranscatheter versus medical treatment of patients with symptomatic severe tricuspid \nregurgitation. J Am Coll Cardiol 2019;74:2998–3008. https://doi.org/10.1016/j.jacc.2019. \n09.028 \n749. Kodali S, Hahn RT, Makkar R, Makar M, Davidson CJ, Puthumana JJ, et al. Transfemoral \ntricuspid valve replacement and one-year outcomes: the TRISCEND study. Eur Heart J \n2023;44:4862–73. https://doi.org/10.1093/eurheartj/ehad667 \n750. Donal E, Sitges M, Panis V, Schueler R, Lapp H, Moellmann H, et al. Characterization of \ntricuspid valve anatomy and coaptation gap in subjects receiving tricuspid transcath-\neter edge-to-edge repair: observations from the bRIGHT TriClip study. J Am Soc \nEchocardiogr 2024;37:397–404. https://doi.org/10.1016/j.echo.2023.12.002 \n751. Wild MG, Löw K, Rosch S, Gercek M, Higuchi S, Massberg S, et al. Multicenter experi-\nence with the transcatheter leaflet repair system for symptomatic tricuspid regurgita-\ntion. JACC Cardiovasc Interv 2022;15:1352–63. https://doi.org/10.1016/j.jcin.2022.05. \n041 \n752. Sarralde JA, Bernal JM, Llorca J, Pontón A, Diez-Solorzano L, Giménez-Rico JR, et al. \nRepair of rheumatic tricuspid valve disease: predictors of very long-term mortality \nand reoperation. Ann Thorac Surg 2010;90:503–8. https://doi.org/10.1016/j. \nathoracsur.2010.03.105 \n753. Saran N, Dearani JA, Said SM, Greason KL, Pochettino A, Stulak JM, et al. Long-term \noutcomes of patients undergoing tricuspid valve surgery. Eur J Cardiothorac Surg \n2019;56:950–8. https://doi.org/10.1093/ejcts/ezz081 \n754. McElhinney DB, Cabalka AK, Aboulhosn JA, Eicken A, Boudjemline Y, Schubert S, et al. \nTranscatheter tricuspid valve-in-valve implantation for the treatment of dysfunctional \nsurgical bioprosthetic valves: an international, multicenter registry study. Circulation \n2016;133:1582–93. https://doi.org/10.1161/CIRCULATIONAHA.115.019353 \n755. Pereyra M, Farina JM, Chao CJ, Ayoub C, Arsanjani R. Percutaneous transcatheter pul-\nmonary and tricuspid valve replacements in a patient with carcinoid heart disease. Eur \nHeart J Case Rep 2023;7:ytad511. https://doi.org/10.1093/ehjcr/ytad511 \n756. Connolly HM, Schaff HV, Abel MD, Rubin J, Askew JW, Li Z, et al. Early and late out-\ncomes of surgical treatment in carcinoid heart disease. J Am Coll Cardiol 2015;66: \n2189–96. https://doi.org/10.1016/j.jacc.2015.09.014 \n757. Yunoki K, Naruko T, Itoh A, Ohashi J, Fujimoto K, Shirai N, et al. Percutaneous trans-\ncatheter balloon valvuloplasty for bioprosthetic tricuspid valve stenosis. Circulation \n2006;114:e558–9. https://doi.org/10.1161/CIRCULATIONAHA.106.618611 \n758. Tribouilloy C, Bohbot Y, Kubala M, Ruschitzka F, Popescu B, Wendler O, et al. \nCharacteristics, management, and outcomes of patients with multiple native valvular \nheart disease: a substudy of the EURObservational Research Programme Valvular \nHeart Disease II Survey. Eur Heart J 2022;43:2756–66. https://doi.org/10.1093/ \neurheartj/ehac209 \n759. Iung B, Baron G, Tornos P, Gohlke-Bärwolf C, Butchart EG, Vahanian A. Valvular heart \ndisease in the community: a European experience. Curr Probl Cardiol 2007;32:609–61.  \nhttps://doi.org/10.1016/j.cpcardiol.2007.07.002 \n760. Cutter DJ, Schaapveld M, Darby SC, Hauptmann M, van Nimwegen FA, Krol AD, et al. \nRisk of valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst \n2015;107:djv008. https://doi.org/10.1093/jnci/djv008 \n761. Unger P, Pibarot P, Tribouilloy C, Lancellotti P, Maisano F, Iung B, et al. Multiple and \nmixed valvular heart diseases. Circ Cardiovasc Imaging 2018;11:e007862. https://doi. \norg/10.1161/CIRCIMAGING.118.007862 \n762. Ajmone Marsan N, Delgado V, Shah DJ, Pellikka P, Bax JJ, Treibel T, et al. Valvular heart \ndisease: shifting the focus to the myocardium. Eur Heart J 2023;44:28–40. https://doi. \norg/10.1093/eurheartj/ehac504 \n763. de Marchi SF, Windecker S, Aeschbacher BC, Seiler C. Influence of left ventricular re-\nlaxation on the pressure half time of aortic regurgitation. Heart 1999;82:607–13.  \nhttps://doi.org/10.1136/hrt.82.5.607 \n764. Unger P, Tribouilloy C. Aortic stenosis with other concomitant valvular disease: aortic \nregurgitation, mitral regurgitation, mitral stenosis, or tricuspid regurgitation. Cardiol \nClin 2020;38:33–46. https://doi.org/10.1016/j.ccl.2019.09.002 \n765. Unger P, Clavel M-A. Mixed aortic valve disease: a diagnostic challenge, a prognostic \nthreat. Structural Heart 2020;4:468–74. https://doi.org/10.1080/24748706.2020. \n1817643 \n766. Flachskampf FA, Weyman AE, Gillam L, Liu CM, Abascal VM, Thomas JD. Aortic regur-\ngitation shortens Doppler pressure half-time in mitral stenosis: clinical evidence, in vi-\ntro simulation and theoretic analysis. J Am Coll Cardiol 1990;16:396–404. https://doi. \norg/10.1016/0735-1097(90)90592-d \n767. Tribouilloy C, Shen WF, Rey JL, Adam MC, Lesbre JP. Mitral to aortic velocity-time in-\ntegral ratio: a non-geometric pulsed-Doppler regurgitant index in isolated pure mitral \nregurgitation. Eur Heart J 1994;15:1335–9. https://doi.org/10.1093/oxfordjournals. \neurheartj.a060390 \n768. Benfari G, Clavel M-A, Nistri S, Maffeis C, Vassanelli C, Enriquez-Sarano M, et al. \nConcomitant mitral regurgitation and aortic stenosis: one step further to low-flow \npreserved ejection fraction aortic stenosis. Eur Heart J Cardiovasc Imaging 2018;19: \n569–73. https://doi.org/10.1093/ehjci/jex172 \n769. Mohan JC, Mukherjee S, Kumar A, Arora R, Patel AR, Pandian NG. Does chronic mitral \nregurgitation influence Doppler pressure half-time–derived calculation of the mitral \nvalve area in patients with mitral stenosis? Am Heart J 2004;148:703–9. https://doi. \norg/10.1016/j.ahj.2003.12.043 \n770. Hauge SW, Estensen ME, Persson R, Abebe S, Mekonnen D, Nega B, et al. The import-\nance of concomitant mitral regurgitation for estimates of mitral valve area by pressure \nhalf time in patients with chronic rheumatic heart disease. Int J Cardiol 2024;398: \n131600. https://doi.org/10.1016/j.ijcard.2023.131600 \n771. Dahou A, Magne J, Clavel MA, Capoulade R, Bartko PE, Bergler-Klein J, et al. Tricuspid \nregurgitation is associated with increased risk of mortality in patients with low-flow \nlow-gradient aortic stenosis and reduced ejection fraction: results of the multicenter \nTOPAS study (True or Pseudo-Severe Aortic Stenosis). JACC Cardiovasc Interv 2015; \n8:588–96. https://doi.org/10.1016/j.jcin.2014.08.019 \n772. Shiran A, Sagie A. Tricuspid regurgitation in mitral valve disease: incidence, prognostic \nimplications, mechanism, and management. J Am Coll Cardiol 2009;53:401–8. https:// \ndoi.org/10.1016/j.jacc.2008.09.048 \n773. Naeije R, Badagliacca R. The overloaded right heart and ventricular interdependence. \nCardiovasc Res 2017;113:1474–85. https://doi.org/10.1093/cvr/cvx160 \n774. Furukawa A, Abe Y, Ito K, Hosogi S, Yamamoto K, Ito H. Mechanisms of changes in \nfunctional mitral regurgitation by preload alterations. J Cardiol 2018;71:570–6.  \nhttps://doi.org/10.1016/j.jjcc.2017.12.005 \n775. Wunderlich NC, Beigel R, Siegel RJ. Management of mitral stenosis using 2D and 3D \necho-Doppler imaging. JACC Cardiovasc Imaging 2013;6:1191–205. https://doi.org/10. \n1016/j.jcmg.2013.07.008  \n4730                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n776. Cho IJ, Lee SE, Jeong H, Chang HJ. Determinants of clinical outcomes in patients with \nmixed mitral valve disease. Echocardiography 2020;37:1164–70. https://doi.org/10. \n1111/echo.14673 \n777. Pawade T, Sheth T, Guzzetti E, Dweck Marc R, Clavel M-A. Why and how to measure \naortic valve calcification in patients with aortic stenosis. JACC Cardiovasc Imaging 2019; \n12:1835–48. https://doi.org/10.1016/j.jcmg.2019.01.045 \n779. Bandera F, Generati G, Pellegrino M, Garatti A, Labate V, Alfonzetti E, et al. Mitral re-\ngurgitation in heart failure: insights from CPET combined with exercise echocardiog-\nraphy. Eur Heart J Cardiovasc Imaging 2017;18:296–303. https://doi.org/10.1093/ehjci/ \njew096 \n780. Bissessor N, Shanahan L, Wee YS, Stewart R, Lowe B, Kerr A, et al. The role of natri-\nuretic peptides in patients with chronic complex (mixed or multiple) heart valve dis-\nease. Congest Heart Fail 2010;16:50–4. https://doi.org/10.1111/j.1751-7133.2009. \n00132.x \n781. Myerson SG. CMR in evaluating valvular heart disease: diagnosis, severity, and out-\ncomes. JACC Cardiovasc Imaging 2021;14:2020–32. https://doi.org/10.1016/j.jcmg. \n2020.09.029 \n782. Grafton G, Cascino TM, Perry D, Ashur C, Koelling TM. Resting oxygen consumption \nand heart failure: importance of measurement for determination of cardiac output \nwith the use of the Fick principle. J Card Fail 2020;26:664–72. https://doi.org/10. \n1016/j.cardfail.2019.02.004 \n783. Singh AD, Mian A, Devasenapathy N, Guyatt G, Karthikeyan G. Percutaneous mitral \ncommissurotomy versus surgical commissurotomy for rheumatic mitral stenosis: a \nsystematic review and meta-analysis of randomised controlled trials. Heart 2020; \n106:1094–101. https://doi.org/10.1136/heartjnl-2019-315906 \n784. Winter MP, Bartko PE, Krickl A, Gatterer C, Donà C, Nitsche C, et al. Adaptive devel-\nopment of concomitant secondary mitral and tricuspid regurgitation after transcath-\neter aortic valve replacement. Eur Heart J Cardiovasc Imaging 2021;22:1045–53.  \nhttps://doi.org/10.1093/ehjci/jeaa106 \n785. Khan F, Okuno T, Malebranche D, Lanz J, Praz F, Stortecky S, et al. Transcatheter aortic \nvalve replacement in patients with multivalvular heart disease. JACC Cardiovasc Interv \n2020;13:1503–14. https://doi.org/10.1016/j.jcin.2020.03.052 \n786. Adamo M, Pagnesi M, Ghizzoni G, Estévez-Loureiro R, Raposeiras-Roubin S, Tomasoni \nD, et al. Evolution of tricuspid regurgitation after transcatheter edge-to-edge mitral \nvalve repair for secondary mitral regurgitation and its impact on mortality. Eur J \nHeart Fail 2022;24:2175–84. https://doi.org/10.1002/ejhf.2637 \n787. Kavsur R, Iliadis C, Spieker M, Brachtendorf BM, Tiyerili V, Metze C, et al. Predictors \nand prognostic relevance of tricuspid alterations in patients undergoing transcatheter \nedge-to-edge mitral valve repair. EuroIntervention 2021;17:827–34. https://doi.org/10. \n4244/eij-d-20-01094 \n788. Mehr M, Karam N, Taramasso M, Ouarrak T, Schneider S, Lurz P, et al. Combined tri-\ncuspid and mitral versus isolated mitral valve repair for severe MR and TR: an analysis \nfrom the TriValve and TRAMI registries. JACC Cardiovasc Interv 2020;13:543–50.  \nhttps://doi.org/10.1016/j.jcin.2019.10.023 \n789. Besler C, Blazek S, Rommel KP, Noack T, von Roeder M, Luecke C, et al. Combined \nmitral and tricuspid versus isolated mitral valve transcatheter edge-to-edge repair in \npatients with symptomatic valve regurgitation at high surgical risk. JACC Cardiovasc \nInterv 2018;11:1142–51. https://doi.org/10.1016/j.jcin.2018.04.010 \n790. Egbe AC, Luis SA, Padang R, Warnes CA. Outcomes in moderate mixed aortic valve \ndisease: is it time for a paradigm shift? J Am Coll Cardiol 2016;67:2321–9. https://doi.org/ \n10.1016/j.jacc.2016.03.509 \n791. Egbe AC, Poterucha JT, Warnes CA. Mixed aortic valve disease: midterm outcome and \npredictors of adverse events. Eur Heart J 2016;37:2671–8. https://doi.org/10.1093/ \neurheartj/ehw079 \n792. Zilberszac R, Gabriel H, Schemper M, Zahler D, Czerny M, Maurer G, et al. Outcome \nof combined stenotic and regurgitant aortic valve disease. J Am Coll Cardiol 2013;61: \n1489–95. https://doi.org/10.1016/j.jacc.2012.11.070 \n793. Isaza N, Desai MY, Kapadia SR, Krishnaswamy A, Rodriguez LL, Grimm RA, et al. \nLong-term outcomes in patients with mixed aortic valve disease and preserved left \nventricular ejection fraction. J Am Heart Assoc 2020;9:e014591. https://doi.org/10. \n1161/jaha.119.014591 \n794. Saijo Y, Isaza N, Conic JZ, Desai MY, Johnston D, Roselli EE, et al. Left ventricular lon-\ngitudinal strain in characterization and outcome assessment of mixed aortic valve dis-\nease phenotypes. JACC Cardiovasc Imaging 2021;14:1324–34. https://doi.org/10.1016/j. \njcmg.2021.01.020 \n795. Bernard J, Jean G, Bienjonetti-Boudreau D, Jacques F, Tastet L, Salaun E, et al. \nPrognostic utility of N-terminal pro B-type natriuretic peptide ratio in mixed aortic \nvalve disease. Open Heart 2023;10:e002361. https://doi.org/10.1136/openhrt-2023- \n002361 \n796. Onishi H, Naganuma T, Izumo M, Ouchi T, Yuki H, Mitomo S, et al. Prognostic rele-\nvance of B-type natriuretic peptide in patients with moderate mixed aortic valve dis-\nease. ESC Heart Fail 2022;9:2474–83. https://doi.org/10.1002/ehf2.13946 \n797. Carpentier AF, Pellerin M, Fuzellier JF, Relland JY. Extensive calcification of the \nmitral valve anulus: pathology and surgical management. J Thorac Cardiovasc Surg \n1996;111:718–29; discussion 729–730. https://doi.org/10.1016/s0022-5223(96) \n70332-x \n798. World Health Organization. Life Expectancy at Birth. https://www.who.int/ \ndata/gho/indicator-metadata-registry/imr-details/3131 (28 March 2025, date \nlast accessed). \n799. Johansson I, Benz AP, Kovalova T, Balasubramanian K, Fukakusa B, Lynn MJ, et al. \nOutcomes of patients with a mechanical heart valve and poor anticoagulation control \non warfarin. Thromb Haemost 2024;124:613–24. https://doi.org/10.1055/s-0043- \n1777827 \n800. Persson M, Glaser N, Nilsson J, Friberg O, Franco-Cereceda A, Sartipy U. Comparison \nof long-term performance of bioprosthetic aortic valves in Sweden from 2003 to 2018. \nJAMA Netw Open 2022;5:e220962. https://doi.org/10.1001/jamanetworkopen.2022. \n0962 \n801. Jiang Y, Wang S, Bian J, Chen S, Shao Y. Mechanical versus bioprosthetic aortic valve \nreplacement in middle-aged adults: a systematic review and meta-analysis. J \nCardiovasc Dev Dis 2023;10:90. https://doi.org/10.3390/jcdd10020090 \n802. Kim MS, Kim HR, Lee SH, Lee S, Joo HC. Aortic valve replacement in patients aged 50 \nto 69 years: analysis using Korean National Big Data. J Card Surg 2022;37:3623–30.  \nhttps://doi.org/10.1111/jocs.16908 \n803. Vogt F, Santarpino G, Fujita B, Frerker C, Bauer T, Beckmann A, et al. Surgical aortic \nvalve replacement in patients aged 50–69 years—insights from the German Aortic \nValve Registry (GARY). Eur J Cardiothorac Surg 2022;62:ezac286. https://doi.org/10. \n1093/ejcts/ezac286 \n804. Glaser N, Jackson V, Holzmann MJ, Franco-Cereceda A, Sartipy U. Aortic valve re-\nplacement with mechanical vs. biological prostheses in patients aged 50–69 years. \nEur Heart J 2016;37:2658–67. https://doi.org/10.1093/eurheartj/ehv580 \n805. Kiyose AT, Suzumura EA, Laranjeira L, Buehler AM, Santo JAE, Berwanger O, et al. \nComparison of biological and mechanical prostheses for heart valve surgery: a system-\natic review of randomized controlled trials. Arq Bras Cardiol 2019;112:292–301. https:// \ndoi.org/10.5935/abc.20180272 \n806. Bouhout I, Ghoneim A, Poirier N, Cartier R, Demers P, Perrault LP, et al. Impact of the \nlearning curve on early outcomes following the Ross procedure. Can J Cardiol 2017;33: \n493–500. https://doi.org/10.1016/j.cjca.2016.11.014 \n807. Tasoudis PT, Varvoglis DN, Vitkos E, Mylonas KS, Sá MP, Ikonomidis JS, et al. \nMechanical versus bioprosthetic valve for aortic valve replacement: systematic review \nand meta-analysis of reconstructed individual participant data. Eur J Cardiothorac Surg \n2022;62:ezac268. https://doi.org/10.1093/ejcts/ezac268 \n808. Leviner DB, Witberg G, Levi A, Landes U, Schwartz N, Shiran A, et al. Mechanical vs \nbioprosthetic aortic valve replacement in patients younger than 70 years of age: a haz-\nard ratio meta-analysis. Can J Cardiol 2022;38:355–64. https://doi.org/10.1016/j.cjca. \n2021.12.008 \n809. Yu J, Qiao E, Wang W. Mechanical or biologic prostheses for mitral valve replacement: \na systematic review and meta-analysis. Clin Cardiol 2022;45:701–16. https://doi.org/10. \n1002/clc.23854 \n810. Yanagawa B, Lee J, Ouzounian M, Bagai A, Cheema A, Verma S, et al. Mitral valve pros-\nthesis choice in patients <70 years: a systematic review and meta-analysis of 20 219 \npatients. J Card Surg 2020;35:818–25. https://doi.org/10.1111/jocs.14478 \n811. Ahmed A, Awad AK, Varghese KS, Sehgal VS, Hisham K, George J, et al. Bioprosthetic \nversus mechanical valves for mitral valve replacement in patients <70 years: an up-\ndated pairwise meta-analysis. Gen Thorac Cardiovasc Surg 2024;72:95–103. https:// \ndoi.org/10.1007/s11748-023-01956-1 \n812. Capodanno D, Petronio AS, Prendergast B, Eltchaninoff H, Vahanian A, \nModine T, et al. Standardized definitions of structural deterioration and valve \nfailure in assessing long-term durability of transcatheter and surgical aortic \nbioprosthetic valves: a consensus statement from the European Association \nof Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the \nEuropean Society of Cardiology (ESC) and the European Association for \nCardio-Thoracic Surgery (EACTS). Eur Heart J 2017;38:3382–90. https://doi. \norg/10.1093/eurheartj/ehx303 \n813. Meskin M, Dimasi A, Votta E, Jaworek M, Fusini L, Muratori M, et al. A novel multipara-\nmetric score for the detection and grading of prosthetic mitral valve obstruction in \ncases with different disc motion abnormalities. Ultrasound Med Biol 2019;45: \n1708–20. https://doi.org/10.1016/j.ultrasmedbio.2019.03.011 \n814. Passaglia LG, de Barros GM, de Sousa MR. Early postoperative bridging antic-\noagulation after mechanical heart valve replacement: a systematic review and \nmeta-analysis. J Thromb Haemost 2015;13:1557–67. https://doi.org/10.1111/jth. \n13047 \n815. Li BX, Liu SD, Qi L, Sun S, Sun W, Li YM, et al. Comparison of different bridging antic-\noagulation therapies used after mechanical heart valve replacement in Chinese patients \n—a prospective cohort study. J Cardiothorac Surg 2020;15:40. https://doi.org/10.1186/ \ns13019-020-1084-7 \n816. Tao E, Luo YL, Tao Z, Wan L. A meta-analysis of bridging anticoagulation between low \nmolecular weight heparin and heparin. Medicine (Baltimore) 2020;99:e18729. https:// \ndoi.org/10.1097/MD.0000000000018729 \n817. Baudet EM, Puel V, McBride JT, Grimaud JP, Roques F, Clerc F, et al. Long-term results \nof valve replacement with the St. Jude Medical prosthesis. J Thorac Cardiovasc Surg 1995; \n109:858–70. https://doi.org/10.1016/s0022-5223(95)70309-8  \nESC Guidelines                                                                                                                                                                                          4731 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n818. Massel DR, Little SH. Antiplatelet and anticoagulation for patients with prosthetic \nheart valves. Cochrane Database Syst Rev 2013;2013:CD003464. https://doi.org/10. \n1002/14651858.CD003464.pub2 \n819. Torella M, Torella D, Chiodini P, Franciulli M, Romano G, De Santo L, et al. LOWERing \nthe INtensity of oral anticoaGulant therapy in patients with bileaflet mechanical aortic \nvalve replacement: results from the “LOWERING-IT” Trial. Am Heart J 2010;160: \n171–8. https://doi.org/10.1016/j.ahj.2010.05.005 \n820. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, et al. Benefit \nof oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the qual-\nity of international normalized ratio control achieved by centers and countries as mea-\nsured by time in therapeutic range. Circulation 2008;118:2029–37. https://doi.org/10. \n1161/CIRCULATIONAHA.107.750000 \n821. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. \nDabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; \n369:1206–14. https://doi.org/10.1056/NEJMoa1300615 \n822. Puskas JD, Gerdisch M, Nichols D, Fermin L, Rhenman B, Kapoor D, et al. \nAnticoagulation and antiplatelet strategies after On-X mechanical aortic valve replace-\nment. J Am Coll Cardiol 2018;71:2717–26. https://doi.org/10.1016/j.jacc.2018.03.535 \n823. Schlitt A, von Bardeleben RS, Ehrlich A, Eimermacher A, Peetz D, Dahm M, et al. \nClopidogrel and aspirin in the prevention of thromboembolic complications after \nmechanical aortic valve replacement (CAPTA). Thromb Res 2003;109:131–35.  \nhttps://doi.org/10.1016/s0049-3848(03)00143-9 \n824. Wang TY, Svensson LG, Wen J, Vekstein A, Gerdisch M, Rao VU, et al. Apixaban or \nwarfarin in patients with an On-X mechanical aortic valve. NEJM Evid 2023;2: \nEVIDoa2300067. https://doi.org/10.1056/EVIDoa2300067 \n825. Wang M, Zeraatkar D, Obeda M, Lee M, Garcia C, Nguyen L, et al. Drug–drug inter-\nactions with warfarin: a systematic review and meta-analysis. Br J Clin Pharmacol 2021; \n87:4051–100. https://doi.org/10.1111/bcp.14833 \n826. Tan CSS, Lee SWH. Warfarin and food, herbal or dietary supplement interactions: a \nsystematic review. Br J Clin Pharmacol 2021;87:352–74. https://doi.org/10.1111/bcp. \n14404 \n827. Heneghan CJ, Garcia-Alamino JM, Spencer EA, Ward AM, Perera R, Bankhead C, et al. \nSelf-monitoring and self-management of oral anticoagulation. Cochrane Database Syst \nRev 2016;7:CD003839. https://doi.org/10.1002/14651858.CD003839.pub3 \n828. Khouja C, Brunton G, Richardson M, Stokes G, Blanchard L, Burchett H, et al. Oral \nanticoagulants: a systematic overview of reviews on efficacy and safety, genotyping, \nself-monitoring, and stakeholder experiences. Syst Rev 2022;11:232. https://doi.org/ \n10.1186/s13643-022-02098-w \n829. Park YK, Lee MJ, Kim JH, Lee JS, Park RW, Kim GM, et al. Genetic and non-genetic fac-\ntors affecting the quality of anticoagulation control and vascular events in atrial fibril-\nlation. J Stroke Cerebrovasc Dis 2017;26:1383–90. https://doi.org/10.1016/j. \njstrokecerebrovasdis.2017.02.022 \n830. Praxedes MFDS, Silva JLPD, Cruz AJAD, Viana CC, Barbosa HC, Guimaraes NS, et al. \nAssessment of the relationship between the level of patient knowledge on warfarin \ntherapy and the quality of oral anticoagulation: a systematic review and meta-analysis. \nPLoS One 2023;18:e0289836. https://doi.org/10.1371/journal.pone.0289836 \n831. Marx N, Federici M, Schütt K, Muller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC \nGuidelines for the management of cardiovascular disease in patients with diabetes. Eur \nHeart J 2023;44:4043–140. https://doi.org/10.1093/eurheartj/ehad192 \n832. Meurin P, Tabet JY, Weber H, Renaud N, Ben Driss A. Low-molecular-weight heparin \nas a bridging anticoagulant early after mechanical heart valve replacement. Circulation \n2006;113:564–9. https://doi.org/10.1161/circulationaha.105.575571 \n833. Ferreira I, Dos L, Tornos P, Nicolau I, Permanyer-Miralda G, Soler-Soler J. Experience \nwith enoxaparin in patients with mechanical heart valves who must withhold acenocu-\nmarol. Heart 2003;89:527–30. https://doi.org/10.1136/heart.89.5.527 \n834. Caldeira D, David C, Santos AT, Costa J, Pinto FJ, Ferreira JJ. Efficacy and safety of low \nmolecular weight heparin in patients with mechanical heart valves: systematic review \nand meta-analysis. J Thromb Haemost 2014;12:650–9. https://doi.org/10.1111/jth. \n12544 \n835. Pengo V, Palareti G, Cucchini U, Molinatti M, Del Bono R, Baudo F, et al. Low-intensity \noral anticoagulant plus low-dose aspirin during the first six months versus \nstandard-intensity oral anticoagulant therapy after mechanical heart valve replace-\nment: a pilot study of low-intensity warfarin and aspirin in cardiac prostheses \n(LIWACAP). Clin Appl Thromb Hemost 2007;13:241–8. https://doi.org/10.1177/ \n1076029607302544 \n836. Meschengieser SS, Fondevila CG, Frontroth J, Santarelli MT, Lazzari MA. Low-intensity \noral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation \nalone: a randomized trial in patients with mechanical prosthetic heart valves. J \nThorac \nCardiovasc \nSurg \n1997;113:910–6. \nhttps://doi.org/10.1016/s0022- \n5223(97)70264-2 \n837. Puskas J, Gerdisch M, Nichols D, Quinn R, Anderson C, Rhenman B, et al. Reduced \nanticoagulation after mechanical aortic valve replacement: interim results from the \nprospective randomized On-X valve anticoagulation clinical trial randomized Food \nand Drug Administration investigational device exemption trial. J Thorac Cardiovasc \nSurg 2014;147:1202–10; discussion 1210–1201. https://doi.org/10.1016/j.jtcvs.2014. \n01.004 \n838. Hanigan S, Kong X, Haymart B, Kline-Rogers E, Kaatz S, Krol G, et al. Standard versus \nhigher intensity anticoagulation for patients with mechanical aortic valve replacement \nand additional risk factors for thromboembolism. Am J Cardiol 2021;159:100–6. https:// \ndoi.org/10.1016/j.amjcard.2021.08.023 \n839. Ray WA, Chung CP, Murray KT, Smalley WE, Daugherty JR, Dupont WD, et al. \nAssociation of proton pump inhibitors with reduced risk of warfarin-related serious \nupper gastrointestinal bleeding. Gastroenterology 2016;151:1105–12.e1110. https:// \ndoi.org/10.1053/j.gastro.2016.08.054 \n840. Kurlander JE, Barnes GD, Fisher A, Gonzalez JJ, Helminski D, Saini SD, et al. Association \nof antisecretory drugs with upper gastrointestinal bleeding in patients using oral antic-\noagulants: a systematic review and meta-analysis. Am J Med 2022;135:1231–43.e1238.  \nhttps://doi.org/10.1016/j.amjmed.2022.05.031 \n841. Crowther MA, Ageno W, Garcia D, Wang L, Witt DM, Clark NP, et al. Oral vitamin K \nversus placebo to correct excessive anticoagulation in patients receiving warfarin: a \nrandomized trial. Ann Intern Med 2009;150:293–300. https://doi.org/10.7326/0003- \n4819-150-5-200903030-00005 \n842. Khatib R, Ludwikowska M, Witt DM, Ansell J, Clark NP, Holbrook A, et al. Vitamin K \nfor reversal of excessive vitamin K antagonist anticoagulation: a systematic review and \nmeta-analysis. Blood Adv 2019;3:789–96. https://doi.org/10.1182/bloodadvances. \n2018025163 \n843. Gunther KE, Conway G, Leibach L, Crowther MA. Low-dose oral vitamin K is safe and \neffective for outpatient management of patients with an INR>10. Thromb Res 2004; \n113:205–9. https://doi.org/10.1016/j.thromres.2004.03.004 \n844. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific \nand Standardization Committee of the International Society on Thrombosis and \nHaemostasis. Definition of major bleeding in clinical investigations of antihemostatic \nmedicinal products in non-surgical patients. J Thromb Haemost 2005;3:692–4. https:// \ndoi.org/10.1111/j.1538-7836.2005.01204.x \n845. Brekelmans MPA, van Ginkel K, Daams JG, Hutten BA, Middeldorp S, Coppens M. \nBenefits and harms of 4-factor prothrombin complex concentrate for reversal of vita-\nmin K antagonist associated bleeding: a systematic review and meta-analysis. J Thromb \nThrombolysis 2017;44:118–29. https://doi.org/10.1007/s11239-017-1506-0 \n846. Chai-Adisaksopha C, Hillis C, Siegal DM, Movilla R, Heddle N, Iorio A, et al. \nProthrombin complex concentrates versus fresh frozen plasma for warfarin reversal. \nA systematic review and meta-analysis. Thromb Haemost 2016;116:879–90. https://doi. \norg/10.1160/TH16-04-0266 \n847. Hood C, Goldstein JN, Milling TJ, Refaai MA, Bajcic P, Goldstein B, et al. INR and vita-\nmin K-dependent factor levels after vitamin K antagonist reversal with 4F-PCC or plas-\nma. Blood Adv 2023;7:2206–13. https://doi.org/10.1182/bloodadvances.2022009015 \n848. Sarode R, Milling TJJ, Refaai MA, Mangione A, Schneider A, Durn BL, et al. Efficacy and \nsafety of a 4-factor prothrombin complex concentrate in patients on vitamin K antago-\nnists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb \nstudy. Circulation 2013;128:1234–43. https://doi.org/10.1161/CIRCULATIONAHA. \n113.002283 \n849. Erdoes G, Koster A, Ortmann E, Meesters MI, Bolliger D, Baryshnikova E, et al. A \nEuropean consensus statement on the use of four-factor prothrombin complex con-\ncentrate for cardiac and non-cardiac surgical patients. Anaesthesia 2021;76:381–92.  \nhttps://doi.org/10.1111/anae.15181 \n850. Eichinger S. Reversing vitamin K antagonists: making the old new again. Hematology Am \nSoc Hematol Educ Program 2016;2016:605–11. https://doi.org/10.1182/asheducation- \n2016.1.605 \n851. Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, et al. Pacemaker or \ndefibrillator surgery without interruption of anticoagulation. N Engl J Med 2013;368: \n2084–93. https://doi.org/10.1056/NEJMoa1302946 \n852. Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R, et al. \nPeriprocedural stroke and bleeding complications in patients undergoing catheter ab-\nlation of atrial fibrillation with different anticoagulation management: results from the \nRole of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients \nUndergoing Catheter Ablation (COMPARE) randomized trial. Circulation 2014;129: \n2638–44. https://doi.org/10.1161/CIRCULATIONAHA.113.006426 \n853. Engelen ET, Schutgens RE, Mauser-Bunschoten EP, van Es RJJ, van Galen KPM. \nAntifibrinolytic therapy for preventing oral bleeding in people on anticoagulants under-\ngoing minor oral surgery or dental extractions. Cochrane Database Syst Rev 2018;7: \nCD012293. https://doi.org/10.1002/14651858.CD012293.pub2 \n854. Ghanbari H, Phard WS, Al-Ameri H, Latchamsetty R, Jongnarngsin K, Crawford T, \net al. Meta-analysis of safety and efficacy of uninterrupted warfarin compared to \nheparin-based bridging therapy during implantation of cardiac rhythm devices. Am J \nCardiol 2012;110:1482–8. https://doi.org/10.1016/j.amjcard.2012.06.057 \n855. Makuloluwa AK, Tiew S, Briggs M. Peri-operative management of ophthalmic patients \non anti-thrombotic agents: a literature review. Eye (Lond) 2019;33:1044–59. https:// \ndoi.org/10.1038/s41433-019-0382-6 \n856. Nagata N, Yasunaga H, Matsui H, Fushimi K, Watanabe K, Akiyama J, et al. Therapeutic \nendoscopy-related GI bleeding and thromboembolic events in patients using warfarin \nor direct oral anticoagulants: results from a large nationwide database analysis. Gut \n2018;67:1805–12. https://doi.org/10.1136/gutjnl-2017-313999  \n4732                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n857. Dohler I, Roder D, Schlesinger T, Nassen CA, Germer CT, Wiegering A, et al. \nRisk-adjusted perioperative bridging anticoagulation reduces bleeding complications \nwithout increasing thromboembolic events in general and visceral surgery. BMC \nAnesthesiol 2023;23:56. https://doi.org/10.1186/s12871-023-02017-z \n858. Shah S, Nayfeh T, Hasan B, Urtecho M, Firwana M, Saadi S, et al. Perioperative man-\nagement of vitamin K antagonists and direct oral anticoagulants: a systematic review \nand meta-analysis. Chest 2023;163:1245–57. https://doi.org/10.1016/j.chest.2022.11. \n032 \n859. Gigante B, Tamargo J, Agewall S, Atar D, Ten Berg J, Campo G, et al. Update on an-\ntithrombotic therapy and body mass: a clinical consensus statement of the \nEuropean \nSociety \nof \nCardiology \nWorking \nGroup \non \nCardiovascular \nPharmacotherapy and the European Society of Cardiology Working Group on \nThrombosis. Eur Heart J Cardiovasc Pharmacother 2024;10:614–45. https://doi.org/10. \n1093/ehjcvp/pvae064 \n860. Jeppsson A, Rocca B, Hansson EC, Gudbjartsson T, James S, Kaski JK, et al. 2024 \nEACTS Guidelines on perioperative medication in adult cardiac surgery. Eur J \nCardiothorac Surg 2024;67:ezae355. https://doi.org/10.1093/ejcts/ezae355 \n861. Kovacs MJ, Wells PS, Anderson DR, Lazo-Langner A, Kearon C, Bates SM, et al. \nPostoperative low molecular weight heparin bridging treatment for patients at high \nrisk of arterial thromboembolism (PERIOP2): double blind randomised controlled \ntrial. BMJ 2021;373:n1205. https://doi.org/10.1136/bmj.n1205 \n862. Kuo HC, Liu FL, Chen JT, Cherng YG, Tam KW, Tai YH. Thromboembolic and bleed-\ning risk of periprocedural bridging anticoagulation: a systematic review and \nmeta-analysis. Clin Cardiol 2020;43:441–9. https://doi.org/10.1002/clc.23336 \n863. Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC. Periprocedural hep-\narin bridging in patients receiving vitamin K antagonists: systematic review and \nmeta-analysis of bleeding and thromboembolic rates. Circulation 2012;126:1630–9.  \nhttps://doi.org/10.1161/CIRCULATIONAHA.112.105221 \n864. Yong JW, Yang LX, Ohene BE, Zhou YJ, Wang ZJ. Periprocedural heparin bridging in \npatients receiving oral anticoagulation: a systematic review and meta-analysis. BMC \nCardiovasc Disord 2017;17:295. https://doi.org/10.1186/s12872-017-0719-7 \n865. Brennan JM, Edwards FH, Zhao Y, O’Brien S, Booth ME, Dokholyan RS, et al. Early an-\nticoagulation of bioprosthetic aortic valves in older patients: results from the Society of \nThoracic Surgeons Adult Cardiac Surgery National Database. J Am Coll Cardiol 2012; \n60:971–7. https://doi.org/10.1016/j.jacc.2012.05.029 \n866. Rafiq S, Steinbrüchel DA, Lilleør NB, Moller CH, Lund JT, Thiis JJ, et al. Antithrombotic \ntherapy after bioprosthetic aortic valve implantation: warfarin versus aspirin, a rando-\nmized controlled trial. Thromb Res 2017;150:104–10. https://doi.org/10.1016/j. \nthromres.2016.11.021 \n867. Butnaru A, Shaheen J, Tzivoni D, Tauber R, Bitran D, Silberman S. Diagnosis and treat-\nment of early bioprosthetic malfunction in the mitral valve position due to thrombus \nformation. Am J Cardiol 2013;112:1439–44. https://doi.org/10.1016/j.amjcard.2013.06. \n014 \n868. Russo A, Grigioni F, Avierinos JF, Freeman WK, Suri R, Michelena H, et al. \nThromboembolic complications after surgical correction of mitral regurgitation inci-\ndence, predictors, and clinical implications. J Am Coll Cardiol 2008;51:1203–11.  \nhttps://doi.org/10.1016/j.jacc.2007.10.058 \n869. Dangas GD, Tijssen JGP, Wöhrle J, Sondergaard L, Gilard M, Mollmann H, et al. A con-\ntrolled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med \n2020;382:120–9. https://doi.org/10.1056/NEJMoa1911425 \n870. Alkhalil M, Edwards R, Puri R, Kalra A, Zaman A, Das R. Aspirin versus dual antiplatelet \ntherapy in patients undergoing trans-catheter aortic valve implantation, updated \nmeta-analysis. Cardiovasc Drugs Ther 2022;36:279–83. https://doi.org/10.1007/ \ns10557-021-07146-6 \n871. El Bèze N, Himbert D, Suc G, Brochet E, Ajzenberg N, Cailliau A, et al. Comparison of \ndirect oral anticoagulants vs vitamin K antagonists after transcatheter mitral valve re-\nplacement. J Am Coll Cardiol 2024;83:334–46. https://doi.org/10.1016/j.jacc.2023.10. \n031 \n872. Carnicelli AP, De Caterina R, Halperin JL, Renda G, Ruff CT, Trevisan M, et al. \nEdoxaban for the prevention of thromboembolism in patients with atrial fibrillation \nand bioprosthetic valves. Circulation 2017;135:1273–5. https://doi.org/10.1161/ \nCIRCULATIONAHA.116.026714 \n873. Guimarães HP, Lopes RD, de Barros E Silva PGM, Liporace IL, Sampaio RO, \nTarasoutchi F, et al. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic \nmitral valve. N Engl J Med 2020;383:2117–26. https://doi.org/10.1056/NEJM \noa2029603 \n874. Philippart R, Brunet-Bernard A, Clementy N, Bourguignon T, Mirza A, Angoulvant D, \net al. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibril-\nlation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project. Thromb \nHaemost 2016;115:1056–63. https://doi.org/10.1160/TH16-01-0007 \n875. Shim CY, Seo J, Kim YJ, Lee SH, De Caterina R, Lee S, et al. Efficacy and safety of edox-\naban in patients early after surgical bioprosthetic valve implantation or valve repair: a \nrandomized clinical trial. J Thorac Cardiovasc Surg 2023;165:58–67.e54. https://doi.org/ \n10.1016/j.jtcvs.2021.01.127 \n876. Siontis KC, Yao X, Gersh BJ, Noseworthy PA. Direct oral anticoagulants in patients \nwith atrial fibrillation and valvular heart disease other than significant mitral stenosis \nand mechanical valves: a meta-analysis. Circulation 2017;135:714–6. https://doi.org/ \n10.1161/CIRCULATIONAHA.116.026793 \n877. Suppah M, Kamal A, Saadoun R, Baradeiya AMA, Abraham B, Alsidawi S, et al. An \nevidence-based approach to anticoagulation therapy comparing direct oral anticoagu-\nlants and vitamin K antagonists in patients with atrial fibrillation and bioprosthetic \nvalves: a systematic review, meta-analysis, and network meta-analysis. Am J Cardiol \n2023;206:132–50. https://doi.org/10.1016/j.amjcard.2023.07.141 \n878. Nijenhuis VJ, Brouwer J, Delewi R, Hermanides RS, Holvoet W, Dubois CLF, et al. \nAnticoagulation with or without clopidogrel after transcatheter aortic-valve implant-\nation. N Engl J Med 2020;382:1696–707. https://doi.org/10.1056/NEJMoa1915152 \n879. Van Mieghem NM, Unverdorben M, Hengstenberg C, Mollmann H, Mehran R, \nLopez-Otero D, et al. Edoxaban versus vitamin K antagonist for atrial fibrillation after \nTAVR. N Engl J Med 2021;385:2150–60. https://doi.org/10.1056/NEJMoa2111016 \n880. Collet JP, Van Belle E, Thiele H, Berti S, Lhermusier T, Manigold T, et al. Apixaban vs. \nstandard of care after transcatheter aortic valve implantation: the ATLANTIS trial. Eur \nHeart J 2022;43:2783–97. https://doi.org/10.1093/eurheartj/ehac242 \n881. Brouwer J, Nijenhuis VJ, Delewi R, Hermanides RS, Holvoet W, Dubois CLF, et al. \nAspirin with or without clopidogrel after transcatheter aortic-valve implantation. N \nEngl J Med 2020;383:1447–57. https://doi.org/10.1056/NEJMoa2017815 \n882. Maes F, Stabile E, Ussia GP, Tamburino C, Pucciarelli A, Masson JB, et al. Meta-analysis \ncomparing single versus dual antiplatelet therapy following transcatheter aortic valve \nimplantation. Am J Cardiol 2018;122:310–5. https://doi.org/10.1016/j.amjcard.2018. \n04.006 \n883. Rodés-Cabau J, Masson JB, Welsh RC, Garcia Del Blanco B, Pelletier M, Webb JG, et al. \nAspirin versus aspirin plus clopidogrel as antithrombotic treatment following trans-\ncatheter aortic valve replacement with a balloon-expandable valve: the ARTE \n(Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve \nImplantation) randomized clinical trial. JACC Cardiovasc Interv 2017;10:1357–65.  \nhttps://doi.org/10.1016/j.jcin.2017.04.014 \n884. Meurin P, Tabet JY, Iliou MC, Pierre B, Corone S, Cristofini P, et al. Thromboembolic \nevents early after mitral valve repair: incidence and predictive factors. Int J Cardiol 2008; \n126:45–52. https://doi.org/10.1016/j.ijcard.2007.03.115 \n885. van der Wall SJ, Olsthoorn JR, Heuts S, Klautz RJM, Tomsic A, Jansen EK, et al. \nAntithrombotic therapy after mitral valve repair: VKA or aspirin? J Thromb \nThrombolysis 2018;46:473–81. https://doi.org/10.1007/s11239-018-1724-0 \n886. Mazur PK, Arghami A, Macielak SA, Nei SD, Viehman JK, King KS, et al. Apixaban for \nanticoagulation after robotic mitral valve repair. Ann Thorac Surg 2023;115:966–73.  \nhttps://doi.org/10.1016/j.athoracsur.2022.07.045 \n887. Paparella D, Di Mauro M, Bitton Worms K, Bolotin G, Russo C, Trunfio S, et al. \nAntiplatelet versus oral anticoagulant therapy as antithrombotic prophylaxis after mi-\ntral valve repair. J Thorac Cardiovasc Surg 2016;151:1302–8.e1301. https://doi.org/10. \n1016/j.jtcvs.2015.12.036 \n888. Trevis J, Akowuah E. Which antithrombotic strategy provides the best outcomes after \nmitral valve repair in patients who remain in sinus rhythm? Interact Cardiovasc Thorac \nSurg 2022;35:ivac085. https://doi.org/10.1093/icvts/ivac085 \n889. Moser N, Omar MA, Koshman SL, Lin M, Youngson E, Kent W, et al. Direct oral antic-\noagulants for atrial fibrillation in early postoperative valve repair or bioprosthetic re-\nplacement. J Thorac Cardiovasc Surg 2023;168:523–32.e3. https://doi.org/10.1016/j. \njtcvs.2023.03.004 \n890. Mentias A, Saad M, Michael M, Nakhla S, Menon V, Harb S, et al. Direct oral anticoa-\ngulants versus warfarin in patients with atrial fibrillation and valve replacement or re-\npair. J Am Heart Assoc 2022;11:e026666. https://doi.org/10.1161/jaha.122.026666 \n891. Philippart R, Brunet-Bernard A, Clementy N, Bourguignon T, Mirza A, Babuty D, et al. \nPrognostic value of CHA2DS2-VASc score in patients with ‘non-valvular atrial fibrilla-\ntion’ and valvular heart disease: the Loire Valley Atrial Fibrillation Project. Eur Heart J \n2015;36:1822–30. https://doi.org/10.1093/eurheartj/ehv163 \n892. Jochheim D, Barbanti M, Capretti G, Stefanini GG, Hapfelmeier A, Zadrozny M, et al. \nOral anticoagulant type and outcomes after transcatheter aortic valve replacement. \nJACC Cardiovasc Interv 2019;12:1566–76. https://doi.org/10.1016/j.jcin.2019.03.003 \n893. Didier R, Lhermusier T, Auffret V, Eltchaninoff H, Le Breton H, Cayla G, et al. TAVR \npatients requiring anticoagulation: direct oral anticoagulant or vitamin K antagonist? \nJACC Cardiovasc Interv 2021;14:1704–13. https://doi.org/10.1016/j.jcin.2021.05.025 \n894. Tanawuttiwat T, Stebbins A, Marquis-Gravel G, Vemulapalli S, Kosinski AS, Cheng A. \nUse of direct oral anticoagulant and outcomes in patients with atrial fibrillation after \ntranscatheter aortic valve replacement: insights from the STS/ACC TVT registry. J \nAm Heart Assoc 2022;11:e023561. https://doi.org/10.1161/jaha.121.023561 \n895. VARC-3 Writing Committee; Généreux P, Piazza N, Alu MC, Nazif T, Hahn RT, et al. \nValve academic research consortium 3: updated endpoint definitions for aortic valve \nclinical research. J Am Coll Cardiol 2021;77:2717–46. https://doi.org/10.1016/j.jacc. \n2021.02.038 \n896. Pibarot P, Herrmann HC, Wu C, Hahn RT, Otto CM, Abbas AE, et al. Standardized \ndefinitions for bioprosthetic valve dysfunction following aortic or mitral valve replace-\nment: JACC state-of-the-art review. J Am Coll Cardiol 2022;80:545–61. https://doi.org/ \n10.1016/j.jacc.2022.06.002 \n897. Kaneko T, Bapat VN, Alakhtar AM, Zaid S, George I, Grubb KJ, et al. Transcatheter \nheart valve explantation for transcatheter aortic valve replacement failure: a Heart  \nESC Guidelines                                                                                                                                                                                          4733 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nValve Collaboratory expert consensus document on operative techniques. J Thorac \nCardiovasc Surg 2024;169:878–89. https://doi.org/10.1016/j.jtcvs.2024.04.025 \n898. Bleiziffer S, Rudolph TK. Patient prosthesis mismatch after SAVR and TAVR. Front \nCardiovasc Med 2022;9:761917. https://doi.org/10.3389/fcvm.2022.761917 \n899. Hirji SA, Percy ED, Zogg CK, Malarczyk A, Harloff MT, Yazdchi F, et al. Comparison of \nin-hospital outcomes and readmissions for valve-in-valve transcatheter aortic valve re-\nplacement vs. reoperative surgical aortic valve replacement: a contemporary assess-\nment of real-world outcomes. Eur Heart J 2020;41:2747–55. https://doi.org/10.1093/ \neurheartj/ehaa252 \n900. Tam DY, Vo TX, Wijeysundera HC, Dvir D, Friedrich JO, Fremes SE. Transcatheter \nvalve-in-valve versus redo surgical aortic valve replacement for the treatment of de-\ngenerated bioprosthetic aortic valve: a systematic review and meta-analysis. Catheter \nCardiovasc Interv 2018;92:1404–11. https://doi.org/10.1002/ccd.27686 \n901. Bleiziffer S, Simonato M, Webb JG, Rodes-Cabau J, Pibarot P, Kornowski R, et al. \nLong-term outcomes after transcatheter aortic valve implantation in failed biopros-\nthetic valves. Eur Heart J 2020;41:2731–42. https://doi.org/10.1093/eurheartj/ehaa544 \n902. Guerrero M, Vemulapalli S, Xiang Q, Wang DD, Eleid M, Cabalka AK, et al. Thirty-day \noutcomes of transcatheter mitral valve replacement for degenerated mitral bioprosth-\neses (valve-in-valve), failed surgical rings (valve-in-ring), and native valve with severe mi-\ntral annular calcification (valve-in-mitral annular calcification) in the United States: data \nfrom the Society of Thoracic Surgeons/American College of Cardiology/Transcatheter \nValve Therapy Registry. Circ Cardiovasc Interv 2020;13:e008425. https://doi.org/10. \n1161/CIRCINTERVENTIONS.119.008425 \n903. Eleid MF, Whisenant BK, Cabalka AK, Williams MR, Nejjari M, Attias D, et al. Early out-\ncomes of percutaneous transvenous transseptal transcatheter valve implantation in \nfailed bioprosthetic mitral valves, ring annuloplasty, and severe mitral annular calcifica-\ntion. JACC Cardiovasc Interv 2017;10:1932–42. https://doi.org/10.1016/j.jcin.2017.08. \n014 \n904. Little SH, Bapat V, Blanke P, Guerrero M, Rajagopal V, Siegel R. Imaging guidance for \ntranscatheter mitral valve intervention on prosthetic valves, rings, and annular calcifi-\ncation. JACC Cardiovasc Imaging 2021;14:22–40. https://doi.org/10.1016/j.jcmg.2019.10. \n027 \n905. Fallon JM, DeSimone JP, Brennan JM, O’Brien S, Thibault DP, DiScipio AW, et al. The \nincidence and consequence of prosthesis-patient mismatch after surgical aortic valve \nreplacement. Ann Thorac Surg 2018;106:14–22. https://doi.org/10.1016/j.athoracsur. \n2018.01.090 \n906. Flameng W, Herregods MC, Vercalsteren M, Herijgers P, Bogaerts K, Meuris B. \nProsthesis-patient mismatch predicts structural valve degeneration in bioprosthetic \nheart \nvalves. \nCirculation \n2010;121:2123–9. \nhttps://doi.org/10.1161/ \nCIRCULATIONAHA.109.901272 \n907. Zorn GLI, Little SH, Tadros P, Deeb GM, Gleason TG, Heiser J, et al. Prosthesis–pa-\ntient mismatch in high-risk patients with severe aortic stenosis: a randomized trial of \na self-expanding prosthesis. J Thorac Cardiovasc Surg 2016;151:1014–23.e3, \n1023.e1011–1013. https://doi.org/10.1016/j.jtcvs.2015.10.070 \n908. Thourani VH, Abbas AE, Ternacle J, Hahn RT, Makkar R, Kodali SK, et al. \nPatient-prosthesis mismatch after surgical aortic valve replacement: analysis of the \nPARTNER trials. Ann Thorac Surg 2024;117:1164–71. https://doi.org/10.1016/j. \nathoracsur.2024.01.023 \n909. Tomii D, Okuno T, Heg D, Nakase M, Lanz J, Praz F, et al. Long-term outcomes of mea-\nsured and predicted prosthesis-patient mismatch following transcatheter aortic valve \nreplacement. EuroIntervention 2023;19:746–56. https://doi.org/10.4244/eij-d-23- \n00456 \n910. Vriesendorp MD, De Lind Van Wijngaarden RAF, Head SJ, Kappetein AP, Hickey GL, \nRao V, et al. The fallacy of indexed effective orifice area charts to predict prosthesis– \npatient mismatch after prosthesis implantation. Eur Heart J Cardiovasc Imaging 2020;21: \n1116–22. https://doi.org/10.1093/ehjci/jeaa044 \n911. Sorajja P, Bae R, Lesser JA, Pedersen WA. Percutaneous repair of paravalvular pros-\nthetic regurgitation: patient selection, techniques and outcomes. Heart 2015;101: \n665–73. https://doi.org/10.1136/heartjnl-2014-306270 \n912. Ruiz CE, Hahn RT, Berrebi A, Borer JS, Cutlip DE, Fontana G, et al. Clinical trial prin-\nciples and endpoint definitions for paravalvular leaks in surgical prosthesis. Eur Heart J \n2018;39:1224–45. https://doi.org/10.1093/eurheartj/ehx211 \n913. Laplace G, Lafitte S, Labèque JN, Perron JM, Baudet E, Deville C, et al. Clinical signifi-\ncance of early thrombosis after prosthetic mitral valve replacement: a postoperative \nmonocentric study of 680 patients. J Am Coll Cardiol 2004;43:1283–90. https://doi. \norg/10.1016/j.jacc.2003.09.064 \n914. Symersky P, Budde RPJ, de Mol BAJM, Prokop M. Comparison of multidetector-row \ncomputed tomography to echocardiography and fluoroscopy for evaluation of pa-\ntients with mechanical prosthetic valve obstruction. Am J Cardiol 2009;104:1128–34.  \nhttps://doi.org/10.1016/j.amjcard.2009.05.061 \n915. Egbe AC, Pislaru SV, Pellikka PA, Poterucha JT, Schaff HV, Maleszewski JJ, et al. \nBioprosthetic valve thrombosis versus structural failure: clinical and echocardiographic \npredictors. J Am Coll Cardiol 2015;66:2285–94. https://doi.org/10.1016/j.jacc.2015.09. \n022 \n916. Rheude T, Pellegrini C, Stortecky S, Marwan M, Xhepa E, Ammon F, et al. Meta-analysis \nof bioprosthetic valve thrombosis after transcatheter aortic valve implantation. Am J \nCardiol 2021;138:92–9. https://doi.org/10.1016/j.amjcard.2020.10.018 \n917. Blanke P, Leipsic JA, Popma JJ, Yakubov SJ, Deeb GM, Gada H, et al. Bioprosthetic aor-\ntic valve leaflet thickening in the Evolut Low Risk sub-study. J Am Coll Cardiol 2020;75: \n2430–42. https://doi.org/10.1016/j.jacc.2020.03.022 \n918. Chakravarty T, Sondergaard L, Friedman J, De Backer O, Berman D, Kofoed KF, et al. \nSubclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: \nan observational study. Lancet 2017;389:2383–92. https://doi.org/10.1016/S0140- \n6736(17)30757-2 \n919. Makkar RR, Blanke P, Leipsic J, Thourani V, Chakravarty T, Brown D, et al. Subclinical \nleaflet thrombosis in transcatheter and surgical bioprosthetic valves: PARTNER 3 car-\ndiac computed tomography substudy. J Am Coll Cardiol 2020;75:3003–15. https://doi. \norg/10.1016/j.jacc.2020.04.043 \n920. De Backer O, Dangas GD, Jilaihawi H, Leipsic JA, Terkelsen CJ, Makkar R, et al. \nReduced leaflet motion after transcatheter aortic-valve replacement. N Engl J Med \n2020;382:130–9. https://doi.org/10.1056/NEJMoa1911426 \n921. Montalescot G, Redheuil A, Vincent F, Desch S, De Benedictis M, Eltchaninoff H, et al. \nApixaban and valve thrombosis after transcatheter aortic valve replacement: the \nATLANTIS-4D-CT randomized clinical trial substudy. JACC Cardiovasc Interv 2022; \n15:1794–804. https://doi.org/10.1016/j.jcin.2022.07.014 \n922. Ruile P, Jander N, Blanke P, Schoechlin S, Reinöhl J, Gick M, et al. Course of early sub-\nclinical leaflet thrombosis after transcatheter aortic valve implantation with or without \noral anticoagulation. Clin Res Cardiol 2017;106:85–95. https://doi.org/10.1007/s00392- \n016-1052-3 \n923. Günduz S, Özkan M, Kalçik M, Gürsoy OM, Astarcioglu MA, Karakoyun S, et al. \nSixty-four-section cardiac computed tomography in mechanical prosthetic heart valve \ndysfunction: thrombus or pannus. Circ Cardiovasc Imaging 2015;8:e003246. https://doi. \norg/10.1161/CIRCIMAGING.115.003246 \n924. Lancellotti P, Pibarot P, Chambers J, Edvardsen T, Delgado V, Dulgheru R, et al. \nRecommendations for the imaging assessment of prosthetic heart valves: a report \nfrom the European Association of Cardiovascular Imaging endorsed by the Chinese \nSociety of Echocardiography, the Inter-American Society of Echocardiography, and \nthe Brazilian Department of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging \n2016;17:589–90. https://doi.org/10.1093/ehjci/jew025 \n925. Tanis W, Habets J, van den Brink RBA, Symersky P, Budde RP, Chamuleau SA. \nDifferentiation of thrombus from pannus as the cause of acquired mechanical pros-\nthetic heart valve obstruction by non-invasive imaging: a review of the literature. Eur \nHeart J Cardiovasc Imaging 2014;15:119–29. https://doi.org/10.1093/ehjci/jet127 \n926. Karthikeyan G, Senguttuvan NB, Joseph J, Devasenapathy N, Bahl VK, Airan B. Urgent \nsurgery compared with fibrinolytic therapy for the treatment of left-sided prosthetic \nheart valve thrombosis: a systematic review and meta-analysis of observational studies. \nEur Heart J 2013;34:1557–66. https://doi.org/10.1093/eurheartj/ehs486 \n927. Castilho FM, De Sousa MR, Mendonca AL, Ribeiro AL, Caceres-Loriga FM. \nThrombolytic therapy or surgery for valve prosthesis thrombosis: systematic review \nand meta-analysis. J Thromb Haemost 2014;12:1218–28. https://doi.org/10.1111/jth. \n12577 \n928. Chopard R, Vidoni C, Besutti M, Ismail M, Ecarnot F, Favoulet B, et al. Surgery versus \nthrombolytic therapy for the management of left-sided prosthetic valve thrombosis \nwithout hemodynamic compromise: a systematic review and meta-analysis. J Am \nHeart Assoc 2024;13:e035143. https://doi.org/10.1161/jaha.124.035143 \n929. Özkan M, Günduz S, Güner A, Kalcik M, Gursoy MO, Uygur B, et al. Thrombolysis or \nsurgery in patients with obstructive mechanical valve thrombosis: the multicenter \nHATTUSHA study. J Am Coll Cardiol 2022;79:977–89. https://doi.org/10.1016/j.jacc. \n2021.12.027 \n930. Özkan M, Günduz S, Gürsoy OM, Karakoyun S, Astarcioglu MA, Kalcik M, et al. \nUltraslow thrombolytic therapy: a novel strategy in the management of PROsthetic \nMEchanical valve thrombosis and the prEdictors of outcomE: the ultra-slow \nPROMETEE trial. Am Heart J 2015;170:409–18. https://doi.org/10.1016/j.ahj.2015.04. \n025 \n931. Sadeghipour P, Saedi S, Saneei L, Rafiee F, Yoosefi S, Parsaee M, et al. Fast vs. ultraslow \nthrombolytic infusion regimens in patients with obstructive mechanical prosthetic \nvalve thrombosis: a pilot randomized clinical trial. Eur Heart J Cardiovasc \nPharmacother 2022;8:668–76. https://doi.org/10.1093/ehjcvp/pvab083 \n931a. Karthikeyan G, Rajashekar P, Devasenapathy N, Biswas S, Kidambi B, Singal A, et al. \nUrgent surgery vs fibrinolytic therapy for left-sided prosthetic valve thrombosis: a ran-\ndomized trial. Eur Heart J 2025;46:3373–81. https://doi.org/10.1093/eurheartj/ehaf391 \n932. Bemurat LR, Laffort PR, Deville CJ, Roques XG, Baudet EM, Roudaut RP. Management \nof nonobstructive thrombosis of prosthetic mitral valve in asymptomatic patients in \nthe early postoperative period: a study in 20 patients. Echocardiography 1999;16: \n339–46. https://doi.org/10.1111/j.1540-8175.1999.tb00823.x \n933. Mutuberría-Urdaniz M, Rodríguez-Palomares JF, Ferreira I, Bañeras J, Teixidó G, \nGutiérrez L, et al. Non-obstructive prosthetic heart valve thrombosis (NOPVT): really \na benign entity? Int J Cardiol 2015;197:16–22. https://doi.org/10.1016/j.ijcard.2015.06. \n021  \n4734                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n934. Egbe AC, Connolly HM, Pellikka PA, Schaff HV, Hanna R, Maleszewski JJ, et al. \nOutcomes of warfarin therapy for bioprosthetic valve thrombosis of surgically im-\nplanted valves: a prospective study. JACC Cardiovasc Interv 2017;10:379–87. https:// \ndoi.org/10.1016/j.jcin.2016.11.027 \n935. Jose J, Sulimov DS, El-Mawardy M, Sato T, Allali A, Holy EW, et al. Clinical bioprosthetic \nheart valve thrombosis after transcatheter aortic valve replacement: incidence, char-\nacteristics, and treatment outcomes. JACC Cardiovasc Interv 2017;10:686–97. https:// \ndoi.org/10.1016/j.jcin.2017.01.045 \n936. Petrescu I, Egbe AC, Ionescu F, Nkomo VT, Greason KL, Pislaru C, et al. Long-term \noutcomes of anticoagulation for bioprosthetic valve thrombosis. J Am Coll Cardiol \n2020;75:857–66. https://doi.org/10.1016/j.jacc.2019.12.037 \n937. Pislaru SV, Hussain I, Pellikka PA, Maleszewski JJ, Hanna RD, Schaff HV, et al. \nMisconceptions, diagnostic challenges and treatment opportunities in bioprosthetic \nvalve thrombosis: lessons from a case series. Eur J Cardiothorac Surg 2015;47: \n725–32. https://doi.org/10.1093/ejcts/ezu201 \n938. Puri R, Auffret V, Rodés-Cabau J. Bioprosthetic valve thrombosis. J Am Coll Cardiol \n2017;69:2193–211. https://doi.org/10.1016/j.jacc.2017.02.051 \n939. Sellers SL, Turner CT, Sathananthan J, Cartlidge TRG, Sin F, Bouchareb R, et al. \nTranscatheter aortic heart valves: histological analysis providing insight to leaflet thick-\nening and structural valve degeneration. JACC Cardiovasc Imaging 2019;12:135–45.  \nhttps://doi.org/10.1016/j.jcmg.2018.06.028 \n940. Alkhouli M, Rihal CS, Zack CJ, Eleid MF, Maor E, Sarraf M, et al. Transcatheter and sur-\ngical management of mitral paravalvular leak: long-term outcomes. JACC Cardiovasc \nInterv 2017;10:1946–56. https://doi.org/10.1016/j.jcin.2017.07.046 \n941. Dvir D, Webb JG, Bleiziffer S, Pasic M, Waksman R, Kodali S, et al. Transcatheter aortic \nvalve implantation in failed bioprosthetic surgical valves. JAMA 2014;312:162–70.  \nhttps://doi.org/10.1001/jama.2014.7246 \n942. Yoon SH, Whisenant BK, Bleiziffer S, Delgado V, Dhoble A, Schofer N, et al. Outcomes \nof transcatheter mitral valve replacement for degenerated bioprostheses, failed annu-\nloplasty rings, and mitral annular calcification. Eur Heart J 2019;40:441–51. https://doi. \norg/10.1093/eurheartj/ehy590 \n943. Whisenant B, Kapadia SR, Eleid MF, Kodali SK, McCabe JM, Krishnaswamy A, et al. \nOne-year outcomes of mitral valve-in-valve using the SAPIEN 3 transcatheter heart \nvalve. JAMA Cardiol 2020;5:1245–52. https://doi.org/10.1001/jamacardio.2020.2974 \n944. McElhinney DB, Aboulhosn JA, Dvir D, Whisenant B, Zhang Y, Eicken A, et al. \nMid-term valve-related outcomes after transcatheter tricuspid valve-in-valve or \nvalve-in-ring replacement. J Am Coll Cardiol 2019;73:148–57. https://doi.org/10.1016/ \nj.jacc.2018.10.051 \n945. Muratori M, Montorsi P, Teruzzi G, Celeste F, Doria E, Alamanni F, et al. Feasibility and \ndiagnostic accuracy of quantitative assessment of mechanical prostheses leaflet motion \nby transthoracic and transesophageal echocardiography in suspected prosthetic valve \ndysfunction. Am J Cardiol 2006;97:94–100. https://doi.org/10.1016/j.amjcard.2005.07. \n112 \n946. Barbetseas J, Nagueh SF, Pitsavos C, Toutouzas PK, Quiñones MA, Zoghbi WA. \nDifferentiating thrombus from pannus formation in obstructed mechanical prosthetic \nvalves: an evaluation of clinical, transthoracic and transesophageal echocardiographic \nparameters. J Am Coll Cardiol 1998;32:1410–7. https://doi.org/10.1016/s0735- \n1097(98)00385-4 \n947. Suchá D, Symersky P, Vonken EJPA, Provoost E, Chamuleau SA, Budde RP. \nMultidetector-row computed tomography allows accurate measurement of mechan-\nical prosthetic heart valve leaflet closing angles compared with fluoroscopy. J Comput \nAssist Tomogr 2014;38:451–6. https://doi.org/10.1097/RCT.0b013e3182ab5f15 \n948. Daniel WG, Mügge A, Grote J, Hausmann D, Nikutta P, Laas J, et al. Comparison of \ntransthoracic and transesophageal echocardiography for detection of abnormalities \nof prosthetic and bioprosthetic valves in the mitral and aortic positions. Am J Cardiol \n1993;71:210–5. https://doi.org/10.1016/0002-9149(93)90740-4 \n949. Özkan M, Çakal B, Karakoyun S, Gürsoy OM, Çevik C, Kalçık M, et al. Thrombolytic \ntherapy for the treatment of prosthetic heart valve thrombosis in pregnancy with low- \ndose, slow infusion of tissue-type plasminogen activator. Circulation 2013;128:532–40.  \nhttps://doi.org/10.1161/circulationaha.113.001145 \n950. Taherkhani M, Hashemi SR, Hekmat M, Safi M, Taherkhani A, Movahed MR. \nThrombolytic therapy for right-sided mechanical pulmonic and tricuspid valves: the lar-\ngest survival analysis to date. Tex Heart Inst J 2015;42:543–7. https://doi.org/10.14503/ \nTHIJ-14-4659 \n951. Roudaut R, Roques X, Lafitte S, Choukroun E, Laborde N, Madona F, et al. Surgery for \nprosthetic valve obstruction. A single center study of 136 patients. Eur J Cardiothorac \nSurg 2003;24:868–72. https://doi.org/10.1016/s1010-7940(03)00568-2 \n952. Nishanth KR, Shankar M, Srinivasa KH, Manjunath CN, Ravindranath KS. Fibrinolysis in \nleft-sided mechanical prosthetic valve thrombosis with high INR. Eur Heart J Acute \nCardiovasc Care 2020;9:S58–62. https://doi.org/10.1177/2048872619846329 \n953. Separham A, Ghaffari S, Aslanabadi N, Sohrabi B, Ghojazadeh M, Anamzadeh E, et al. \nProsthetic valve thrombosis. J Card Surg 2015;30:246–50. https://doi.org/10.1111/jocs. \n12510 \n954. Farzaneh K, Mortazavi SH, Oraii A, Abbasi K, Salehi Omran A, Ahmadi Tafti SH, et al. \nSafety of thrombolytic therapy in patients with prosthetic heart valve thrombosis who \nhave high international normalized ratio levels. J Card Surg 2020;35:2522–8. https://doi. \norg/10.1111/jocs.14777 \n955. Jander N, Kienzle RP, Kayser G, Neumann FJ, Gohlke-Baerwolf C, Minners J. \nUsefulness of phenprocoumon for the treatment of obstructing thrombus in bio-\nprostheses in the aortic valve position. Am J Cardiol 2012;109:257–62. https://doi. \norg/10.1016/j.amjcard.2011.08.038 \n956. Oliver JM, Gallego P, Gonzalez A, Dominguez FJ, Gamallo C, Mesa JM. Bioprosthetic \nmitral valve thrombosis: clinical profile, transesophageal echocardiographic features, \nand follow-up after anticoagulant therapy. J Am Soc Echocardiogr 1996;9:691–9.  \nhttps://doi.org/10.1016/s0894-7317(96)90066-8 \n957. Agarwal S, Rajamanickam A, Bajaj NS, Griffin BP, Catacutan T, Svensson LG, et al. \nImpact of aortic stenosis on postoperative outcomes after noncardiac surgeries. Circ \nCardiovasc \nQual \nOutcomes \n2013;6:193–200. \nhttps://doi.org/10.1161/CIRC \nOUTCOMES.111.000091 \n958. Taniguchi T, Morimoto T, Shiomi H, Ando K, Shirai S, Kanamori N, et al. Elective non- \ncardiac surgery in patients with severe aortic stenosis — observations from the \nCURRENT AS registry. Circ J 2020;84:1173–82. https://doi.org/10.1253/circj.CJ-20- \n0026 \n959. Luis SA, Dohaei A, Chandrashekar P, Scott CG, Padang R, Lokineni S, et al. Impact of \naortic valve replacement for severe aortic stenosis on perioperative outcomes follow-\ning major noncardiac surgery. Mayo Clin Proc 2020;95:727–37. https://doi.org/10.1016/ \nj.mayocp.2019.10.038 \n960. Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, et al. 2022 ESC \nGuidelines on cardiovascular assessment and management of patients undergoing non- \ncardiac surgery. Eur Heart J 2022;43:3826–924. https://doi.org/10.1093/eurheartj/ \nehac270 \n961. Okuno T, Demirel C, Tomii D, Erdoes G, Heg D, Lanz J, et al. Risk and timing of non-\ncardiac surgery after transcatheter aortic valve implantation. JAMA Netw Open 2022;5: \ne2220689. https://doi.org/10.1001/jamanetworkopen.2022.20689 \n962. Tashiro T, Pislaru SV, Blustin JM, Nkomo VT, Abel MD, Scott CG, et al. Perioperative \nrisk of major non-cardiac surgery in patients with severe aortic stenosis: a reappraisal \nin contemporary practice. Eur Heart J 2014;35:2372–81. https://doi.org/10.1093/ \neurheartj/ehu044 \n963. Okuno T, Yahagi K, Horiuchi Y, Sato Y, Tanaka T, Koseki K, et al. The role of transcath-\neter aortic valve replacement in the patients with severe aortic stenosis requiring ma-\njor non-cardiac surgery. Cardiovasc Interv Ther 2019;34:345–51. https://doi.org/10. \n1007/s12928-019-00575-z \n964. Calleja AM, Dommaraju S, Gaddam R, Cha S, Khandheria BK, Chaliki HP. Cardiac risk \nin patients aged >75 years with asymptomatic, severe aortic stenosis undergoing non-\ncardiac surgery. Am J Cardiol 2010;105:1159–63. https://doi.org/10.1016/j.amjcard. \n2009.12.019 \n965. Sohrabi B, Kazemi B, Mehryar A, Teimouri-Dereshki A, Toufan M, Aslanabadi N. \nCorrelation between pulmonary artery pressure measured by echocardiography \nand right heart catheterization in patients with rheumatic mitral valve stenosis (a pro-\nspective study). Echocardiography 2016;33:7–13. https://doi.org/10.1111/echo.13000 \n966. Smilowitz NR, Armanious A, Bangalore S, Ramakrishna H, Berger JS. Cardiovascular \noutcomes of patients with pulmonary hypertension undergoing noncardiac surgery. \nAm J Cardiol 2019;123:1532–7. https://doi.org/10.1016/j.amjcard.2019.02.006 \n967. Bajaj NS, Agarwal S, Rajamanickam A, Parashar A, Poddar KL, Griffin BP, et al. Impact of \nsevere mitral regurgitation on postoperative outcomes after noncardiac surgery. Am J \nMed 2013;126:529–35. https://doi.org/10.1016/j.amjmed.2012.12.005 \n968. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomstrom-Lundqvist C, Cifkova \nR, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular dis-\neases during pregnancy. Eur Heart J 2018;39:3165–241. https://doi.org/10.1093/ \neurheartj/ehy340 \n969. Roos-Hesselink J, Baris L, Johnson M, De Backer J, Otto C, Marelli A, et al. Pregnancy \noutcomes in women with cardiovascular disease: evolving trends over 10 years in the \nESC Registry Of Pregnancy And Cardiac disease (ROPAC). Eur Heart J 2019;40: \n3848–55. https://doi.org/10.1093/eurheartj/ehz136 \n970. Pande SN, Yavana Suriya J, Ganapathy S, Pillai AA, Satheesh S, Mondal N, et al. \nValidation of risk stratification for cardiac events in pregnant women with valvular \nheart disease. J Am Coll Cardiol 2023;82:1395–406. https://doi.org/10.1016/j.jacc. \n2023.07.023 \n971. van Hagen IM, Thorne SA, Taha N, Youssef G, Elnagar A, Gabriel H, et al. Pregnancy \noutcomes in women with rheumatic mitral valve disease: results from the Registry of \nPregnancy and Cardiac Disease. Circulation 2018;137:806–16. https://doi.org/10.1161/ \nCIRCULATIONAHA.117.032561 \n972. Orwat S, Diller GP, van Hagen IM, Schmidt R, Tobler D, Greutmann M, et al. Risk of \npregnancy in moderate and severe aortic stenosis: from the multinational ROPAC \nregistry. J Am Coll Cardiol 2016;68:1727–37. https://doi.org/10.1016/j.jacc.2016.07.750 \n973. Meijboom LJ, Vos FE, Timmermans J, Boers GH, Zwinderman AH, Mulder BJ. \nPregnancy and aortic root growth in the Marfan syndrome: a prospective study. Eur \nHeart J 2005;26:914–20. https://doi.org/10.1093/eurheartj/ehi103 \n974. McKellar SH, MacDonald RJ, Michelena HI, Connolly HM, Sundt TMI. Frequency of car-\ndiovascular events in women with a congenitally bicuspid aortic valve in a single  \nESC Guidelines                                                                                                                                                                                          4735 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\ncommunity and effect of pregnancy on events. Am J Cardiol 2011;107:96–9. https://doi. \norg/10.1016/j.amjcard.2010.08.061 \n975. Wichert-Schmitt B, Grewal J, Malinowski AK, Pfaller B, Losenno KL, Kiess MC, et al. \nOutcomes of pregnancy in women with bioprosthetic heart valves with or without \nvalve dysfunction. J Am Coll Cardiol 2022;80:2014–24. https://doi.org/10.1016/j.jacc. \n2022.09.019 \n976. van Hagen IM, Roos-Hesselink JW, Ruys TPE, Merz WM, Goland S, Gabriel H, et al. \nPregnancy in women with a mechanical heart valve: data of the European Society of \nCardiology Registry of Pregnancy and Cardiac Disease (ROPAC). Circulation 2015; \n132:132–42. https://doi.org/10.1161/CIRCULATIONAHA.115.015242 \n977. Pfaller B, Dave Javier A, Grewal J, Gabarin N, Colman J, Kiess M, et al. Risk associated \nwith valvular regurgitation during pregnancy. J Am Coll Cardiol 2021;77:2656–64.  \nhttps://doi.org/10.1016/j.jacc.2021.03.327 \n978. Hameed A, Karaalp IS, Tummala PP, Wani OR, Canetti M, Akhter MW, et al. The effect \nof valvular heart disease on maternal and fetal outcome of pregnancy. J Am Coll Cardiol \n2001;37:893–9. https://doi.org/10.1016/s0735-1097(00)01198-0 \n979. Hoover E, Corlin T, Lohr J, Sabol B, Yamamura Y, Jacobs K, et al. TAVR beyond fetal \nviability: an alternative to preterm delivery in symptomatic severe aortic stenosis. JACC \nCase Rep 2023;27:102104. https://doi.org/10.1016/j.jaccas.2023.102104 \n980. Sajja A, Dassanayake M, Morales IA, Wenger NK, Smith C, Xie J, et al. Valve-in-valve \ntranscatheter aortic valve replacement during second trimester of pregnancy. JACC \nCase Rep 2023;27:102074. https://doi.org/10.1016/j.jaccas.2023.102074 \n981. D’Souza R, Ostro J, Shah PS, Silversides CK, Malinowski A, Murphy KE, et al. \nAnticoagulation for pregnant women with mechanical heart valves: a systematic review \nand meta-analysis. Eur Heart J 2017;38:1509–16. https://doi.org/10.1093/eurheartj/ \nehx032 \n982. Fuchs A, Urena M, Chong-Nguyen C, Kikoine J, Brochet E, Abtan J, et al. Valve-in-valve \nand valve-in-ring transcatheter mitral valve implantation in young women contemplat-\ning pregnancy. Circ Cardiovasc Interv 2020;13:e009579. https://doi.org/10.1161/ \nCIRCINTERVENTIONS.120.009579 \n983. Mascherbauer J, Kammerlander A, Nitsche C, Bax J, Delgado V, Evangelista A, et al. \nSex-related differences in severe native valvular heart disease: the ESC-EORP \nValvular Heart Disease II survey. Eur Heart J 2024;45:3818–33. https://doi.org/10. \n1093/eurheartj/ehae523 \n984. Cote N, Clavel MA. Sex differences in the pathophysiology, diagnosis, and manage-\nment of aortic stenosis. Cardiol Clin 2020;38:129–38. https://doi.org/10.1016/j.ccl. \n2019.09.008 \n985. Habib G, Erba PA, Iung B, Donal E, Cosyns B, Laroche C, et al. Clinical presentation, \naetiology and outcome of infective endocarditis. Results of the ESC-EORP \nEURO-ENDO (European infective endocarditis) registry: a prospective cohort study. \nEur Heart J 2019;40:3222–32. https://doi.org/10.1093/eurheartj/ehz620 \n986. Avierinos JF, Inamo J, Grigioni F, Gersh B, Shub C, Enriquez-Sarano M. Sex differences \nin morphology and outcomes of mitral valve prolapse. Ann Intern Med 2008;149: \n787–95. https://doi.org/10.7326/0003-4819-149-11-200812020-00003 \n987. Brown JM, O’Brien SM, Wu C, Sikora JA, Griffith BP, Gammie JS. Isolated aortic valve \nreplacement in North America comprising 108,687 patients in 10 years: changes in \nrisks, valve types, and outcomes in the Society of Thoracic Surgeons National \nDatabase. J Thorac Cardiovasc Surg 2009;137:82–90. https://doi.org/10.1016/j.jtcvs. \n2008.08.015 \n988. O’Brien SM, Feng L, He X, Xian Y, Jacobs JP, Badhwar V, et al. The Society of Thoracic \nSurgeons 2018 adult cardiac surgery risk models: part 2—statistical methods and re-\nsults. Ann Thorac Surg 2018;105:1419–28. https://doi.org/10.1016/j.athoracsur.2018. \n03.003 \n989. Shan Y, Pellikka PA. Aortic stenosis in women. Heart 2020;106:970–6. https://doi.org/ \n10.1136/heartjnl-2019-315407 \n990. Voisine M, Hervault M, Shen M, Boilard AJ, Filion B, Rosa M, et al. Age, sex, and valve \nphenotype differences in fibro-calcific remodeling of calcified aortic valve. J Am Heart \nAssoc 2020;9:e015610. https://doi.org/10.1161/JAHA.119.015610 \n991. Capoulade R, Clavel MA, Le Ven F, Dahou A, Thebault C, Tastet L, et al. Impact of left \nventricular remodelling patterns on outcomes in patients with aortic stenosis. Eur \nHeart J Cardiovasc Imaging 2017;18:1378–87. https://doi.org/10.1093/ehjci/jew288 \n992. Simard L, Côté N, Dagenais F, Mathieu P, Couture C, Trahan S, et al. Sex-related dis-\ncordance between aortic valve calcification and hemodynamic severity of aortic sten-\nosis: is valvular fibrosis the explanation? Circ Res 2017;120:681–91. https://doi.org/10. \n1161/CIRCRESAHA.116.309306 \n993. Bienjonetti-Boudreau D, Fleury MA, Voisine M, Paquin A, Chouinard I, Tailleur M, et al. \nImpact of sex on the management and outcome of aortic stenosis patients. Eur Heart J \n2021;42:2683–91. https://doi.org/10.1093/eurheartj/ehab242 \n994. Tribouilloy C, Bohbot Y, Rusinaru D, Belkhir K, Diouf M, Altes A, et al. Excess mortality \nand undertreatment of women with severe aortic stenosis. J Am Heart Assoc 2021;10: \ne018816. https://doi.org/10.1161/JAHA.120.018816 \n995. Hartzell M, Malhotra R, Yared K, Rosenfield HR, Walker JD, Wood MJ. Effect of gender \non treatment and outcomes in severe aortic stenosis. Am J Cardiol 2011;107:1681–6.  \nhttps://doi.org/10.1016/j.amjcard.2011.01.059 \n996. Lowenstern A, Sheridan P, Wang TY, Boero I, Vemulapalli S, Thourani VH, et al. Sex \ndisparities in patients with symptomatic severe aortic stenosis. Am Heart J 2021;237: \n116–26. https://doi.org/10.1016/j.ahj.2021.01.021 \n997. Onorati F, D’Errigo P, Barbanti M, Rosato S, Covello RD, Maraschini A, et al. Different \nimpact of sex on baseline characteristics and major periprocedural outcomes of trans-\ncatheter and surgical aortic valve interventions: results of the multicenter Italian \nOBSERVANT registry. J Thorac Cardiovasc Surg 2014;147:1529–39. https://doi.org/ \n10.1016/j.jtcvs.2013.05.039 \n998. Tchetche D, Pibarot P, Bax JJ, Bonaros N, Windecker S, Dumonteil N, et al. \nTranscatheter vs. surgical aortic valve replacement in women: the RHEIA trial. Eur \nHeart J 2025;46:2079–88. https://doi.org/10.1093/eurheartj/ehaf133 \n999. Saad M, Nairooz R, Pothineni NVK, Almomani A, Kovelamudi S, Sardar P, et al. \nLong-term outcomes with transcatheter aortic valve replacement in women com-\npared with men: evidence from a meta-analysis. JACC Cardiovasc Interv 2018;11: \n24–35. https://doi.org/10.1016/j.jcin.2017.08.015 \n1000. Akintoye E, Saijo Y, Braghieri L, Badwan O, Patel H, Dabbagh MM, et al. Impact of age \nand sex on left ventricular remodeling in patients with aortic regurgitation. J Am Coll \nCardiol 2023;81:1474–87. https://doi.org/10.1016/j.jacc.2023.02.037 \n1001. Kammerlander AA, Donà C, Nitsche C, Koschutnik M, Zafar A, Eslami P, et al. Sex \ndifferences in left ventricular remodeling and outcomes in chronic aortic regurgita-\ntion. J Clin Med 2020;9:4100. https://doi.org/10.3390/jcm9124100 \n1002. Basso C, Iliceto S, Thiene G, Perazzolo Marra M. Mitral valve prolapse, ventricular ar-\nrhythmias, and sudden death. Circulation 2019;140:952–64. https://doi.org/10.1161/ \nCIRCULATIONAHA.118.034075 \n1003. Stolfo D, Uijl A, Vedin O, Stromberg A, Faxen UL, Rosano GMC, et al. Sex-based dif-\nferences in heart failure across the ejection fraction spectrum: phenotyping, and \nprognostic and therapeutic implications. JACC Heart Fail 2019;7:505–15. https://doi. \norg/10.1016/j.jchf.2019.03.011 \n1004. El Sabbagh A, Al-Hijji M, Wang DD, Eleid M, Urena M, Himbert D, et al. Predictors of \nleft ventricular outflow tract obstruction after transcatheter mitral valve replacement \nin severe mitral annular calcification: an analysis of the Transcatheter Mitral Valve \nReplacement in Mitral Annular Calcification Global Registry. Circ Cardiovasc Interv \n2021;14:e010854. https://doi.org/10.1161/CIRCINTERVENTIONS.121.010854 \n1005. Willner N, Burwash IG, Beauchesne L, Chan V, Vulesevic B, Ascah K, et al. Natural \nhistory of mitral annular calcification and calcific mitral valve disease. J Am Soc \nEchocardiogr 2022;35:925–32. https://doi.org/10.1016/j.echo.2022.05.007 \n1006. Offen S, Playford D, Strange G, Stewart S, Celermajer DS. Adverse prognostic impact \nof even mild or moderate tricuspid regurgitation: insights from the National \nEchocardiography Database of Australia. J Am Soc Echocardiogr 2022;35:810–17.  \nhttps://doi.org/10.1016/j.echo.2022.04.003 \n1007. Mutlak D, Khalil J, Lessick J, Kehat I, Agmon Y, Aronson D. Risk factors for the devel-\nopment of functional tricuspid regurgitation and their population-attributable frac-\ntions. JACC Cardiovasc Imaging 2020;13:1643–51. https://doi.org/10.1016/j.jcmg. \n2020.01.015 \n1008. Prihadi EA, van der Bijl P, Gursoy E, Abou R, Mara Vollema E, Hahn RT, et al. \nDevelopment of significant tricuspid regurgitation over time and prognostic implica-\ntions: new insights into natural history. Eur Heart J 2018;39:3574–81. https://doi.org/ \n10.1093/eurheartj/ehy352 \n1009. Beale AL, Nanayakkara S, Segan L, Mariani JA, Maeder MT, van Empel V, et al. Sex dif-\nferences in heart failure with preserved ejection fraction pathophysiology: a detailed \ninvasive hemodynamic and echocardiographic analysis. JACC Heart Fail 2019;7: \n239–49. https://doi.org/10.1016/j.jchf.2019.01.004 \n1010. Dietz MF, Prihadi EA, van der Bijl P, Fortuni F, Marques AI, Ajmone Marsan N, et al. \nSex-specific differences in etiology and prognosis in patients with significant tricuspid \nregurgitation. Am J Cardiol 2021;147:109–15. https://doi.org/10.1016/j.amjcard.2021. \n02.016 \n1011. Pfannmueller B, Eifert S, Seeburger J, Misfeld M, Borger M, Mende M, et al. \nGender-dependent differences in patients undergoing tricuspid valve surgery. \nThorac Cardiovasc Surg 2013;61:37–41. https://doi.org/10.1055/s-0032-1324406 \n1012. Fortmeier V, Lachmann M, Körber MI, Unterhuber M, Schober AR, Stolz L, et al. \nSex-related differences in clinical characteristics and outcome prediction among pa-\ntients undergoing transcatheter tricuspid valve intervention. JACC Cardiovasc Interv \n2023;16:909–23. https://doi.org/10.1016/j.jcin.2023.01.378 \n1013. Scotti A, Coisne A, Taramasso M, Granada JF, Ludwig S, Rodes-Cabau J, et al. \nSex-related characteristics and short-term outcomes of patients undergoing trans-\ncatheter tricuspid valve intervention for tricuspid regurgitation. Eur Heart J 2023; \n44:822–32. https://doi.org/10.1093/eurheartj/ehac735  \n4736                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "keywords": [
        "aortic stenosis",
        "anticoagulant",
        "elderly",
        "angiography",
        "blood pressure",
        "ezetimibe",
        "framingham",
        "heart failure",
        "echo",
        "recommended",
        "pulmonary hypertension",
        "systolic dysfunction",
        "indication",
        "contraindication",
        "physical activity",
        "class iii",
        "valve repair",
        "anticoagulation",
        "hypertension",
        "lvef",
        "echocardiography",
        "crt",
        "aneurysm",
        "syncope",
        "ethnicity",
        "prosthetic valve",
        "mitral stenosis",
        "coronary artery",
        "lipid",
        "tavr"
      ],
      "tables": []
    }
  ]
}